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Dengue virus (DENV) causes the most important arthropod-borne viral disease of humans. 
Dengue (DEN) pathogenesis is not well understood and there are neither fully protective vaccines 
nor antiviral drugs to prevent DEN. A diagnostic test to predict disease severity is also lacking. A 
greater understanding of the cellular changes that occur in response to DENV infection will 
increase our understanding of pathogenesis and potentially lead to the development of new 
treatment options. In this study, quantitative mass spectrometry (MS) was therefore used to 
systematically analyse the host response to DENV infection both in vitro and in vivo.  
Initially, the proteome and secretome of DENV infected HEK293T cells and HEK293T 
cells expressing a DENV replicon were compared. Bioinformatic analysis of the results showed 
that the replicon system was good surrogate for viral replication studies. 
The combined proteomic/secretomic analysis was then extended to DENV infected Huh-7 
liver cells. Bioinformatic analysis of the results showed that the predominant effect of infection 
was a significant decrease in the levels of proteins, both in the proteome and secretome, that were 
involved in “complement and coagulation cascades” and “lipid metabolic” processes.  
Proteomic analysis of serum from patients with different grades of DEN identified proteins 
that were significantly altered in response to DENV infection and two proteins, C-reactive protein 
and apolipoprotein CII, that could be used to discriminate disease states.  
The results of the proteomic analyses using cell-based models and patient serum were then 
compared, which revealed that Huh-7 cells provide a good model for studying the role of 
complement, coagulation and acute phase proteins (APPs) in DEN. 
 
The results of the proteomic analyses were validated for selected APPs. The levels of APPs 
in DENV infected Huh-7 cells could be rescued by treatment with MG132, suggesting liver APPs 
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aa  amino acid(s)  
ADE       antibody-dependent enhancement  
AGC automatic gain control  
AGT angiotensinogen 
ALB albumin 
AMBP protein AMBP  
APO apolipoprotein A1 
APOA1 apolipoprotein 
APOB apolipoprotein B 
APOC2 apolipoprotein C2 
APPs acute phase proteins  
APS ammonium persulphate  
ATF6 activating transcription factor-6 
AUFI  acute undifferentiated febrile illness 
BCA bicinchoninic acid 
CALR calreticulin 
cDNA complementary DNA  
CFI coagulation factor I 
CFH coagulation factor H 
CIC circulated immune complexs 
CM complete media 
CNX caknexin 
CPE cytopathic effect  
Co-IP    co-immunoprecipitation 
COX cytochrome c oxidase  
COX6C Cytochrome c oxidase subunit VIc  
CRP C-reactive proteins  
DAPI 4',6-diamidino-2-phenylindole 
DAVID Database for Annotation, Visualization and Integrated Discovery  
DC-SIGN dendritic cell-specific intercellular adhesion molecule-3-
grabbing non-integrin 
DDX DEAD-Box Helicase  
DEN dengue  
DENV dengue virus  
DF dengue fever  
DHF dengue haemorrhagic fever  
DIC disseminated intravascular coagulation 
DMEM Dulbecco’s modified Eagles medium  
DMSO dimethyl sulfoxide 




DSS dengue shock syndrome  
DTT dithiothreitol 
EDTA ethylenediaminetetraacetic acid 
eIF2A alpha subunit of eukaryotic initiation factor 2  
ENO1 alpha enolase 
ER  endoplasmic reticulum  
FASN fatty acid synthase  
FBLN1 fibulin-1 
FBG fibrinogen 
FBS foetal bovine serum 
FDR false discovery rate  
FFU focus forming units 
FGA fibrinoge alpha 
FGB fibrinogen beta 
FGG fibrinogen gamma 
FGL1 fibrinogen-like protein 1  
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F2 prothrombin 
F13B coagulation factor XIII B chain  
g gram 
g gravity 
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GFP green fluorescent protein 
GO Gene ontology  
GOBP Gene ontology biological process 
GOCC Gene ontology  cellular component 
GOMF Gene ontology molecular function 
GRP78 glucose-regulated protein 78  
GWAS genome-wide study  
h hour(s) 
hpi hour poost-infection 
Hct hematocrit 
HDL high-density lipoproteins 
HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid  
HIST1H4L histone H4  
HIV-1         human immunodeficiency virus type 1 
HLA human leukocyte antigen  
HNF4A hepatocyste nuclear factor 4 alpha 
HNRNPH1 heterogeneous nuclear ribonucleoprotein H1 
HP haptoglobin 
HRP horseradish peroxidase 
HSP heat shock protein 




ICAT isotope-coded affinity tags method  
IF imunofocus 
IFA immunofluorescence assay  
IFITM3 Interferon-induced transmembrane protein 3 
IFN interferon  
Ig immunoglobulin 
IL-6 interleukin-6 
IL-8 interleukin-8  
IPA ingenuity pathway analysis 
IRE1 inositol-requiring protein-1  
iTRAQ isotope tags for relative and absolute quantitation 
JEV Japanese encephalitis virus 
k  kilo 
kDa kilo-Dalton 
l   liter 
LAMP1 lysosome-associated membrane proteins 1 
LC   liquid chromatography  
LD  lipid droplet  
LDL low densitry lipoproteins 
m  milli 
M  Molar 
MALDI-TOF   matrix-assisted laser desorption/ionization time-of-flight 
MAN1A1 mannosyl-oligosaccharide 1,2-alpha-mannosidase IA  
MEM minimal essential medium    
MHC major histocompatibility complex 
MIF macrophage migration inhibitory factor 
min minute(s) 
miRNA microRNAs 
MOI multiplicity of infection 
MS mass spectrometry  
MS/MS tandam mass spectrometry 
n nano 
NCR noncoding regions 
NEAA non-essential amino acids  
NF-κB nuclear factor-κB 
NH4Cl  ammonium chloride 
NID1 nidogen-1 
NLS nuclear localisation signal   
NPC nuclear pore complex 
NS non-structural 
NTPase nucleotide triphosphatase 
NUPs Nucleoporins 




OFI other febrile illness  
ORF open reading frame  
ORM1 alpha-1-acid glycoprotein 1  
ORM2 alpha-1-acid glycoprotein 2 
p pico 
PBS phosphate buffered saline  
PCR polymerase Chain Reaction 
PDL poly-D-lysine  
PEP posterior error probability  
PERK PKR-like endoplasmic reticulum kinase 
pi post-infection  
Plt     platelet 
PLTP phospholipid transfer protein  
PPH primary human hepatocytes  
PROC protein C 
PROS1 protein S 
PSMs  peptide-to-spectrum matches  
PTM post translational modification 
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qRT-PCR real-time reverse-transcription PCR 
RBP4 retinol binding protein 4  
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REP HEK293T-DV-Rep 
RNA ribonucleic acid 
RP reversed-phase  
rpm revolutions per minute 
RT reverse transcription 
RTemp room temperature 
RT-PCR     reverse transcription PCR 
sec second(s) 
SEC61 protein transport protein Sec61  
SERPINA1 alpha-1-antitrypsin 
SERPINA5 protein C inhibitor  
SERPINC1 antithrombin III 
SERPIND1 heparin cofactor II 
SERPING1  C1 inhibitor 
SFM serum free media 
SILAC Stable Isotope Labelling by Amino acids in Cell culture  
shRNA short hairpin RNA  
siRNA small interfering RNA 
sNS1 secreted nonstructural protein 1 
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STAT3 signal transducer and activator of transcription 3 
STRING Search Tool for the Retrieval of Interacting Genes/Proteins  
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TG triglycerides  
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TMT Tandam Mass Tag 
TRX thioredoxin  
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UBE1 ubiquitin-activating enzyme E1  
UP Uniport 
UPR unfolded protein response  
UPS ubiquitin proteasome system 
UTR untranslated region 
V volts 
VDAC1 voltage-dependent anion channel 1  
v/v volume/volume 
VLDL very low density lipoproteins 
WHO      World Health Organization  
WNV      west Nile virus  
WS warning signs 
XRCC5 X-ray repair cross-complementing protein 5  
w/v weught/volume 
YFV yellow fever virus  
ZIKV Zika virus  
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 GE N E R A L I NT R OD U C T I ON  
 Dengue: Global impact and challenges  
 Global burden 
Dengue (DEN), a mosquito-borne disease caused by infection with dengue virus 
(DENV) serotypes 1-4, has been a major global public health problem for decades. Despite 
much effort to prevent infection and improve treatment, morbidity and mortality due to 
DEN is high and constantly increasing. The true burden of DEN is unknown. The most 
cited report estimates an incidence of 390 million DENV infected cases with 96 million 
symptomatic cases annually, worldwide (WHO, 2019; Bhatt et al., 2013). Among the 
symptomatic cases, ~22,000 deaths are reported annually, a mortality rate of ~2.5% (WHO, 
2019; Lam, 2013). However, this number was estimated in 2013 based on the official report 
cases which was believed to be only 8% of symptomatic cases (Stanaway et al., 2016).  
 Clinical spectrum of DEN disease 
DEN has a wide range of clinical presentations and complications as well as an 
unpredictable clinical course. The classic clinical course starts with high grade fever and 
non-specific symptoms lasting for 2-7 days during the “febrile phase”, followed by a 
“defervescence” or “critical phase” which usually lasts 24-48 h and a “recovery phase” 
(WHO, 2012) (Figure 1.1). In the febrile phase, patients have fever with two or more of the 
following symptoms and signs: headache, retroorbital pain, myalgia, arthralgia, rash, 
haemorhagic manifestations and/or leucopenia (WHO, 1997). However, some patients can 
present with fever with non-specific symptoms and signs. Dehydration (from fever and 
vomiting) and spontaneous bleeding can be found as complications in this phase. Following 
the febrile phase, fever abruptly subsides and most individuals recover, however some 
individuals enter a critical phase when plasma leakage and more severe complications may 
occur. In mild cases, fever disappears spontaneously without signs of plasma leakage and 
patients recover from illness with improvement of laboratory parameters. For other 
individuals, leakage of the intravascular volume to interstitial spaces results in a decreased 




and pleural effusion. Together with leakage, platelets and white blood cell count markedly 
decrease in this period. The severity of disease and the nature of complications during this 
phase varies. In the most severe case, patients suffer from shock, severe bleeding and 
multiple organ failures. The organ failures in this phase occur from both the direct 
pathology of DENV infection (Povoa et al., 2014) and as a result of shock and disseminated 
intravascular coagulopathy (DIC). In severe cases, the multi-organ failures which are a 
consequence of prolonged shock in the critical phase continues and congestive heart failure 
from fluid overload occurs. The vicious cycle of uncontrolled shock, multi-organ failure, 
DIC and bleeding finally leads to death. However, most individuals enter a recovery or 
convalescent phase, during which fluid reabsorbs back to the circulation and the laboratory 
parameters gradually improve.  Patients return to a normal appetite and might develop a 












Figure 1.1 The course of DEN illness.  
The classic clinical parameters and laboratory results of DEN disease progression can be 
divided in to three phases (febrile, critical and recovery phases). The body temperature (°C) 
and pulse rate (/min) are plotted in blue and red, respectively. In the febrile phase, the 
patient suffers from dehydration. The haematocrit (Hct) gradually increases and reaches a 
peak in the day that fever subsides when plasma leakage may occur. In contrast, platelets 
(Plt) decrease to the lowest level in the critical phase. Spontaneous bleeding may occur in 
the critical phase. After the critical phase which lasts 24-48 h, fluid reabsorbs into the 
circulation, the Hct decreases, Plt increases and the patient recovers. For diagnosis, DENV 
viremia and antigenemia can be detected in the febrile phase whilst the antibody response 





Moreover, the spectrum of disease ranges from asymptomatic infection, 
undifferentiated febrile illness, dengue fever (DF), dengue haemorrhagic fever (DHF) and 
dengue shock syndrome (DSS) as classified by the World Health Organisation (WHO) in 
1975 and 1997 (WHO, 1997) (Figure 1.2A). In 2009, the WHO announced a new 
classification scheme for DEN infection which divided clinical symptoms into DEN 
without warning signs (DEN w/o WS), DEN with warning signs (DEN w WS) and severe 
DEN (SD) (WHO, 2009) (Figure 1.2B). This classification scheme is very useful for 
patient triage in the resource limited countries. However, it might not reflect the true 
severity of leakage, which is the hallmark of pathogenesis and therefore may not be the 
best classification system for studies on the pathogenesis of disease. Furthermore, there 
have been increasing reports of unusual manifestations of DEN which were not previously 
included in the classification schemes. Thus, the WHO (regional office of South-East Asia) 
launched a new classification scheme in 2011 (WHO 2011) (Figure 1.2C). In brief, this 
definition used DF and DHF as in the 1997 scheme, but added a broader range of clinical 
signs including undifferentiated fever and expanded DEN, syndrome/isolated organopathy. 
Therefore, the major challenges of managing DEN clinically, are how to distinguish 
DEN from other febrile diseases which have the specific treatments and how to diagnose 











Figure 1.2 DEN case classifications. 
WHO DEN case classifications are summarised. (A) WHO 1975 and 1997 (B) WHO 2009 





 Gaps in clinical practice  
Due to the wide spectrum and complications of DEN, as well as limited therapeutic 
and preventative methods, there are many gaps in clinical practice that urgently require 
scientific investigation. According to a study modelling the natural history of DEN, only 
5% of those exposed to DEN has infection and one-fourth of them have symptoms 
(Shepard et al., 2004). An increased understanding of disease pathogenesis, especially in 
regards to the host factors contributing to disease, has the potential to improve methods to 
predict symptomatic cases and effectively prevent disease. 
For patients with febrile illnesses, distinguishing patients with viral syndrome 
(acute undifferentiated febrile illness; AUFI) and DF is difficult but necessary. In tropical 
areas, a number of other common febrile illnesses mimic DEN symptoms, including 
bacterial infections such as salmonellosis, leptospirosis, and rickettsiosis, which require 
specific antibiotic treatments (Luvira et al., 2019). Currently available diagnostic tests for 
DEN such as antigen and viral detection are only of use in the early phase of fever (before 
five days after onset) while there is no effective diagnostic test for patients who present in 
the critical phase of disease. Serology tests can be detected during/after the critical period 
but have a low sensitivity and need follow up convalescent specimens for confirmation. 
For patients with severe DEN that present clinically with shock and bleeding, it is difficult 
to distinguish DEN from severe forms of specific bacterial infections by clinical 
parameters, although the treatment of the two conditions are totally different. Thus, 
biomarkers for the diagnosis of DEN, especially in late phase of disease are still required. 
The most important problem in the management of DEN is that there are no tools 
available that physicians can use to predict those patients at risk of progressing to severe 
disease. The 2009 WHO classification of DEN w WS (Figure 1.2B), primarily aimed to 
identify potentially severe cases for management. However, the definition and criteria are 
not well defined and mostly subjective (Srikiatkhachorn et al, 2011). Moreover, 
Kalayanarooj (Kalayanarooj, 2011) reported that the application of guidelines of “warning 
signs” in children led to a two-fold increase in healthcare provider demand. In order to 




and care of patients whilst not overburdening the healthcare system, the identification of 
reliable biomarkers for predicting the severity of disease are urgently needed. 
Finally, there is no available specific treatment for DEN. Aside from developing 
antivirals, understanding the host response/s to DENV infection has the potential to 
improve therapeutic invention measures, as the major pathology of severe DEN results 











Figure 1.3 Spectrum of disease and gaps in clinical practice.  
The estimation of disease progression without vaccination (Modified from Shepard et al., 
2004) based on a modelling study using data from South-East Asia. The clinical challenges 





 Dengue virus (DENV) 
DENV is an enveloped virus belonging to the Flaviviridae family, genus Flavivirus. 
Using serological methods, DENV has been antigenically classified into four serotypes: 
serotypes 1-4. The Flaviviridae family can be classified into clusters based on vector: non-
vector (eg. hepatitis C virus; HCV), mosquito-borne, tick borne (eg. tick-borne encephalitis 
virus; TBEV) and viruses with no known vectors (Kuno et al, 1998; Daep et al., 2014). 
Flaviviruses of importance to human health in the mosquito-borne cluster include; yellow 
fever virus (YFV), Japanese encephalitis virus (JEV), West Nile virus (WNV), Zika virus 
(ZIKV) and DENV. Antigenic relatedness amongst flaviviruses results in serological 
cross-reactivity when testing for viral infections which circulate in the same geographic 
areas especially for DENV, ZIKV and JEV (Muller et al., 2017; Ngono and Shresta, 2018). 
Humans are generally a dead-end host for most flaviviruses, which circulate between 
arthropod vectors and mammalian or avian hosts. Sylvatic forms of DENV exist and are 
maintained in transmission cycles between non-human primate hosts and forest 
mosquitoes. However DEN outbreaks in humans arise from DENV strains maintained in 
human to mosquito transmission cycles which involve no intermediate hosts (Daep et al., 
2014). Aedes mosquitoes, including A. aegypti and A. albopictus are the major DENV 
vectors.  
 DENV particle and genome organisation 
The DENV particle (~ 50 nm in diameter) consists of an envelope and nucleocapsid 
which contains the RNA genome surrounded by the capsid (C) protein (Bartenschlager and 
Miller, 2008). The envelope consists of a host derived bilayer lipid membrane and an outer 
glycoprotein shell which is formed by 180 copies of the envelope (E) protein and precursor 
of membrane/membrane (prM/M) protein (Perera and Kuhn, 2009).  
 Similarly to other flaviviruses, DENV has a single–stranded positive sense RNA 
genome ~11 kilobases in size, which contains a single long open reading frame (ORF) 
flanked by 5′ and 3′ untranslated regions (UTR) (Figure 1.3). The ORF encodes a large 
polyprotein (~3400 amino acids) that is proteolytically processed into ten proteins and two 




prM and E and seven non-structural proteins (NS) including NS1, NS2A, NS2B, NS3, 
NS4A, NS4B and NS5. These proteins are multifunctional and play important roles in viral 
replication and the modulation of host cell processes. The known character and functions 
of each protein are listed in Table 1.1.  
 DENV structural proteins  
Capsid protein 
The DENV C protein is a 12 kDa homodimer which interacts with the RNA genome 
to form the nucleocapsid. It plays a role in DENV assembly and releases the genome after 
cell entry. It localizes in both nucleus and cytoplasm of DENV infected cells. In the 
nucleus, the C protein accumulates in nucleoli, whilst it is distributed between endoplasmic 
reticulum (ER) membranes and lipid droplets in the cytoplasm (Byk and Gamarnik et al, 
2016). The C protein has been found to interact with lipid droplets in both mosquito and 
human cell models as well as with very low density lipoproteins (VLDL) isolated from 
human blood (Faustino et al., 2014). 
prM/M protein 
 The prM/M protein stabilizes the E protein structure and prevents the E protein 
from prematurely fusing with host cell membranes. The prM protein is initially localised 
to the ER and interacts with the E protein to form a heterodimer in the immature virion. 
During release of the immature virus particle, prM is cleaved to pr and M by a cellular 
furin-like protease. The M protein is found on the mature virion (Cruz-Oliveira et al, 2014). 
The M protein has also been localised to the cell surface and can be found secreted as dimer 
and tetramer (Wong et al., 2012). Antibodies to prM (anti-PrM) have been proposed to 
precipitate antibody dependent enhancement (ADE) and therefore play a role in 
pathogenesis. 
E protein 
The E protein, a 53 kDa protein, consists of three domains (Cruz-Oliveira et al., 
2014). In the immature virion, the E protein is found as a prM-E heterodimer on the surface. 
After cleavage of the prM protein, the E protein rearranges to form a dimer in the mature 




is the dimerization domain, and plays a role in the fusion of the viral particle with cellular 
membranes during the viral entry process. The third domain, DIII has an immunoglobulin-
like structure and is more exposed on the surface of virus.  
The E protein is important in viral attachment and membrane fusion during viral 
entry. DIII is the attachment site or receptor binding site, while DII mediates rearrangement 
of E into a trimer which forms a fusion pore between virus and host cell membranes (Modis 
et al., 2004). Moreover, glycosylation of the E protein on Asn-67 or -153 plays a role in 
viral –host cell attachment. As the E protein mediates attachment of the virus particle to 
the host cell, it is a major target for drug development and neutralizing antibody studies 












Figure 1.4 Structure of the flavivirus genome and brief functions of the structural and 
non-structural proteins.  





Table 1.1 Summary of DENV proteins 
Structure Localization  Functions 
C protein  Nucleoli and 
cytoplasm, virus 
particle 
Packaging and protection of the viral genome 
E protein Lumen of ER, virus 
particle  
Viral attachment and membrane fusion in 
viral entry, major antigen 
PrM/M 
protein 
Pr- lumen of ER 
M-transmembrane 
protein, virus particle 
Prevention of premature fusion 
NS1 Intracellular NS1-
lumen of ER, cell 
surface, 
secreted NS1- sera 
Intracellular NS1: co-factor for viral 
replication  
Secreted NS1: virulence factor 
NS2A Transmembrane 
protein 
Part of the replication complex , assembly 




Cofactor for the protease domain of NS3  
NS3 Cytoplasm Enzyme for viral replication: protease, 
helicase and NTPase 
NS4A Transmembrane 
protein 




Part of replication complex, an antagonist of 
host IFN signalling 
NS5 Cytoplasm Enzyme for viral replication: 
methyltransferase and RNA polymerase, an 





 DENV non-structural proteins  
NS1 protein 
The NS1 protein plays important roles in viral replication and as a virulence factor. 
It is a 45 kDa glycoprotein, found in multiple oligomeric forms and can be detected in 
multiple locations in the infected cell (Muller and Yong, 2013). The NS1 protein is divided 
into three domains: a “β roll” domain, a “wing” domain and a “β-ladder domain”.  
Intracellular NS1 forms a dimer which is found in the ER lumen and on the cell surface 
(Akey et al., 2015). Whilst, secreted NS1 (sNS1) is a lipid associated hexamer.  
Intracellular NS1 is co-factor for viral replication while sNS1 plays a major role in 
immune associated pathogenesis. There are two glycosylation sites in NS1, at Asn-130 and 
Asn-207 and twelve conserved cysteine (Cys) residues. Interestingly, sNS1 circulates in 
the sera of acute DENV infected patients. Circulating sNS1 and antibodies recognising it 
are used in diagnostic tests. Moreover, sNS1 is a target for antiviral and vaccine 
development (Muller and Yong, 2013).  
NS2A protein 
The NS2A protein is a small hydrophobic protein (~22 kDa in size) which has 
multiple functions. It facilitates the viral replication and assembly processes and is involved 
in virus-induced membrane formation (Idrees and Ashfaq, 2012). Moreover, NS2A can 
inhibit interferon-β. NS2A can be found in cytoplasm of DENV infected cells.  
NS2B protein 
NS2B, a 14 kDa hydrophobic protein, is required as a cofactor for the protease 
function of the NS3 protein (described in more detail below) (Idrees and Ashfaq, 2012). 
NS3 protein 
The NS3 protein a ~70 kDa protein, contains two domains which have protease and 
helicase activity. These two viral enzyme activities are essential in many viral processes 
involved in viral replication and virus infectivity. NS3 is a conserved viral protein which 





The serine protease domain, encompassing the N-terminal 180 amino acid residues, 
forms a complex with NS2B. The main function of the NS2B-NS3 serine proteinase is to 
cleave the viral polyproteins at multiple sites internal sites including; C-Canchor NS2A-
NS2B, NS2B-NS3, NS3‑NS4A, NS4A-2K, NS4B-NS5 and within NS3 itself (Luo et al., 
2008).  Whilst host furin and signalase proteases cleave the remainder of the viral 
polyprotein at the Canchor-prM, pr-M, prM-E, E-NS1, NS1-NS2A and 2K-NS4B 
junctions. Moreover, the NS2B-NS3 proteinase influences the enzymatic activity of the 
helicase domain (Perera and Kuhn, 2008).  
The C-terminal domain (residues 181-618) of NS3, contains 3 subdomains and 
possesses RNA helicase/NTPase/RTPase activities. The NS3 helicase is essential for 
RNA binding.   Moreover, the helicase domain was found to be involved in DENV viral 
assembly.  
NS4A protein 
The NS4A protein is a 16 kDa transmembrane protein that forms part of the 
replication complex. NS4A can induce ER hypertrophy and the unfolded protein response 
(UPR) (Guzman and Harris, 2014). NS4A is found in the cytoplasm of infected cells and 
colocalizes with double-stranded RNA.  
NS4B protein 
NS4B, is a 27 kDa integral hydrophobic membrane protein, which has been found 
to interact with many viral proteins including; NS1, NS2B, NS3 and NS4A in order to 
regulate viral RNA replication (Xie et al, 2015). In addition, NS4B is involved in 
antagonising the IFN response by acting to inhibit phosphorylation of signal transducer 
and activator of transcription 1 (STAT1), preventing downstream signalling and has also 
been shown to potently suppresses RNA interference (RNAi) (Xie et al, 2015). As such, 
NS4B is a major target for anti-DENV drug discovery.  
NS5 protein 
The NS5 protein is the largest and most highly conserved DENV protein, it is ~ 
104kDa in size and contains 900 amino acid residues. It has two domains. The N-terminal 




domain contains RNA polymerase activity (Perera and Kuhn, 2009). The MTase activities 
are required for capping of the viral genome whilst the RNA dependent RNA polymerase 
activity of NS5 plays a key role in RNA replication. The NS5 protein has been shown to 
localise to the nucleus in a serotype specific fashion (Hannemann et al., 2013). NS5 also 
plays an important role in inhibiting the IFN response as it binds to STAT2 and targets it 
for proteasomal degradation (Ashour et al., 2008; Mazzon et al., 2009). 
 DENV life cycle 
After infection, DENV enters the host cell and uses the host machinery to produce 
new virus particles. The processes are virus attachment and entry, viral replication, and 
viral maturation and release (Figure 1.5). 
 A number of cell surface receptors have been identified to bind the DENV particle 
including; heparan sulfate, mannose receptor, dendritic cell-specific intercellular adhesion 
molecule-3-grabbing non-integrin (DC-SIGN), heat shock protein (HSP) 90/HSP70, 
macrophage Fc receptor, endoplasmic reticulum chaperone BiP (HSPA5) and CD14  
(Cruz-Oliveira et al., 2015). After viral attachment, the virus is taken into the cell by 
receptor-mediated endocytosis followed by fusion of the viral membrane with that of the 
endosome to mediate virus release. These processes are mainly mediated by the E protein 
and triggered by acid pH as the endosome becomes acidified (Rodenhuis-Zybert et al., 
2010). After that, the DENV genome is uncoated and translated in association with 
perinuclear ER membranes. The viral non-structural proteins induce changes to the host 
ER morphology to form a virus induced membrane enclosing the viral RNA and viral 
proteins, termed a “replication complex” (Welsch et al., 2009). Viral genome replication 
occurs in the replication complex via the formation of a negative strand RNA that is 
complementary to the viral genome. The negative sense RNA is used in turn, as a template 
for the production of new positive strand genomes that are either used for further rounds 
of translation and replication or are extruded from the replication complex to associate with 
the C protein to form a nucleocapsid. The nucleocapsid buds into the ER lumen, acquiring 
a lipid envelope containing the prM and E proteins. At the end of this process the immature 
virion is released from ER.  The immature virion consists of a nucleocapsid covered with 




then transits through the trans-Golgi network (TGN) where glycoprotein processing 
occurs. The slight acidity of the TGN triggers prM cleavage by a cellular furin-like protease 
to generate the mature particle (Rodenhuis-Zybert et al., 2010). When the mature virus 
particles are secreted, the pr peptide is released from the virions. However, for some virus 
particles processing is incomplete, resulting in a mixture of immature and the partially 
immature virions secreted from infected cells (Guzman et al., 2015) (Figure 1.5). The viral 
NS1 protein is initially translocated into the ER lumen where it is glycosylated and plays 
a crucial role in genome replication. However, it is also secreted from cells in a hexameric 
form. 
DENV modulates multiple host proteins and processes throughout its life cycle. 
The main cellular processes modified by DENV infection/replication are the unfolded 
protein response (UPR), ubiquitin proteasome system (UPS), lipid metabolism/autophagy 












Figure 1.5 DENV life cycle. 





Modulation and remodeling of ER structures during DENV replication and virion 
secretion results in ER stress (Blazquez et al., 2014). Activation of the UPR as a response 
to ER stress has been documented for many flaviviruses including DENV (Blazquez et al., 
2014). The interaction between misfolded proteins and HSPA5, stimulates the UPR 
response via three main ways: phosphorylation of protein kinase RNA-like endoplasmic 
reticulum kinase (PERK), cleavage of activating transcription factor 6 (ATF6) and 
phosphorylation of inositol-requiring enzyme 1 (IRE1). Moreover, there is crosstalk 
between the UPR and autophagy by PERK and IRE1 signaling pathways. Lee and co-
workers demonstrated an activation in PERK and IRE1 signaling pathways during early 
DENV infection whilst the ATF6 pathway was not found to be activated by DENV 
infection (Lee et al., 2018). In addition to reducing cellular stress in the infected host cells, 
the UPR is also required for DENV replication. Inhibition of PERK and IRE1 signaling 
pathways by shRNA transfection resulted in a decrease in the level of NS1 and autophagy 
markers as well as a reduction in viral titre (Lee et al., 2018). 
DENV replication involves lipid metabolism in many ways: host lipid droplets 
(LD) are used as an energy supply, the virus attaches and enters via lipid rafts and LDL 
receptors and hijacks the ER, the organelle used for cholesterol and fatty acid synthesis, to 
form the RC. In addition, the sNS1 hexamer has lipoprotein content (Fischl and 
Bartenschlager, 2011; Osuna-Ramos et al., 2018). Autophagosome formation was 
proposed to enhance DENV replication and prevent apoptosis of host cells (Orozco-García 
and Gallego-Gómez, 2016). Moreover, autophagic processes produce energy for viral 
replication by autophagy-dependent processing of LD, free fatty acids and triglycerides 
(Heaton and Randall, 2010).  
The UPS which involves regulated protein degradation is also stimulated during 
DENV replication. The UPS is required for the uncoating of a number of RNA viruses, 
including DENV, so it is a vital host process for viral replication (Byk et al., 2016). 
Blocking ubiquitin-activating enzyme E1 (UBE1) by a specific inhibitor was shown to 
block the step of viral uncoating (Byk et al., 2016) and caused a decrease in DENV protein 
synthesis and infectivity (Kanlaya et al., 2010). DENV infection also results in the 




is required for viral escape from the host innate antiviral response (Fischl and 
Bartenschlager, 2011).  
 Replicon 
Replicons are subgenomic viral RNAs that lack the genes encoding one or more of 
the viral structural proteins, whilst retaining key nonstructural genes required for RNA 
replication. Replicons are therefore capable of replication in permissive cells without the 
production of infectious virus particles. The introduction of genes into flavivirus replicons, 
encoding selectable markers in place of the structural genes, typically C-prM-E or prM-E, 
allows cells containing replicons (once introduced by transfection) to be selected and 
grown continually in the presence of the selection agent (Figure 1. 6). A number of studies 
have reported the production of DENV replicons and cell lines stably containing the 
replicons. Such cell lines have been demonstrated to be useful models for investigating 
viral replication and its effect on the host cell as well as for screening antiviral agents (Ward 






























 Dengue pathogenesis 
The pathogenesis of DEN is not completely understood and it is believed to be 
multifactorial (Martina et al., 2009). The hallmarks of severe DEN disease are an increase 
in vascular permeability, thrombocytopenia and coagulopathy which are believed to be 
immune mediated. Many factors are believed to play a role in pathogenesis including; host 
factors (genetics, age, underlying diseases and nutritional status), viral virulence factors 
(strains) and immune status (primary or secondary infection). 
 The virus - host interaction  
Initial infection to systemic infection 
 After the bite of a DENV infected mosquito, the first infected cells are skin 
dendritic cells, macrophages and mast cells. After that, a local inflammatory process, via 
natural killer cells (NK cells) and T-cells, clears the infection from the skin. A systemic 
infection starts after infected DENV cells are drained to the lymphatic system. A viremic 
stage occurs 24-48 h before the onset of symptoms (St John et al., 2013) and lasts for 4-5 
days after onset (range 2-12 days) (Gubler et al., 1981). 
Target cells 
The major target cells of DENV are monocytes, endothelial cells, liver cells, splenic 
macrophages, tissue macrophages and stromal cells of the bone marrow (Martina et al., 
2009). Moreover, DENV has been isolated from other organs such as the skin, lymph 
nodes, lungs, kidneys, thymus and brain (Martina et al., 2009). 
 Mechanisms of pathogenesis 
1.3.2.1 1.3.2.1 Antibody-Dependent Enhancement of Dengue (ADE) 
In a secondary DENV infection, a non-neutralising cross-reactive antibody 
response from a previous infection has been proposed to enhance infection. After primary 
DENV infection, patients are believed to have long term protection to that serotype due to 
the production of serotype-specific neutralising antibodies. However, the cross reactive 
antibodies are believed to be a key factor in the development of severe disease during a 




Halstead et al. as antibody-dependent enhancement of DEN or ADE (Halstead, 1979; 
Halstead et al.,1980; Alan L Rothman, 2011). ADE occurs when a cross reactive antibody-
virus complex binds to a Fc receptor on a suitable target cell (monocytes, macrophages and 
others) leading to enhanced uptake of the virus and infection. This in turn leads to an 
increase in the secretion of vasoactive cytokines and vascular mediators from these cells 
or cells that recognise them (T-cells) during infection.  
The antibodies which play major roles in ADE are anti-E and anti-prM antibodies. 
Although antibodies to highly conserved regions of the E protein have high serotype 
specificity and neutralising ability, antibodies to other parts of the E protein are cross 
reactive and induce ADE (Guzman and Harris, 2015; Rothman, 2011). During the process 
of viral assembly, some immature virions are released from cells. Antibodies to the prM 
protein can enhance the entry of immature virions in secondary DENV infection (Rothman, 
2011). 
 
1.3.2.2 1.3.2.2 Cell mediated immunity 
B cells clearly play a major role in DEN pathogenesis via antibody production; 
however, the role of T cells in preventing and contributing to disease is still unclear 
(Malavige and Ogg, 2013). CD8+ T cells are believed to play a more important role in 
DENV protection than CD4+ T cells (Ngono and Shresta, 2018). CD8+ T cell responses are 
directed against epitopes in the NS3, NS4B, and NS5 proteins while CD4+ T cells target 
epitopes in the C and E proteins as well as sNS1 protein (Rivino, 2018). It has been 
proposed that cross reactive memory T cells from a prior DENV infection have an effect 
on the severity of DENV infection via the secretion of pro-inflammatory and 
immunosuppressive cytokines including IFN-ɤ, TNF-α and IL-13 (Malavige and Ogg, 
2013; Martina et al., 2009). The ineffective T cell response during a secondary infection 
due to stimulation of a response to prior DEN infection has been described as “original 
antigenic sin” (Mongolsapaya et al., 2003). However, there is evidence that activated 
DENV-specific CD8+ T cells can produce antiviral effectors in acute DEN (Rivino et al., 
2015). Thus, to date, the consequence of “original antigenic sin” is unclear whether it is 




(Rivino, 2016).  Furthermore, HLA alleles were reported to have effect on the extent of 
both the CD4+ and CD8+ T cell responses (Weiskopf and Sette, 2014). 
 
1.3.2.3 1.3.2.3 Autoimmune response 
Thrombocytopenia caused by cross reactivity of antibodies to the NS1 protein with 
human platelets and plasma leakage caused by cross reactivity of those autoantibodies with 
endothelial cells (Lin et al., 2016) has been reported and may also play a role in 
pathogenesis. Supporting evidence is the similarity of the protein structure of the DENV E 
and NS1 proteins and human coagulatory molecules (Lin et al, 2011). Furthermore, Lin et 
al. showed that the levels of antibodies to NS1 in DHF/DSS cases were significantly higher 
than those in DF cases and could induce endothelial apoptosis (Lin et al., 2004).  
 
1.3.2.4 1.3.2.4 NS1 
The NS1 protein has been proposed as a key virulence factor in DEN pathogenesis. 
There is a high level of secreted NS1 in early DENV infection which has been correlated 
with disease severity (Libraty et al., 2002; Aviruntnan et al., 2006). Furthermore, a higher 
titre of anti-NS1 antibody was found in severe acute secondary DEN infection compared 
with non-severe cases (Jayathilaka et al., 2018). In addition to its role in viral replication, 
NS1 has been well characterised to activate the complement cascade followed by the 
induction of proinflammatory cytokines. Furthermore, Aviruntnan et al. (Aviruntnan et al., 
2006) demonstrated NS1 purified from the supernatants of DENV infected cells could also 
activate complement.  Furthermore, binding of NS1 with prothrombin resulted in the 
inhibition of prothrombin activation and a prolonged activated partial thromboplastin time 
(APTT) (Lin et al., 2012). More recently, NS1 from all DENV serotypes has been shown 
to directly increase human pulmonary microvascular endothelial cell permeability in vitro 
(Beatty et al., 2015; Modhiran et al., 2015).   
One theory alone cannot explain all aspects of DEN pathogenesis and most studies 
have been based on in vitro studies or the use of mouse models which do not fully 




 Treatment and Prevention of DEN 
 Treatment 
Treatment of DEN basically relies only on good supportive care; close monitoring 
and fluid resuscitation as well as treatment of complications such as bleeding and shock. 
Proper volume evaluation and resuscitation is the key treatment for case of shock;  
inadequate volume replacement in the leakage stage results in prolonged shock and leads 
to organs damage while over-replacement of fluid can lead to fluid overload in the recovery 
phase. Many compounds have been shown to have promising antiviral properties in vitro 
but were not effective at suppressing DENV replication in clinical trials (Low et al, 2017). 
To suppress the immune response associated with DEN, many anti-inflammatory drugs 
such as corticosteroid and statins (3-hydroxy-3-methyl‑glutaryl coenzyme A (HMG-CoA) 
reductase inhibitors) have been tested in clinical trials, but all failed to improve the outcome 
of disease (reviewed in Chan and Ooi, 2015)  
There are many ongoing in vitro studies aiming to identify drugs that target DENV 
entry/fusion and/or the E glycoprotein, which play a key role in viral attachment (Guardia 
and Lleonart, 2014). Examples of these agents include DN59 (a fusion inhibitor, E protein 
stem and E trimer binder) and tetracycline derivatives such as doxycycline and 
rolitetracycline (fusion inhibitors and E protein hydrophobic pocket binder). Celgosivir, an 
alkaloid castanospermine, inhibits ER-associated α glucosidase causing E, prM and NS1 
protein misfolding during maturation and glycosylation of these proteins. Despite a 
successful inhibitory profile in vivo using a mouse model, a Phase Ib clinical trial of 
celgosivir in DEN patients showed no difference in virological reduction and clinical 
parameters between treatment and placebo groups (Low et al., 2014) 
Other direct-acting antiviral agents have been developed that target NS3 (both 
helicase and protease inhibitors), NS4B and NS5. Among these, only Balapiravir which is 
an NS5 polymerase inhibitor was trialled clinically. Although Balapiravir was able to 
inhibit replication of all serotypes of DENV in vitro, it failed to decrease viremia and NS1 





DEN surveillance and vector control have been applied as a public policy in all 
endemic areas; however, the increase in prevalence of DEN reflects the failure to control 
the spread of DENV and requires urgent development of other preventive methods. DEN 
vaccines have been in development for decades and the first licenced DEN vaccine was 
launched in 2015.  
CYD-TDV (Dengvaxia®) is a recombinant live-attenuated vaccine containing the 
yellow fever 17D vaccine virus backbone chimerized with the prM and E proteins from 
DENV 1-4. Three doses of a live attenuated tetravalent vaccine at 0, 6 and 12 months 
showed an efficacy of 56.5% and 60.8% in phase III trials in Asian and Latin American 
children, respectively (Capeding et al.,2014; Villar et al., 2015). However, the efficacy is 
serotype-specific; 50.3% for serotype 1, 42.3% for serotype 2, 74.0% for serotype 3, and 
77.7% for serotype 4 (Villar et al., 2015). Unfortunately, post-marketing reanalysis of data 
associated with the trials revealed a higher risk of more severe DEN and hospitalizations 
among the subgroup of vaccinated children with no prior DEN infection (Sridhar et al, 
2018). It has been hypothesised that CYD-TDV acts similarly to a primary infection for 
DEN naïve children, so they become prone to the development of more severe disease in 
natural infection from ADE.  
A number of other vaccine candidates are in phase III clinical trials including; 
TV003/TV005 and DENVax.  The TV003/TV005 vaccine candidate is a live attenuated 
tetravalent vaccine developed by deletion of 30 nucleotides from 3´ UTR of DENV-1, 
DENV-3 DENV-4, and a chimeric DENV-2/DENV-4 (rDEN1Δ30, rDEN3Δ30/31, 
rDEN4Δ30 and rDEN2/4Δ30) (Whitehead, 2016). In DENVax, the prM and E genes of an 
attenuated DENV-2 strain PDK-53, has been replaced with the prM and E genes of other 
serotypes (DENV-2/-1, -2/-3, and -2/-4 chimeras). Other vaccine approaches in early 
clinical phase development include an inactivated vaccine (purified formalin-inactivated 
virus; PIV), DNA vaccines (monovalent DENV-1 and tetravalent prM/E), a subunit 




 High throughput proteomic techniques to identify changes in host 
protein amounts 
 Discovery proteomics 
Mass spectrometry (MS) based proteomics can be classified into “Discovery” or 
“Shot gun” based strategies and “Targeted” strategies. The goal of discovery-based 
proteomics is the identification and possible quantitation of as many proteins as possible 
whilst targeted proteomics aims to identify and monitor a selected number of target proteins 
(Doerr, 2013). Thus, discovery proteomics is a popular method for identifying candidate 
biomarkers before developing targeted proteomic methods for clinical diagnosis. A 
challenge of discovery proteomics is the validation of candidate biomarkers and to translate 
the results so they can be used clinically (Harlan and Zhang, 2014).  
 Discovery proteomics can be divided into “bottom-up” and “top-down” 
approaches. In bottom-up proteomics, proteins are digested into peptides using specific 
proteases before identification and quantitation by MS, simplifying analysis. On the other 
hand, top-down proteomics involves direct analysis of intact proteins, which provides more 
data on protein isoforms and post-translational modifications (PTM) (Hung and Tholey, 
2012) 
 Quantitative proteomics 
Many proteomic techniques can be used to quantify proteins by MS. The traditional 
approach has been to use 2D SDS-PAGE to identify differentially expressed proteins, 
before excision of protein spots of interest, followed by protein identification by MS. 
Although this method can provide information on PTMs, it is limited in its reproducibility 
and the low dynamic range of detection (Rhea et al., 2010).  
For high-throughput analysis, peptides/proteins can be relatively quantified by 
stable isotope labelling. There are many stable isotope labelling techniques with different 
advantages and limitations. The Stable Isotope Labelling by Amino acids in Cell culture 
(SILAC) is the method of choice for in vivo labelling of cells in continuous cell culture; 
however, SILAC cannot be used to analyse clinical specimens such as sera and body fluids. 




Isotope Tags for Relative and Absolute Quantitation (iTRAQ) are commonly used in vitro. 
The use of ICAT can reduce the complexity of the sample and variation, but there is a 
selective detection of proteins containing high cysteine amounts and there are limitations 
on the detection of acidic proteins. The use of iTRAQ has the advantages that four - eight 
specimens are analysed in the same run and internal controls can be included, but the need 
for enzymatic digestion and fractionation before MS analysis makes the sample preparation 
more complex (Rhea et al., 2010). 
The advance stable isotope labelling, tandem mass tags (TMT) was first invented 
by Thompson and team (Thompson et al., 2003). The use of isobaric tags means that 
identical TMT labelled peptides from different samples have an equal mass and coelute 
better in chromatography fractionation steps compared to previous techniques which use 
heavy/light isotope labelling. TMT labelling also results in the detection of peptides with 
a high sensitivity and reproducibility compared to other stable isotope labelling techniques. 
TMT can be used for both in vitro analysis and to analyse clinical specimens. Moreover, 
up to 11 samples can be analysed in one run and internal standards included to normalise 
between runs. 
 Role of the “Proteome” and “Secretome” in biomarker 
identification 
 Proteomic analysis of DENV infected cells 
A number of studies have reported the proteomic analysis of DENV infected cells 
in order to identify host cell proteins that are modulated in response to infection. Such 
studies have the potential to increase our understanding of pathogenesis and also to identify 
biomarkers and targets against which therapeutic agents can be developed. Previous 
proteomic studies have been performed using various cell lines and different proteomic 
techniques and are summarised in Table 1.2.  
Many interesting host proteins and important biological processes were identified 
to be dysregulated during DENV infection by pathway analysis; however, much still needs 
to be done to identify key proteins involved in DEN pathogenesis and to identify 




the results obtained from the proteomic analysis of in vitro and in vivo samples, in order to 





Table 1.2 Summary of cellular proteome studies. 
 
 











No. and important** 
differential expression 
proteins (DENV/mock) 
























7: vinculin 2D WB:  
EF-Tu, vinculin 
Upregulated -transcription 
and translation processes 



































cellular metabolism  





















































































Upregulated - endocytosis 
system  Downregulated- 
molecular chaperone 


















































NA Downregulated - 
glycolytic pathway, citrate, 
and pyruvate metabolism 




















































 -Nuclear: cell cycle  
-Cytoplasm: positive 
regulation of cell 
cytokinesis, ER membrane 
Martínez-

















































































RNA splicing and 
processing, immune 
system, cellular response 














* detected in only DENV infected cells 
**Proteins that were focused and /or discussed in the studies 
IPA=Ingenuity pathway analysis, EF =elongation factor, PRP4=Pre-mRNA processing factor 4 homologue, Alix= apoptosis-linked gene-2-interacting protein X, 
UBE1= ubiquitinactivating enzyme E1, MxA= interferon induced Mx protein, GSS=glutathione, TrxR1= synthetase thioredoxin reductase 1, Prx1=peroxiredoxin 
1, PYCR1= pyrroline-5-carboxylate reductase 1, mitochondrial, GRP78= glucose-regulated protein 78, EIF= eukaryotic initiation factor, hnRNPH1= 
heterogeneous nuclear ribonucleoprotein, HSP= heat shock protein, PDIA3= Protein Disulfide Isomerase A3, HSPA5= Endoplasmic reticulum chaperone BiP, 
HYOU1= hypoxia up-regulated protein 1, CDK=cyclin dependent kinases, CCNB1=cyclin B1, AURK= aurora kinases, PA2G4= proliferation-associated protein 
2G4,  ZRANB2=zinc finger Ran-binding domain-containing protein 2, HMGA1= mobility group AT hook1, PREB =prolactin regulatory element binding protein, 
HDAC1= histone deacetylase 1, GRB2= growth factor receptor-bound protein 2, BID= BH3 Interacting Domain Death Agonist, SAP18= Sin3A Associated Protein 





 Secretome analysis of DENV infected cells 
In terms of cell models of infection, the secretome consists of both pathogen and 
host cellular proteins secreted in response to infection and may include; virulence factors 
encoded by the pathogen, intracellular processes (pathogens’ and cellular enzymes), 
proteins involved in cell-cell signal transduction (cytokines and chemokines), as well as 
host immune components (antibodies) (Ranganathan and Garg, 2009; Cao et al., 2011). 
The use of high-throughput proteomics to investigate the cellular secretome in response to 
virus infection potentially provides knowledge that can be used to gain a deeper 
understanding of pathogenesis and hopefully leads to the identification of proteins that can 
be used clinical as biomarkers or can be targeted to develop new treatments/vaccines 
(Ranganathan and Garg, 2009). 
There have been only two studies investigating the changes in the cellular 
secretome in response to DENV infection. A study by Higa and colleagues (Higa et al., 
2008) used 1D SDS-PAGE and liquid chromatography (LC) coupled with tandem MS 
(MS/MS) to characterise the secretome of DENV-2 infected human HepG2 liver cells. The 
proteins that were identified and analysed focused in this study were α-enolase (ENO1), 
superoxide dismutase (SOD), peptidyl-prolyl isomerases A and B (cyclophilins A and B), 
tissue inhibitor of metalloproteinases 1 and 2 (TIMP-1 and 2) and macrophage migration 
inhibitory factor (MIF) (Higa et al., 2008). A second study was also done on DENV-2 
infected HepG2 cells using two different proteomic approaches: tryptic digestion of 
proteins followed by bottom up MS analysis and top down MS analysis of whole intact 
proteins strategies (Caruso et al., 2017). The dual analysis identified 175 proteins; 57, 59 
and 59 proteins were detected only in mock infected cells, DENV-2 infected cells and both 
cell types, respectively. The study focussed on proteins identified to play a role in 
proteolytic processes and identified inter-alpha-trypsin inhibitor (heavy chain H2) and 
ADAM10 only in the secretome of mock infected cells whereas tissue factor pathway 
inhibitor (TFPI), neurotrypsin and trypsin were only identified in the secretome of DENV-




Thus, more studies examining the secretome of DENV infected cells are needed in 
order to better understand the host response to viral infection and determine if DENV 
infection dysregulates cellular secretion. 
 Biomarkers: a new hope from translation medicine 
Currently, there is no reliable biomarker available to predict whether DEN patients 
in the early phase of disease will progress to severe disease. Furthermore, reliable tests to 
diagnose patients with DEN after the viremic phase need to be improved. Biomarkers 
proposed for purely diagnostic use and to predict disease severity can be divided into a 
number of categories; viral markers, immune activation markers, coagulation and 
endothelial activation markers, other soluble factors, biochemical markers and host genetic 
markers (Srikiatkhachorn and Green, 2010; Yacoub et al 2014; John et al., 2015).  
Biomarkers currently used in clinical practice for distinguishing DEN from other 
febrile illness (AUFI) include; NS1 a surrogate of viremia and clinical laboratory markers 
such as liver function tests, the percentage of atypical lymphocytes and platelet count 
(Luvira et al., 2019). Low white blood cell count, low levels of C-reactive proteins (CRP) 
and procalcitonin were also proposed as a biomarkers to diagnose viral infection, mainly 
DEN, from other bacterial infections in tropical areas (Wangrangsimakul et al., 2018). 
Biomarkers proposed for predicting disease severity in the early febrile phase 
include; viral markers (NS1) and IFNα (Srikiatkhachorn and Green, 2010). High levels of 
NS1 and anti-NS1 antibody as well as high viral loads have been proposed as markers of 
disease severity (Jayathilaka et al., 2018, Vaughn et al., 2000). However, decreased levels 
of NS1 reported in secondary DENV infection (de la Cruz-Hernandez et al., 2013) might 
limit its usage as a biomarker. Moreover, a higher level of viremia in DF compared with 
DHF has been reported (de la Cruz-Hernandez et al., 2013). Elevated levels of CRP have 
also been proposed as marker of DSS in the early febrile phase (Chen et al., 2015). 
Biomarkers proposed in late febrile phase include i) cytokines such as IL-10, CXCL3, 
complements C3a and C5a, ii) soluble receptors including TNF-α receptor, IL-2 receptor, 
vascular endothelial growth factor (VEGF) and soluble CD4+/CD8+ T-cells iii) endothelial 




thrombomodulin, IL-8, intercellular adhesion molecule (ICAM)-I and vascular cell 
adhesion molecule (VCAM)-I as well as vascular endothelial growth factor (VEGF) 
(Srikiatkhachorn and Green, 2010; Yacoub et al 2014). The levels of specific serum 
lipoproteins have also been proposed as useful predictors of DEN severity but racial and 
age differences need to be taken into account (Lima et al., 2019). 
However, at the present time there are no universal biomarkers to predict DEN 
disease severity and there are conflicting results amongst the studies that have been 
undertaken. Many factors need to be taken into account in studies aiming to identify 
biomarkers and translate them clinically; for example, variation between serotypes, host 
factors (race, age and sex) and immune response (Yacoub et al., 2014) as well as the 
specimen type (serum or plasma) and methods of testing (Srikiatkhachorn and Green, 
2010). Furthermore, the timing of specimen collection is an important factor that affects 
the results; thus, biomarkers should be examined by the time of defervescence, instead of 
at the onset of fever (Srikiatkhachorn and Green, 2010). Ideally, sequential sample 
collections are needed for a better understanding of predictive biomarkers (Srikiatkhachorn 
and Green, 2010). Hopefully, the study of host proteins that are modulated in response to 
DENV infection, both in vitro and in vivo, will facilitate biomarker discovery.   
 Proteomic analysis of serum/plasma from DEN patients. 
A number of researchers have used LC-MS/MS based approaches to identify 
potential biomarkers of SD. However, the studies used different methodologies leading to 
different results. Fragnoud and colleagues (Fragnoud et al., 2012) used Isotope Coded 
Protein Labeling (ICPL) coupled with MS/MS to analyse pooled sera from patients with 
SD and DF as well as healthy people, analysing five samples in each group. There were 
seven proteins identified that significantly increased or decreased in amount (>1.6 fold) in 
the sera from patients with SD compared to DF: (peroxyredoxin-2, vitamin D Binding-
Protein (VitDBP), afamin, fibronectin, leucine-rich alpha-2 glycoprotein 1 (LRG1), 
galectin 3 Binding-Protein, CRP and ferritin light-chain). The amounts of three proteins 
(VitDBP, LRG1, and ferritin light-chain) were validated by Western blotting and suggested 




excessive depletion of serum proteins might have been a limitation of the study. Another 
approach used discovery proteomics together with a nonparametric modeling pipeline 
(Brasier et al., 2012). Matrix Assisted Laser Desorption/Ionization/ Time of Flight MS 
(MALDI TOF/TOF) was used to analyse proteins from 42 DF and 13 DHF cases. The data 
obtained was then combined with clinical data relating to the samples, leading to the 
analysis of two cytokines and 42 proteins by multivariate adaptive regression splines 
(MARS) to assess their potential as biomarkers. The most accurate model that correlated 
with 100% of DHF cases, was based on IL-10, C4A, fibrinogen, tropomyosin, 
immunoglobulin G and three isoforms of albumin (Brasier et al., 2012). This complicated 
model still requires verification in a large sample size. Kumar and colleague’s (Kumar et 
al., 2012) sequentially examined patient sera sampled during the course of disease using 
Quadrupole Time-of-Flight (Q-TOF) LC-MS. Samples from 44 DF and 18 DHF cases, 
collected at three time points during infection for each patient (early febrile, defervescence 
and convalescent phase) were examined. Multiple statistical methods were then used to 
classify a subset of markers for DHF prediction. The elevated acute phase proteins which 
were observed from this study were CRP, serum amyloid A2, haptoglobin, alpha-2 
macroglobulin and ferritin (Kumar et al., 2012). The use of pooled sera might be a 
limitation of this study. 
 Aims of the project 
 The OVERALL AIM of this project is to use high-throughput proteomics to 
analyse the cellular proteome and secretome of DENV infected cells and patient sera to 
conduct combined proteomic/secretome analysis and sera proteomic analysis in response 
to DENV infection. 
Specific Aims 
1) To analyse the proteome and secretome of DENV infected human 
HEK293 and Huh-7 liver cells using high-throughput proteomics to identify proteins 
modulated in response to infection. 
2) To analyse the proteome and secretome of human HEK293 cells 




3) To analyse the results of a high-throughput analysis of clinical samples 
from DENV infected individuals to determine if changes in the abundance of specific 
proteins correlate with disease diagnosis and severity prediction. 
4) To determine whether DENV replication in cultured cells results in 
changes in the levels of secreted proteins that are also modulated in clinical samples from 





  M E T HOD  AN D  M AT E RIA L S   
 Cells and cell culture 
 Cells and cell culture 
Human hepatocellular carcinoma (Huh-7), human embryonic kidney (HEK293T) 
and HEK293T cells containing the DENV replicon DV-Rep-GP2A (HEK293T-DV-Rep-
GP2A (REP)) cells  (Masse et al. 2010), were cultured in Dulbecco’s modified Eagle’s 
medium (DMEM) (Lonza, Basel, Switzerland) supplemented with 10% heat-inactivated 
foetal bovine serum (FBS) (GibcoTM, Thermo Fisher Scientific, MA, USA), 100 μg/ml 
streptomycin and 100 U/ml penicillin (GibcoTM, Thermo Fisher Scientific), 0.1 mM non-
essential amino acids (NEAA) (GibcoTM, Thermo Fisher Scientific) and 2 mM L-glutamine 
(GibcoTM, Thermo Fisher Scientific). REP cells were maintained under 3.5 µg/ml 
puromycin (Sigma-Aldrich, Gillingham, UK) selection. All cells were maintained in a 
humidified incubator at 37 °C and 5% CO2. For serum free experiments, cells were grown 
in Pro293a-CDM serum free media (SFM) (Lonza) supplemented with streptomycin, 
penicillin, NEAA and 2 mM L-glutamine as described above. Vero cells, kidney epithelial 
cells isolated from an African green monkey, were cultured in Eagle’s medium M199 
(GibcoTM, Thermo Fisher Scientific) with 5% FBS at 37 °C in a humidified incubator with 
5% CO2. The C6/36 mosquito cell line isolated from Aedes albopictus (Igarashi et al., 
1978) was maintained in Leibowitz’s L-15 medium (Lonza) supplemented with 10% FBS, 
8% (v/v) tryptose phosphate broth (GibcoTM, Thermo Fisher Scientific), 0.1 mM NEAA 
and 2 mM L-glutamine. Cells were maintained in a humidified incubator at 28 °C with 
atmospheric CO2. 
To passage cells, the growth medium was removed before washing cells once with 
warm Dulbecco’s phosphate buffered saline (PBS) (Lonza). An appropriate volume of 
0.05% trypsin/EDTA (GibcoTM, Thermo Fisher Scientific) was added to cover the cell 
monolayer. The cells were incubated at 37 °C until they detached. The appropriate media 
was added and the cells collected by centrifugation at 150 g for 8 min before resuspension 
of the cell pellet in the appropriate media. Finally, the desired proportion of cells was added 




To seed cells for secretomes experiment, poly-D-lysine (PDL) (Sigma-Aldrich) 
diluted in PBS at the concentration of 0.1 mg/ml was coated to flask for 5 min before three 
times washing with PBS. 
As required for cell seeding, the cell number was counted using a haemocytometer. 
In order to assess the number of viable cells, 0.4 % (w/v) trypan blue (Sigma-Aldrich) was 
added in a 1:1 ratio. 
In some of the experiments performed, the following agents were added to media 
either before or after infection, as indicated. 
- Recombinant human IL-6 (R&D systems, Minneapolis, USA), prepared by dilution 
in 0.1% bovine serum albumin (BSA) (Sigma-Aldrich) 
-MG132 (Alfa Aesar™, Thermo Fisher Scientific), prepared by dilution in DMSO 
(Sigma-Aldrich).  
 Cell viability assay 
Cell viability was determined using a Vybrant MTT assay (InvitrogenTM, Thermo 
Fisher Scientific). Cells were seeded in PDL coated 96 well plates at a density of 30,000 
cells each/well and cultivated in DMEM with 10% FBS for 24 h. The supernatant was 
removed, the cells were washed three to five times with warm PBS, and then cultured in 
either Pro293a-CDM with 10% FBS or Pro293a-CDM SFM for either 30 h (Huh-7) or 48 
h (HEK293T). The media was then removed and replaced with 100 μl of either Pro293a-
CDM containing 10 % FBS or Pro293a-CDM SFM alone followed by the addition of 10 
μl of 12 mM MTT stock solution (Appendix A). The plate was incubated for 4 h before 
100 μl of SDS-HCl solution was added (Appendix A) and mixed well by pipetting. The 
plate was incubated for a further 4-6 h and mixed again by pipetting. The absorbance was 
then measured at 570 nm on a plate reader (SpectraMax 190 microplate reader, Molecular 
Devices, Silicon Valley, California, USA). The percentage of cell viability was calculated 
using the formula: 
cell viability (%) = (absorbance value of sample – absorbance value of blank) x 100  




 Cell culture supernatant preparation for secretome analysis 
Cells (~ 2.6E+06/ T25 flask) were then seeded into the PDL coated flasks and 
cultivated in the appropriate media (containing FBS) for 24 h until they were 60-80% 
confluent. The supernatant was then removed, and the cells were gently washed five times 
with warm PBS to remove all traces of serum. An appropriate volume of SFM was added 
to each flask. The supernatant was collected and centrifuged at 2000 g for 10 min to remove 
any cells. The supernatants were then concentrated ~ 40 fold using a 3 kDa cut-off 
Amicon® Ultra-4 Centrifugal Filter Unit (Merck-Millipore, Hertfordshire, UK) by 
centrifugation at 4,000 g for 45-50 min at 4 °C. The concentrated samples were then stored 
at -80 °C before analysis by either LC-MS/MS or Western blotting. The confluency and 
condition/morphology of the cells, as well as the final culture supernatant volume after 
concentration were recorded. 
  Virus growth, infection and assay 
 Virus infection conditions 
Huh-7 and HEK293T cells (including replicon containing) were grown either in T25 
flasks or on coverslips in a 24 well plate until ~ 60-80% confluent. The media was removed 
and cells were washed with warm PBS, which was then removed and replaced with the 
virus inoculum diluted to the required multiplicity of infection (MOI) in MEM (minimal 
essential medium (MEM) containing Earles salts (Lonza) supplemented with 2% FBS, 0.1 
mM NEAA and 2 mM L-glutamine). Heat inactivated virus was prepared by heating the 
same lot of virus at 55 °C for 1 h and then diluting to the same MOI. The flasks/coverslips 
were then incubated in a humidified incubator at 37 °C and 5% CO2 and gently rocked 
every 15 minutes. After 90 min, the inoculum was removed and the cells were gently 
washed five times with warm PBS, then cultured in either MEM maintenance medium or 
SFM at 37 °C and 5% CO2. The culture supernatants were harvested 30 h post infection 
(hpi) for Huh-7 cells and at 48 hpi for HEK293T cells. The supernatants were concentrated 
as described above. Cells were then washed twice with warm PBS. The cells were 
harvested using a cell scraper and stored at -80 °C. Cells grown on coverslips were analysed 




 Virus stock production 
DENV-2 strain New Guinea C (NGC) produced from the DENV-2 infectious clone 
pDVWS601 (Pryor  et al., 2001; Gualano et al., 1998) was used in this study. C6/36 cells 
were cultured in a T225 flask until they reached 80-90% confluence. The media was 
removed and cells were washed with warm PBS. DENV-2 stocks were diluted in L-15 
medium (L-15 medium supplemented with 2% FBS, 0.1 mM NEAA and 2 mM L-
glutamine) and added to the mosquito cell monolayer. Flasks with the viral inoculum were 
incubated in a humidified incubator at 28 °C with atmospheric CO2 for 90 min with gentle 
rocking every 20 min.  Additional L-15 medium was then added to each flask and further 
incubated at 28 °C with atmospheric CO2. 
 Culture supernatants containing virus were harvested when either the infected 
cells showed ~ 80% cytopathic effect (CPE) or 5-6 days after infection. The culture 
supernatants were clarified by centrifugation at 4000 g for 10 min followed by the 
addition of 1M HEPES pH 8.0 (GibcoTM, Thermo Fisher Scientific) to a final 
concentration of 25 mM. Culture supernatants were aliquoted and stored at -80 °C.  
 Virus immunofocus assay 
 Vero cells were seeded in PDL-coated 24 well plates and grown until 90% confluent. 
Tenfold serial dilutions of virus stock or cell culture supernatant were prepared in MEM. 
The growth medium was removed and the cells washed twice with PBS before 200 µl of 
virus diluent was added. The plates were incubated in humidified incubator at 37 °C with 
5% CO2 for 90 min and rocked intermittently. The virus inoculum was then removed and 
the cells washed twice with warm PBS before a 1:1 mixture of Avicell (RC-581; FMC 
Biopolymer) and 2X MEM (Appendix A) was added into each well. The plates were then 
incubated at 37 °C for 3-4 days, after which time the overlay medium was removed. The 
cells were washed twice with warm PBS and then fixed with cold methanol for 5 min. 
Subsequently, blocking solution (2% (w/v) skim milk powder in PBS) was added to the 
cells and incubated for 30 mins at room temperature (RTemp). The blocking solution was 
removed and then the cells were incubated with an in-house anti-DENV E (4G2) antibody 
diluted in blocking solution for 1 h at RTemp. The antibody solution was then removed 




a horseradish peroxidase (HRP) conjugated secondary antibody in blocking solution by 
rocking for 1 h at RTemp, followed by four 5 min washes in PBS. Finally, 200 µl of 
TrueBlueTM Peroxidase substrate (SeraCare Life Sciences Inc., Massachusetts, USA) was 
added into each well and the plates were incubated at RTemp until well-defined plaques 
were visible. The plaques were counted in each well (when not too numerous to count) and 
the viral titre was calculated as focus forming units (FFU)/ml (taking into account all 
dilution factors). All experiments were done in duplicate and the average viral titre 
reported. 
 50% Tissue culture infectious dose (TCID50) assay 
 Vero cells were seeded at a density of 1 x 104 cells/well into 96-well plates in 100 µl 
of Eagle’s medium M199/well. Tenfold serial dilutions of virus were prepared in MEM.  
Each dilution (100 µl /well) was added to 12 wells of the plate. Plates were incubated at 37 
C with 5% CO2 until CPE was observed. At this time, the number of wells positive and 
negative for CPE in a 96-well plate were recorded and used to calculate the TCID50 titre 
following the method of Reed and Muench (Reed and Muench, 1938). 
  Protein detection 
 Protein sample preparation 
Total cell lysates were prepared from adherent cells. The cell monolayer was 
washed twice with PBS. Following this, 2X sample buffer (~ 50 – 100 μl / 1 x 106 cells; 
Appendix A) was added to the cells, which were then detached using a cell scraper and 
transferred to a tube. This cell lysate was heated at 95 °C for 5 min and placed on ice 
before being passed through a 25-gauge needle. Lysates were either used immediately or 
stored at -80 °C until required for analysis. 
For co-immunoprecipitation (co-IP), adherent cells were washed twice with PBS. 
Co-IP lysis buffer (Appendix A) (1 ml/ 8x 106 cells) was added to the cell monolayer on 
ice and incubated for 5 min before the cells were detached with a cell scraper  and 
transferred to a tube. The lysate was incubated on ice for a further 30 min, before being 




finally transferred to new tube. Lysates were either used immediately or stored at -80 °C 
until required for analysis. 
Secretome lysates were prepared from cell cultured supernatants for proteomic 
analysis as described in Section 2.1.3. For Western blotting, the proteins in the culture 
supernatants were either concentrated by ultra-centrifugation or by trichloroacetic acid 
(TCA) (Sigma-Aldrich) precipitation. For TCA precipitation, the supernatants were 
centrifuged at 2,000 g for 10 min to remove cell debris and 100% (w/v) TCA added to the 
clarified supernatant to a final concentration of 20%. The solutions were mixed and 
incubated on ice for 1 h and then centrifuged at 17,000 g for 30 min at 4 °C. The resulting 
pellet was washed twice with 500 μl of ice-cold acetone, collecting the pellet by 
centrifugation at 10,000 g for 5 min at 4 °C each time. The pellet was air-dried and 
resuspended in 80 μl of 2X sample buffer before being heated to 95 °C for 5 min. The 
samples were either used immediately or stored at -80 °C until required for analysis.  
 Protein quantification (BCA Protein Assay) 
The protein concentration of all lysates was determined using a Pierce™ BCA 
Protein Assay Kit (Thermo Fisher Scientific), as per the manufacturer’s instructions. 
Briefly, BSA standards of known protein concentration and samples of unknown protein 
concentration were seeded in 96 well plates. A working reagent (Reagent A and Reagent 
B, 50:1) was made up and added to all wells. Plates were incubated at 37 °C for 30 min 
and absorbance at 562 nm of each well measured on a plate reader (SpectraMax 190 
microplate reader, Molecular Devices). The protein concentration in each sample was 
calculated by comparison to the standard curve produced using the BSA standards and 
taking into account any dilution factor. 
 Sodium Dodecyl Sulphate-Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
 Protein lysates were prepared by the addition of 4X Laemmli buffer (Bio-rad, 
California, USA) containing either 355 mM β-mercaptoethanol (BME) or 100 mM 
dithiothreitol (DTT) as reducing agents and heated to 95 °C for 5 min. Proteins were then 
separated by SDS-PAGE on 10% or 15% gels at 80-120 V in running buffer (Appendix A) 




Rad Power AC300, Bio-Rad) following the method of Laemmli (Laemmli UK, 1970). 
Protein molecular masses were estimated by omparison with a PageRulerTM Prestained 
protein ladder (Thermo Fisher Scientific) run in an adjacent well.  
 Coomassie blue staining 
Proteins in SDS-PAGE gels were detected by staining with a Coomassie Brilliant 
Blue R-250 staining solution for 1-2 h by rocking at RTemp (Appendix A). The gels were 
subsequently destained using destain solution for at least 4 h at RTemp (Appendix A). 
 SYPRO Ruby staining 
Proteins in SDS-PAGE gels were detected by staining with a SYPRO® Ruby 
(Molecular ProbesTM, Invitrogen, Thermo Fisher Scientific) dye staining solution 
according to manufacturer’s protocol. Briefly, gels were fixed in 100 ml of fix solution 
containing 50% methanol and 7% acetic acid for 30 min before overnight stained in 60 
ml of SYPRO Ruby dye by rocking at RTemp under cover to exclude from light. The gels 
were then transferred to a new container and washed twice with 100 ml of wash solution 
(10% methanol, 7% acetic acid) 30 min each by rocking at RTemp. Finally, the gels were 
scanned by TyphoonTM Variable Mode Imager (Amersham Biosciences, GE Healthcare, 
Buckinghamshire, UK) using ImageQuant™ Image Analysis Software. 
 Western blotting 
Sample preparation and SDS-PAGE were performed as described above except using 
a Precision Plus ProteinTM KaleidoscopeTM standard (Bio-Rad) as a marker. After 
electrophoresis was complete, the separated proteins were transferred from SDS-PAGE 
gels to a polyvinylidene difluoride (PVDF) membrane (GE Healthcare) using a Trans-Blot 
Semi-Dry Transfer Cell (Bio-Rad). Following electrophoresis, gels were equilibrated in 
transfer buffer (Appendix A) at RTemp. PVDF membrane was activated by subsequent 
soaking in methanol, water and transfer buffer.  
After the transfer was complete, the membrane was incubated in blocking solution 
(5% (w/v) skim milk powder in PBST (Appendix A) either for 1 h at RTemp or overnight 
at 4 °C. The membrane was then washed with PBST and incubated in a solution containing 




for either 1 h at RTemp or overnight at 4 °C. The antibody containing solution was removed 
and the membrane was then washed four times with PBST for 5 min each time. The 
membrane was then incubated with the appropriate secondary antibody (Table 2.2) diluted 
in 5% (w/v) skim milk powder or 5% (w/v) BSA in PBST for 1 h at RTemp before four 
washes with PBST each for 5 min. The membrane was drained and incubated for 1 min in 
LumiGLO® Chemiluminescent Substrate (Kirkegaard & Perry Laboratories, Inc, 
Maryland, USA). The membrane was drained, placed in a plastic envelope and transferred 
into an X-ray cassette with a sheet of X-ray film (Amersham HyperfilmTM ECL, GE 
Healthcare Limited) exposed to the membrane. The film was developed using a Compact 
X4 Automatic X-ray Film Processor (Xograph Healthcare, Gloucestershire, UK). 
Where necessary, membranes were stripped and reprobed with new antibody. To do 
so, used membranes were incubated in Abcam mild stripping buffer (Appendix A) for 5-
10 min by rocking at RTemp followed by two times washes with PBS each for 10 min and 






















27 Rabbit 1:1000 GTX103349 GeneTex 
Anti-DENV NS5 105 Rabbit 1:500 ----------- Dr A. Davidson 
Anti-DENV E 60 Mouse 1:500 ----------- Dr A. Davidson 
Anti-DENV E 60 Rabbit 1:500 NBP2-52666 Novus Biological (Bio-
Techne, Abingdon, UK) 
Anti-DENV prM 60 Rabbit 1:1000 GTX128092 GeneTex 
Anti-GAPDH   36 Rabbit 1:5000 GTX100118 GeneTex 
Anti-APOH 38 Mouse 1:200 sc-515677 Santa Cruz 
Biotechnology (Texas, 
USA)  
Anti-C4A 193 Mouse 1:200 sc-271181 Santa Cruz 
Biotechnology  
Anti-HSPA5 72 Rabbit 1:1000  ab108613 Abcam (Cambridge, UK) 
Anti-ERC1 128 Mouse 1:2000 ab50312 Abcam  
Anti-CALR 48 Rabbit 1:1000 ab92516 Abcam  
Anti-FGA 95 Rabbit 1:3000 ab92572 Abcam 
Anti-FGB 56 Rabbit 0.4 
µg/ml 
NBP1-90956 Novus Biological 






55 Rabbit 1:500 ab126598 Abcam 





Mouse 1:200 sc-8354 Santa Cruz 
Biotechnology  
Anti-VTN 54 Mouse 1:500 ab13413 Abcam 
Anti-APOA1 31 Rabbit 1:1000 ab52945 Abcam 
Anti-HNF4A 53 Rabbit 1:1000 ab92378 Abcam 
Anti-HP 45 Rabbit 1:1000 ab131236 Abcam 
Anti-APOC2 8, 12 Sheep 0.5 
µg/mL 
AF4497 R&D systems 
(Minneapolis, USA) 
Anti-DICER1 219 Rabbit 1:2000 NBP1-06521 Novus Biological 
Anti-HMGA2 12 Mouse 1:500 NBP2-43640 Novus Biological 












Goat anti-mouse IgG, HRP 
conjugated 
1:1000 12-349 Millipore-Merck 
(Burlington, USA) 
Goat anti-rabbit IgG, HRP 
conjugated 
1:5000 sc-2054 Santa Cruz 
Biotechnology  
Goat anti-rabbit IgG, HRP 
conjugated 






 Immunofluorescence assay (IFA)  
Cells were grown on glass coverslips which were coated with PDL (0.1 mg/ml in 
PBS) when appropriate. For each experiment the culture media was removed, the 
coverslips were washed twice with warm PBS and fixed by the addition of ice-cold 
methanol for 5 min.  The fixed cells were then allowed to air dry and either stored at -80 
°C or used directly for IFA.  
Coverslips were washed with PBS and incubated in blocking solution (10% (v/v) 
FBS in PBS) for 1 h at RTemp, before being incubated with the appropriate primary 
antibody (Table 2.3) diluted in blocking solution for 1 h at RTemp. The antibody 
containing solution was removed and the coverslips were washed four times with PBS for 
5 min per wash and subsequently incubated with an appropriate secondary antibody (Table 
2.4) diluted in blocking solution for 1 h at RTemp. The secondary antibody was removed 
and the coverslips were washed again four times with PBS for 5 min per wash. Finally, the 
coverslips were drained and mounted with VectaShield containing 4′,6-diamidino-2-
phenylindole (DAPI) (Vector Laboratories, Burlingham, USA). The cells were analysed 
with either a widefield imaging system (Leica DM IRB inverted epifluorescence 
microscope, Leica Microsystems GmbH, Wetzlar, Germany) or using a confocal laser 
imaging system (Leica SP5-AOBS confocal laser scanning microscope,  Leica 
Microsystems GmbH) in the Wolfson Bioimaging Facility (Faculty of Life Sciences, 
University of Bristol). The software Leica Application Suite X (LAS X) and ImageJ 
















Anti-DENV E (4G2) 60 Mouse 1:400 In house Dr A. Davidson 
Anti-DENV E 60 Rabbit 1:500 NBP2-52666 Novus Biological 
Anti-DENV NS1 46 Mouse 1:200 In house. Dr A. Davidson 
Anti-FGB 56 Mouse 1:50 sc-271035 Santa Cruz 
Biotechnology  
Anti-FGG 52 Mouse 1:50 sc-133156 Santa Cruz 
Biotechnology  
 







Alexa Fluor® 568 Goat anti-rabbit IgG 
(H+L) antibody, 
1:1000 A11036 InvitrogenTM, 
Thermo Fisher 
Scientific 
Alexa Fluor® 568 goat anti-mouse IgG 
(H+L) antibody 
1:1000 A11004 InvitrogenTM, 
Thermo Fisher 
Scientific 
Alexa Fluor® 488 goat anti-mouse IgG 
(H+L) antibody, 
1:1000 A11029 InvitrogenTM, 
Thermo Fisher 
Scientific 
Alexa Fluor® 488 goat anti-rabbit IgG 
(H+L) antibody 






 Co-immunoprecipitation (Co-IP) assay 
 One ml of unconcentrated cell culture supernatant or cell lysate (prepared as 
described in Section 2.3.1) was incubated with 10 μg of an appropriate antibody (Table 
2.5) overnight at 4 ºC under gentle agitation. 40 μl of packed bead volume of PierceTM 
Protein A or G Magnetic Beads (Thermo Fisher Scientific) were pre-equilibrated with 
washing buffer (Appendix A) as per the manufacturers’ instructions. The magnetic beads 
were then added to the lysate/antibody mixture and incubated by rotation at RTemp. After 
1 h, the beads were magnetically collected and washed twice with equilibration buffer, 
before a final wash with ultrapure water.  Protein was eluted from the beads by adding 80 
µl of 2X SDS-PAGE reducing sample buffer (Appendix A) to the tube and either heating 
at 95 ºC for 10 min (Protein G beads) or incubation at RTemp for 10 min with rotation 
(Protein A beads). The beads were captured magnetically and the supernatant was removed 
for further analysis. 








Anti-APOH 38 Mouse sc-515677 Santa Cruz 
Biotechnology  
Anti-C4A 193 Mouse sc-271181 Santa Cruz 
Biotechnology  
Anti-FGG 52 Mouse sc-133156 Santa Cruz 
Biotechnology  
Normal mouse serum 
(used as control) 






 RNA quantification 
 Total RNA isolation from adherent cells 
RNA was isolated using an SV Total RNA Isolation System (Promega, Madison, 
USA) according to the manufacturer’s instruction. Briefly, 200 µl of RNA lysis buffer 
containing BME was added to a T25 flask, containing ~2.6 x 106 cells and the cells were 
removed by scraping. The microcentrifugation purification method was applied as 
described by the manufacturer. Finally, the purified RNA was eluted in a final volume of 
100 μl with nuclease-free water and stored at -70 °C. The RNA concentration was 
measured using a NanodropTM spectrophotometer (Thermo Fisher Scientific).  
 Extraction of viral RNA from cell culture fluids 
A QIAamp Viral RNA Mini Kit (Qiagen, Hilden, Germany) was used to extract 
DENV RNA from 140 μl of culture supernatant from infected cells according to the 
manufacturer’s instructions. The mini spin procedure was applied. The purified RNA was 
finally eluted in 60 μl of AVE buffer (0.04% sodium azide in RNase-free water) and stored 
at -70 °C. 
 Two-step reverse-transcription PCR (RT-PCR) 
Two-step RT-PCR was performed. RNA extracted from adherent cells and 
supernatants were used for cDNA synthesis in the first step followed by PCR in the second 
step. 
2.4.3.1 2.4.3.1 Reverse transcription (RT) reaction 
The cDNA was synthesized from equal amounts of RNA in each sample using the 
ImProm-IITM Reverse Transcription System (Promega). Firstly, 0.2 µg of random 
hexamers (Promega) was added to 0.5 µg RNA and the volume adjusted to 10 µl with 
nuclease-free water.   
For RT of viral RNA, either 5 ng of an in vitro transcribed DENV-2 transcript or 2 
µl of DENV RNA (from an eluate of 60 µl (as described above)) was used with 0.5M of 




a final volume of 10 µl. The in vitro transcribed RNA were produced by using a T7 RNA 
polymerase based RiboMAXTM Large Scale RNA Production System (Promega). The 
reaction mixture consisted of 3-4 µg of linear DNA template, 7.5 mM of rNTPs (ATP, 
CTP, GTP, and UTP), T7 Transcription 1X Buffer, enzyme mix (T7) and nuclease-free 
water to a final volume of 50 µl. The reaction mixture was incubated at 37 °C for 4 h before 
adding 3-4 µl of RQ1 RNase-Free DNase (1 U/µg RNA; Promega) and further incubating 
at 37 °C for 1 h. 
Subsequently, the tubes containing the RNA/primer mixtures were incubated at 70 
°C for 5 min and then quickly chilled on ice. An RT reaction mix was then added to the 
denatured RNA/primer mix on ice. Each RT reaction mix contained 4 µl of ImProm-II™ 
5X Reaction Buffer (Promega), 25 mM MgCl2, 0.5 mM dNTPs, 1 µl of ImProm-IITM 
Reverse Transcriptase (Promega) and nuclease-free water to a final volume of 10 µl.  
Finally, the tubes were placed in a GS1 thermocycler machine (G-Storm, UK) with a heated 
lid set to 100 °C and incubated as follows:  25 °C for 5 min, 42 °C for 60 min and 70 °C 
for 15 min. The final cDNA product was either processed for further analysis or stored at 
-70 °C. 
2.4.3.2 2.4.3.2 PCR amplification 
For the PCR step, the cDNA template was diluted with nuclease free water to a final 
concentration of 5 ng/µl (based on the starting concentration of input RNA used for RT). 
A PCR master mix was added to 2 µl of cDNA template. Each PCR master mix contained 
2.2 µl of a gene specific primer set (Qiagen) (Table 2.6), 2 µl of 10 X Maxima Hot Start 
Taq buffer, 2 µl of 0.5 mM dNTPs, 2 mM MgCl2, 1U of Maxima Hot Start Taq DNA 
Polymerase (Thermo Fisher Scientific) and nuclease free water to a final volume of 18 µl. 
For quantification of DENV RNA, the gene specific primers were substituted with the 
DENV specific primers (listed in Table 2.7), 0.3 M forward primer and 0.3 M reverse 
primer. Finally, the reactions were placed in a PCR machine (with a heated lid set to 100 
°C) and cycled as follows: 95 °C for 15 s followed by 42 °C for 60 s for 35-40 cycles. The 




 Primers optimization and efficiency  
 Optimisation of primer sets was performed using PCR (Section 2.3.4.2) on RT-
PCR product samples and agarose gel electrophoresis (Section 2.4.6). Efficiency of the 
primers was then determined by quantitative real time RT-PCR (qRT-PCR) (section 2.4.5) 
  Quantitative real time RT-PCR (qRT-PCR) 
The efficiency of the primers for qRT-PCR analysis was analysed as follows. Ten-
fold serial dilutions of the cDNA templates (derived from cellular or viral RNA/in vitro 
RNA transcripts) were made in nuclease-free water to generate the standard curves for 
qRT-PCR. 1 µl of diluted cDNA template was then mixed with 11.5 µl of qPCR reaction 
mixture. The qPCR reaction mixture consisted of 6.25 µl of the 2X Maxima Hot Start Taq 
buffer (Thermo Fisher Scientific), 1.25 µl of the appropriate gene specific primer set 
(QIAGEN) (Table 2.7) and made to a final volume of 11.5 µl with sterile nuclease-free 
water. For quantification of DENV RNA, the forward and reverse primers (Table 2.7) 
were used at a concentration 0.3 M. Subsequently, the qPCR reaction was performed 
using a Stratagene Mx3005P QPCR System (Agilent Technologies, California, USA). The 
program was set for initial activation at 95 °C for 10 min, followed by 40 cycles of 
denaturation (15 s at 95 °C) and annealing (60 s at 60 °C). Finally, CT values were used for 
calculating the amount of mRNA. SoftMax Pro program was used to quantify CT value and 
calculate the efficiency curves.  
Once the specificity, sensitivity and efficiency of the primers was validated, qRT-
PCR reactions were set up using 1 µl of cDNA template (≤500 ng) and 11.5 µl of qPCR 
reaction mixture using the cycling conditions described above. CT values were used for 
quantitation of mRNA. The relative quantification was determined by the double-delta Ct 
(ΔΔCt) analysis. The value-of-interested gene was firstly normalized by those of a 
reference gene from the same sample; GAPDH was used as the reference gene. Then the 
ΔΔCt value was calculated for each gene in each cell type, as described in (Livak and 
Schmittgen, 2001), using Microsoft Excel. Gene expression values obtained from mock 
infected cells were used as control.  
Gene specific primers using in this study were purchased from QIAGEN (Hilden, 




Table 2.6: Oligonucleotide primers used in this study 
Gene Source Catalog number Amplicon length (bp) 
GAPDH Qiagen QT00079247 95 
FGA Qiagen QT00046711 113 
FGG Qiagen QT01000727 64 
FGB Qiagen QT00031003) 105 
HNF4A Qiagen QT00019411 90 
SERPINA1 Qiagen QT00077469 87 
SERPINC1 Qiagen QT00013013 145 
HP Qiagen QT00071449 94 
F2 Qiagen QT00013314 103 
CEBP Qiagen QT00203357 88 
F13B Qiagen QT00056945 87 
IL6 Qiagen QT00083720 107 
 
Table 2.7 DENV-specific primers used for qPCR and their sequences 
Type Primer DENV-2 
target  
Primer sequence (5’  3’) 
Forward C14A C gene AATATGCTGAAACGCGAGAGAAACCGCG 
Reverse DV2-C69Br  C gene CCCATCTCTTCAGTATCCCTGCTGTTGG 
Reverse DV-C69Br-AM C gene CCCATCTCITCAIIATCCCTGCTGTTGG 
*I indicates Deoxyinosine substituted at position 
 Agarose gel electrophoresis 
PCR products were mixed with 6X gel loading buffer (Appendix A) and separated 
on a 4 % (w/v) agarose gel by electrophoresis using 1X TBE running buffer (Appendix A) 
containing 0.5 μg/ml ethidium bromide. An O'RangeRuler 20 bp DNA Ladder (Thermo 
Fischer Scientific) was used as a marker. The PCR products were imaged using a BioDoc-




 Clinical specimen selection  
The clinical specimens assessed by proteomic analysis were obtained from patients 
and volunteers in the Philippines (kindly provided by Dr Raul Destura, National Institute 
of Health, University of the Philippines Manila (NIH UPM)). 
The retrospective study used archived sera from the biobank housed at NIH UPM. 
Serum samples were collected upon admission hospitals from patients with febrile illness 
(Project number UPMREB 2016-110-01; Research Ethics Board, University of the 
Philippines Manila).  
The DEN infection case was defined by clinical symptoms and positive laboratory 
confirmation (DENV specific RT-PCR and/or NS1 antigen testing and/or DENV IgM 
testing). Sera from healthy individuals were used as control groups. DEN-positive cases 
were then further classified based on clinical outcome by severity into 3 groups according 
to the WHO 2009 definition: DEN w/o WS, DEN w WS and SD (WHO 2009).  
From the available samples, specimens were prioritised for analysis based on an 
early sampling time (day after fever onset) with a similar proportion of ages (where 
possible) and genders in all groups.  
  Preparation of samples for LC-MS/MS analysis 
  Preparation of cell lysates and cell culture supernatant specimens for MS analysis  
Cells were washed twice with PBS, detached by cell scraper and collected by 
centrifugation. RIPA buffer containing protease inhibitors (Appendix A) was added and 
the resulting lysates were incubated on ice for 30 min and passed through 23-gauge blunt 
needles. Cell lysates were used for further BCA and LC-MS/MS analysis or kept at -80°C. 
Before labelling by 10-plex tandem mass tagging (TMT) and proteomic analysis, 
the protein concentration in cell lysates and concentrated supernatants were determined by 
BCA assay as described previously. The sample volumes were then adjusted (with PBS) 
to reflect equal starting volumes and approximate cell numbers with no sample containing 




 Preparation of clinical specimens for mass spectrometry analysis 
Serum samples from patients with different grades of dengue disease severity were 
depleted of human serum albumin (ALB) and IgG using a ProteoPrep® Blue Albumin and 
IgG Depletion kit (Sigma-Aldrich) following the manufacturer’s instructions. Briefly, 75 
µl of each serum sample was applied to the equilibrated resin. The eluate was applied to 
the resin again before washing of the resin with equilibration buffer. The eluate and wash 
were combined to give a final volume of ~ 175 µl. The concentration of protein in each 
sample was determined using a BCA assay using a 1:25 dilution of each sample. A 
“mastermix” reference sample was produced by combining proportional amounts of each 
sample used in the analysis. 
  Quantitative mass spectrometry analysis 
  TMT labelling and high pH reversed-phase chromatography 
The protein concentration for each sample prepared as described in 2.6.2 was 
determined via BCA assay. For samples which could not contain DENV; 100 µg of each 
sample was sent to the Proteomics Facility for TMT labelling using a TMT10plex Isobaric 
Label Reagent Set (Thermo Fisher Scientific) by Dr Kate Heesom and co-workers. If the 
samples potentially could have contained inactivated DENV then the first steps of the TMT 
labelling were done in the BL3 laboratory before sending to the Proteomics Facility as 
follows. 100 µg of sample was adjusted to a volume of 50 µl using nuclease free water and 
then adjusted to a final volume of 100 µl with 100 mM triethyl ammonium bicarbonate 
(TEAB). 5 µl of 200 mM Tris (2-Carboxyethyl) phosphine Hydrochloride (TCEP) was 
added and the samples incubated at 55 °C for 1 h.  Then 5 µl of 375mM iodoacetamide 
(prepared immediately before use by dissolving 9 mg of iodoacetamide in 132 µl of 100 
mM TEAB) was added to each sample, mixed and incubated for 30 min at RTemp, 
protected from light. Six volumes (~600 µl) of pre-chilled acetone was then added to each 
tube and proteins precipitated overnight at -20 °C. The precipitated proteins were then sent 
to the Proteomics Facility for further processing as follows. Briefly, the precipitated 
proteins were collected by centrifugation and then digested with trypsin (2.5 μg of trypsin 




to the manufacturer’s instruction (Thermo Fisher Scientific). A different isobaric tag was 
applied to each sample. All 10 samples were then mixed together before fractionation and 
clean-up.  
The pooled sample was evaporated to dryness, resuspended in 5% formic acid and 
desalted using a SepPak cartridge according to the manufacturer’s protocol (Waters, 
Milford, Massachusetts, USA). Eluate from the SepPak cartridge was then evaporated to 
dryness and resuspended in buffer A (20 mM ammonium hydroxide, pH 10) then 
fractioned by high pH reversed-phase (RP) chromatography using an Ultimate 3000 liquid 
chromatography system (Thermo Scientific).  The sample was loaded onto an XBridge 
BEH C18 Column (130Å, 3.5 µm, 2.1 mm x 150 mm, Waters) in buffer A and ran in 
gradient of buffer B (20 mM Ammonium Hydroxide in acetonitrile, pH 10) from 0-95% 
over 60 min. The resulting fractions were evaporated to dryness and resuspended in 1% 
formic acid prior to analysis by nano-LC MSMS using an Orbitrap Fusion Lumos mass 
spectrometer. 
 Nano-LC Mass Spectrometry 
High pH RP fractions were further fractionated using an Ultimate 3000 nano-LC 
system in line with an Orbitrap Fusion Lumos mass spectrometer. Briefly, peptides in 1% 
formic acid were injected onto an Acclaim PepMap C18 nano-trap column (Thermo 
Scientific). After washing with 0.5% acetonitrile, 0.1%  formic acid, peptides were 
resolved on a 250 mm × 75 μm Acclaim PepMap C18 RP analytical column (Thermo 
Scientific) over a 150 min organic gradient, using 7 gradient segments (1-6% solvent B 
over 1min., 6-15% B over 58min, 15-32%B over 58min, 32-40%B over 5min, 40-90%B 
over 1 min, held at 90%B for 6 min and then reduced to 1%B over 1 min) with a flow rate 
of 300 nl/min.  Solvent A was 0.1% formic acid and Solvent B was aqueous 80% 
acetonitrile in 0.1% formic acid.  Peptides were ionized by nano-electrospray ionization at 
2.0 kV and temperature of 275°C. 
All acquired spectra from the Orbitrap MS controlled by Xcalibur 4.1 software 
(Thermo Scientific) were operated in data-dependent acquisition mode using an 
Synchronous Precursor Selection (SPS)-MS3 workflow. FTMS1 spectra were collected at 




injection time of 50 ms. Precursors were filtered with an intensity threshold of 5,000 
according to charge state (to include charge states 2-7) and with monoisotopic peak 
determination set to Peptide. Previously interrogated precursors were excluded using a 
dynamic window (60s +/-10ppm). The MS2 precursors were isolated with a quadrupole 
isolation window of 0.7 m/z. Then the ITMS2 spectra were collected with an AGC target 
of 10,000 max injection time of 70 ms and CID collision energy of 35%. 
For FTMS3 analysis, the Orbitrap was operated at 50,000 resolution with an AGC 
target of 50,000 and a max injection time of 105 ms. Precursors were then fragmented by 
high energy collision dissociation (HCD) at a normalised collision energy of 60% to ensure 
maximal TMT reporter ion yield.  SPS was enabled to include up to five MS2 fragment 
ions in the FTMS3 scan. 
  Data Analysis 
The raw data files were processed and quantified using Proteome DiscovererTM 
software v2.1 (Thermo Scientific) and searched against the UniProt Human database 
(downloaded September 2018: 152927 entries) and the DENV-2 New Guinea C strain 
(GenBank accession number: AF038403) using the SEQUEST algorithm. Peptide 
precursor mass tolerance was set at 10 ppm, and MS/MS tolerance was set at 0.6 Da. Search 
criteria included oxidation of methionine (+15.9949) as a variable modification and 
carbamidomethylation of cysteine (+57.0214) and the addition of the TMT mass tag 
(+229.163) to peptide N-termini and lysine as fixed modifications. Searches were 
performed with full tryptic digestion and a maximum of 2 missed cleavages were allowed.  
The reverse database search option was enabled and all data was filtered to satisfy false 
discovery rate (FDR) of 5%. The main search was done by Dr Kate Heesom and the 
ThermoFischer .msf file and excel spreadsheet produced for further analysis. The above 
proteomics analysis, and as such the protocols listed in sections 2.7.2 and 2.7.3, are 
provided as a service from the faculty proteomics facility. 
 Quantification and bioinformatics analysis 
The raw dataset was filtered to exclude proteins identified by less than 2 peptides. 




2016). The ratios were log2 transformed and normalised by subtraction of the median ratio 
in each comparison from the other ratios. Proteins were used for statistical analysis where 
a valid value was present for at least 2 of 3 experiments. An unpaired two-sample student 
t-test with the permutation-based FDR 0.05 was performed. Proteins that increased or 
decreased in amount (≥ 1.3 fold and ≥ 1.5 fold) in the condition under investigation 
compared to the control condition were analysed using the Database for Annotation, 
Visualization and Integrated Discovery (DAVID) version 6.8 (Huang et al., 2009) and the 
Search Tool for the Retrieval of Interacting Genes/Proteins (STRING) 9.1 database 
(Franceschini et al., 2013) to identify groups of functional enriched proteins corresponding 
to specific gene ontology terms and identify protein networks and processes over-presented 
in DENV infected cells. 
The STRING analysis produces an interaction network with each protein 
represented as a node (labelled with the gene symbol) and predicted functional links shown 
by up to eight coloured lines representing different types of evidence for the link. STRING 
uses the following evidence terms: “Neighborhood” = genes in immediate neighbourhood 
on the genome; “Gene Fusion”; “Occurrence” = two genes have a similar phylogenetic 
profile; “Coexpression” = two genes have been detected to have similar expression 
profiles; “Experiments” = protein-protein interaction detected by physical association or 
co-localisation; “Database”= do the two genes occur in annotated pathways in databases; 
“Textmining” = protein is mentioned with other proteins in publications.  
The FunRich program version 3.1.3 (Pathan et al, 2015) was used to identify 
overlapping of data sets and produce Venn diagram.  
Following the HUGO Gene Nomenclature Committee’s general guidelines (Wain 
et al, 2002), the protein names and symbols in this thesis are the same as the gene symbol, 
but not italicised. 
  Statistical analysis  
Statistical analysis of significance was calculated by using Student’s t-test and 
statistical significance was defined as P-value < 0.05. Data were analysed by using Excel 




 OPT I M I S AT ION  OF M E T HOD S  FOR  
L C - M S /M S  AN A LY S IS  OF C U LT U RE  
S U PE R N ATAN T S  
  Introduction 
The study of cell secretomes by high through-put proteomics is still a growing and 
developing field. Compared to the proteomic analysis of cell lysates there are a number of 
challenges that must be overcome. Methods must be determined and optimised to remove 
abundant bovine serum proteins present in typical cell culture media and concentrate the 
proteins in cell culture supernatants for subsequent LC-MS/MS analysis. The latter is 
important due to the decrease in concentration of cellular proteins that occurs, when they 
are secreted into the culture supernatant, which is much larger in volume compared to the 
cell volume. Additionally, it is not trivial to normalise the amounts of proteins present in 
different samples using a loading control, which is typical when analysing the amounts of 
proteins in cell lysates by Western blotting.  
Highly abundant proteins in FBS, such as BSA and IgG, need to be removed, as 
much as possible, from cell culture supernatant samples before LC-MS/MS analysis, as 
they may mask the detection of lower abundant secreted proteins (Stastna and Van Eyk, 
2012). To achieve this, in many previous secretomes studies, cultured cells were initially 
grown in media containing serum, before removal of the media, washing several times with 
PBS or SFM and changing the media to SFM. However, the details of each method varied. 
For example, in studies analysing the secretome of DENV-2 infected HepG2 cells, the cells 
were initially grown and infected in complete media (CM). Further incubation in CM 
occurred until 32 hpi when the cells were extensively washed with PBS followed by further 
incubation of the cells in SFM for 16 h before harvest and analysis (Higa et al., 2008; 
Caruso et al., 2017). Whereas in a study analysing the secretome study of chikungunya 
virus infected WRL68 cells, the cells were grown in CM overnight, infected in SFM and 
then extensively washed with SFM and incubated with SFM for a further 24 hpi before 




may affect normal cell growth and function, thus the effects of each protocol for secretome 
preparation requires validation to ensure the optimal growth of cells (Stastna and Van Eyk, 
2012). Although previous studies revealed no significant differences in the growth of cells 
in SFM compared with CM, as determined by cell lysis and viability assays, they used 
different cell lines and conditions to those planned in this study (Higa et al., 2008; Thio et 
al., 2015).  
An alternative approach to the use of SFM is to grow cells in CM throughout but 
remove highly abundant serum proteins such as albumin and IgG, before proteomic 
analysis. However, the depletion methods risk losing proteins bound with albumin and IgG 
(Stastna and Van Eyk, 2012).  
Typically, cell culture supernatants need to be concentrated before proteomic 
analysis. Three major techniques are used for this purpose; ultrafiltration, precipitation 
and/or dialysis. The most common approach is to concentrate supernatants (both for LC-
MS/MS and Western blotting) using membrane ultrafiltration concentrators. Different 
studies have used membranes with different molecular weight cut-offs, depending on the 
proteins to be analysed. Whilst proteins > 10 kDa in size were studied by Higa and 
colleagues (Higa et al., 2008), Caruso and colleagues used two ultrafiltration steps to 
isolate proteins < 10 kDa but > 3 kDa in size, as the study focused on an examination of 
the products of protein proteolysis (Caruso et al., 2017).  
Protein precipitation techniques using reagents such as TCA/acetone and 
ethanol/acetone have also been used to concentrate and prepare cell culture supernatants 
for MS analysis and Western blotting (Geddes et al., 2015). Dialysis methods in which the 
cell culture supernatant is first dialysed against water/buffer using a cut-off membrane 
before concentration of the supernatant by vacuum concentration or ultrafiltration have 
also been used prior to MS analysis (Cao J et al., 2011; Romanello M. et al, 2014). 
Although dialysis is simple, it is time consuming, taking up to 2 days. A study that 
compared different secretome preparation methods using the culture supernatant from a 
hepatocellular carcinoma cell line, revealed that ultrafiltration was most efficient in terms 




identifications and a greater detection of low molecular weight proteins by MS analysis 
(Cao J et al., 2011). 
Thus, the work reported in this chapter was aimed at developing a protocol to 
optimise the conditions required to prepare culture supernatants derived from DENV 
infected cells for proteomic analysis, whilst ensuring normal cell growth. 
Results 
To comprehensively analyse the cellular proteomes and secretomes of DENV and 
mock infected cells, simultaneous proteomic analysis of both cell lysates and the 
corresponding cell culture supernatants was planned. The time of harvest post-infection 
was chosen according to the results of previous proteomic analyses of DENV infected cells, 
done in the laboratory; 30 and 48 hpi for Huh-7 and HEK293T cells, respectively (Yousuf, 
2016; Chiu et al., 2014). At these times the virus was still in the exponential phase of 
replication but there was little cell death. However, before the combined 
proteomic/secretome analyses could be undertaken, a number of optimisation experiments 
were done to determine the optimal conditions for secretome analysis, which had not 
previously been undertaken in the laboratory. 
 Establishment of conditions for minimising serum proteins in the 
secretome 
Based on previous secretome studies (reviewed in section 3.1), it was planned to 
grow the cells in CM, prior to DENV infection and then exchange the media with SFM, 
after DENV infection, to ensure that abundant proteins contained in the FBS added to CM 
did not interfere with the secretome analysis. Furthermore, the washing step and change 
from CM to SFM were done immediately after infection, to prevent any interruption in 
protein secretion that may occur early after infection. 
Initially, conditions were optimised to ensure removal of exogenous bovine serum 
proteins from the secretome. Uninfected Huh-7 cells were seeded and grown in CM for 24 
h, at which point they were ~ 60-80% confluent. The CM was then removed and the cells 




or SFM. The cells were incubated for up to 48 h after changing the media, to simulate the 
conditions to be used for viral infection. Analysis of the culture supernatants by SDS-
PAGE and Coomassie blue staining revealed a protein of ~ 69 kDa, which is the molecular 
mass of BSA, in the culture supernatants prepared with CM, but no comparable band in 
the culture supernatants prepared using SFM after initial growth in CM (Figure 3.1A). 
To ensure cells were not lost during the extensive wash procedure, the flasks were 
pre-coated with PDL before the cells were seeded into the flasks. The effect of PDL coating 
was tested, to ensure proteins in CM did not bind to the PDL. PDL coated flasks (with no 
cells) were incubated with either CM or SFM alone for 24 h followed by a 48 h incubation 
with SFM (without a washing step). To ensure sensitive detection of any serum proteins, 
the culture supernatants were concentrated by ultrafiltration, using a membrane with a 3 
kDa cut-off and examined by SDS-PAGE and Coomassie blue staining (Figure 3.1B). An 
ultrafiltration device with a 3 kDa cut-off was chosen to retain as many secreted proteins 
as possible in the concentrated culture supernatants. Coating flasks with PDL did not result 








Figure 3.1 SDS-PAGE analysis of cell culture supernatants from cells grown in CM and 
SFM.  
(A) Culture supernatants from Huh-7 cells grown in CM were harvested at 24, 48 and 72 
h after seeding. Cells were seeded and grown in CM for 24 h before being washed with 
PBS and the media exchanged to SFM. The culture supernatant from cells further incubated 
in SFM were harvested at the same time point.  Proteins in the cell culture supernatants (10 
µl of each supernatant) were denatured in 2X sample buffer and analysed by 10% SDS-
PAGE followed by Coomassie blue staining. (B) Flasks without cells were coated with 
PDL and then incubated with either SFM alone for 72 h, or complete media for 24 h 
followed by a 48 h incubation with SFM (COM/SFM). Equal volumes of media were then 
harvested and concentrated to the same volume (~ 40X) by ultrafiltration using a membrane 
with a 3 kDa cut-off (Amicon® Ultra 4 Centrifugal filter unit). Proteins in the concentrated 
media (10 µl of each supernatant) were denatured with 2X sample buffer and analysed by 
10% SDS-PAGE and Coomassie blue staining. Concentrated CM (CM; not in contact with 
a PDL coated flask) was analysed in parallel as a control. The molecular masses (in kDa) 





The efficiency of the PBS wash step in the removal of serum proteins was examined 
in more detail. All cell lines planned to be used in this study (HEK293T, HEK293T-DV-
Rep (REP) and Huh-7 cells) were seeded in PDL coated flasks and grown for 24 h in 
complete medium. The cells were then washed with PBS five times and SFM added to the 
flasks. Equal volumes of unconcentrated and ultrafiltration-concentrated cell culture 
supernatants were analysed by SDS-PAGE followed by Coomassie blue staining (Figure 
3.2). Analysis of the unconcentrated cell culture supernatants showed that there were 
undetectable levels of protein after washing and growth in SFM. However, analysis of the 
concentrated cell culture supernatants revealed that despite the wash step there was still 
residual protein, of the size expected for BSA, in the media of some samples. By contrast, 
protein was not detected in the concentrated media that was obtained after incubation with 
PDL coated flasks in the previous experiment (Figure 3.1B), suggesting that the abundant 












Figure 3.2 Analysis of concentrated cell culture supernatants from HEK293T, REP and 
Huh-7 cells grown in SFM.  
HEK293T and REP (A) as well as Huh-7 (B) cells were grown in CM for 24 h until 
reaching 80% confluency before extensive washing with PBS. The cells were then grown 
in SFM for a further 48 h (HEK293T and HEK293T-DV-Rep) or 30 h (Huh-7). The cell 
culture supernatants, before media exchange (containing FBS; 24 h CM) and at harvest 
time (48 h or 30 h after media exchange) were collected and 4 ml of each supernatant 
concentrated to 90 µl. Twenty µl of the unconcentrated (UC) and concentrated (C) culture 
supernatants were analysed by 10% SDS-PAGE analysis and Coomassie blue staining. The 






 Effects of SFM on cell growth and virus infection 
Growing cells in the absence of serum may affect cell growth and virus infection. 
The effects of serum starvation had not previously been tested using the cell lines and time 
points used in this study. Therefore, initially, Huh-7 and HEK293T cells were examined 
by microscopy after growth in CM for 24 h, washing with PBS and changing the media to 
SFM, for 30 and 48 h, respectively. The results revealed that the cells grown in SFM still 
had a normal healthy appearance and grew to confluency at a similar rate to cells grown in 
CM (data not shown). The viability of the HEK293T and Huh-7 cells after growth in CM 
or SFM (using the protocol described above) was then determined using a MTT assay 
(Figure 3.3). The results revealed that there was no significant change in the viability of 
HEK293T and Huh-7 cells grown in SFM compared with complete media with 78.7% (P-
value = 0.20) and 77.8% (P-value = 0.33) viability for HEK293T and Huh-7 cells 
respectively.  
To confirm that the growth of the cells in SFM did not affect DENV infection, 
HEK293T and Huh-7 cells were grown in CM, infected with DENV-2 at a MOI of 5, 
washed with PBS and then grown in SFM. At 30 and 48 hpi, for Huh-7 and HEK293T cells 
respectively, the cells were fixed and analysed by IFA using an anti-E antibody. The results 
showed that when the cells were grown in SFM conditions, the infection rate (determined 









Figure 3.3 Cell viability testing of HEK293T and Huh-7 cells grown in media with or 
without serum. 
 The viability of HEK293T and Huh-7 cells grown in complete media (CM) and SFM was 
determined using a MTT test. Cells (1 x 104) were seeded into 8 wells of a PDL-coated 96 
well-plate in CM for 24 h before being washed and the media changed to either SFM or 
SFM containing 10% FBS. After incubation in the respective media for 48 and 30 h for 
HEK293T and Huh-7 cells, respectively, the cell viability was tested using an MTT assay. 
Data are presented as the mean ± SEM. A two sample Student’s t-test was used to compare 
the difference between the 2 groups. There was no statistically significant difference 
between cells grown in SFM containing 10 % FBS and SFM, (P-values of 0.20 and 0.33 






  Detection of proteins in concentrated cell culture supernatants by 
SYPRO Ruby staining and LC-MS/MS.  
The optimisation experiments showed that conditions had been established to 
produce cell culture supernatant samples for secretome analysis using SFM, with minimal 
effects on cell viability or virus infection efficiency, but with a large reduction in the 
protein/s derived from CM. However, after these procedures, proteins could not be detected 
in the concentrated supernatant samples by Coomassie blue staining (Figure 3.2). The more 
sensitive stain SYPRO Ruby was therefore used for protein detection. HEK293T and REP 
cells were seeded and grown in CM for 24 h. The HEK293T cells were then infected with 
DENV-2 (at MOI of 5) or mock infected. After infection, all cells were washed five times 
with warm PBS and further grown in SFM for 48 h. The cell culture supernatants (5 ml 
each) were collected and concentrated by TCA precipitation to a final volume of 80 µl (as 
described in section 2.3.1). Finally, the proteins in the concentrated supernatants (10 µl 
each) were analysed by 10% SDS PAGE followed by SYPRO Ruby staining (as described 
in section 2.3.5) as shown in Figure 3.4. The results showed the presence of proteins in the 













Figure 3.4 Analysis of concentrated cell culture supernatants from mock and DENV-2 
infected HEK293T and REP cells.  
HEK293T and REP cells were seeded and grown in CM for 24 h until reaching 80% 
confluency. The HEK293T cells then were DENV-2 (at MOI 5) or mock infected. After 
infection, all cells were washed five times with warm PBS and further grown in SFM. At 
48 hpi, the cell culture supernatants were collected and concentrated by TCA precipitation. 
Twenty µg of mock infected HEK293T cells was used as control. Equal amounts (10 µl) 
of the concentrated culture supernatants were analysed by 10% SDS-PAGE and SYPRO 






To determine whether the protocol established was suitable for the detection of 
proteins in the culture supernatants by LC-MS/MS, preliminary LC-MS/MS secretome 
analysis was performed using HEK293T cells. The cells were initially grown in a PDL 
coated flask in CM for 24 h, followed by PBS washing before further growth in SFM for 
48 h. The cell culture supernatant was harvested and concentrated ~ 40X and then a sample 
(20 µl) analysed by LC-MS/MS. The MS/MS spectral files were searched against a list of 
bovine and human proteins, resulting in the identification of 1567 proteins. Of these 
proteins, 963 were identified by ≥2 peptides, there were 773 human proteins and 190 
bovine proteins including BSA (Supplementary Table S 3.1). 
 The human proteins detected in secretome from HEK293T cells were analysed 
using the program STRING, to determine whether the proteins detected were typical of 
secreted proteins. The human proteins detected in secretome from HEK293T cells were 
significantly enriched in the GOBP terms “secretion by cell” (GO:0032940), “vesicle-
mediated transport” (GO:0016192) and “cell activation involved in immune response” 








Figure 3.5 STRING analysis of human proteins detected in the secretome of HEK293T 
cells.  
The STRING database was searched to analyse human proteins detected in the secretome 
of HEK293T cells by LC-MS/MS. Nodes representing proteins associated with the 
significantly enriched GOBP terms “secretion by cell”, “vesicle-mediated transport” and 
“cell activation involved in immune response” are shaded in blue, red and green, 
respectively. The number of coloured nodes/total proteins involved for each term and the 




Finally, to determine whether DENV infection had any major effect on the final 
yield of proteins using the protocol established, the protein amounts in the supernatants 
from mock and DENV-2 infected HEK293T and Huh-7 cells were estimated using a BCA 
assay (Figure 3.6). The estimate was performed for six samples in each group. For 
HEK293T cells, the amounts of protein in the concentrated supernatants from mock and 
DENV-2 infected cells were similar, with an average of 1761.7 and 1789.9 µg/ml, 
respectively (P-value= 0.93). Although the average amount of protein in the concentrated 
supernatants from mock infected Huh-7 cells was slightly higher than that from DENV-2 
infected cells, this difference was not statistically significant (2762.2 and 2456.7 µg/ml, P-
value = 0.61).  
 
Supplementary Table  











Figure 3.6 Determination of protein amounts in concentrated supernatants from DENV-2 
and mock infected HEK293T and Huh-7 cells. 
HEK293T and Huh-7 cells were grown in CM for 24 h before mock and DENV-2 (at MOI 
5) infection. After infection cells were extensively washed and media was changed to SFM. 
At 48 and 30 hpi for HEK293T and Huh-7 cells respectively, cell culture supernatants were 
collected and concentrated ~ 40X with ultrafiltration technique. The protein amounts in 
concentrated supernatants were measured by BCA assay, n=6 in each group. Data are 
presented as the mean ± SEM. A two sample Student’s t-test was used to compare the 
difference between the mock and DENV-2 group. The results showed no significant 
difference in protein amount between supernatants derived from mock and DENV-2 cells 


































 This chapter describes the development of an optimised protocol that can now be 
used for secretome analysis by LC-MS/MS and Western blotting. In brief, cells were 
seeded in PDL-coated flasks and grown in CM for 24 h. After DENV infection, the cells 
were extensively washed with PBS and further incubated in SFM. At the time of harvest, 
the cell culture supernatants were collected and the supernatants were then concentrated by 
ultrafiltration. Furthermore, the cells remaining after removal of the culture supernatants 
can also be harvested and used to prepare cell lysates using standard methods, to allow 
simultaneous analysis of the proteome and secretome of DENV infected cells. 
 Reports in the literature of comprehensive proteomic studies analysing both the 
cellular proteome and secretome are limited, and there are none for DENV. A previous 
study which investigated the subcellular proteome and secretome of influenza A virus 
infected human primary macrophages analysed cell lysates grown in CM whilst the 
secretomes were separately prepared using SFM conditions (Lietzen et al., 2011). In 
contrast, this study was designed to analyse cell lysates and secretomes from cells grown 
under the same experimental conditions to better correlate any changes in the proteome 
and associated secretome. Thus, the cells were grown under SFM conditions. The viability 
of HEK293T and Huh-7 cells grown under in CM and then abruptly exchanged into SFM 
conditions, rather than undergoing a slower adaptation process (Beltran Paschoal et al, 
2014) has not been reported. Therefore, the viability of cells grown under the established 
protocol were verified using an MTT assay, which is more sensitive than trypan blue 
staining. Furthermore, growth of the cells in SFM had no obvious effect on the efficiency 
of DENV at high MOI as determined by IFA. In a previous study, which analysed DENV-
2 infected HepG2 cells, the effect of SFM on cell growth was also verified using both 
trypan blue staining and a MTT assay (Higa et al., 2008). However, Higa’s study used a 
low MOI (MOI of 1) for DENV-2 infection and did not describe the effect of the SFM cell 
growth conditions on infection.  
The proteins present in the concentrated supernatants from HEK293T and Huh-7 
cells could not be detected by Ponceau and/or Coomassie blue staining. Thus, the more 




present in the prepared samples. Finally, a preliminary LC-MS/MS analysis was done to 
confirm the presence of proteins in the secretome prepared with the optimised protocol. 
Although the cells were extensively washed before changing to SFM, some bovine proteins 
were still detectable by LC-MS/MS results. However, a much greater number of human 
proteins were detected than bovine proteins, which could also be discriminated as 
contaminants by the analysis. The residual bovine proteins detected may be due to binding 
of the bovine proteins to cells, as the PDL coating did not appear to result in binding of 
bovine proteins to the culture vessel (Figure 3.1B). Furthermore, many of the human 
proteins detected in secretome of HEK293T cells were associated with the GOBP terms 
“secretion by cell” and “vesicle-mediated transport”, ensuring that the protocol resulted in 
the detection of secreted proteins.  
The preliminary secretome results were compared with the results of a previous 
study which analysed the secretome of HEK293T cells. In the study of Kuhn et al., (Kuhn 
et al., 2015) the secretome of HEK293T cells that either overexpressed or were depleted 
of signal peptide peptidase-like 3 (SPPL3), were analysed by label free LC-MS/MS. A total 
of 428 proteins were reliably identified, compared with 963 human proteins in the 
preliminary MS analysis (a comprehensive analysis of the proteins identified in each study 
is described in Chapter 4). In Kuhn’s study (Kuhn et al., 2015) the HEK293T cells were 
grown in CM. The cell culture supernatants were then concentrated by ultrafiltration and 
depleted of ALB; however, this approach did not effectively remove all bovine proteins 
which may have led to a lower number of identifications by LC-MS/MS analysis. Overall, 
the results obtained in the preliminary analysis demonstrated that the protocol established 
in this study had the sensitivity required for a full-scale analysis.  
 There are lots of challenges in secretomic analysis that need to be considered and 
potentially improved. Firstly, the best way to minimise contamination with bovine proteins. 
The abundance of these proteins, if not removed, will interfere with the LC-MS/MS 
analysis. Growing cells in SFM may affect cell growth and metabolism. Starvation of FBS 
may skew normal cell metabolic processes, especially energy metabolism, and may affect 
the levels of proteins involved in these processes. There might be more protein and/or fatty 




followed by ALB depletion would maintain normal cell growth and metabolism but could 
still lead to excessive amounts of BSA and other bovine serum proteins as mentioned 
before. A second consideration is the method of concentration. Ultrafiltration provides the 
best results for protein concentration but can lead to a loss of low molecular weight and 
hydrophilic proteins (Cao J et al., 2011). Finally, validation after LC-MS/MS analysis is 
still a problem in secretome studies as depending on the cell type, the secreted proteins 
may be present in low amounts in the cell culture supernatants. Additionally, unlike the 
analysis of intracellular proteins, there are no standard loading controls for secretome 
analysis. The results presented in this chapter (Figure 3.6) imply that equal volumes of 
concentrated supernatants could be used for validation by Western blotting because they 
contained equal total amounts of protein. However, even small amounts of residual bovine 
serum proteins have the potential to skew the results.  
In summary, a protocol for the analysis of the secretome derived from DENV-2 
infected cells was established, based on the growth of cells in SFM. This protocol can now 
be combined with intracellular protein analysis to undertake a simultaneous proteomic and 
secretomic analysis of DENV infected cell by high-throughput LC-MS/MS, as described 






 HI GH T HR O U GHPU T PR OT E OM I C  
A N A LY S IS  OF T HE  PR OT E OM E  A N D  
S E C R ETOM E OF D E N V I N FE C T E D  A N D  
D E N V R E PL IC ON  C ON TA N I N G HE K2 93 T  
C E L L S  
  Introduction 
Similar to other RNA viruses, DENV replication relies heavily on the subversion 
of normal host cell processes, resulting in the dysregulation of host gene expression and 
protein amounts. Thus, investigations aiming to define the changes that occur in the host 
proteome in response to DENV infection have the potential to identify key host proteins 
and processes required for viral replication. However, limited studies have been done on 
the effects of DENV replication on proteins secreted from cells, known as the host cell 
secretome; these proteins function in cell-cell signal transduction and play key roles in the 
host immune response. Therefore, studying the effects of DENV replication on the 
proteome and secretomes of different cell populations will not only identify intracellular 
targets for antiviral strategies but will increase our understanding of how infection disrupts 
communication between cells, ultimately resulting in DEN pathogenesis. A number of 
studies have previously analysed changes in cellular protein amounts in response to DENV 
infection in vitro (reviewed in Chapter 1, Table 1.2), however few of these studies used 
high throughput proteomic approaches (Pando-Robles et al., 2014; Chiu et al., 2014; Miao 
et al., 2019). Moreover, to date, no integrated analysis of the effect of DENV replication 
on both the cellular proteome and secretome has been done, either by traditional low 
throughput (2D SDS-PAGE) or high throughput LC-MS/MS based analysis.  
Flavivirus replicon systems have been widely used to study flavivirus molecular 
biology and as platforms for antiviral screening. These replicons are virus subgenomic 
RNAs in which the virus structural genes have been deleted (either C-prM-E or prM-E) by 
reverse genetics whilst retaining the viral 5 and 3 UTRs and the non-structural genes 




permissive for virus replication results in autonomous replication of the replicon 
subgenome but does not result in the release of infectious virus particles. Replicons 
therefore provide a biosafe system for studying many aspects of virus replication. 
Replicons may be either transiently expressed in cell lines permissive for virus replication 
or continuously expressed. In the latter case, drug resistance markers and reporter genes 
are introduced into the viral genome in place of the structural genes, allowing selection and 
identification of cells containing the replicons (Ward and Davidson, 2008). Although 
replicon systems have been used to validate the results of proteomic and interactomic 
studies (Khadka et al, 2011), only limited studies have analysed changes in the proteome 
of replicon containing cell lines. Recently, Hafirassou and colleagues characterised the host 
protein-NS1 interactome using DENV replicons expressing FLAG and HA tagged NS1 
proteins in three different cell lines (HeLa, Raji and HAP1) and a two-step co-IP approach 
followed by LC-MS/MS analysis (Hafirassou et al, 2017).  
Although DENV replicons have widely been used as a biosafe platform for 
screening antiviral compounds (Ng et al., 2007), changes in the host cell, in response to 
replicon replication in comparison to viral infection have not been well characterised. A 
study directly comparing the proteomic changes that occur in a replicon cell line with the 
corresponding cell line that is DENV infected would fill this gap and provide more 
information on how specific viral processes effect the host response. To compare a replicon 
system with DENV infected cells, HEK293T cells stably expressing a DENV-2 
subgenomic replicon (HEK293T-DV-Rep; REP) was used, this replicon represented the 
only available DENV replicon system in the laboratory at the commencement of this study.  
The HEK293 cells and derivatives including HEK293T cells are widely used for 
transient gene expression studies as they have a high transfection efficiency. HEK293 cells 
are also widely used for recombinant protein production (Thomas and Smart, 2005; Petiot 
et al., 2015). As HEK293 cells are permissive for DENV infection, they have also been 
used for DENV infection experiments especially when coupled with transient gene 
expression studies (Hannemann et al., 2013; Tongluan et al., 2017). Furthermore, HEK293 
cells were found to provide a good in vitro model for DENV-induced chemokine studies 




The investigations described in this chapter aimed to determine the effect of DENV 
replication on the cellular proteome and secretome of HEK293T cells, either during 
DENV-2 infection or using REP cells, compared to mock infected cells. The results were 
subjected to bioinformatic analysis to explore the effect of DENV infection and viral 
replication on host biological processes and to identify similarities and differences in host 
protein dysregulation between DENV infected and replicon containing cells. 
Results 
  Preparation of cell lysates and concentrated cell culture 
supernatants from DENV-2 and mock infected HEK293T cells and 
REP cells for proteomic analysis. 
To analyse the effects of DENV-2 on the proteome and secretome of HEK293T 
cells, these cells were infected with DENV-2 at MOI of 5 or mock infected. Before 
infection, the cells were grown in CM. After infection the cells were washed extensively 
with PBS and then grown in SFM for 48 h, at which time the culture supernatants and cells 
were harvested. REP cells were also prepared at the same time using the same conditions 
(except for infection). At 48 hpi, the cell culture supernatants were harvested and 
concentrated and the corresponding cells were harvested in RIPA buffer to produce cell 
lysates (Figure 4.1). The infection rate was estimated to be 95%-100% by IFA (Figure 
4.2A) and the presence of the replicon in the REP cells was verified by the detection of 
GFP and the DENV NS1 protein by IFA (Figure 4.2B). The experiments were performed 
independently in triplicate. The amount of protein in the concentrated supernatants and cell 
lysates was measured by BCA assay and samples containing equal amounts of protein were 
then sent for TMT labelling and LC-MS/MS analysis at the Faculty Proteomics facility 









Figure 4.1 Diagram of workflow to analyse the proteomes and secretomes of DENV-2 
infected HEK293T cells and REP cells.  
In brief, HEK293T and REP cells were grown in CM for 24 h, then infected with DENV-
2 or mock infected. After infection, the cells were extensively washed with PBS and further 
grown in SFM for 48 h. At 48 hpi, the cells were harvested and used to produce lysates and 
the cell culture supernatants were concentrated by centrifugation. Experiments were done 









Figure 4.2 IFA analysis of HEK293T cells infected with DENV-2 or mock infected, and 
REP cells. 
 (A) HEK293T cells were infected with DENV-2 or mock infected. After 48 h of 
incubation in SFM, the cells were fixed with ice cold methanol and immunostained with 
an antibody against the DENV-2 E protein (Anti-E, red), nuclear DNA was visualised with 
DAPI (blue). (B) REP cells, after 48 h of incubation in SFM, were fixed with ice cold 
methanol and immunostained with an antibody against the DENV-2 NS1 protein (Anti-
NS1, red). Cells were examined for the presence of GFP (green), nuclear DNA was 






  Quantitative LC-MS/MS analysis 
The spectral files from the LC-MS/MS analysis of the cell lysates and concentrated 
supernatants from DENV and mock infected HEK293T cells and the REP cells were 
analysed using Proteome Discoverer 2.1 to identify and quantify proteins. The human 
Uniprot list, common contaminant list as well as the individual proteins and complete 
polyprotein encoded by DENV-2 were used as the protein search lists. The proteins 
identified and quantitated in the cell lysates and concentrated cell culture supernatants are 
hereafter referred to as the “proteome” and “secretome”, respectively. For the proteomes, 
a total of 8,139 proteins were identified. Of these proteins, 7,540 were reliably identified 
and quantified based on a ratio determined using ≥ 2 peptides. Subsequently, 7,250 proteins 
were processed for statistical analysis using the Perseus program; inclusion of proteins in 
this group required that they were quantified in at least two of the three experiments in each 
group. The significance of the change in protein abundance was determined over the three 
experiments using an unpaired two-sided Student’s t-test and a significant change defined 
as p < 0.05. Finally, the non-human contaminant proteins were excluded, leaving 7,217 
human proteins for further bioinformatic analysis. 
 For the secretomes, a total of 5,369 proteins were identified, of which 4,579 
proteins were reliably identified and quantified based on a ratio determined using ≥ 2 
peptides. 3,960 proteins that were quantified in at least two of the three experiments in each 
group were processed by statistical analysis as described above. After excluding non-
human proteins, there were 3,867 human proteins that were used for further bioinformatic 
analysis.  
The protein abundance in the proteomes and secretomes from DENV-2 infected 
and REP cells were compared with their abundance in mock infected cells (Supplementary 
Tables S4.1-4.2). The number of proteins in the proteomes and secretomes that increased 
or decreased in abundance with fold change cut-off values of ≥ 2, ≥ 1.5 and ≥ 1.3 in each 







Table 4.1 The number of host proteins that changed in abundance in the proteomes 
of DENV-2 infected HEK293T and REP cells compared with mock infected cells. 
 
Number of proteins 
changed in abundance 
Number of proteins 
significantly changed in 






Increased ≥ 2 fold 14 181 3 159 
Increased ≥ 1.5 fold 335 789 168 616 
Increased ≥ 1.3 fold 1159 1577 422 1203 
Decreased ≥ 2 fold 16 301 1 283 
Decreased ≥ 1.5 fold 145 852 31 752 
Decreased ≥ 1.3 fold 683 1480 115 1118 
 
Table 4.2 The number of host proteins that changed in abundance in the secretomes 
from DENV-2 infected HEK293T and REP cells compared with mock infected cells. 
 
Number of proteins 
changed in abundance 
Number of proteins 
significantly changed in 






Increased ≥ 2 fold 12 267 5 164 
Increased ≥ 1.5 fold 129 599 29 368 
Increased ≥ 1.3 fold 445 899 82 490 
Decreased ≥ 2 fold 12 256 2 209 
Decreased ≥ 1.5 fold 119 662 23 472 





By MS analysis, all DENV-2 structural and NS proteins and NS proteins only were 
detected in the proteome of DENV-2 infected and REP cells respectively by MS analysis, 
respectively. While all structural proteins, NS1, NS4B and NS5 and NS1, NS4B and NS5 
were detected in secretomes of DENV-2 infected and REP cells, respectively.  The % 
coverage, number of peptides, unique peptides and peptide-to-spectrum match (PSMs) of 
DENV-2 proteins detected in the proteomes/secretomes of DENV-2 infected HEK293T 
and REP cells are summarised in Table 4.3. 






Peptides  Unique 
Peptides 
PSMs % coverage Peptides  Unique 
Peptides 
PSMs 
C* 13.2 44.74 6 6 10 15.79 2 2 2 
E* 54.3 30.91 14 14 60 22.63 11 11 16 
pr* 18.7 20.61 3 3 6 9.09 1 1 1 
NS1 39.9 50.28 19 2 62 53.13 24 3 144 
NS2A 23.7 11.47 2 2 3 ND ND ND ND 
NS2B 14 16.15 2 2 4 ND ND ND ND 
NS3 69.3 66.67 42 35 88 ND ND ND ND 
NS4A 14 19.69 2 2 3 ND ND ND ND 
NS4B 26.8 6.05 2 1 4 3.23 1 1 3 
NS5 103.1 51.44 47 41 83 2.11 2 2 2 
* detected in DENV-2 but not REP cells at a > 2 fold change compared to mock infected 
cells. 






Overall, the number of proteins that changed in abundance in the proteome and 
secretome of DENV-2 infected cells compared with mock infected cells increased rather 
than decreased (Tables 4.1 and 4.2). Moreover, there were a greater number of proteins 
that significantly changed in abundance in both the proteome and secretome of REP cells 
than those of DENV-2 infected cells. 
Proteins that significantly changed in abundance in the proteomes/secretomes of 
DENV-2 infected and REP cells compared with mock infected cells, with a fold change in 
abundance cut-off of ≥ 1.5, were selected for further downstream bioinformatics analysis. 
The proteins that met this cut-off in the proteomes and secretomes from DENV-2 infected 
cells compared with mock infected cells are listed in Tables 4.4 and 4.5, respectively. The 
proteins that significantly changed in the proteomes and secretome of REP cells compared 





Table 4.4 Proteins that significantly changed ≥ 1.5 fold in abundance in proteomes 
of DENV-2 infected HEK293T cells compared to mock infected cells. 





Significantly increased ≥1.5 fold in proteome of DENV-2 infected HEK293T  
P56199 Integrin alpha-1  ITGA1 2.24 4.43E-02 
Q9P2F9 Zinc finger protein 319 ZNF319 2.17 8.78E-03 
Q6IAQ2 SDHC protein  SDHC 2.10 4.82E-02 
Q5T8I3 Protein FAM102B  FAM102B 1.90 1.80E-02 
Q9NX18 Succinate dehydrogenase assembly factor 
2, mitochondrial  
SDHAF2 1.88 9.91E-03 
H3BQT6 Tyrosine-protein phosphatase  PTPN9 1.87 3.41E-02 
Q9UEI6 Polio virus related protein 2, alpha isoform  N/A 1.82 4.04E-02 
A0A024R5
K5 
Alpha-1,3-glucosyltransferase  ALG8 1.81 2.53E-02 
Q9HB66 Alternative protein MKKS  MKKS 1.79 1.06E-02 
E9PJL9 NADH dehydrogenase [ubiquinone] 
flavoprotein 1, mitochondrial 
NDUFV1 1.78 4.54E-02 
Q15651 High mobility group nucleosome-binding 
domain-containing protein 3 
HMGN3 1.76 2.87E-02 
J3QL06 Hypoxia up-regulated protein 1 HYOU1 1.75 1.19E-04 
B2R749 Cell division cycle associated 3  CDCA3 1.75 1.36E-02 
B7Z2V6 Vacuolar ATP synthase catalytic subunit 
A, ubiquitous isoform 
ATP6V1A 1.75 2.20E-02 
Q9Y5J6 Mitochondrial import inner membrane 
translocase subunit Tim10 B  
TIMM10B 1.75 3.38E-02 
H0Y9Z5 CCR4-NOT transcription complex subunit 
6-like (Fragment) 
CNOT6L 1.74 3.66E-02 
O14548 Cytochrome c oxidase subunit 7A-related 
protein, mitochondrial 
COX7A2L 1.73 2.13E-02 
D6RB85 Calnexin  CANX 1.73 6.11E-03 
P04179 Superoxide dismutase [Mn], mitochondrial  SOD2 1.72 3.92E-02 
Q69YU5 Uncharacterized protein C12orf73  C12orf73 1.71 2.07E-02 
Q496I0 COX7A2 protein  COX7A2 1.71 3.33E-02 
Q9NX40 OCIA domain-containing protein 1  OCIAD1 1.71 4.22E-03 
P05114 Non-histone chromosomal protein HMG-
14 
HMGN1 1.71 1.83E-02 
A0A024R9
G3 
Derlin  DERL1 1.70 2.64E-02 
Q9NUJ1 Mycophenolic acid acyl-glucuronide 
esterase, mitochondrial  
ABHD10 1.69 4.01E-02 
A8K7T4 Lectin, mannose-binding 2 (LMAN2), 
mRNA 




P15954 Cytochrome c oxidase subunit 7C, 
mitochondrial  
COX7C 1.68 8.53E-03 
A0A2P9A
UF2 
Pyruvate carboxylase  pyc 1.66 1.25E-02 
A0A024R
C97 
Phosphatidylserine synthase 2, isoform  PTDSS2 1.66 1.22E-02 
Q9BQE4 Selenoprotein S  SELENOS 1.66 1.88E-02 
B2R761 Sterol carrier protein 2 (SCP2), mRNA  N/A 1.66 3.81E-02 
Q92520 Protein FAM3C  FAM3C 1.66 3.06E-02 
P48380 Transcription factor RFX3  RFX3 1.66 4.39E-02 
Q7Z4X2 Neuronal protein  N/A 1.66 3.65E-02 
Q0IIN1 Keratin 77  KRT77 1.65 1.74E-02 
P53370 Nucleoside diphosphate-linked moiety X 
motif 6  
NUDT6 1.65 2.75E-02 
Q6DKI0 Raptor protein (Fragment)  raptor 1.65 3.40E-02 
Q6IB54 ATP synthase-coupling factor 6, 
mitochondrial  
ATP5J 1.65 2.56E-02 
D6W551 Chromosome 2 open reading frame 28, 
isoform  
C2orf28 1.64 7.17E-03 
Q4KWH8 1-phosphatidylinositol 4,5-bisphosphate 
phosphodiesterase eta-1  
PLCH1 1.64 7.91E-03 
O60637 Tetraspanin-3  TSPAN3 1.64 2.43E-02 
Q6P587 Acylpyruvase FAHD1, mitochondrial  FAHD1 1.64 3.39E-02 
Q92526 T-complex protein 1 subunit zeta-2 CCT6B 1.64 3.37E-02 
H9STE0 Cytochrome c oxidase subunit 2  COX2 1.64 3.79E-02 
B2R673 Dihydrolipoamide acetyltransferase 
component of pyruvate dehydrogenase 
complex 
N/A 1.64 4.57E-02 
H0YIC4 Citrate synthase (Fragment)  CS 1.63 4.83E-02 
B9ECT5 NADH-ubiquinone oxidoreductase chain 4  NADH4 1.63 5.01E-02 
A0A024R6
A0 
Arginase  ARG2 1.63 2.04E-02 
P08962 CD63 antigen  CD63 1.62 3.59E-02 
O95169 NADH dehydrogenase [ubiquinone] 1 beta 
subcomplex subunit 8, mitochondrial  
NDUFB8 1.62 2.56E-02 
P62072 Mitochondrial import inner membrane 
translocase subunit Tim10  
TIMM10 1.62 3.55E-02 
Q86U75 Dihydropyrimidinase-like 2  N/A 1.62 1.68E-02 
A8K5D4 Myelin protein zero-like 1, isoform  MPZL1 1.61 2.94E-02 
A0A024R8
T9 
Synaptogyrin  SYNGR2 1.61 1.75E-02 
Q9BSF4 Mitochondrial import inner membrane 
translocase subunit Tim29  
TIMM29 1.61 4.03E-02 
B1Q2B0 URCC5 URCC5 1.60 5.11E-03 




B2R6N9 Signal sequence receptor, alpha 
(translocon-associated protein alpha) 
(SSR1) 
N/A 1.60 1.39E-02 
Q9H490 Phosphatidylinositol glycan anchor 
biosynthesis class U protein  
PIGU 1.60 4.17E-02 







Tetraspanin CD151 1.59 2.36E-02 
Q6IBA0 NADH dehydrogenase (Ubiquinone) Fe-S 
protein 5, 15kDa (NADH-coenzyme Q 
reductase)  
NDUFS5 1.59 4.04E-02 
Q9NX24 H/ACA ribonucleoprotein complex subunit 
2  
NHP2 1.59 2.62E-02 
P36957 Dihydrolipoyllysine-residue 
succinyltransferase component of 2-
oxoglutarate dehydrogenase complex, 
mitochondrial  
DLST 1.59 2.76E-02 
A0A1B0G
W05 
Probable C-mannosyltransferase DPY19L1  DPY19L1 1.58 2.37E-02 
A0A0S2Z3
G4 
Frataxin isoform 1 (Fragment)  FXN 1.58 2.88E-02 
G3V556 ATP synthase membrane subunit 6.8PL  ATP5MPL 1.58 2.67E-02 
A4D1U3 Single-stranded DNA binding protein 1,  SSBP1 1.58 2.34E-02 
B4DLN7 Cytochrome P450, family 20, subfamily A, 
polypeptide 1, transcript variant 1 
N/A 1.58 4.73E-02 
V9HWB4 Endoplasmic reticulum chaperone BiP HSPA5 1.58 2.29E-02 
Q59GX2 Solute carrier family 2 (Facilitated glucose 
transporter), member 1 variant  
N/A 1.57 2.59E-02 
A0A0R4J2
F2 
Claudin domain-containing protein 1  CLDND1 1.57 2.90E-03 
A0A024R
BY9 
Cytochrome c heme lyase  HCCS 1.57 4.73E-03 
P35914 Hydroxymethylglutaryl-CoA lyase, 
mitochondrial  
HMGCL 1.56 2.83E-02 
Q4QQP8 PTGFRN protein (Fragment)  PTGFRN 1.56 1.72E-02 
P62487 DNA-directed RNA polymerase II subunit 
RPB7  
POLR2G 1.56 4.28E-02 
B3KQB4 PRA1 family protein  N/A 1.56 3.26E-02 
O75381 Peroxisomal membrane protein PEX14  PEX14 1.56 3.33E-02 
E5KSU5 Mitochondrial transcription factor A TFAM 1.56 3.84E-02 
Q9H173 Nucleotide exchange factor SIL1 SIL1 1.56 2.06E-02 
E9PIE4 Mitochondrial carrier homolog 2 
(Fragment) 
MTCH2 1.56 1.69E-02 
Q15907 Ras-related protein Rab-11B  RAB11B 1.56 3.84E-02 
O60783 28S ribosomal protein S14, mitochondrial  MRPS14 1.56 2.43E-02 




Q9BV79 Enoyl-[acyl-carrier-protein] reductase, 
mitochondrial 
MECR 1.56 4.04E-02 
B4DDK9 Alpha-1,6-mannosyl-glycoprotein2-beta-
N- acetylglucosaminyltransferase  
N/A 1.56 4.04E-02 
Q9C0E8 Endoplasmic reticulum junction formation 
protein lunapark  
LNPK 1.55 2.63E-02 
O43181 NADH dehydrogenase [ubiquinone] iron-
sulfur protein 4, mitochondrial  
NDUFS4 1.55 3.32E-02 
P11117 Lysosomal acid phosphatase  ACP2 1.55 3.19E-02 
Q5RI15 Cytochrome c oxidase assembly protein 
COX20, mitochondrial  
COX20 1.55 4.60E-02 
Q9Y320 Thioredoxin-related transmembrane 
protein 2  
TMX2 1.55 4.66E-02 
Q9UII2 ATPase inhibitor, mitochondrial  ATP5IF1 1.55 2.93E-02 
O00479 High mobility group nucleosome-binding 
domain-containing protein 4  
HMGN4 1.55 3.52E-02 
Q92791 Endoplasmic reticulum protein SC65  P3H4 1.55 2.58E-02 
A0A024R9
D2 
Metadherin, isoform  MTDH 1.55 3.07E-02 
A0A024R8
S5 
Protein disulfide-isomerase  P4HB 1.55 4.89E-02 
Q68D91 Metallo-beta-lactamase domain-containing 
protein 2  
MBLAC2 1.55 2.98E-02 
Q9NWQ8 Phosphoprotein associated with 
glycosphingolipid-enriched microdomains 
1 
PAG1 1.55 3.72E-02 
Q9HDC9 Adipocyte plasma membrane-associated 
protein  
APMAP 1.55 3.85E-02 
Q9HB40 Retinoid-inducible serine carboxypeptidase  SCPEP1 1.55 1.77E-02 





Q6ZMG9 Ceramide synthase 6  CERS6 1.54 2.85E-02 
P30049 ATP synthase subunit delta, mitochondrial  ATP5F1D 1.54 3.19E-02 
V9GYT7 PC4 and SFRS1-interacting protein 
(Fragment)  
PSIP1 1.54 3.29E-02 
O75380 NADH dehydrogenase [ubiquinone] iron-
sulfur protein 6, mitochondrial  
NDUFS6 1.54 4.16E-02 
E9PKU7 Neutral alpha-glucosidase AB  GANAB 1.54 2.98E-02 
O75844 CAAX prenyl protease 1 homolog  ZMPSTE2
4 
1.54 3.58E-02 
Q6P1L8 39S ribosomal protein L14, mitochondrial  MRPL14 1.54 4.07E-02 
B2R9T9 Transmembrane protein 109 TMEM10
9 
1.54 1.59E-02 
B3KN15 Heparan sulfate 2-O-sulfotransferase 1  HS2ST1 1.53 4.02E-02 
A0A0S2Z5
H0 
Mitochondrial ribosomal protein S28 
isoform 2 (Fragment)  
MRPS28 1.53 2.05E-02 
A8K337 Catechol-O-methyltransferase domain 
containing 1 (COMTD1), mRNA  




Q5T6U8 High mobility group AT-hook 1  HMGA1 1.53 3.75E-02 
Q5T1C6 Acyl-coenzyme A thioesterase THEM4  THEM4 1.53 4.35E-02 
O43493 Trans-Golgi network integral membrane 
protein 2 
TGOLN2 1.53 2.64E-02 
Q9UDW1 Cytochrome b-c1 complex subunit 9  UQCR10 1.53 2.99E-02 
A0A024R
BE7 
Thymopoietin, isoform  TMPO 1.53 4.49E-02 
A0A024R4
K3 
Malate dehydrogenase  MDH2 1.53 4.81E-02 
Q9H6E4 Coiled-coil domain-containing protein 134  CCDC134 1.52 4.44E-02 
Q05DH5 EXTL2 protein (Fragment)  EXTL2 1.52 2.59E-02 
P14927 Cytochrome b-c1 complex subunit 7 UQCRB 1.52 4.64E-02 
Q5JTV8 Torsin-1A-interacting protein 1  TOR1AIP
1 
1.52 4.38E-02 
E9PCR7 2-oxoglutarate dehydrogenase, 
mitochondrial  
OGDH 1.52 4.62E-02 
Q8N4H5 Mitochondrial import receptor subunit 
TOM5 homolog  
TOMM5 1.52 1.39E-02 
Q8NFQ8 Torsin-1A-interacting protein 2  TOR1AIP
2 
1.52 1.31E-02 
H3BNX8 Cytochrome c oxidase subunit 5A, 
mitochondrial  
COX5A 1.52 3.66E-02 
A0A090N8
Y2 
Protein disulfide-isomerase A4  ERP70 1.52 4.31E-02 
Q96BP2 Coiled-coil-helix-coiled-coil-helix domain-
containing protein 1  
CHCHD1 1.52 4.09E-02 
Q09328 Alpha-1,6-mannosylglycoprotein 6-beta-
N-acetylglucosaminyltransferase A  
MGAT5 1.52 4.46E-02 
Q3ZAQ7 Vacuolar ATPase assembly integral 
membrane protein VMA21  
VMA21 1.52 1.22E-02 
L0R6Q1 SLC35A4 upstream open reading frame 
protein  
SLC35A4 1.52 4.83E-02 
Q96AY3 Peptidyl-prolyl cis-trans isomerase 
FKBP10  
FKBP10 1.52 1.48E-02 
A0A087W
SV8 
Nucleobindin 2, isoform  NUCB2 1.52 4.94E-02 
Q8N766 ER membrane protein complex subunit 1  EMC1 1.51 4.28E-02 
P35609 Alpha-actinin-2  ACTN2 1.51 2.55E-02 
Q13443 Disintegrin and metalloproteinase domain-
containing protein 9  
ADAM9 1.51 4.78E-02 
V9HWF6 Alpha-1-acid glycoprotein  ORM1 1.51 1.03E-02 
P51970 NADH dehydrogenase [ubiquinone] 1 
alpha subcomplex subunit 8  
NDUFA8 1.51 3.43E-02 
A8K4V4 Mitochondrial ribosomal protein L43 
(MRPL43), transcript variant 1 
MRPL43 1.51 3.72E-02 
E7EPT4 NADH dehydrogenase [ubiquinone] 
flavoprotein 2, mitochondrial  





protein glycosyltransferase subunit DAD1 
DAD1 1.51 4.59E-02 
Q9NPJ3 Acyl-coenzyme A thioesterase 13  ACOT13 1.51 3.05E-02 
O95881 Thioredoxin domain-containing protein 12  TXNDC12 1.51 3.50E-02 
B2R4A2 Cytochrome b-c1 complex subunit 7  N/A 1.51 3.88E-02 
A0A024R8
Q1 
Glucosidase, alpha acid (Pompe disease, 
glycogen storage disease type II) 
GAA 1.51 9.26E-03 
Q99720 Sigma non-opioid intracellular receptor 1  SIGMAR1 1.51 4.90E-02 
Q15084 Protein disulfide-isomerase A6  PDIA6 1.51 2.58E-02 
A0A024R
BS4 
Scavenger receptor class B, member 1, 
isoform  
SCARB1 1.51 3.11E-02 
Q96EL3 39S ribosomal protein L53, mitochondrial  MRPL53 1.51 1.87E-02 
A8K769 Secretory carrier-associated membrane 
protein  
N/A 1.51 4.61E-02 
A0A087W
ZE9 
High mobility group nucleosome-binding 
domain-containing protein 3  
HMGN3 1.50 3.80E-02 
Q96HE7 ERO1-like protein alpha  ERO1A 1.50 2.67E-02 
Q53GR7 Solute carrier family 25, member 13 
(Citrin) variant (Fragment)  
N/A 1.50 4.30E-02 
Q9UKU7 Isobutyryl-CoA dehydrogenase, 
mitochondrial  
ACAD8 1.50 4.12E-02 
Q14165 Malectin  MLEC 1.50 4.87E-02 
P16104 Histone H2AX  H2AFX 1.50 4.32E-02 
P60468 Protein transport protein Sec61 subunit 
beta  
SEC61B 1.50 2.39E-02 
Q59E90 Alpha-mannosidase (Fragment)  N/A 1.50 4.07E-02 
A8K2Q6 Peptidyl-prolyl cis-trans isomerase N/A 1.50 2.09E-02 
A0A2S1P
H31 
Methylmalonyl-CoA mutase variant  MUT 1.50 4.94E-02 
B0QYW5 Peroxisomal membrane protein PMP34 SLC25A17 1.50 2.95E-02 
B2R6X6 Peptidyl-prolyl cis-trans isomerase N/A 1.50 4.29E-02 
A0A024R
DY3 
Lysosomal-associated membrane protein 1  LAMP1 1.50 3.83E-02 
B4E2S3 RFTN1 protein RFTN1 1.50 2.73E-02 
Q9BRX8 Redox-regulatory protein FAM213A  PRXL2A 1.50 3.35E-02 
Q2M1J6 Oxidase (Cytochrome c) assembly 1-like OXA1L 1.50 3.67E-02 
A0A024R3
C4 
KDEL (Lys-Asp-Glu-Leu) containing 2, 
isoform 
KDELC2 1.50 3.74E-02 
Q5HYK3 2-methoxy-6-polyprenyl-1,4-benzoquinol 
methylase, mitochondrial 
COQ5 1.50 2.89E-02 
Significantly decreased ≥1.5 fold in proteome of DENV-2 infected HEK293T cells  
Q6FIC5 Chloride intracellular channel protein  CLIC4 0.67 3.35E-02 
A8K646 Osteoclast stimulating factor 1 (OSTF1)  OSTF1 0.67 3.71E-02 
Q12933 TNF receptor-associated factor 2  TRAF2 0.67 3.18E-02 
H7C3M7 FERM, ARHGEF and pleckstrin domain-
containing protein 2 (Fragment) 






Eukaryotic translation initiation factor 5, 
isoform  
EIF5 0.66 3.48E-02 
F2Z2X4 Exportin-4  XPO4 0.66 1.49E-02 
P43490 Nicotinamide phosphoribosyltransferase  NAMPT 0.65 3.50E-02 
Q9C0D3 Protein zyg-11 homolog B ZYG11B 0.65 3.02E-02 
P30291 Wee1-like protein kinase  WEE1 0.65 1.72E-04 
Q6FI81 Anamorsin  CIAPIN1 0.65 3.74E-02 
O76064 E3 ubiquitin-protein ligase RNF8  RNF8 0.65 3.50E-02 
O43639 Cytoplasmic protein NCK2  NCK2 0.64 3.64E-02 
Q96D05 Uncharacterized protein FAM241B  FAM241B 0.64 1.59E-02 
A0A024Q
Z45 
BRCA1 interacting protein C-terminal 
helicase 1, isoform  
BRIP1 0.64 2.69E-03 
Q59FS2 ZNF589 protein variant (Fragment)  N/A 0.64 2.68E-02 





O75953 DnaJ homolog subfamily B member 5  DNAJB5 0.61 2.40E-02 
B4DUT8 Calponin  CNN2 0.61 1.99E-02 
P31629 Transcription factor HIVEP2  HIVEP2 0.61 1.98E-02 
Q8IXQ3 Uncharacterized protein C9orf40  C9orf40 0.60 3.98E-02 
Q00534 Cyclin-dependent kinase 6  CDK6 0.60 2.96E-02 
X6RLX0 ELKS/Rab6-interacting/CAST family 
member 1  
ERC1 0.59 2.07E-02 
Q8N9N8 Probable RNA-binding protein EIF1AD  EIF1AD 0.59 3.13E-02 
P42677 40S ribosomal protein S27  RPS27 0.58 2.75E-02 
O15541 RING finger protein 113A  RNF113A 0.58 3.07E-02 
Q66K64 DDB1- and CUL4-associated factor 15  DCAF15 0.57 5.00E-02 
B7ZLK1 KIAA0528 protein  KIAA0528 0.56 3.60E-02 
P52788 Spermine synthase  SMS 0.56 7.80E-03 
A0A024R2
T2 
KIAA1143, isoform  KIAA1143 0.55 3.00E-02 
P02533 Keratin, type I cytoskeletal 14  KRT14 0.53 1.59E-02 







Table 4.5 Proteins that significantly changed ≥ 1.5 fold in abundance in secretomes 
from DENV-2 infected HEK293T cells compared to mock infected cells. 





Significantly increased ≥1.5 fold in secretome of DENV-2 infected HEK293T 
H3BMS5 PH domain leucine-rich repeat-
containing protein phosphatase 2  
PHLPP2 13.46 2.62E-03 
B2R4R0 Histone H4  HIST1H4L 2.97 1.87E-02 
Q12797 Aspartyl/asparaginyl beta-hydroxylase  ASPH 2.74 8.80E-04 
Q7L5D6 Golgi to ER traffic protein 4 homolog  GET4 2.10 3.27E-02 
Q15008 26S proteasome non-ATPase regulatory 
subunit 6  
PSMD6 2.02 3.46E-02 
Q9HBI1 Beta-parvin  PARVB 1.98 4.78E-02 
O43345 Zinc finger protein 208  ZNF208 1.97 7.00E-03 
P51784 Ubiquitin carboxyl-terminal hydrolase 
11  
USP11 1.81 2.30E-02 
F8W8D3 Histone RNA hairpin-binding protein  SLBP 1.80 3.46E-02 
Q9Y657 Spindlin-1  SPIN1 1.74 1.80E-02 
A8K061 Angiopoietin-like 3, mRNA  N/A 1.69 4.81E-02 
P22059 Oxysterol-binding protein 1  OSBP 1.67 5.04E-03 
A0A024R
1Z6 
Vesicle amine transport protein 1 
homolog  
VAT1 1.64 1.52E-02 
A8K5Y7 Exportin 5  XPO5 1.62 3.51E-02 
E5KLL9 Mitochondrial dynamin-like 120 kDa 
protein  
N/A 1.60 4.70E-02 
P61225 Ras-related protein Rap-2b  RAP2B 1.60 4.84E-02 
B5BU08 U2 small nuclear RNA auxillary factor 1 
isoform a  
U2AF1 1.59 3.56E-02 
O60568 Procollagen-lysine,2-oxoglutarate 5-
dioxygenase 3  
PLOD3 1.58 1.88E-02 
Q9BZX2 Uridine-cytidine kinase 2 UCK2 1.58 3.17E-02 
O14929 Histone acetyltransferase type B 
catalytic subunit 
HAT1 1.57 3.03E-02 
P26599 Polypyrimidine tract-binding protein 1  PTBP1 1.56 4.52E-02 
Q13162 Peroxiredoxin-4  PRDX4 1.56 5.42E-04 
Q9BV44 THUMP domain-containing protein 3  THUMPD3 1.55 8.68E-03 
Q86XP3 ATP-dependent RNA helicase DDX42 DDX42 1.54 3.97E-02 
A0A023T
6R1 
Mago nashi protein  FLJ10292 1.54 2.50E-02 
P25490 Transcriptional repressor protein YY1  YY1 1.53 4.23E-02 
A0A024R
C37 
Uncharacterized protein  P15RS 1.50 1.31E-02 
P13010 X-ray repair cross-complementing 
protein 5  




P48556 26S proteasome non-ATPase regulatory 
subunit 8  
PSMD8 1.49 1.31E-02 
Significantly decreased ≥1.5 fold in secreteome of DENV-2 infected HEK293T 
Q96BK5 PIN2/TERF1-interacting telomerase 
inhibitor 1  
PINX1 0.66 2.48E-02 
Q6IAX2 RPL21 protein  RPL21 0.66 1.92E-02 
B2RDV7 tRNA-dihydrouridine(47) synthase  N/A 0.66 2.14E-02 
Q03701 CCAAT/enhancer-binding protein zeta  CEBPZ 0.64 3.01E-02 
B3KNS8 Surfeit locus protein 6  SURF6 0.64 2.28E-03 
A0A024R
0Z3 
DEAD (Asp-Glu-Ala-Asp) box 
polypeptide 23  
DDX23 0.64 1.85E-02 
Q03164 Histone-lysine N-methyltransferase 2A  KMT2A 0.64 3.51E-02 
O95292 Vesicle-associated membrane protein-
associated protein B/C  
VAPB 0.63 2.88E-02 
A5D8W8 Gamma-glutamyltransferase 7  GGT7 0.63 4.46E-02 
Q9Y4W2 Ribosomal biogenesis protein LAS1L  LAS1L 0.63 2.04E-02 
A0A087W
YZ4 
Glycoprotein hormones alpha chain  CGA 0.62 1.26E-02 
Q9UPN4 Centrosomal protein of 131 kDa  CEP131 0.61 3.88E-02 
A0A0X1K
G71 
Negative elongation factor B NELFB 0.58 2.95E-02 
Q86UE8 Serine/threonine-protein kinase tousled-
like 2  
TLK2 0.55 1.97E-03 
Q9Y4C8 Probable RNA-binding protein 19  RBM19 0.55 4.78E-02 
Q15059 Bromodomain-containing protein 3  BRD3 0.55 4.77E-02 
P49916 DNA ligase 3 LIG3 0.55 4.65E-02 
Q6P1M0 Long-chain fatty acid transport protein 4  SLC27A4 0.55 4.38E-02 
G5EA30 CUG triplet repeat, RNA binding 
protein 1  
CELF1 0.54 3.88E-02 
A0A0A0
MQX1 
Unconventional myosin-X  MYO10 0.54 1.64E-02 
B2R5U7 CCAAT-box-binding transcription 
factor (CBF2)  
N/A 0.53 1.22E-02 
Q99442 Translocation protein SEC62  SEC62 0.43 8.22E-03 
A0A0J9Y
XC7 
LIM and senescent cell antigen-like-
containing domain protein  





An integrated analysis of the proteins that significantly changed in both the 
proteomes and secretomes from DENV-2 infected HEK293T and REP cells compared to 
mock infected cells was done to determine the relationship of intracellular and secreted 
proteins (Figure 4.3A). There were 2,984 proteins that were commonly identified in both 
the proteomes and secretomes.  
A less stringent cut-off (compared to the ≥ 1.5 fold  cut-off used for the analysis of 
either data set alone) of a ≥ 1.3 fold change in abundance was applied for combined data 
analysis, to allow for proteins that altered in one data set but not to the threshold of 1.5 fold 
in the other dataset. The number of proteins that significantly changed ≥1.3 fold in amount 
in both the proteomes and secretomes from DENV-2 infected HEK293T and REP cells 
compared to mock infected cells are summarised in Figures 4.3B and 4.3C, respectively. 
There were only 5 common proteins that were significantly altered ≥1.3 fold in amount in 
the proteomes and secretomes from DENV-2 infected HEK293T cells compared to mock 
infected cells (listed in Table 4.6). Whereas, there were 309 common proteins that were 
significantly altered ≥1.3 fold in amount in the proteome and secretome of REP cells 
compared to mock infected cells (Figure 4.3C). Half of these proteins (150 of 309 proteins) 







Figure 4.3 Overlap between proteins detected in proteomes and secretomes of DENV-2 
infection and in REP cells. 
 (A)  Venn diagram shows the number of proteins that were detected in either the proteomes 
or secretomes of DENV-2 infected HEK293T and REP cells, as well as those detected in 
both. (B-C) Venn diagram shows the number of proteins that significantly (P-value < 0.05) 
increased and decreased (≥1.3 fold) in the proteomes and secretomes from DENV-2 





Table 4.6 Host proteins that were significantly changed ≥ 1.3 fold in amount in both 
the proteomes and secretomes from DENV-2 infected HEK293T cells compared to 
mock infected cells. 













































Increased in both cell lysates and secretomes 
Q8NFH4 Nucleoporin Nup37  NUP37 1.39 9.80E-03 1.45 4.09E-02 
A0A024R
9B7 
Cytochrome c oxidase 
subunit VIc  
COX6C 1.46 4.63E-02 1.45 3.55E-02 
Increased in cell lysates but decrease in secretomes 
Q96KC8 DnaJ homolog subfamily C 
member 1  
DNAJC1 1.30 2.30E-02 0.76 4.30E-02 
O95292 Vesicle-associated membrane 
protein-associated protein 
B/C  
VAPB 1.47 4.18E-02 0.63 2.88E-02 
Decreased in cell lysates but increase in secretomes 
A8K646 Osteoclast stimulating factor 
1  
OSTF1 0.67 3.71E-02 1.47 2.83E-03 
 
Proteins that were commonly altered in amount (increased and decreased) in 
proteomes and secretomes of DENV-2 infected and REP cells compared to mock infected 
cells were also identified (Figure 4.4). The proteins that were significantly altered ≥ 1.3 
fold in the proteomes (n=304) and secretomes (n=56) from both DENV-2 infected and REP 
cells compared to mock infected cells are listed in Tables 4.7 and 4.8, respectively. 
Interestingly, nucleoporin Nup37 (NUP37) was the only protein that significantly 
increased ≥1.3 fold in the proteome and secretome of both DENV-2 infected and REP cells 







Figure 4.4 Overlap between proteins commonly altered (≥ 1.3 fold) in both proteomes and 
secretomes of DENV-2 infected HEK293T and REP cells compared to mock infected cells. 
 Venn diagram shows the number of common proteins that significantly (P-value < 0.05) 
increased and decreased (≥1.3 fold) in proteomes (A) and secretomes (B) from DENV-2 





Table 4.7 List of common proteins that were significantly altered ≥ 1.3 fold in 
amount in proteomes of both DENV-2 infected HEK293T and REP cells compared 
to mock infected cells. 




































Increased in proteome of both DENV-2 and REP cells  
Q9P2F9 Zinc finger protein 319  ZNF319 2.17 8.78E-03 2.29 6.17E-04 
Q5T8I3 Protein FAM102B  FAM102B 1.90 1.80E-02 2.02 2.37E-02 
Q9NX18 Succinate dehydrogenase 
assembly factor 2 
SDHAF2 1.88 9.91E-03 1.77 2.83E-02 
H3BQT6 Tyrosine-protein 
phosphatase  
PTPN9 1.87 3.41E-02 2.87 7.49E-03 
Q9HB66 Alternative protein MKKS  MKKS 1.79 1.06E-02 1.67 3.16E-02 
B7Z2V6 Vacuolar ATP synthase 
catalytic subunit A, 
ubiquitous  
N/A 1.75 2.20E-02 2.29 5.30E-03 
H0Y9Z5 CCR4-NOT transcription 
complex subunit 6-like  
CNOT6L 1.74 3.66E-02 3.00 6.19E-03 
Q69YU5 Uncharacterized protein 
C12orf73  
C12orf73 1.71 2.07E-02 1.64 3.31E-02 
Q496I0 COX7A2 protein  COX7A2  1.71 3.33E-02 1.47 1.82E-02 
Q9NX40 OCIA domain-containing 
protein 1  
OCIAD1 1.71 4.22E-03 1.52 3.50E-02 
Q9NUJ1 Mycophenolic acid acyl-
glucuronide esterase, 
mitochondrial  




synthase 2, isoform 
CRA_a  
PTDSS2 1.66 1.22E-02 1.77 5.47E-03 
B2R761 Sterol carrier protein 2 
(SCP2), mRNA 
N/A 1.66 3.81E-02 1.56 3.18E-02 
Q92520 Protein FAM3C  FAM3C 1.66 3.06E-02 2.11 8.88E-03 
Q7Z4X2 Neuronal protein  N/A 1.66 3.65E-02 1.41 3.92E-02 
Q0IIN1 Keratin 77 KRT77 1.65 1.74E-02 1.52 6.55E-04 
Q6IB54 ATP synthase-coupling 
factor 6, mitochondrial  
ATP5J 1.65 2.56E-02 1.59 1.55E-02 
Q4KWH8 1-phosphatidylinositol 4,5-
bisphosphate 
phosphodiesterase eta-1  
PLCH1 1.64 7.91E-03 1.39 3.29E-02 
Q6P587 Acylpyruvase FAHD1, 
mitochondrial  




Q92526 T-complex protein 1 
subunit zeta-2  
CCT6B 1.64 3.37E-02 1.35 4.39E-02 
H9STE0 Cytochrome c oxidase 
subunit 2  
COX2 1.64 3.79E-02 1.38 3.16E-02 
B2R673 Dihydrolipoamide 
acetyltransferase 
component of pyruvate 
dehydrogenase complex  
N/A 1.64 4.57E-02 1.96 6.18E-03 
O95169 NADH dehydrogenase 
[ubiquinone] 1 beta 
subcomplex subunit 8, 
mitochondrial  
NDUFB8 1.62 2.56E-02 1.65 6.58E-03 
P62072 Mitochondrial import 
inner membrane 
translocase subunit Tim10  
TIMM10 1.62 3.55E-02 1.45 2.90E-02 
A8K5D4 Myelin protein zero-like 1, 
isoform CRA_b  
MPZL1 1.61 2.94E-02 1.66 1.71E-02 
Q9BSF4 Mitochondrial import 
inner membrane 
translocase subunit Tim29  
TIMM29 1.61 4.03E-02 1.54 5.25E-03 
B1Q2B0 URCC5  URCC5 1.60 5.11E-03 2.20 1.52E-04 
B2R6N9 Signal sequence receptor, 
alpha (translocon-
associated protein alpha) 
(SSR1), mRNA  
SSR1 1.60 1.39E-02 1.33 2.75E-02 
A0A024R
CB3 
Tetraspanin CD151 1.59 2.36E-02 2.14 4.12E-03 
Q6IBA0 NADH dehydrogenase 
(Ubiquinone) Fe-S protein 
5, 15kDa  
NDUFS5 1.59 4.04E-02 1.37 1.67E-02 
Q9NX24 H/ACA ribonucleoprotein 
complex subunit 2  







DLST 1.59 2.76E-02 1.67 8.36E-03 
A0A0S2Z3
G4 
Frataxin isoform 1  FXN 1.58 2.88E-02 1.36 4.76E-02 
A4D1U3 Single-stranded DNA 
binding protein 1, isoform 
CRA_a  
SSBP1 1.58 2.34E-02 1.88 3.39E-03 
B4DLN7 Cytochrome P450, family 20, subfamily 
A, polypeptide 1, transcript variant 1, 
mRNA  




containing protein 1  
CLDND1 1.57 2.90E-03 1.48 9.02E-03 
P35914 Hydroxymethylglutaryl-
CoA lyase, mitochondrial  




Q4QQP8 PTGFRN protein 
(Fragment)  
PTGFRN 1.56 1.72E-02 3.70 8.02E-04 
P62487 DNA-directed RNA 
polymerase II subunit 
RPB7  
POLR2G 1.56 4.28E-02 1.71 1.24E-02 
B3KQB4 PRA1 family protein  N/A 1.56 3.26E-02 1.59 3.57E-03 
O75381 Peroxisomal membrane 
protein PEX14  
PEX14 1.56 3.33E-02 1.54 2.34E-02 
E5KSU5 Mitochondrial 
transcription factor A 
TFAM 1.56 3.84E-02 2.47 1.03E-03 
E9PIE4 Mitochondrial carrier 
homolog 2 (Fragment)  
MTCH2 1.56 1.69E-02 1.70 4.64E-03 
Q15907 Ras-related protein Rab-
11B  
RAB11B 1.56 3.84E-02 1.50 3.82E-02 
O60783 28S ribosomal protein 
S14, mitochondrial  
MRPS14 1.56 2.43E-02 1.79 6.79E-03 
O75947 ATP synthase subunit d, 
mitochondrial  









N/A 1.56 4.04E-02 1.65 3.55E-02 
O43181 NADH dehydrogenase 
[ubiquinone] iron-sulfur 
protein 4, mitochondrial  
NDUFS4 1.55 3.32E-02 1.42 2.90E-02 
Q5RI15 Cytochrome c oxidase 
assembly protein COX20, 
mitochondrial  
COX20 1.55 4.60E-02 1.63 2.26E-02 
Q9UII2 ATPase inhibitor, 
mitochondrial 
ATP5IF1 1.55 2.93E-02 1.53 2.70E-02 




HMGN4 1.55 3.52E-02 1.53 2.78E-02 
Q9HB40 Retinoid-inducible serine 
carboxypeptidase  
SCPEP1 1.55 1.77E-02 1.53 1.23E-02 
Q9NPL8 Complex I assembly factor 
TIMMDC1, mitochondrial  
TIMMDC1 1.54 3.61E-02 1.55 8.51E-03 
Q6ZMG9 Ceramide synthase 6  CERS6 1.54 2.85E-02 1.70 2.27E-02 
V9GYT7 PC4 and SFRS1-
interacting protein 
(Fragment) 
PSIP1 1.54 3.29E-02 1.72 1.77E-02 
O75380 NADH dehydrogenase 
[ubiquinone] iron-sulfur 
protein 6, mitochondrial  
NDUFS6 1.54 4.16E-02 1.32 2.45E-02 
O75844 CAAX prenyl protease 1 
homolog  




Q6P1L8 39S ribosomal protein 
L14, mitochondrial 
MRPL14 1.54 4.07E-02 1.43 2.90E-02 
B2R9T9 Transmembrane protein 
109 
N/A 1.54 1.59E-02 1.66 1.57E-02 
B3KN15 Heparan sulfate 2-O-
sulfotransferase 1  




protein S28 isoform 2  
MRPS28 1.53 2.05E-02 1.68 1.28E-02 
A8K337 Catechol-O-
methyltransferase domain 
containing 1 (COMTD1) 
N/A 1.53 1.44E-02 1.51 3.22E-03 
Q5T1C6 Acyl-coenzyme A 
thioesterase THEM4 
THEM4 1.53 4.35E-02 1.42 2.73E-02 
O43493 Trans-Golgi network 
integral membrane protein 
2  
TGOLN2 1.53 2.64E-02 2.61 9.49E-03 
A0A024R
BE7 
Thymopoietin TMPO 1.53 4.49E-02 1.79 5.92E-03 
A0A024R4
K3 
Malate dehydrogenase  MDH2 1.53 4.81E-02 1.63 2.16E-02 
Q9H6E4 Coiled-coil domain-
containing protein 134 
CCDC134 1.52 4.44E-02 1.70 2.16E-02 
Q05DH5 EXTL2 protein EXTL2 1.52 2.59E-02 3.07 5.22E-04 
Q5JTV8 Torsin-1A-interacting 
protein 1  
TOR1AIP1 1.52 4.38E-02 1.58 1.41E-02 
Q8NFQ8 Torsin-1A-interacting 
protein 2  
TOR1AIP2 1.52 1.31E-02 1.35 1.63E-02 
H3BNX8 Cytochrome c oxidase 
subunit 5A, mitochondrial  
COX5A 1.52 3.66E-02 1.37 3.36E-02 
Q96BP2 Coiled-coil-helix-coiled-
coil-helix domain-
containing protein 1 
CHCHD1 1.52 4.09E-02 1.52 9.30E-03 
Q3ZAQ7 Vacuolar ATPase 
assembly integral 
membrane protein VMA21  
VMA21 1.52 1.22E-02 1.53 6.96E-03 
L0R6Q1 SLC35A4 upstream open 
reading frame protein  
SLC35A4 1.52 4.83E-02 1.32 1.72E-02 
P35609 Alpha-actinin-2  ACTN2 1.51 2.55E-02 1.61 3.69E-03 
Q13443 Disintegrin and 
metalloproteinase domain-
containing protein 9  
ADAM9 1.51 4.78E-02 1.59 1.03E-02 
A8K4V4 Mitochondrial ribosomal 
protein L43 (MRPL43), 
transcript variant 1 
N/A 1.51 3.72E-02 1.49 6.22E-03 
E7EPT4 NADH dehydrogenase 
[ubiquinone] flavoprotein 
2, mitochondrial 
NDUFV2 1.51 1.74E-02 1.34 2.78E-02 
Q9NPJ3 Acyl-coenzyme A 
thioesterase 13  





containing protein 12  
TXNDC12 1.51 3.50E-02 1.73 1.16E-02 
A0A024R8
Q1 
Glucosidase, alpha acid 
(Pompe disease, glycogen 
storage disease type II) 
GAA 1.51 9.26E-03 1.43 1.58E-02 
A0A024R
BS4 
Scavenger receptor class 
B, member 1, isoform 
CRA_b  
SCARB1 1.51 3.11E-02 1.67 2.52E-02 
Q96EL3 39S ribosomal protein 
L53, mitochondrial 




N/A 1.51 4.61E-02 1.53 3.64E-02 
A0A087W
ZE9 




HMGN3 1.50 3.80E-02 1.73 7.67E-03 




ACAD8 1.50 4.12E-02 1.94 9.68E-04 
Q14165 Malectin  MLEC 1.50 4.87E-02 1.89 7.09E-04 




mutase variant  
MUT 1.50 4.94E-02 1.39 1.94E-02 
B2R6X6 Peptidyl-prolyl cis-trans 
isomerase  




membrane protein 1, 
isoform CRA_a  
N/A 1.50 3.83E-02 2.21 3.33E-03 
Q5HYK3 2-methoxy-6-polyprenyl-
1,4-benzoquinol 
methylase, mitochondrial  
N/A 1.50 2.89E-02 1.49 2.50E-02 
Q13232 Nucleoside diphosphate 
kinase 3  
NME3 1.49 1.01E-02 1.39 3.01E-02 
Q7LD69 NADH-ubiquinone 
oxidoreductase Fe-S 
protein 7 variant  
N/A 1.49 4.10E-02 1.48 7.51E-03 
A0A024R
B75 
Citrate synthase  CS 1.49 2.86E-02 1.51 1.20E-02 
B4DEF8 39S ribosomal protein 
L45, mitochondrial  
N/A 1.48 4.62E-02 1.37 2.10E-02 
Q96DP0 NADH-UBIQUINONE 
OXIDOREDUCTASE 9 
KD SUBUNIT  
N/A 1.48 3.23E-02 1.33 4.76E-02 
A0A087W
WD4 
Neural cell adhesion 
molecule 1  







LETM1 1.48 3.81E-02 1.40 4.29E-02 
Q6P1N1 PPM2C protein 
(Fragment)  




ACAT1 1.47 3.64E-02 1.62 1.79E-02 
J3QLS3 28S ribosomal protein S7, 
mitochondrial  
MRPS7 1.47 3.17E-02 1.61 1.35E-02 
Q8IXM3 39S ribosomal protein 
L41, mitochondrial  
MRPL41 1.47 2.22E-02 1.45 3.39E-02 
O15446 DNA-directed RNA 
polymerase I subunit 
RPA34  
CD3EAP 1.47 4.30E-02 2.31 4.36E-03 
Q3KRB4 MRPS33 protein  MRPS33 1.47 4.57E-02 1.65 7.40E-03 
O43678 NADH dehydrogenase 
[ubiquinone] 1 alpha 
subcomplex subunit 2  




isoform 1 (Fragment) 
FH 1.47 4.14E-02 1.69 2.36E-02 
O94919 Endonuclease domain-
containing 1 protein 
ENDOD1 1.47 1.99E-02 1.69 5.28E-03 
Q9NYU2 UDP-glucose:glycoprotein 
glucosyltransferase 1  
UGGT1 1.46 4.88E-02 1.46 2.92E-02 
P83876 Thioredoxin-like protein 
4A  




component of pyruvate 
dehydrogenase complex  
DLAT 1.46 4.12E-02 1.32 3.44E-02 
Q4U2R6 39S ribosomal protein 
L51, mitochondrial  
MRPL51 1.46 3.87E-02 1.37 3.70E-02 
A0A024R9
B7 
Cytochrome c oxidase 
subunit VIc, isoform 
CRA_a  
COX6C 1.46 4.63E-02 1.53 3.56E-02 
Q9HC06 Cd002 protein  N/A 1.45 4.02E-02 1.80 4.13E-02 
A8K0M6 cDNA FLJ76697  MRPL37 1.45 4.99E-02 2.03 7.60E-04 
Q9BZE1 39S ribosomal protein 
L37, mitochondrial  
MRPL37 1.45 1.75E-02 1.30 4.48E-03 
A0A090N
8G7 
Similar to RP9 protein  LOC402478 1.45 4.57E-04 1.67 2.10E-02 
Q14696 LRP chaperone MESD MESD 1.45 2.82E-02 1.62 1.04E-02 
E9LUH4 Methyl-CpG-binding 
protein 2  
MECP2 1.45 4.74E-02 1.78 8.11E-03 
Q8N183 NADH dehydrogenase 
[ubiquinone] 1 alpha 
subcomplex assembly 
factor 2  







(Ubiquinone) 1 alpha 
subcomplex, 5, 13kDa, 
isoform CRA_b  
NDUFA5 1.45 3.89E-02 1.42 9.92E-03 
Q05DF2 SF3A2 protein (Fragment)  SF3A2 1.45 3.77E-02 1.45 2.63E-02 
Q9BVK6 Transmembrane emp24 
domain-containing protein 
9 
TMED9 1.44 3.95E-02 1.41 1.51E-02 
A0A024R2
P4 
Chromosome 3 open 
reading frame 39, isoform 
CRA_a  
C3orf39 1.44 4.16E-02 1.39 1.67E-02 
Q9Y385 Ubiquitin-conjugating 
enzyme E2 J1 
UBE2J1 1.44 3.52E-03 1.69 1.71E-04 
Q9Y3B7 39S ribosomal protein 
L11, mitochondrial  
MRPL11 1.44 3.37E-02 1.54 1.61E-02 
A0A0S2Z5
M1 
SEC63-like (S. cerevisiae) 
(Fragment)  
SEC63 1.44 4.29E-02 1.99 2.16E-03 
A0A024Q
Z86 
T-box 2, isoform CRA_a TBX2 1.44 2.06E-02 1.86 3.55E-02 
Q9BSR8 Protein YIPF4 YIPF4 1.44 1.77E-02 2.01 1.88E-03 
Q96A33 Coiled-coil domain-
containing protein 47  
CCDC47 1.44 3.62E-02 1.46 2.23E-02 
P16402 Histone H1.3  HIST1H1D 1.43 1.09E-02 3.34 1.28E-04 
A2A274 Aconitate hydratase, 
mitochondrial  





GNS 1.43 2.59E-02 1.55 1.23E-02 
P11177 Pyruvate dehydrogenase 
E1 component subunit 
beta, mitochondrial  
PDHB 1.43 3.17E-02 1.45 2.30E-02 
O00469 Procollagen-lysine,2-
oxoglutarate 5-
dioxygenase 2  
PLOD2 1.43 2.55E-02 2.05 1.21E-03 
B7Z6S9 Glucosylceramidase  N/A 1.43 4.16E-02 2.12 3.59E-03 
O75489 NADH dehydrogenase 
[ubiquinone] iron-sulfur 
protein 3, mitochondrial  
NDUFS3 1.43 3.11E-02 1.40 7.95E-03 
V9HW88 Calreticulin, isoform 
CRA_b  





factor 3, isoform CRA_a  
MTIF3 1.43 4.26E-02 1.47 4.08E-02 
M0QXB5 Persulfide dioxygenase 
ETHE1, mitochondrial  
ETHE1 1.43 4.32E-02 1.49 4.68E-02 
Q6PUJ7 Epididymis luminal 
protein 215  
HEL-215 1.42 3.35E-02 1.39 6.25E-03 
Q8IY95 Transmembrane protein 
192  




P52815 39S ribosomal protein 
L12, mitochondrial  
MRPL12 1.42 4.64E-02 1.49 2.97E-02 
Q9H2W6 39S ribosomal protein 
L46, mitochondrial  
MRPL46 1.42 4.26E-02 1.55 1.28E-03 
P84090 Enhancer of rudimentary 
homolog  




AK3 1.42 4.11E-02 2.01 2.34E-03 
Q9H2J9 DC39  N/A 1.41 4.76E-02 1.93 1.42E-02 
Q96S66 Chloride channel CLIC-
like protein 1  
CLCC1 1.41 2.56E-02 1.43 3.79E-02 
Q07021 Complement component 1 
Q subcomponent-binding 
protein, mitochondrial  
C1QBP 1.41 4.54E-02 1.51 1.19E-02 
Q96A35 39S ribosomal protein 
L24, mitochondrial  
MRPL24 1.41 3.66E-02 1.40 1.65E-02 





GNG10 1.40 3.19E-02 1.42 1.27E-02 
Q9H1K1 Iron-sulfur cluster 
assembly enzyme ISCU, 
mitochondrial  




domain containing 1, 
isoform CRA_a  
GLT8D1 1.40 4.15E-03 1.51 1.24E-02 
Q59EK0 Epsilon isoform of 
regulatory subunit B56, 
protein phosphatase 2A 
variant  
N/A 1.40 2.36E-02 1.47 2.85E-02 
Q9BYC9 39S ribosomal protein 
L20, mitochondrial  
MRPL20 1.40 4.12E-02 1.33 2.17E-02 
Q13405 39S ribosomal protein 
L49, mitochondrial  
MRPL49 1.39 4.35E-02 1.38 2.90E-02 
Q16630 Cleavage and 
polyadenylation specificity 
factor subunit 6  
CPSF6 1.39 3.72E-02 1.43 4.61E-02 
Q8NFH4 Nucleoporin Nup37  NUP37 1.39 9.80E-03 1.35 7.80E-03 
B4E2B5 MICOS complex subunit 
MIC60  
N/A 1.39 1.64E-02 1.70 1.90E-02 
Q59GR1 Niemann-Pick disease, 
type C1 variant 
(Fragment)  




containing 5, isoform 
CRA_c  




P17693 HLA class I 
histocompatibility antigen, 
alpha chain G  
HLA-G 1.39 4.57E-02 1.59 2.60E-02 
B4DRS6 Sideroflexin  N/A 1.38 3.13E-02 1.47 3.51E-02 
Q8NDZ4 Deleted in autism protein 1 DIPK2A 1.38 2.60E-02 1.50 3.05E-02 
Q9BQ95 Evolutionarily conserved 
signaling intermediate in 
Toll pathway, 
mitochondrial 
ECSIT 1.38 4.43E-02 1.69 2.09E-03 
P62875 DNA-directed RNA 
polymerases I, II, and III 
subunit RPABC5 




CPS1 1.38 4.92E-02 1.42 2.51E-03 
Q16795 NADH dehydrogenase 
[ubiquinone] 1 alpha 
subcomplex subunit 9, 
mitochondrial  
NDUFA9 1.38 4.57E-02 1.37 2.66E-02 
D3DSQ1 N-acylsphingosine 
amidohydrolase (Acid 
ceramidase) 1, isoform 
CRA_c  
ASAH1 1.38 1.12E-03 2.24 1.19E-03 
Q969X5 Endoplasmic reticulum-
Golgi intermediate 
compartment protein 1  
ERGIC1 1.37 4.77E-02 1.63 1.84E-03 
Q8NCN5 Pyruvate dehydrogenase 
phosphatase regulatory 
subunit, mitochondrial  
PDPR 1.37 3.87E-02 1.61 9.84E-03 
J3KTA1 F-box and leucine-rich 
repeat protein 20, isoform 
CRA_a  
FBXL20 1.37 3.85E-03 1.47 7.30E-03 
T2C6S4 WWC family member 3  WWC3 1.37 4.14E-02 1.56 3.69E-02 
Q6P4F2 Ferredoxin-2, 
mitochondrial  
FDX2 1.37 4.71E-02 1.69 4.39E-02 
Q8WWV3 Reticulon-4-interacting 
protein 1, mitochondrial  
RTN4IP1 1.37 2.69E-03 1.66 1.00E-02 
Q9NQ50 39S ribosomal protein 
L40, mitochondrial  
MRPL40 1.36 4.99E-02 1.31 4.48E-02 
A8KAL2 Golgi autoantigen, golgin 
subfamily a, 5 (GOLGA5), 
mRNA 




ligase, mitochondrial  
HARS2 1.36 2.14E-02 1.55 1.32E-03 
Q96HY6 DDRGK domain-
containing protein 1  
DDRGK1 1.36 2.61E-02 1.34 1.94E-02 
Q6ZXV5 Transmembrane and TPR 
repeat-containing protein 3  




V9HWD3 Epididymis luminal 
protein 117 




SCCPDH 1.35 4.48E-02 1.67 1.70E-02 
Q5T2R2 Decaprenyl-diphosphate 
synthase subunit 1  
PDSS1 1.35 2.61E-02 1.47 1.32E-02 
A5YM53 ITGAV protein  ITGAV 1.35 4.82E-02 1.47 3.43E-02 
K7EMG5 AP-1 complex subunit mu-
2 (Fragment)  
AP1M2 1.35 4.44E-02 1.38 3.81E-03 
Q96EY7 Pentatricopeptide repeat 
domain-containing protein 
3, mitochondrial  
PTCD3 1.34 4.65E-02 1.39 2.98E-02 
A0A024R
DW4 
Uncharacterized protein  FLJ10154 1.34 4.69E-02 1.33 1.29E-02 
Q7L0Y3 tRNA methyltransferase 
10 homolog C  




transcript 5, isoform 
CRA_b  
ABHD16A 1.34 4.48E-02 1.53 1.10E-02 
Q53EU6 Glycerol-3-phosphate 
acyltransferase 3  
GPAT3 1.34 3.05E-02 1.75 1.23E-02 
Q05048 Cleavage stimulation 
factor subunit 1  
CSTF1 1.34 4.38E-02 1.32 5.93E-03 
Q9NY12 H/ACA ribonucleoprotein 
complex subunit 1  
GAR1 1.34 4.38E-02 1.67 3.64E-03 
Q6IQ19 Centriole, cilia and 
spindle-associated protein  
CCSAP 1.34 3.88E-02 1.51 6.11E-03 
Q96F25 UDP-N-acetylglucosamine 
transferase subunit ALG14 
homolog  
ALG14 1.33 2.30E-02 1.76 1.61E-03 




LYSMD3 1.33 3.17E-02 1.36 7.63E-03 
Q92575 UBX domain-containing 
protein 4  
UBXN4 1.33 3.83E-02 1.44 3.01E-02 
Q8TA92 Similar to AFG3 ATPase 
family gene 3-like 2  
N/A 1.32 4.74E-02 1.37 1.66E-02 




1.32 4.86E-02 1.51 3.45E-03 
P82912 28S ribosomal protein 
S11, mitochondrial  




AGPAT5 1.32 4.88E-02 1.94 4.03E-04 
A8K1K8 Chromosome 18 open 
reading frame 55, isoform 
CRA_b  




B4E3G8 cDNA FLJ61576, highly 
similar to Mitochondrial 
fission regulator 1  
PON2 1.31 1.10E-04 1.34 1.18E-02 
A0A0J9Y
XF2 
Paraoxonase 2, isoform 
CRA_a  
SP1 1.31 4.69E-02 1.91 7.51E-05 




DNAH17 1.31 5.82E-03 1.41 2.33E-02 
Q9UFH2 Dynein heavy chain 17, 
axonemal 
PWWP2A 1.31 1.22E-03 1.41 1.33E-03 
Q96N64 PWWP domain-containing 
protein 2A  
 
1.30 1.27E-02 1.43 1.38E-02 
Increased in proteome of DENV-2 but decreased in those of REP cells 
Q16762 Thiosulfate 
sulfurtransferase 
TST 1.48 3.99E-02 0.73 1.07E-02 
P35612 Beta-adducin  ADD2 1.40 7.69E-03 0.72 1.36E-02 
G3V3D1 NPC intracellular 
cholesterol transporter 2 
(Fragment)  
NPC2 1.38 4.12E-02 0.73 2.20E-02 
E9PGC8 Microtubule-associated 
protein 1A  
MAP1A 1.31 4.55E-02 0.42 1.98E-03 
A0A024R8
71 
Solute carrier family 2, 
(Facilitated glucose 
transporter) member 8, 
isoform CRA_a  
SLC2A8 1.30 4.50E-03 0.72 3.32E-02 
  Decreased in proteome of DENV-2 but increased in those of REP cells 
P85298 Rho GTPase-activating 
protein 8  
ARHGAP8 0.72 4.91E-02 1.44 1.88E-03 
Q8WUU5 GATA zinc finger 
domain-containing protein 
1  
GATAD1 0.69 1.01E-02 1.39 6.57E-03 
  Decreased in proteomes of both DENV-2 and  REP cells 
Q9UBC2 Epidermal growth factor 
receptor substrate 15-like 
1  
EPS15L1 0.77 3.54E-02 0.59 8.63E-04 
Q9ULH1 Arf-GAP with SH3 
domain, ANK repeat and 
PH domain-containing 
protein 1  
ASAP1 0.77 4.07E-02 0.64 6.91E-03 
Q5T6F2 Ubiquitin-associated 
protein 2  
UBAP2 0.76 4.78E-02 0.69 1.95E-03 
Q9UBV8 Peflin  PEF1 0.76 4.14E-02 0.62 8.64E-03 
D3DWY7 Prefoldin subunit 3  VBP1 0.76 3.06E-03 0.66 1.87E-03 
Q14687 Genetic suppressor 
element 1  
GSE1 0.76 2.71E-02 0.44 2.54E-04 
Q7KZ85 Transcription elongation 
factor SPT6  




Q96C86 m7GpppX diphosphatase  DCPS 0.76 1.98E-02 0.70 1.01E-02 
Q8IWV8 E3 ubiquitin-protein ligase 
UBR2  
UBR2 0.76 4.01E-02 0.70 3.61E-03 
Q96Q83 Alpha-ketoglutarate-
dependent dioxygenase 
alkB homolog 3 
ALKBH3 0.76 4.92E-02 0.74 3.81E-02 
Q9Y2Z0 Protein SGT1 homolog SUGT1 0.76 3.60E-02 0.65 1.28E-03 
Q7Z7A4 PX domain-containing 
protein kinase-like protein  
PXK 0.76 2.14E-02 0.62 1.86E-04 
A0A2R8Y
E63 
Epidermal growth factor 
receptor kinase substrate 8  
EPS8 0.75 3.07E-02 0.74 2.13E-02 
P11802 Cyclin-dependent kinase 4  CDK4 0.75 3.91E-02 0.70 3.31E-02 
Q5U0F4 Eukaryotic translation 
initiation factor 3 subunit I  






activation protein, eta 
polypeptide, isoform 
CRA_b  
YWHAH 0.75 4.13E-02 0.46 5.12E-04 
D3DUW5 Dynamin 1-like, isoform 
CRA_c  




containing protein 1 
variant  
FHOD1 0.74 2.06E-02 0.42 6.28E-04 
Q9NZ63 Telomere length and 
silencing protein 1 
homolog  
C9orf78 0.74 2.62E-02 0.57 9.86E-04 
P50479 PDZ and LIM domain 
protein 4  
PDLIM4 0.74 6.36E-03 0.54 6.90E-03 
Q99622 Protein C10  C12orf57 0.74 2.56E-02 0.69 7.20E-03 
Q96PU5 E3 ubiquitin-protein ligase 
NEDD4-like  
NEDD4L 0.73 2.07E-02 0.60 3.34E-02 
Q147X3 N-alpha-acetyltransferase 
30  
NAA30 0.73 4.42E-02 0.56 2.15E-02 
Q9BUA3 Spindlin interactor and 
repressor of chromatin-
binding protein  
SPINDOC 0.73 2.33E-02 0.66 2.72E-03 
J3KNN3 Phosphorylase b kinase 
gamma catalytic chain, 
liver/testis isoform 






GCLC 0.73 3.15E-02 0.53 2.55E-03 
Q15814 Tubulin-specific 
chaperone C  
TBCC 0.73 2.96E-02 0.69 1.37E-03 
Q9BZI7 Regulator of nonsense 
transcripts 3B  




Q71RG4 Transmembrane and 
ubiquitin-like domain-
containing protein 2  
TMUB2 0.72 3.51E-02 0.47 9.93E-03 
Q2NL82 Pre-rRNA-processing 
protein TSR1 homolog 
TSR1 0.72 4.74E-02 0.62 2.81E-03 
B0QZ18 Copine-1  CPNE1 0.72 2.03E-02 0.72 2.63E-02 
P17707 S-adenosylmethionine 
decarboxylase proenzyme 
AMD1 0.72 1.08E-02 0.68 3.01E-03 
A8K486 Peptidyl-prolyl cis-trans 
isomerase 





N/A 0.71 3.23E-02 0.37 1.59E-03 
Q9NP79 Vacuolar protein sorting-
associated protein VTA1 
homolog  




tumor protein  
TPT1 0.71 2.46E-02 0.54 1.41E-02 
O75132 Zinc finger BED domain-
containing protein 4  
ZBED4 0.71 3.65E-02 0.70 1.00E-02 
A0A0S2Z4
62 
ArfGAP with FG repeats 1 
isoform 2 (Fragment)  
AGFG1 0.71 1.53E-02 0.56 4.14E-04 
Q15369 Elongin-C  ELOC 0.71 4.21E-02 0.58 7.69E-03 
A8K2A8 Importin 13 (IPO13), 
mRNA  
N/A 0.71 2.53E-02 0.53 3.86E-03 
B3KSH8 Inositol polyphosphate 1-
phosphatase  
N/A 0.71 7.62E-03 0.30 6.53E-04 
V9HW44 Epididymis secretory 
protein Li 303  
HEL-S-303 0.70 6.64E-03 0.44 5.87E-05 
Q9NP77 RNA polymerase II 
subunit A C-terminal 
domain phosphatase 
SSU72  










protein 1-like 1, isoform 
CRA_a  
NAP1L1 0.70 4.09E-02 0.55 8.06E-03 
Q8TE76 MORC family CW-type 
zinc finger protein 4  
MORC4 0.70 1.82E-02 0.70 1.81E-02 
Q96CW6 Probable RNA polymerase 
II nuclear localization 
protein SLC7A6OS  
SLC7A6OS 0.70 4.95E-02 0.57 4.43E-03 
Q9Y508 E3 ubiquitin-protein ligase 
RNF114  
RNF114 0.70 1.69E-02 0.59 6.89E-03 
O95433 Activator of 90 kDa heat 
shock protein ATPase 
homolog 1  












SHMT1 0.69 3.75E-02 0.55 4.93E-03 
P49327 Fatty acid synthase  FASN 0.69 4.42E-02 0.35 5.02E-04 
B4DPD5 Ubiquitin thioesterase  N/A 0.69 4.94E-02 0.56 3.38E-03 
Q15417 Calponin-3  CNN3 0.69 2.10E-02 0.35 5.60E-04 
A8K0J3 cDNA FLJ76732, highly 
similar to Homo sapiens 
TAO kinase 3 (TAOK3), 
mRNA  
N/A 0.69 3.38E-02 0.73 4.50E-02 
P47813 Eukaryotic translation 
initiation factor 1A, X-
chromosomal 
EIF1AX 0.69 1.17E-02 0.57 4.50E-04 
Q5T9B7 Adenylate kinase 
isoenzyme 1  
AK1 0.69 3.87E-02 0.56 1.10E-03 
Q8N543 Prolyl 3-hydroxylase 
OGFOD1  
OGFOD1 0.68 1.11E-02 0.40 2.44E-03 
Q9BVA1 Tubulin beta-2B chain  TUBB2B 0.68 3.49E-03 0.32 5.66E-04 
O60763 General vesicular transport 
factor p115 
USO1 0.68 3.41E-02 0.42 1.43E-04 
A8KA19 Exportin, tRNA (nuclear 
export receptor for tRNAs) 
(XPOT), mRNA  
N/A 0.68 4.65E-02 0.47 2.38E-03 
Q9NQT8 Kinesin-like protein 
KIF13B  
KIF13B 0.67 1.73E-02 0.75 3.57E-02 
Q6FIC5 Chloride intracellular 
channel protein  
CLIC4 0.67 3.35E-02 0.55 1.39E-03 
A8K646 Osteoclast stimulating 
factor 1 (OSTF1), mRNA  
N/A 0.67 3.71E-02 0.40 1.10E-04 
Q12933 TNF receptor-associated 
factor 2  




initiation factor 5, isoform 
CRA_b  
EIF5 0.66 3.48E-02 0.56 1.17E-03 
F2Z2X4 Exportin-4  XPO4 0.66 1.49E-02 0.52 2.14E-04 
P43490 Nicotinamide 
phosphoribosyltransferase  
NAMPT 0.65 3.50E-02 0.39 2.82E-03 
Q9C0D3 Protein zyg-11 homolog B  ZYG11B 0.65 3.02E-02 0.40 1.88E-03 
P30291 Wee1-like protein kinase  WEE1 0.65 1.72E-04 0.74 7.64E-05 
Q6FI81 Anamorsin CIAPIN1 0.65 3.74E-02 0.41 3.70E-04 
O76064 E3 ubiquitin-protein ligase 
RNF8  
RNF8 0.65 3.50E-02 0.69 4.10E-02 
O43639 Cytoplasmic protein 
NCK2 




Q96D05 Uncharacterized protein 
FAM241B  
FAM241B 0.64 1.59E-02 0.21 3.12E-04 
P31629 Transcription factor 
HIVEP2  
HIVEP2 0.61 1.98E-02 0.61 3.72E-02 
Q8IXQ3 Uncharacterized protein 
C9orf40  
C9orf40 0.60 3.98E-02 0.23 2.59E-02 
Q00534 Cyclin-dependent kinase 6  CDK6 0.60 2.96E-02 0.31 2.17E-04 
Q8N9N8 Probable RNA-binding 
protein EIF1AD  
EIF1AD 0.59 3.13E-02 0.59 1.99E-03 
P42677 40S ribosomal protein S27 RPS27 0.58 2.75E-02 0.45 3.78E-02 
O15541 RING finger protein 113A  RNF113A 0.58 3.07E-02 0.29 2.51E-04 
Q66K64 DDB1- and CUL4-
associated factor 15  
DCAF15 0.57 5.00E-02 0.34 4.23E-04 
B7ZLK1 KIAA0528 protein  KIAA0528 0.56 3.60E-02 0.52 1.12E-02 










Table 4.8 List of common proteins that were significantly altered ≥ 1.3 fold in amount 
in secretomes from both DENV-2 infected HEK293T and REP cells compared to 
mock infected cells. 




































Increased in secretomes of both DENV-2 and REP cells 
H3BMS5 PH domain leucine-rich repeat-







B2R4R0 Histone H4  HIST1H4L 2.97 1.87E-02 2.97 2.13E-02 
Q12797 Aspartyl/asparaginyl beta-
hydroxylase  
ASPH 2.74 8.80E-04 13.3
7 
2.21E-05 
Q7L5D6 Golgi to ER traffic protein 4 
homolog  
GET4 2.10 3.27E-02 2.14 3.21E-02 
Q15008 26S proteasome non-ATPase 
regulatory subunit 6  
PSMD6 2.02 3.46E-02 2.92 2.80E-03 
O43345 Zinc finger protein 208  ZNF208 1.97 7.00E-03 1.98 5.81E-03 
A8K061 Angiopoietin-like 3, mRNA  ANGPTL3 1.69 4.81E-02 2.33 1.15E-02 
A0A024R1
Z6 
Vesicle amine transport protein 
1 homolog (T californica)  
VAT1 1.64 1.52E-02 1.56 1.11E-02 
A8K5Y7 Exportin 5  XPO5 1.62 3.51E-02 1.45 3.42E-02 
P61225 Ras-related protein Rap-2b  RAP2B 1.60 4.84E-02 2.46 6.15E-03 
O14929 Histone acetyltransferase type 
B catalytic subunit 
HAT1 1.57 3.03E-02 1.39 2.53E-02 
P26599 Polypyrimidine tract-binding 
protein 1 
PTBP1 1.56 4.52E-02 1.58 3.44E-02 
Q86XP3 ATP-dependent RNA helicase 
DDX42  
DDX42 1.54 3.97E-02 1.54 3.25E-02 
A0A023T6R1 Mago nashi protein  FLJ10292 1.54 2.50E-02 1.90 2.14E-03 
P25490 Transcriptional repressor 
protein YY1 
YY1 1.53 4.23E-02 2.01 6.03E-03 
P48556 26S proteasome non-ATPase 
regulatory subunit 8  
PSMD8 1.49 1.31E-02 1.44 6.51E-03 
P16298 Serine/threonine-protein 
phosphatase 2B catalytic 
subunit beta isoform  
PPP3CB 1.46 3.27E-02 1.48 2.17E-02 
A0A2P9A
AR3 
Uncharacterized protein  BQ8482_ 
110136 
1.46 3.92E-02 1.58 2.97E-02 
Q14686 Nuclear receptor coactivator 6  NCOA6 1.46 2.22E-02 1.46 1.69E-02 
Q8NFH4 Nucleoporin Nup37  NUP37 1.45 4.09E-02 1.71 2.14E-02 
A8K245 Vaccinia related kinase 1  VRK1 1.43 4.28E-02 2.01 2.53E-03 
P21283 V-type proton ATPase subunit C 1  ATP6V1C1 1.42 4.43E-03 1.36 2.00E-02 
B7Z2U5 Heparan-sulfate 6-O-
sulfotransferase  




O00148 ATP-dependent RNA helicase 
DDX39A  
DDX39A 1.42 3.86E-02 1.71 1.55E-02 
Q6FG99 RPLP1 protein RPLP1 1.41 3.87E-02 1.40 4.62E-02 
B2R6D4 Phosphomannomutase  REEP5 1.41 1.65E-02 1.84 2.33E-03 
Q00765 Receptor expression-enhancing 
protein 5  
VPS25 1.37 1.20E-02 1.50 1.71E-02 
Q9BRG1 Vacuolar protein-sorting-
associated protein 25  
TK1 1.37 3.95E-02 1.43 3.02E-02 
A0A024R8N6 Thymidine kinase sapiens  FAM50A 1.37 3.85E-02 1.43 5.93E-03 
Q14320 Protein FAM50A  CKMT1A 1.37 4.44E-03 1.47 1.19E-02 
P12532 Creatine kinase U-type, 
mitochondrial  
CKMT1B 1.35 1.62E-02 2.39 1.74E-03 
G8JLB6 Heterogeneous nuclear 
ribonucleoprotein H  
HNRNPH1 1.32 3.42E-02 1.32 1.46E-02 
V9HWP2 Epididymis luminal protein 35 HSP90B1 1.32 2.72E-02 1.67 7.53E-03 
Increased in secretomes of DENV-2 cells but decreased in those of REP cells 
O60568 Procollagen-lysine,2-
oxoglutarate 5-dioxygenase 3  
PLOD3 1.58 0.01878 0.39 2.78E-02 
Q8WVF1 Protein OSCP1 OSCP1 1.42 0.025136 0.58 4.77E-02 
B3KN55 RBR-type E3 ubiquitin 
transferase  
RNF14 1.34 0.024722 0.67 5.71E-03 
Decreased in secretomes of DENV-2 cells but increased in those of REP cells 
Q86UE8 Serine/threonine-protein kinase 
tousled-like 2 
N/A 0.55 0.001965 1.70 1.56E-03 
Q9Y4W2 Ribosomal biogenesis protein 
LAS1L  
LAS1L 0.63 0.020365 1.59 2.89E-02 
Decreased in secretomes of both DENV-2 and REP cells 
Q96KC8 DnaJ homolog subfamily C 
member 1  
DNAJC1 0.76 0.042957 0.66 1.49E-02 
P23284 Peptidyl-prolyl cis-trans 
isomerase B  
PPIB 0.76 0.028982 0.70 3.15E-03 
A0A087WX97 Bcl-2-like protein 13  BCL2L13 0.75 0.014139 0.43 7.11E-03 
O95104 Splicing factor, arginine/serine-rich 15  SCAF4 0.73 0.030422 0.72 4.47E-02 
Q99549 M-phase phosphoprotein 8  MPHOSPH8 0.73 0.027138 0.52 5.59E-04 
Q96ST2 Protein IWS1 homolog  IWS1 0.73 0.03852 0.70 3.14E-02 
A0A0D9S
F53 
ATP-dependent RNA helicase 
DDX3X  
DDX3X 0.71 0.047945 0.56 1.51E-02 
A0A0A0MT49 Transcription activator BRG1  SMARCA4 0.70 0.022724 0.75 7.74E-03 
Q3KQU3 MAP7 domain-containing 
protein 1  
MAP7D1 0.70 0.005772 0.60 1.84E-02 
A0A024R0L4 Ets2 repressor factor, isoform  ERF 0.69 0.029911 0.70 1.77E-02 
Q9P0B6 Coiled-coil domain-containing 
protein 167  
CCDC167 0.68 0.00123 0.40 1.01E-02 
B2RDV7 tRNA-dihydrouridine(47) synthase  DUS3L 0.66 0.021352 0.60 4.60E-03 
B3KNS8 Surfeit locus protein 6 SURF6 0.64 0.002283 0.72 1.21E-02 
A0A087WYZ4 Glycoprotein hormones alpha  CGA 0.62 0.012637 0.62 1.54E-02 
Q6P1M0 Long-chain fatty acid transport 
protein 4  
SLC27A4 0.55 0.043769 0.59 3.29E-02 
B2R5U7 CCAAT-box-binding 
transcription factor (CBF2)  




To examine the effect of the DENV structural proteins and virus particle secretion 
on host cell protein amounts, the cellular and secreted proteins that were significantly 
altered (≥1.3 fold) in only DENV-2 infected HEK293T cells but not significantly changed 
in REP cells (< 1.3 fold or not significant) compared to mock infected cells were identified 
(Tables 4.9-4.10). All the groups of proteins identified above were subjected to 





Table 4.9 List of proteins significantly altered (≥1.3 fold) in proteome of DENV-2 
infected HEK293T cells but not in REP cells (< 1.3 fold or not significant). 




































P56199 Integrin alpha-1  ITGA1 2.24 4.43E-02 2.37 5.10E-02 
Q6IAQ2 SDHC protein  SDHC 2.10 4.82E-02 2.02 5.05E-02 
Q9UEI6 Polio virus related protein 2, 
alpha isoform 
N/A 1.82 4.04E-02 1.55 7.40E-02 
A0A024R5
K5 
Alpha-1,3-glucosyltransferase  ALG8 1.81 2.53E-02 0.84 6.56E-01 
E9PJL9 NADH dehydrogenase 




1.78 4.54E-02 1.57 4.20E-01 
Q15651 High mobility group 
nucleosome-binding domain-
containing protein 3 
HMGN
3 
1.76 2.87E-02 1.35 1.62E-01 
J3QL06 Hypoxia up-regulated protein 1  HYOU
1 
1.75 1.19E-04 1.07 7.91E-01 
B2R749 Cell division cycle associated 3 
(CDCA3), mRNA  
N/A 1.75 1.36E-02 1.40 8.47E-02 
Q9Y5J6 Mitochondrial import inner 
membrane translocase subunit 
Tim10 B  
TIMM
10B 
1.75 3.38E-02 1.32 1.43E-01 





1.73 2.13E-02 0.93 5.51E-01 
D6RB85 Calnexin CANX 1.73 6.11E-03 1.40 3.49E-01 
P04179 Superoxide dismutase [Mn], 
mitochondrial  
SOD2 1.72 3.92E-02 1.21 2.95E-01 
P05114 Non-histone chromosomal 
protein HMG-14  
HMGN
1 
1.71 1.83E-02 1.05 5.17E-01 
A0A024R9
G3 
Derlin  DERL1 1.70 2.64E-02 1.73 3.63E-01 
A8K7T4 Mannose-binding 2 (LMAN2), 
mRNA  
N/A 1.68 1.87E-02 1.01 9.30E-01 
P15954 Cytochrome c oxidase subunit 
7C, mitochondrial  
COX7
C 
1.68 8.53E-03 1.26 9.69E-02 
A0A2P9A
UF2 
Pyruvate carboxylase  pyc 1.66 1.25E-02 1.76 6.96E-02 
Q9BQE4 Selenoprotein S  SELEN
OS 
1.66 1.88E-02 1.28 8.09E-02 
P48380 Transcription factor RFX3  RFX3 1.66 4.39E-02 0.98 9.35E-01 
P53370 Nucleoside diphosphate-linked 
moiety X motif 6 
NUDT
6 




Q6DKI0 Raptor protein (Fragment)  raptor 1.65 3.40E-02 1.16 1.87E-01 
D6W551 Chromosome 2 open reading 
frame 28, isoform CRA_d 
C2orf2
8 
1.64 7.17E-03 1.24 1.75E-02 
O60637 Tetraspanin-3  TSPA
N3 
1.64 2.43E-02 1.26 6.83E-02 
H0YIC4 Citrate synthase (Fragment)  CS 1.63 4.83E-02 1.51 8.63E-02 
B9ECT5 NADH-ubiquinone 
oxidoreductase chain 4  
NADH
4 
1.63 5.01E-02 1.12 7.05E-01 
A0A024R6A0 Arginase  ARG2 1.63 2.04E-02 1.42 6.01E-02 
P08962 CD63 antigen  CD63 1.62 3.59E-02 0.87 1.01E-01 





1.61 1.75E-02 0.75 2.36E-01 
D3DP46 Signal peptidase complex 
subunit 3  
SPCS3 1.60 2.66E-02 1.21 4.55E-01 
Q9H490 Phosphatidylinositol glycan 
anchor biosynthesis class U 
protein  
PIGU 1.60 4.17E-02 1.29 2.88E-01 
Q9NVV0 Trimeric intracellular cation 
channel type B  
TMEM
38B 







1.58 2.37E-02 1.44 5.19E-02 




1.58 2.67E-02 1.33 1.14E-01 
V9HWB4  Endoplasmic reticulum 
chaperone BiP 
HSPA5 1.58 2.29E-02 1.23 1.08E-01 
Q59GX2 Solute carrier family 2 
(Facilitated glucose transporter), 
member 1 variant  
N/A 1.57 2.59E-02 1.64 6.39E-02 
A0A024R
BY9 
Cytochrome c heme lyase  HCCS 1.57 4.73E-03 0.99 9.54E-01 
Q9H173 Nucleotide exchange factor SIL1  SIL1 1.56 2.06E-02 1.22 2.36E-01 
Q9C0E8 Endoplasmic reticulum junction 
formation protein lunapark  
LNPK 1.55 2.63E-02 1.75 5.38E-02 
P11117 Lysosomal acid phosphatase  ACP2 1.55 3.19E-02 1.21 1.16E-01 
Q9Y320 Thioredoxin-related 
transmembrane protein 2  
TMX2 1.55 4.66E-02 0.96 7.37E-01 
Q92791 Endoplasmic reticulum protein 
SC65  
P3H4 1.55 2.58E-02 1.32 2.03E-01 
A0A024R9
D2 
Metadherin, isoform CRA_a  MTDH 1.55 3.07E-02 1.29 9.97E-02 
A0A024R8
S5 
Protein disulfide-isomerase  P4HB 1.55 4.89E-02 1.32 6.33E-02 
Q68D91 Metallo-beta-lactamase domain-
containing protein 2  
MBLA
C2 
1.55 2.98E-02 0.90 4.50E-01 
Q9NWQ8 Phosphoprotein associated with 
glycosphingolipid-enriched 
microdomains 1  
PAG1 1.55 3.72E-02 0.91 5.30E-01 
Q9HDC9 Adipocyte plasma membrane-
associated protein  
APMA
P 








1.54 3.19E-02 1.36 8.36E-02 
E9PKU7 Neutral alpha-glucosidase AB  GANA
B 
1.54 2.98E-02 1.10 4.89E-01 
Q5T6U8 High mobility group AT-hook 1  HMGA
1 
1.53 3.75E-02 1.09 4.86E-01 
Q9UDW1 Cytochrome b-c1 complex 
subunit 9  
UQCR
10 
1.53 2.99E-02 1.02 8.58E-01 
P14927 Cytochrome b-c1 complex 
subunit 7  
UQCR
B 
1.52 4.64E-02 0.80 7.35E-02 
E9PCR7 2-oxoglutarate dehydrogenase, 
mitochondrial  
OGDH 1.52 4.62E-02 1.27 5.09E-02 
Q8N4H5 Mitochondrial import receptor 
subunit TOM5 homolog  
TOMM
5 
1.52 1.39E-02 1.28 3.39E-02 
A0A090N8
Y2 
Protein disulfide-isomerase A4  ERP70 1.52 4.31E-02 1.29 4.08E-02 
Q09328 Alpha-1,6-mannosylglycoprotein 
6-beta-N-
acetylglucosaminyltransferase A  
MGAT5 1.52 4.46E-02 1.19 1.54E-01 
Q96AY3 Peptidyl-prolyl cis-trans 
isomerase FKBP10  
FKBP10 1.52 1.48E-02 1.10 4.05E-01 
A0A087WSV8 Nucleobindin 2, isoform CRA_b  NUCB2 1.52 4.94E-02 1.18 1.52E-01 
Q8N766 ER membrane protein complex 
subunit 1  
EMC1 1.51 4.28E-02 1.13 2.25E-01 
V9HWF6 Alpha-1-acid glycoprotein  HEL-
S-153w 
1.51 1.03E-02 1.05 8.54E-01 
P51970 NADH dehydrogenase 
[ubiquinone] 1 alpha 
subcomplex subunit 8  
NDUF
A8 




subunit DAD1  
DAD1 1.51 4.59E-02 1.52 6.95E-02 
B2R4A2 Cytochrome b-c1 complex 
subunit 7  
N/A 1.51 3.88E-02 0.92 4.95E-01 




1.51 4.90E-02 1.15 4.63E-01 
Q15084 Protein disulfide-isomerase A6 PDIA6 1.51 2.58E-02 1.34 1.42E-01 
Q53GR7 Solute carrier family 25, member 
13 (Citrin) variant (Fragment)  
 N/A 1.50 4.30E-02 1.06 5.49E-01 
P60468 Protein transport protein Sec61 
subunit beta  
SEC61
B 
1.50 2.39E-02 0.89 5.53E-01 
Q59E90 Alpha-mannosidase (Fragment)  N/A 1.50 4.07E-02 1.15 2.70E-01 
A8K2Q6 Peptidyl-prolyl cis-trans 
isomerase  
N/A 1.50 2.09E-02 1.55 5.71E-02 




1.50 2.95E-02 1.00 9.93E-01 
B4E2S3 cDNA FLJ56561   1.50 2.73E-02 1.07 2.51E-01 








Q2M1J6 Oxidase (Cytochrome c) 
assembly 1-like  
OXA1
L 




containing 2, isoform CRA_a  
KDEL
C2 
1.50 3.74E-02 1.35 7.64E-02 
Q96ET8 Golgi apparatus membrane 
protein TVP23 homolog C  
TVP23
C 
1.49 2.91E-02 1.38 6.40E-02 
B7Z1V4  4-aminobutyrate 
aminotransferase, mitochondrial  
N/A 1.49 2.45E-02 1.03 5.42E-01 




1.49 4.78E-02 1.32 7.87E-02 
O75052 Carboxyl-terminal PDZ ligand 




1.49 2.02E-02 1.11 4.74E-01 
P48723 Heat shock 70 kDa protein 13  HSPA13 1.48 1.99E-02 0.73 6.10E-02 
Q53YE2 Syntaxin 3A, isoform CRA_c  STX3A 1.48 3.82E-02 1.01 9.43E-01 
Q9BWH2 FUN14 domain-containing 
protein 2  
FUND
C2 
1.48 4.85E-02 1.35 6.60E-02 
Q9BS26 Endoplasmic reticulum resident 
protein 44  
ERP44 1.48 1.34E-02 1.09 4.67E-01 
Q9BXK5 Bcl-2-like protein 13 BCL2L
13 
1.48 1.57E-02 0.85 1.34E-01 
A0A140VJ
G8 
Testicular tissue protein Li 42  N/A 1.47 3.94E-02 1.16 2.25E-01 









mfd 1.47 3.32E-02 1.13 8.28E-01 
Q7KYR7 Butyrophilin subfamily 2 
member A1  
BTN2
A1 
1.47 4.00E-02 1.18 2.50E-01 
Q8NF37 Lysophosphatidylcholine 
acyltransferase 1  
LPCA
T1 
1.47 2.77E-02 1.09 5.60E-01 




1.47 3.98E-02 0.93 5.82E-01 
P27824 Calnexin  CANX 1.47 3.10E-02 1.21 4.59E-02 
B2R694 Terpene cyclase/mutase family 
member  
N/A 1.47 4.76E-02 1.12 3.01E-01 
P07686 Beta-hexosaminidase subunit 
beta  
HEXB 1.47 2.91E-02 1.18 1.66E-01 
Q9BQA9 Cytochrome b-245 chaperone 1  CYBC
1 
1.47 2.08E-02 0.76 8.93E-02 
Q9NS69 Mitochondrial import receptor 
subunit TOM22 homolog  
TOMM
22 
1.47 2.55E-02 1.14 3.43E-01 
O95292 Vesicle-associated membrane 
protein-associated protein B/C  
VAPB 1.47 4.18E-02 1.17 3.56E-01 
A8K335 Gamma-glutamyl hydrolase  N/A 1.46 4.31E-02 1.34 1.07E-01 
Q8WUY8 N-acetyltransferase 14  NAT14 1.46 2.39E-02 1.51 5.14E-02 
Q8N353 TMEM106B protein  TMEM
106B 






component 2  
PGRM
C2 
1.46 4.61E-02 1.32 7.30E-02 
P47985 Cytochrome b-c1 complex 
subunit Rieske, mitochondrial 
UQCR
FS1 
1.46 3.11E-02 1.10 3.68E-01 
Q96A26 Protein FAM162A  FAM1
62A 
1.46 2.84E-02 1.26 9.85E-02 
H7BZJ3 Protein disulfide-isomerase A3 
(Fragment) 
PDIA3 1.46 4.53E-02 1.36 9.97E-02 
A0A024R1
E4 
Mitochondrial protein 18 kDa, 
isoform CRA_a  
MTP18 1.46 4.97E-02 1.17 1.32E-01 
Q93050 V-type proton ATPase 116 kDa 
subunit a isoform 1 
ATP6V
0A1 
1.45 4.64E-02 1.16 2.21E-01 
A8K032 Translocating chain-associated 
membrane protein 
N/A 1.45 4.52E-02 1.08 3.52E-01 





N/A 1.45 3.43E-02 0.79 6.86E-02 













1.45 3.02E-02 1.05 6.38E-01 
M0R2A0 ER membrane protein complex 
subunit 10  
EMC10 1.45 1.80E-02 0.90 3.51E-01 
A0A024R2
K1 
RAB5A, member RAS 
oncogene family, isoform 
CRA_a  
RAB5A 1.45 1.85E-02 1.16 2.98E-01 
Q8NHP8 Putative phospholipase B-like 2  PLBD2 1.44 1.35E-02 1.23 1.85E-01 
P17568 NADH dehydrogenase 
[ubiquinone] 1 beta subcomplex 
subunit 7  
NDUF
B7 




dehydrogenase 4, isoform 
CRA_b (Fragment)  
HSD17
B4 
1.44 4.14E-02 1.26 7.68E-02 
P50749 Ras association domain-
containing protein 2  
RASSF
2 
1.44 3.83E-02 1.30 1.10E-01 
Q8NBS9 Thioredoxin domain-containing 
protein 5  
TXND
C5 
1.44 2.94E-02 1.27 1.57E-01 
B2R728 Solute carrier family 7 (cationic 
amino acidtransporter, y+ 
system), member 1  
N/A 1.44 2.46E-02 0.98 8.72E-01 




1.44 4.63E-02 1.27 7.45E-02 
E9PBY3 N-acetylgalactosaminyltransferase 7  GALNT7 1.44 3.31E-02 0.89 4.27E-01 
Q8WY22 BRI3-binding protein BRI3BP 1.44 3.71E-02 1.31 1.17E-01 
P84157 Matrix-remodeling-associated 
protein 7  




Q96DX4 RING finger and SPRY domain-
containing protein 1 
RSPR
Y1 
1.43 9.01E-03 1.64 9.49E-02 
Q96AJ9 Vesicle transport through 
interaction with t-SNAREs 
homolog 1A  
VTI1A 1.43 1.47E-02 1.32 7.94E-02 
A0A218KGN3 Presenilin  PSEN1 1.43 1.57E-02 1.13 2.37E-01 




1.43 4.82E-02 1.03 8.54E-01 
A0A024R0
08 
Solute carrier family 35, member 
B3, isoform CRA_c  
SLC35
B3 
1.43 1.45E-02 1.25 1.90E-01 
P37108 Signal recognition particle 14 
kDa protein  
SRP14 1.42 4.32E-02 1.23 2.39E-01 
P48047 ATP synthase subunit O, 
mitochondrial 
ATP5PO 1.42 2.52E-02 1.32 7.77E-02 
Q96H44 GTPBP3 protein (Fragment) GTPBP3 1.42 7.96E-03 1.19 3.80E-02 
B7ZKQ8 Podocalyxin  PODXL 1.42 4.95E-02 0.91 5.04E-01 
Q16698 2,4-dienoyl-CoA reductase, 
mitochondrial 
DECR1 1.42 5.01E-02 0.92 3.29E-01 
Q9BYV8 Centrosomal protein of 41 kDa  CEP41 1.42 2.73E-02 0.95 9.01E-01 
Q9HBL7 Plasminogen receptor (KT)  PLGR
KT 
1.42 4.07E-02 1.21 2.08E-01 
P51572 B-cell receptor-associated 
protein 31  
BCAP3
1 
1.42 3.59E-02 1.08 4.01E-01 
H0YCZ6 Transcriptional enhancer factor 
TEF-1 (Fragment)  
TEAD
1 
1.42 2.81E-02 1.24 5.42E-02 
P02654 Apolipoprotein C-I APOC
1 
1.41 1.51E-02 0.93 5.07E-01 
Q9UBS4 DnaJ homolog subfamily B 
member 11  
DNAJ
B11 
1.41 3.92E-02 1.17 2.81E-01 
B2RE48 Candidate tumor suppressor 
protein (LOC57107), mRNA  
 N/A 1.41 1.64E-02 1.25 9.24E-02 
P23458 Tyrosine-protein kinase JAK1  JAK1 1.41 3.19E-02 1.32 6.42E-02 
A0A087W
ZQ7 
Beta-soluble NSF attachment 
protein  
NAPB 1.40 8.78E-05 1.22 1.36E-02 
X6R8A1 Carboxypeptidase  CTSA 1.40 4.48E-02 1.24 1.31E-01 
O95873 Uncharacterized protein C6orf47 C6orf47 1.40 4.63E-02 1.21 1.44E-01 
Q6IB11 PGRMC1 protein PGRM
C1 
1.40 3.87E-02 1.09 3.41E-01 
Q7Z5P9 Mucin-19  MUC19 1.40 1.11E-02 1.27 1.15E-01 
Q9Y4L1 Hypoxia up-regulated protein 1  HYOU1 1.40 2.44E-02 1.15 9.57E-02 
Q9H6R6 Palmitoyltransferase ZDHHC6  ZDHH
C6 
1.39 1.26E-02 1.16 8.73E-02 
I6L975 Hydroxysteroid dehydrogenase 
like 1  
HSDL1 1.39 2.27E-02 0.89 2.11E-01 




1.39 4.51E-02 1.07 4.47E-01 








P49821 NADH dehydrogenase 




1.39 4.16E-02 1.24 1.54E-02 
Q9P0S3 ORM1-like protein 1 ORMD
L1 
1.39 4.86E-02 1.08 4.88E-01 
V9HVY3 Protein disulfide-isomerase HEL-
S-269 
1.39 3.28E-02 1.26 5.48E-02 





1.39 2.68E-02 1.07 5.56E-01 
P20226 TATA-box-binding protein  TBP 1.38 3.54E-02 1.28 1.76E-01 
B4DKM0 Mitochondrial 39S ribosomal 
protein L3  
  1.38 4.23E-02 1.18 1.23E-01 
Q8TDB4 Protein MGARP  MGAR
P 
1.38 1.52E-02 1.63 7.89E-02 
Q15836 Vesicle-associated membrane 
protein 3  
VAMP
3 
1.38 3.63E-02 1.07 5.07E-01 




1.38 3.32E-02 1.24 2.30E-01 
A0A024R8
L7 
Acyl-coenzyme A oxidase  ACOX1 1.38 4.90E-02 1.06 5.14E-01 
Q9HBH5 Retinol dehydrogenase 14  RDH14 1.37 2.96E-02 1.23 4.38E-02 
P51149 Ras-related protein Rab-7a  RAB7A 1.37 4.18E-02 1.15 2.55E-01 
Q9NZT2 Opioid growth factor receptor  OGFR 1.37 3.65E-02 1.08 4.20E-01 
Q9BVT8 Transmembrane and ubiquitin-
like domain-containing protein 1 
TMUB
1 
1.37 1.66E-03 0.89 9.68E-02 




lysosomal, isoform CRA_a  
DNAS
E2 
1.37 1.95E-02 1.22 1.68E-01 
A0A0S2Z5
B0 
Atlastin GTPase 1 isoform 1  ATL1 1.36 2.60E-02 1.41 1.86E-01 
B4DV59 REST corepressor 3  RCOR3 1.36 2.64E-02 1.41 1.22E-01 
Q86T03 Type 1 phosphatidylinositol 4,5-
bisphosphate 4-phosphatase 
PIP4P1 1.36 8.32E-03 1.16 4.60E-02 
B3KTR4 ARF-related protein 1   N/A 1.36 2.61E-02 1.23 6.81E-02 
P51398 28S ribosomal protein S29, 
mitochondrial  
DAP3 1.35 4.44E-02 1.29 3.21E-02 





1.35 1.90E-02 0.92 6.94E-01 
Q96ER9 Coiled-coil domain-containing 
protein 51  
CCDC
51 
1.35 4.37E-02 1.12 3.82E-01 




1.35 1.96E-02 1.38 8.48E-02 
G8JLH6 Tetraspanin  CD9 1.35 3.45E-02 1.15 2.05E-01 
A0A024R1
U4 
RAB5C, member RAS oncogene 
family, isoform CRA_a  
RAB5
C 
1.34 3.41E-02 1.05 6.21E-01 
Q13563 Polycystin-2 PKD2 1.34 2.45E-02 1.39 7.76E-02 
Q9H6R3 Acyl-CoA synthetase short-
chain family member 3, 
mitochondrial  








1.34 4.49E-02 1.18 3.23E-02 
Q9Y6X4 Soluble lamin-associated protein 
of 75 kDa 
FAM1
69A 
1.34 2.54E-02 1.01 9.26E-01 
Q9UBI6 Guanine nucleotide-binding 




1.34 4.44E-02 1.29 4.80E-02 
P09661 U2 small nuclear 
ribonucleoprotein A'  
SNRP
A1 
1.34 4.30E-02 1.26 6.07E-02 
B2RE36 cDNA, FLJ96903  N/A 1.34 3.46E-02 1.23 1.31E-01 
O15400 Syntaxin-7  STX7 1.34 1.69E-02 0.92 4.88E-01 
P38646 Stress-70 protein, mitochondrial  HSPA9 1.34 3.39E-02 1.27 3.35E-02 
A1L172 Acyl-CoA thioesterase 1  ACOT1 1.34 2.64E-02 0.99 9.12E-01 
A0A024R2
Y2 
Testicular tissue protein Li 201 TMEM
115 
1.33 3.89E-02 1.15 1.63E-01 
A0A024Q
ZN7 
Chromosome 10 open reading 
frame 70, isoform CRA_b  
C10orf
70 
1.33 2.68E-02 1.09 3.94E-01 
Q13948 Protein CASP  CUX1 1.33 1.77E-02 1.41 6.04E-02 




1.33 4.70E-02 1.15 1.38E-01 




1.33 3.61E-02 1.13 1.07E-01 
Q8IXB1 DnaJ homolog subfamily C 
member 10  
DNAJ
C10 
1.32 2.09E-02 1.16 1.77E-01 
G0XQ39 STIM1L  STIM1 1.32 4.23E-02 1.23 5.91E-02 
P30044 Peroxiredoxin-5, mitochondrial PRDX5 1.32 4.70E-02 1.30 6.01E-02 
A8K644 Splicing factor, arginine/serine-
rich 4, isoform CRA_b  
SFRS4 1.32 9.30E-03 1.12 2.67E-01 
B2R6S9 Low density lipoprotein 
receptor-related protein 




1.32 2.71E-02 0.98 7.38E-01 




1.32 3.98E-03 1.18 5.14E-02 
A0A024R0
06 
Family with sequence similarity 
8, member A1, isoform CRA_a  
FAM8
A1 
1.32 4.13E-02 1.22 2.34E-01 
O95822 Malonyl-CoA decarboxylase, 
mitochondrial  
MLYCD 1.32 2.61E-02 1.29 3.32E-02 
Q7L5N7 Lysophosphatidylcholine 
acyltransferase 2 
LPCAT2 1.31 3.53E-02 1.33 5.27E-02 
A7BI36 p180/ribosome receptor  RRBP1 1.31 1.57E-02 1.24 1.72E-02 
A8K6M4 Vesicle transport through 
interaction with t-SNAREs 
homolog 1B (yeast) (VTI1B), 
mRNA 
N/A 1.31 4.29E-02 0.99 8.82E-01 
E9PK54 Heat shock cognate 71 kDa 
protein  
HSPA8 1.31 6.99E-03 0.91 6.09E-01 
A0A024R7
G7 
Solute carrier family 35, member 
E1, isoform CRA_c  
SLC35
E1 








1.30 4.06E-02 1.03 7.49E-01 




1.30 4.19E-02 1.15 1.22E-01 
Q96KC8 DnaJ homolog subfamily C 
member 1  
DNAJ
C1 
1.30 2.30E-02 1.02 8.78E-01 
Q16629 Serine/arginine-rich splicing 
factor 7  
SRSF7 1.30 3.07E-02 1.27 5.57E-03 
Q16775 Hydroxyacylglutathione 
hydrolase, mitochondrial  
HAGH 1.30 3.18E-02 0.82 2.21E-02 
B2RDT8 Sorting nexin 8 (SNX8), mRNA  N/A 0.77 1.64E-02 0.91 1.95E-01 
Q86WR7 Proline and serine-rich protein 2 PROSE
R2 
0.76 3.13E-02 0.86 1.74E-01 
P55210 Caspase-7  CASP7 0.76 2.61E-02 1.04 7.66E-01 
Q8IYR2 SET and MYND domain-
containing protein 4  
SMYD
4 
0.76 2.77E-02 1.02 8.29E-01 
Q9Y2K3 Myosin-15  MYH1
5 
0.76 1.53E-03 1.13 1.56E-02 
Q59EE8 Nuclear receptor coactivator 3 
isoform a variant  
N/A 0.76 4.22E-02 1.05 5.53E-01 
A8K1Z3 Neural cell 
expressed,developmentally 
down-regulated gene 1 
N/A 0.76 3.92E-02 1.13 2.25E-01 
F8VRH0 Poly(rC)-binding protein 2 
(Fragment) 
PCBP2 0.75 2.12E-02 0.86 1.43E-01 
K7ENW2 Zinc finger protein 286A  ZNF28
6A 
0.74 4.44E-02 0.85 2.13E-01 
Q9Y3P9 Rab GTPase-activating protein 1 RABG
AP1 
0.74 3.00E-02 0.83 4.48E-02 
O95376 E3 ubiquitin-protein ligase 
ARIH2  
ARIH2 0.74 2.19E-02 0.81 1.84E-01 
Q5JTD0 Tight junction-associated protein 
1  
TJAP1 0.73 3.18E-02 0.77 1.82E-01 
Q96E14 RecQ-mediated genome 
instability protein 2  
RMI2 0.73 6.35E-03 0.92 3.58E-01 
Q15654 Thyroid receptor-interacting 
protein 6  
TRIP6 0.73 3.15E-02 0.72 6.54E-02 
Q712K3 Ubiquitin-conjugating enzyme 
E2 R2  
UBE2
R2 
0.72 4.33E-02 0.93 6.28E-01 
P78356 Phosphatidylinositol 5-
phosphate 4-kinase type-2 beta  
PIP4K
2B 





0.69 2.91E-02 0.67 1.68E-01 
Q86SE9 Polycomb group RING finger 
protein 5  
PCGF5 0.69 1.83E-02 0.84 1.69E-01 
Q9BRX2 Protein pelota homolog  PELO 0.67 1.12E-03 1.25 4.97E-01 
H7C3M7 FERM, ARHGEF and pleckstrin 
domain-containing protein 2  






BRCA1 interacting protein C-
terminal helicase 1, isoform 
CRA_a 
N/A 0.64 2.69E-03 1.00 9.87E-01 
Q59FS2 ZNF589 protein variant  ZNF589 0.64 2.68E-02 0.94 3.20E-01 
A6NCF6 Putative MAGE domain-
containing protein MAGEA13P 
MAGE
A13P 
0.62 7.13E-03 0.32 1.23E-01 
O75953 DnaJ homolog subfamily B 
member 5  
DNAJ
B5 
0.61 2.40E-02 0.72 6.89E-02 
B4DUT8 Calponin  CNN2 0.61 1.99E-02 0.78 1.43E-01 
X6RLX0 ELKS/Rab6-interacting/CAST 
family member 1  
ERC1 0.59 2.07E-02 0.81 7.84E-02 
P02533 Keratin, type I cytoskeletal 14  KRT14 0.53 1.59E-02 0.78 6.29E-01 









Table 4.10 List of proteins significantly altered (≥1.3 fold) in the secretomes of 
DENV-2 infected HEK293T cells but not in those of REP cells (< 1.3 fold or not 
significant). 




































Q9HBI1 Beta-parvin  PARVB 1.98 4.78E-02 1.44 1.34E-01 
P51784 Ubiquitin carboxyl-terminal 
hydrolase  
USP11 1.81 2.30E-02 0.79 6.04E-01 
F8W8D3 Histone RNA hairpin-binding 
protein  
SLBP 1.80 3.46E-02 1.36 2.87E-01 
Q9Y657 Spindlin-1  SPIN1 1.74 1.80E-02 1.43 1.31E-01 
P22059 Oxysterol-binding protein 1  OSBP 1.67 5.04E-03 1.34 7.39E-02 
E5KLL9 Mitochondrial dynamin-like 
120 kDa protein 
N/A 1.60 4.70E-02 0.92 7.21E-01 
B5BU08 U2 small nuclear RNA 
auxillary factor 1 isoform a 
U2AF1 1.59 3.56E-02 1.30 1.26E-01 
Q9BZX2 Uridine-cytidine kinase 2 UCK2 1.58 3.17E-02 1.36 1.72E-01 
Q13162 Peroxiredoxin-4  PRDX4 1.56 5.42E-04 1.35 8.04E-02 
Q9BV44 THUMP domain-containing 
protein 3  
THUMP
D3 
1.55 8.68E-03 0.93 4.98E-01 
A0A024RC37 Uncharacterized protein  P15RS 1.50 1.31E-02 1.26 2.53E-01 
P13010 X-ray repair cross-
complementing protein 5  
XRCC5 1.50 2.54E-02 1.35 1.05E-01 
Q96RS6 NudC domain-containing 
protein 1  
NUDC
D1 
1.47 3.30E-02 1.49 6.35E-02 
B3KM36 BAG family molecular 
chaperone regulator 2  
N/A 1.47 2.34E-02 1.40 1.07E-01 
A8K646 Osteoclast stimulating factor 1 
(OSTF1), mRNA  
OSTF1 1.47 2.83E-03 0.74 8.17E-02 
P30050 60S ribosomal protein L12  RPL12 1.46 2.66E-02 1.09 3.97E-01 
Q6NXE6 Armadillo repeat-containing 
protein 6  
ARMC6 1.46 1.52E-02 1.16 7.50E-02 
A0A024R9
B7 
Cytochrome c oxidase subunit 
VIc, isoform CRA_a  
COX6C 1.45 3.55E-02 1.11 7.11E-01 
A8JZZ5 CHK2 checkpoint homolog (S. 
pombe) (CHEK2), transcript 
variant 1 
N/A 1.45 6.10E-03 1.18 1.71E-01 





1.44 4.53E-02 1.05 5.82E-01 
Q14566 DNA replication licensing 
factor MCM6  




Q59HH3 Trifunctional purine 
biosynthetic protein 
adenosine-3  
N/A 1.42 2.68E-02 1.25 5.90E-02 
E5KT65 DNA-directed RNA 
polymerase subunit RPABC1  
N/A 1.41 2.24E-02 1.35 3.04E-01 
Q7Z4Q2 HEAT repeat-containing 
protein 3  
HEATR
3 
1.41 1.89E-02 1.29 1.16E-01 
P05412 Transcription factor AP-1  JUN 1.41 4.21E-02 1.23 2.21E-01 
D3DSW3 Pyridoxal phosphate 
homeostasis protein  
PROSC 1.41 2.22E-02 1.15 2.49E-01 
P08754 Guanine nucleotide-binding 
protein G(k) subunit alpha  
GNAI3 1.40 4.55E-02 1.05 8.74E-01 
Q9UK59 Lariat debranching enzyme  DBR1 1.40 3.15E-02 1.15 5.57E-01 
P12956 X-ray repair cross-
complementing protein 6  






JMJD6 1.40 3.74E-02 1.04 7.84E-01 
Q13596 Sorting nexin-1  SNX1 1.38 2.91E-02 1.02 8.66E-01 
Q96RU3 Formin-binding protein 1 FNBP1 1.37 3.52E-02 1.08 4.24E-01 
Q9BUB5 MAP kinase-interacting 
serine/threonine-protein kinase 1 
MKNK1 1.36 5.65E-03 1.09 2.27E-01 
Q6QNY1 Biogenesis of lysosome-
related organelles complex 1 
subunit 2  
BLOC1
S2 
1.36 2.08E-02 0.86 2.82E-01 




1.35 3.61E-02 0.99 9.11E-01 
P0DI82 Trafficking protein particle 
complex subunit 2B  
TRAPPC
2B 
1.34 3.73E-02 0.99 9.64E-01 
A0A024R2
H7 
tRNA nucleotidyl transferase, 
CCA-adding, 1, isoform 
CRA_b  
TRNT1 1.34 4.52E-02 1.25 2.28E-01 
B4DSS8 Polypyrimidine tract-binding 
protein 2  
N/A 1.34 3.76E-02 1.07 4.21E-01 
E5KN59 Peptidyl-prolyl cis-trans 
isomerase D  
N/A 1.33 1.62E-03 1.11 9.61E-04 




1.32 7.66E-04 1.12 8.72E-01 
Q15185 Prostaglandin E synthase 3  PTGES3 1.32 1.73E-02 1.21 2.64E-01 




1.32 3.06E-02 0.94 9.07E-02 
P48507 Glutamate--cysteine ligase 
regulatory subunit  
GCLM 1.31 2.81E-02 1.18 2.64E-01 




1.31 4.07E-03 0.93 3.33E-01 
B1AHD1 NHP2-like protein 1  SNU13 1.30 3.43E-02 1.02 8.64E-01 
Q8IUH2 Protein CREG2  CREG2 0.77 3.75E-03 0.15 1.51E-01 
Q9BY77 Polymerase delta-interacting 
protein 3  
POLDI
P3 





kinase Nek1  
NEK1 0.76 1.42E-02 0.90 4.61E-01 
Q9NWK9 Box C/D snoRNA protein 1 O ZNHIT6 0.75 3.40E-02 0.88 9.84E-02 
Q5SSJ5 Heterochromatin protein 1-
binding protein 3  
HP1BP
3 
0.74 8.89E-03 1.40 1.78E-01 
Q9NZB2 Constitutive coactivator of 
PPAR-gamma-like protein 1  
FAM120
A 
0.72 1.24E-02 0.75 1.70E-01 
A8K492 Methionine-tRNA synthetase 
(MARS), mRNA 
MARS 0.71 4.93E-02 0.88 4.18E-01 
A8K7E0 Biglycan  BGN 0.70 3.38E-02 1.32 1.79E-01 
A8K5Q1 Bin3, bicoid-interacting 3, 
homolog (Drosophila) 
(BCDIN3) 
N/A 0.70 2.19E-02 0.77 1.44E-01 
Q96IZ7 Serine/Arginine-related 
protein 53  
RSRC1 0.70 2.39E-02 0.78 1.41E-01 
A0A0S2Z4
Z0 
RNA binding motif protein 14 
isoform 1  
RBM14 0.69 3.82E-02 0.77 1.35E-01 
H7C2Q8 EBNA1 binding protein 2 EBNA1B
P2 
0.68 4.09E-02 0.92 6.54E-01 
W5ZR30 Transcription factor 20 (AR1), 
isoform CRA_b  
TCF20 0.68 8.50E-03 0.91 2.50E-01 
B4DUT2 Protein KRI1 homolog KRI1 0.68 3.27E-02 0.91 6.47E-01 
Q15149 Plectin  PLEC 0.68 1.72E-02 1.05 9.03E-01 
Q8ND82 Zinc finger protein 280C  ZNF280C 0.67 3.60E-02 0.73 1.43E-01 
Q96BK5 PIN2/TERF1-interacting 
telomerase inhibitor 1  
PINX1 0.66 2.48E-02 0.72 1.47E-01 
Q6IAX2 RPL21 protein  RPL21 0.66 1.92E-02 0.78 7.44E-02 
Q03701 CCAAT/enhancer-binding 
protein zeta  




box polypeptide 23  
DDX23 0.64 1.85E-02 0.65 5.41E-02 
Q03164 Histone-lysine N-
methyltransferase 2A  
KMT2A 0.64 3.51E-02 0.91 6.21E-01 
O95292 Vesicle-associated membrane 
protein-associated protein B/C  
VAPB 0.63 2.88E-02 1.21 3.52E-01 
A5D8W8 Gamma-glutamyltransferase 7  GGT7 0.63 4.46E-02 0.95 7.95E-01 
Q9UPN4 Centrosomal protein of 131 kDa  CEP131 0.61 3.88E-02 0.36 6.86E-02 
A0A0X1KG71 Negative elongation factor B  NELFB 0.58 2.95E-02 0.73 4.62E-01 
Q9Y4C8 Probable RNA-binding protein 19  RBM19 0.55 4.78E-02 0.60 1.47E-01 
Q15059 Bromodomain-containing 
protein 3  
BRD3 0.55 4.77E-02 0.69 2.62E-01 
P49916 DNA ligase 3  LIG3 0.55 4.65E-02 0.67 4.36E-01 
G5EA30 CUG triplet repeat, RNA 
binding protein 1 
CELF1 0.54 3.88E-02 1.12 6.30E-01 
Q99442 Translocation protein SEC62  SEC62 0.43 8.22E-03 0.68 1.38E-01 
A0A0J9YX
C7 
LIM and senescent cell 
antigen-like-containing 
domain protein  




  Bioinformatic analysis of cellular and secreted proteins altered in 
abundance in response to DENV-2 infection  
 Bioinformatic analysis of cellular proteins altered in abundance in response to 
DENV-2 infection.  
 The 171 and 31 proteins (listed in Table 4.4) that significantly increased and 
decreased ≥ 1.5 fold, respectively, in DENV-2 cells compared to mock infected cells were 
subjected to gene enrichment and network analysis using the DAVID and STRING 
analysis programs (Figures 4.5-4.6 and supplementary Table S4.2).  
DAVID analysis showed that the proteins that significantly increased in response 
to DENV infection included 14 enriched clusters of proteins (Figure 4.5). The top three 
were associated with the GOCC terms “integral component of membrane”, (GO:0016021) 
followed by “mitochondrion” (GO:0005739) and the Uniprot (UP) keyword 
“glycoprotein”. Other significantly enriched GO terms that are related to DENV infection 
included the GOBP term “endoplasmic reticulum unfolded protein response” 
(GO:0030968). The top enriched KEGG pathway was “oxidative phosphorylation” 
(hsa00190: P-value = 9.30E-09) (data not shown). However, the proteins that significantly 
decreased in response to DENV infection were not associated with any specific GO term. 
STRING analysis revealed that proteins increased in response to DENV infection 
were significantly associated with the GOBP terms “generation of precursor metabolites 
and energy”, “cellular respiration” and “ATP metabolic process” (Figure 4.6). An 
enrichment of proteins associated with the GOCC terms “mitochondrion” and KEGG 
pathway of “oxidative phosphorylation” were also observed. Whereas the proteins that 












Figure 4.5 DAVID analysis of cellular proteins that were altered in abundance in DENV-
2 infected HEK293T cells, compared to mock infected cells. 
 Proteins that were significantly (P-value < 0.05) altered in amount by ≥ 1.5 fold in DENV-
2 infected HEK293T cells compared to mock infected cells were analysed using the 
DAVID database. The GO accession numbers/terms that were significantly enriched and 
the properties of the corresponding protein clusters are shown. The GES of significantly 
enriched GO terms are plotted as bar graphs (red) with the corresponding GES score 
shown. The shading shows the type of GO term (GOBP, GOCC or GOMF), UP keywords, 
Interpro term or KEGG pathway. The number of proteins in each cluster (count), number 
of proteins associated with each GO term/total number of proteins in the dataset (%) and 







Figure 4.6STRING analysis of cellular proteins that were altered in abundance in DENV-
2 infected HEK293T cells, compared to mock infected cells.    
The STRING database was searched to analyse cellular proteins that significantly (P-value 
< 0.05) increased (A) and decreased (B) ≥ 1.5 fold in response to DENV-2 infection. (A) 
Nodes representing proteins associated with the significantly enriched GO terms 
“generation of precursor metabolites and energy”, “cellular respiration”, “ATP metabolic 
process” and “mitochondrion” as well as the KEGG pathway “Oxidative phosphorylation”  
are shaded in green, yellow, light blue, blue, and red, respectively. (B) Nodes representing 
proteins associated with the significantly enriched UP keyword term “phosphoprotein” are 
shaded in red. The number of coloured nodes/ total proteins involved for each term and the 




 Bioinformatic analysis of the secretomes from DENV-2 infected HEK293T cells 
 The 31 and 23 host proteins (listed in Table 4.5) that significantly increased and 
decreased ≥ 1.5 fold, respectively, in the secretomes from DENV-2 cells, compared to 
mock infected cells, were also analysed using the DAVID and STRING analysis programs. 
These secreted proteins were not significantly associated with any GO term by DAVID 
analysis. In contrast, STRING analysis showed that for proteins that increased in amount, 
there was an enrichment of proteins that were associated with the GO terms “metabolic 
process”, “gene expression”, “mRNA splicing, via spliceosome”, “proteasome regulatory 
particle” and “secretory granule" (Figure 4.7A). The secreted proteins that decreased in 
amount in response to DENV-2 infection were associated with the GOCC term 
“intracellular membrane-bounded organelle” and the UP keyword “phosphoprotein” 
similar to the proteins that decreased in abundance in the proteome (Figure 4.7B). 
 Bioinformatic analysis of proteins that significantly changed in both the proteome 
and secretome of HEK293T cells in response to DENV infection.  
The five proteins that significantly changed (≥1.3 fold, both increased and 
decreased) in both the cellular proteome and secretome (Table 4.6) were analysed using 
STRING. Three of five proteins (NUP37, COX6C and DNAJC1) were associated with the 










Figure 4.7 STRING analysis of secreted proteins that were altered in abundance in the 
secretomse from DENV-2 infected HEK293T cells, compared to mock infected cells. 
 The STRING database was searched to analyse secreted proteins that significantly (P-
value < 0.05) increased (A) and decreased (B) ≥ 1.5 fold in response to DENV-2 infection. 
(A) Nodes representing proteins associated with the significantly enriched GO terms 
“metabolic process”, “gene expression”, “mRNA splicing, via spliceosome”, “proteasome 
regulatory particle” and “secretory granule”, are shaded in blue, red, yellow, pink and 
green, respectively. (B) Nodes representing proteins associated with the significantly 
enriched GO terms “intracellular membrane-bounded organelle” and the UP keyword 
“phosphoprotein” are shaded in blue and red, respectively. The number of coloured nodes/ 





 Bioinformatic analysis of cellular and secreted proteins that were 
commonly altered in abundance in both DENV-2 infected 
HEK293T and REP cells 
 Bioinformatic analysis of cellular proteins that commonly altered in abundance in 
both DENV-2 infected HEK293T and REP cells. 
To identify cellular host proteins dysregulated by replication of the DENV genome, 
proteins that were commonly altered in DENV-2 infected HEK293T and REP cells 
compared to mock infected cells were analysed. There were 297 proteins that were 
significantly altered ≥ 1.3 fold, so a more stringent cut-off (≥ 1.5 fold) was applied for 
bioinformatics analysis to increase specificity. Thus, 71 and 20 common host proteins that 
significantly increased and decreased ≥ 1.5 fold, respectively, in DENV-2 infected cells 
and REP cells compared to mock infected cells were subjected to gene enrichment and 
network analysis using the DAVID and STRING analysis programs (Figures 4.8-4.9 and 
supplementary Table S4.3).  
DAVID analysis showed that three clusters of proteins were significantly enriched 
in the proteins commonly increased in abundance. The clusters were associated with the 
GOCC terms “mitochondrion” (GO:0005739), “integral component of membrane” 
(GO:0016021), the UP keyword “Signal/signal peptide” (Figure 4.8) and the KEGG 
pathway “Metabolic pathways” (hsa01100: P-value= 3.10E-03). STRING analysis 
revealed a significant enrichment of proteins associated with the GOCC term 
“mitochondrial part” and the KEGG pathway “metabolic pathways”, similar to the DAVID 
analysis. Moreover, STRING analysis also revealed enriched proteins associated with the 
GOBP terms “mitochondrion organization”, “aerobic respiration” and “ATP metabolic 
process” (Figure 4.9A). 
DAVID analysis of the proteins that significantly decreased in both DENV-2 
infected HEK293T and REP cells compared to mock infected cells revealed no 
significantly enriched proteins. STRING analysis revealed that this group of proteins was 








Figure 4.8 DAVID analysis of cellular proteins that were altered in abundance in both 
DENV-2 infected HEK293T and REP cells.  
 Proteins that were significantly (P-value < 0.05) altered in amount by ≥ 1.5 fold in both 
DENV-2 infected HEK293T and REP cells compared to mock infected cells were analysed 
using the DAVID database. The GO accession numbers/terms that were significantly 
enriched and the properties of the corresponding protein clusters are shown. The GES of 
significantly enriched GO terms are plotted as bar graphs (red) with the corresponding GES 
score shown. The shading shows the type of GO term (GOBP, GOCC or GOMF), UP 
keywords, Interpro term or KEGG pathway. The number of proteins in each cluster (count), 
number of proteins associated with each GO term/total number of proteins in the dataset 







Figure 4.9 STRING analysis of cellular proteins that were altered in abundance in both 
DENV-2 infected HEK293T and REP cells, compared to uninfected cells. 
 The STRING database was searched to analyse cellular proteins that significantly (P-value 
< 0.05) increased (A) and decreased (B) ≥ 1.5 fold in both DENV-2 infected HEK293T 
and REP cells compared to mock infected cells. (A) Nodes representing proteins associated 
with the significantly enriched GO terms “mitochondrion organization”, “aerobic 
respiration”, “ATP metabolic process” and “mitochondrial part” as well as KEGG pathway 
“Metabolic pathways” are shaded in red, blue, green, yellow, and pink respectively. (B) 
Nodes representing proteins associated with the significantly enriched UP keyword 
“phosphoprotein” are shaded in red. The number of coloured nodes/ total proteins involved 




  Bioinformatic analysis of proteins commonly altered in abundance in the 
secretomes from both DENV-2 infected HEK293T and REP cells compared to 
mock infected cells. 
Using a cut-off value of ≥ 1.5 fold, there were only 13 and 3 proteins that commonly 
significantly increased and decreased in secretomes from both DENV-2 infected HEK293T 
and REP cells compared with mock infected cells. Thus, a lower cut-off ≥ 1.3 fold was 
applied. The 33 and 13 secreted proteins (listed in Table 4.8) that commonly significantly 
increased and decreased, respectively, in secretomes from both DENV-2 infected 
HEK293T and REP cells were analysed using DAVID and STRING. There was no 
significant enriched cluster of proteins by DAVID analysis.  
STRING analysis showed that almost all of the secreted proteins that significantly 
increased in abundance in the secretomes from both DENV infected and REP cells 
compared to mock infected cells were associated with the GOCC and GOBP terms 
“membrane-bounded organelle” (GO:0043227) and “cellular metabolic process” 
(GO:0044237) respectively (Figure 4.10A). Protein associated with the GOBP term 
“mRNA splicing, via spliceosome” (GO:0000398) and the GOCC term “spliceosomal 
complex” (GO:0005681) were also significantly enriched. Moreover, proteins associated 
with the GOBP term “mRNA export from nucleus” were significantly enriched among this 
group of proteins. The proteins that commonly decreased in the secretomes of DENV-2 
infected HEK293T and REP cells showed an enrichment of proteins associated with the 
GOBP terms “positive regulation of viral process” and “positive regulation of viral genome 







Figure 4.10 STRING analysis of secreted proteins that were altered in abundance in both 
secretomes from DENV-2 infected HEK293T and REP cells, compared in mock infected 
cells. 
 The STRING database was searched to analyse secreted proteins that significantly (P-
value < 0.05) increased (A) and decreased (B) ≥ 1.3 fold in abundance in both the 
secretomes from DENV-2 infected HEK293T and REP cells compared to mock infected 
cells. (A) Nodes representing proteins associated with the significantly enriched GOBP  
“cellular metabolic process”, “mRNA splicing, via spliceosome” and “mRNA export from 
nucleus”  as well as GOCC of  “membrane-bounded organelle” and  “spliceosomal 
complex” are shaded in red, blue, yellow, green, and pink, respectively. (B) Nodes 
representing proteins associated with the significantly enriched GOBP “positive regulation 
of viral process” and “positive regulation of viral genome replication” are shaded in red 
and blue, respectively.  The number of coloured nodes/total proteins involved for each term 





  Analysis of proteins that significantly altered in abundance  in the 
proteome and secretomes of DENV-2 infected HEK293T cells (≥1.3 
fold) but not in REP cells (< 1.3 fold or not significant)  
To determine the effect of the DENV structural proteins and virus assembly and 
secretion processes on the host proteome and secretome, proteins that significantly 
increased or decreased (≥1.3 fold) in DENV-2 infected HEK293T cells but not in REP 
cells (< 1.3 fold or not significant) compared to mock infected cells were analysed.  
 Bioinformatic analysis of cellular proteins that were significantly altered in only 
DENV-2 infected HEK293T cells but not in REP cells  
The 208 and 28 proteins that significantly increased and decreased (≥1.3 fold), 
respectively, only in DENV-2 infected HEK293T cells but not in REP cells were analysed 
using the DAVID and STRING programs. DAVID analysis showed that the cellular 
proteins that increased in abundance only during DENV infection included 11 clusters of 
significantly enriched proteins (Figure 4.11 and Supplementary Table S4.4). The top three 
clusters were associated with the GO terms “integral component of membrane”, 
“endoplasmic reticulum” and the keyword “signal/signal peptide” (Figure 4.11). The top 
two significant KEGG pathways were “protein processing in endoplasmic reticulum” 
(hsa04141: P-value= 3.75E-08) and “phagosome” (hsa04145: P-value= 7.95E-05) 
(Supplementary Table S 4.3). STRING analysis revealed a similar trend to the DAVID 
analysis, with an enrichment of proteins associated with the GOBP terms “cell redox 
homeostasis” and “response to unfolded protein” as well as the KEGG pathway terms 
“protein processing in endoplasmic reticulum” and “phagosome” (Figure 4.12A). 
Furthermore, there was a significant enrichment of proteins associated with GO terms 
related to processes known to be modified by DENV infection, including “ubiquitin-
dependent” and “lipid metabolic process”.  
The proteins that significantly decreased (≥1.3 fold) in DENV infected HEK293T 
cells but not in REP cells were not significantly enriched in any cluster of proteins by 




significantly enriched in proteins associated with the UP keyword “phosphoprotein” and 











Figure 4.11 DAVID analysis of cellular proteins that were altered in only DENV-2 
infected HEK293T cells but not in REP cells.  
Proteins that were significantly (P-value < 0.05) altered in amount by ≥ 1.3 fold in DENV-
2 infected HEK293T cells but not in REP cells (< 1.3 fold or not significant) compared to 
mock infected cells were analysed using the DAVID database. The GO accession 
numbers/terms that were significantly enriched and the properties of the corresponding 
protein clusters are shown. The GES of significantly enriched GO terms are plotted as bar 
graphs (red) with the corresponding GES score shown. The shading shows the type of GO 
term (GOBP, GOCC or GOMF), UP keywords, Interpro term or KEGG pathway. The 
number of proteins in each cluster (count), number of proteins associated with each GO 
term/total number of proteins in the dataset (%) and P-value for each of the annotation 







Figure 4.12 STRING analysis of cellular proteins that were altered in abundance in only 
DENV-2 infected HEK293T cells but not in REP cells. 
 The STRING database was searched to analyse cellular proteins that significantly (P-value 
< 0.05) increased (A) and decreased (B) ≥ 1.3 fold in in only DENV-2 infected cells but 
changed < 1.3 fold or not significantly changed in REP cells. (A)  Nodes representing 
proteins associated with the significantly enriched GO terms “cell redox homeostasis”, 
“ubiquitin-dependent” “response to unfolded protein” and “lipid metabolic process” as 
well as KEGG pathway “protein processing in endoplasmic reticulum” and “phagosome” 
are shaded in yellow, purple, green, light blue, red and blue, respectively. (B) Nodes 
representing proteins associated with the significantly enriched UP keyword 
“phosphoprotein” and KEGG pathway of “Fanconi anemia pathway” are shaded in red and 
blue, respectively. The number of coloured nodes/ total proteins involved for each term 






 Bioinformatic analysis of proteins that were significantly altered (≥1.3 fold) in the 
secretome from DENV-2 infected HEK293T cells but not in those of REP cells 
The 46 and 32 secreted proteins that significantly increased and decreased ≥ 1.3 
fold, respectively, only in the secretome from DENV-2 infected HEK293T cells were 
subjected to functional analysis by DAVID and STRING. There were neither significantly 
enriched clusters of proteins nor KEGG pathways by DAVID analysis.  
STRING analysis showed that the 46 proteins that significantly increased only in 
the secretomes from DENV infected cells were associated with the the KEGG pathway 
“non-homologous end-joining”,  GOBP term “cellular hyperosmotic salinity response” and 
GOMF term “RNA binding” (Figure 4.13A). By contrast, the majority of the 32 secreted 
proteins that significantly decreased in only the secretome of DENV-2 infected cells were 
associated with the GOCC and GOBP terms “intracellular membrane-bounded organelle” 








Figure 4.13 STRING analysis of secreted proteins that were altered in abundance in only 
secretomes from DENV-2 infected HEK293T cells but not in those of REP cells. 
 
The STRING database was searched to analyse secreted proteins that significantly (P-value 
< 0.05) increased (A) and decreased (B) ≥ 1.3 fold in only secretomes from DENV-2 
infected cells but changed < 1.3 fold or did not significantly change in REP cells. (A)  
Nodes representing proteins associated with the significantly enriched KEGG pathway 
“non-homologous end-joining” and the GO terms “cellular hyperosmotic salinity 
response” and “RNA binding” are shaded in red, blue, and green, respectively. (B) Nodes 
representing proteins associated with the significantly enriched GO terms “nucleic acid 
metabolic process”, “intracellular membrane-bounded organelle” and “ribonucleoprotein 
complex” are shaded in red, blue, and green, respectively. The number of coloured nodes/ 





  Validation of the LC-MS/MS analysis 
  Viral proteins  
The DENV-2 NS1 protein, a 45 kDa glycoprotein, is well known as a secreted viral 
protein which plays an important role in DEN pathogenesis. As expected, LC-MS/MS 
analysis detected the NS1 protein in both the proteomes and secretomes of DENV-2 
infected HEK293T and REP cells. The detection of the NS1 protein was successfully 
validated using both cell lysates and supernatants from DENV-2 infected HEK293T and 
REP cells (Figures 4.14A and B).  
DENV-2 NS4B, an integral membrane protein, was also selected for validation. As 
expected, Western blotting analysis successfully validated the presence of NS4B in cell 
lysates of both DENV-2 infected HEK293T and REP cells (Figure 4.14A). 
As GAPDH was found not to change in amount in DENV-2 infected HEK293T and 
REP cells compared to mock infected cells it was used as a loading control. However, 











Figure 4.14 Detection of viral proteins in cell lysates and cell culture supernatants of 
DENV-2 infected HEK293T and REP cells. 
 HEK293T cells were infected with DENV-2 at a MOI of 5 or mock infected were 
harvested at 48 hpi and collected as total cell lysates and concentrated supernatants (by 
TCA precipitation). REP cells were also prepared in the same manner as mock infected 
cells.  Equal amounts of protein from cell lysates (10 µg) and equal volumes of the 
concentrated culture supernatants (5 µl) were loaded in each lane and the proteins separated 
by SDS-PAGE prior to Western blotting. Antibodies raised against the NS1, NS4B and 
GAPDH proteins were used to detect the respective proteins (expected positions arrowed). 
GAPDH was used as a loading control for cell lysates. Relevant molecular mass markers 





 Host proteins 
The bioinformatic analysis revealed that proteins that significantly changed in the 
proteome of DENV-2 infected HEK293T cells were enriched in proteins located in the ER 
or associated with ER processes such as the UPR. Thus, key ER proteins (ER markers) 
were selected for validation. 
4.7.2.1 4.7.2.1 Endoplasmic reticulum chaperone BiP (HSPA5) 
  HSPA5 is a 78 kDa molecular chaperone located in the ER lumen which plays an 
important role in the UPR pathway.  HSPA5 was increased 1.3 fold in DENV infected 
HEK293T cells and did not change in amount in REP cells compared to mock infected 
cells. Although HSPA5 was detected in the secretome by LC-MS/MS analysis, its level did 
not change in either DENV infected HEK293T or REP cells.  
Western blotting analysis resulted in the detection of a faint HSPA5 band in cell 
lysates from DENV infected but not mock infected cells (Figure 14.5). Quantitation of the 
band intensity confirmed the increase in HSPA5 detected by proteomic analysis.  
4.7.2.2 4.7.2.2 Calreticulin (CALR) 
CALR is also an ER chaperone. The increase in CALR in both DENV infected 
HEK293T and REP cells compared with mock infected cells was confirmed by Western 
blotting (Figure 14.5). Although molecular the weight of CALR is approximately 48 kDa, 
the observed bands were around 55-60 kDa in size as reported by the antibody supplier.  
4.7.2.3 4.7.2.3 ELKS/RAB6-interacting/CAST family member 1 (ERC1) 
 The ERC1 protein has previously been reported to decrease in DENV infection 
(Amemiya et al., 2019; Chiu et al., 2014). Although ERC1 may be involved in ER – Golgi 
trafficking, it was also selected for validation as a comparator to previous studies.  
The significant decrease in ERC1 amounts in DENV infected HEK293T cells 
detected by LC-MS/MS analysis was also confirmed by Western blotting (Figure 4.15). 










Figure 4.15 Detection of CALR, HSPA5 and ERC1 in DENV-2 infected HEK293T and 
REP cell lysates. 
 HEK293T cells were infected with DENV-2 at a MOI of 5 or mock infected, harvested at 
48 hpi and used to make total cell lysates. REP cells were also prepared in the same manner 
as mock infected cells.  Twenty µg of cell lysate was loaded in each lane and the proteins 
separated by SDS-PAGE prior to Western blotting. Antibodies raised against the CALR, 
HSPA5, ERC1 and GAPDH proteins were used to detect the respective proteins (expected 
positions arrowed). GAPDH was used as a loading control. Relevant molecular mass 
markers are shown in kDa. The densiometric intensity of the bands was measured using 
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  Discussion 
In this study, proteomic analyses of the cellular proteomes and secretomes of 
DENV-2 infected HEK293T cells and HEK293T cells stably expressing a DENV-2 
replicon were performed and compared for the first time. Comparison of the effects of 
DENV/replicon replication on the proteomes and secretomes of HEK293T cells has 
identified several cellular processes dysregulated in these cells which can be compared to 
proteomic studies on other DENV infected cells to identify common and distinctly 
regulated cellular pathways. Furthermore, comparison of replicon expressing and DENV 
infected HEK293T cells allows the identification of cellular proteins and pathways that are 
dysregulated in response to genome replication, and viral assembly and release, 
respectively. The comparison also highlights pathways for which replicons may not be 
good models for DENV replication.  
To interpret and generalise the results of the presented study, the properties of the 
cell line used should be considered. The HEK293 cell line is a transformed cell line created 
by integrating DNA of human adenovirus 5 to human embryonic kidney cells from an 




of this cell line are still debated (Stepanenko and Dmitrenko, 2015).  Previous 
transcriptomic analysis has revealed no evidence of either a tissue-specific gene expression 
signature or expression associated with differentiated kidney structures (Stepanenko and 
Dmitrenko, 2015). Thus, the use of HEK293 cells as a model for studying kidney function 
is limited. However, in a study of the host cell immune responses to DENV infection, 
HEK293 cells were found to be susceptible to DENV infection and the most appropriate 
cell line, of a number screened, to study the production and secretion of chemokines 
(Medin et al., 2005). Overall, the HEK293 cell line and its derivatives have been useful as 
in vitro models to study specific aspects of the host cell response to DENV infection and 
mammalian cell function in general.  
Cell lines stably expressing DENV replicons have been successfully established for 
a number of cell lines including HeLa, BHK, Huh-7 and HEK293 cells and used for DENV 
replication studies (Hafirassou et al, 2017; Medin et al., 2005; Masse et al., 2010). 
HEK293A cells expressing a DENV-2 replicon were used to study the induction of IL-8 
(Medin et al., 2005) and HEK293FT cells expressing a DENV replicon were used to study 
the effect of an oligosaccharyltransferase (OST) inhibitor on DENV replication (Puschnik 
et al., 2017).  Therefore, it was of interest to determine whether HEK293T cells stably 
expressing a DENV-2 replicon were comparable to DENV-2 infected HEK293T cells, in 
terms of protein dysregulation, both intracellularly and in the associated secretome. 
Overall, compared to mock infected cells, there was a higher number of 
significantly altered proteins in the proteome and secretome of REP cells than DENV 
infected cells. Although the reason for this is unknown, it is hypothesised that the longer 
duration of viral protein production and stable RC complex formation in REP cells may 
lead to a greater dysregulation of host proteins. Whilst REP cells continually express viral 
proteins, in DENV infected cells after an initial lag phase there is a relatively short burst 
of viral protein synthesis. The difference in duration of viral protein expression may result 
in a smaller effect on host protein amounts. 
This study resulted in the identification of a total of 3,867 proteins in the secretome 
of HEK293T cells. This value is much higher than the 428 proteins identified in a previous 




depleted of signal peptide peptidase-like 3 (SPPL3) (Kuhn et al., 2015; mentioned in detail 
in Chapter 3). Approximately 62% (264 proteins) of the proteins detected in the secretome 
of HEK293T cells in the study of Kuhn et al. (Kuhn et al., 2015) were also detected in this 
study, providing confidence in our analysis.  
Correlation of the changes that occurred in the proteome and secretome of DENV-2 
infected and replicon containing HEK293T cells compared to mock infected cells. 
Overall, 41.35% (2984 of 7217 proteins, Figure 4.3A) of the HEK293T cellular 
proteins identified were also secreted. However, there were only a small number of secreted 
proteins that were significantly changed in amount in response to DENV infection and only 
five that were commonly dysregulated in both the proteome and secretome. Thus, 
conclusions regarding correlations between the cellular and secreted proteins dysregulated 
in response to infection are problematic. By contrast, the larger amount of cellular and 
secreted proteins that were identified to be dysregulated in REP cells compared to mock 
infected cells mostly correlated in the direction of abundance change (Figure 4.3C), 
implying that the dysregulation of cellular proteins may impact directly on the levels of 
secreted proteins.  
It is worth mentioning the changes in the levels of NUP37 and Cytochrome c 
oxidase subunit VIc (COX6C), as these two proteins were significantly increased in both 
the proteomes and secretomes of HEK293T cells in response to infection. Nucleoporins 
(NUPs) form the nuclear pore complex (NPC) which serves as a nucleocytoplasmic 
transport channel and RNA viruses are known to subvert the NPC to enhance viral 
replication (Nofrini et al., 2016). Many NUPs have previously been reported to be 
associated with DENV infection. NUP50 was found to interact with DENV NS2B and NS5 
by yeast two hybrid analysis (Khadka et al., 2011). Furthermore, interactions between 
multiple NUPs and NS1, including NUP93, NUP205 and NUP210, were identified using 
a replicon expressing tagged-NS1 (Hafirassou et al, 2017). In addition, proteomic analysis 
of patient plasma using iTRAQ combined with LC-MS/MS, revealed a decrease in 
NUP210 in DENV infected patients with severe leakage compared to patients with warning 
signs (Nhi et al., 2016). It is assumed that in data presented in this thesis the increase in the 




cells, resulted in increased NUP37 secretion. The reason NUP37 is secreted is unknown 
but this study suggests it is upregulated in response to DENV-2 genome replication.  
COX6C is a member of the cytochrome c oxidase (COX) family of proteins which 
are involved in oxidative phosphorylation. The increase in COX6C in the HEK293T 
proteome and secretome in response to infection (but not in REP cells) correlated with the 
significant enrichment of the KEGG pathway term “oxidative phosphorylation” associated 
with proteins that were significantly dysregulated only in DENV infected cells. The results 
relating to other COX proteins are discussed in the next section. However, a previous study 
reported an interaction between COX proteins and the DENV-2 NS3 protein (Silva et al., 
2019).  
Comparison with previous studies 
 The results of previous proteomic studies investigating DENV infection differ 
depending on the cell type and proteomic technique used for analysis (reviewed in Table 
1.2, Chapter 1). Previously, no analysis of the cellular proteome of HEK293T cells after 
DENV infection had been conducted and only a few studies have focused on changes in 
selected proteins in HEK293 cells by Western blotting (Chiu et al., 2014; Tongluan et al., 
2017). Therefore, the results presented in this chapter were compared with both non-
proteomic studies conducted in HEK293T cells, as well as proteomic studies conducted in 
different cells lines.  
Similar alterations in the amounts of ERC1, CTSL1, MNF1 and HYOU1 were 
detected in this study and a previous study analysing DENV-2 infected HEK293 cells at 
48 hpi by Western blotting (Chiu et al., 2014). The proteins PRAF2 and UBE2S, which 
were found to markedly decrease in Chiu’s study were not identified to change in response 
to infection in this study.  
 Fatty acid synthase (FASN), a key protein of lipogenesis, was found to significantly 
decrease in the proteomes but not the secretomes of both DENV infected HEK293T and 
REP cells. In a previous study analysing DENV-2 and -4 infected HEK293T/17 cells, the 
mRNA levels of FASN were reported to initially increase early in infection, before 




throughout infection (Tongluan et al., 2017). However, FASN activity was reported to 
increase without major changes in the level of protein in DENV infected HeLa cells 
(Heaton et al., 2010). In contrast, FASN was significantly decreased in DENV-2 infected 
Huh-7 cells compared with mock infected cells (Chiu HC, 2014). These results may reflect 
a cell type specific response of FASN to DENV infection.  
In line with changes in FASN, we reported two additional proteins involved in lipid 
metabolism that changed in response to DENV infection. Interesting, neither of these 
proteins have previously been reported in DENV studies:  long-chain fatty acid transport 
protein 4 (SLC27A4) and NPC intracellular cholesterol transporter 2 (NPC2). Both 
proteins significantly decreased in the secretomes from both DENV infected and REP cells. 
The dysregulation of cellular and secreted proteins involved in lipid metabolism in both 
DENV infected and REP cells may be a result of the modulation of host lipid metabolism 
that is known to occur during DENV RC formation or in response to production of the NS 
proteins. The results of this study suggest there may be cell type specific differences in the 
effects of DENV infection on lipid metabolism. Thus, the changes in proteins involved in 
lipid metabolism in response to DENV replication warrants further investigation.  
A comparison of the results of proteomic studies investigating the effect of DENV 
infection on different cell types, shows that few proteins have been commonly identified 
as dysregulated across the different studies. HSPA5 was up regulated in DENV infected 
cells in this study similarly to a previous analysis of DENV infected Huh-7 cells and K652 
cells (Pando-Robles et al., 2014; Chiu, 2014; Wati et al., 2009). HSP90 which decreased 
in DENV infected EA.hy926 and Huh-7 cells (Pattanakitsakul et al., 2010; Pando-Robles 
et al., 2014) was also found to be significantly decreased in REP cells (but not changed in 
DENV infected HEK293T cells). The significant increases in heterogeneous nuclear 
ribonucleoprotein H1 (HNRNPH1) detected in the secretomes of both DENV infected and 
REP cells in this study were similar to the results reported in a study investigating DENV 
infected EA.hy926 cells (Kanlaya et al., 2009). In contrast, HNRNPH1 was reported to be 
decreased in DENV infected Huh-7 cells (Pando-Robles et al., 2014) (The details of studies 




The results of the secretome analysis conducted in this thesis were also compared 
with a previous study which analysed the secretome of DENV-2 infected HepG2 cells 
(Higa et al., 2008). X-ray repair cross-complementing protein 5 (XRCC5) which was 
identified to significantly increase ≥ 1.5 fold in the secretomes of DENV infected 
HEK293T cells in data presented in this thesis, was also identified in the secretome of 
DENV infected HepG2 cells (Higa et al., 2008). However, the authors did not report 
whether XRCC5 abundance increased or decreased (Higa et al., 2008). XRCC5 (also 
known as nuclear factor IV, Ku80 and ATP-dependent DNA helicase II 80 kDa subunit) is 
a regulatory subunit of the DNA-dependent protein kinase. Furthermore, increased activity 
of all subunits of DNA-dependent protein kinase, including XRCC5, was identified in 
DENV-2 infected Huh-7 cells. Depletion of XRCC5 by siRNA knockdown resulted in a 
decrease in the IFN-β response (Vetter et al, 2012). Thus, the role of secretory XRCC5 in 
the viral immune response requires further investigation.  
It is interesting to note that given then number of detected and identified proteins 
that altered in response to DENV infection in our analyses, few proteins overlapped with 
previously published proteomic studies. Literature of the top ten proteins that increased 
and decreased in amounts in DENV infected HEK293T cells compared with mock (listed 
in Table 4.4) revealed that 18/20 proteins had not previously been reported to associate 
with DENV infection. The only two proteins could be linked with the previous DENV 
studies were ERC1 and tyrosine-protein phosphatase protein.  A decrease of ERC1 was 
previously reported in DENV (discussed in the next section). An increase of tyrosine-
protein phosphatase protein in the proteome of HEK293T cell in response to DENV in this 
study was in line with an antiviral effect of tyrosine phosphatase inhibitors previously 
reported to inhibit DENV production in HepG2 cells (Limjindaporn et al, 2017).  
A likely explanation for the discrepancy between these results is the different cell 
types and proteomic techniques used for analysis between these studies. Using different 
transformed cell line models will present snap shots of cell type specific responses to 
DENV infection and cannot reflect the whole in vivo pathogenesis of DEN. Thus, the in 




DEN patients to determine the processes for which HEK293T could be a good cellular 
model of studying pathogenesis of DEN. 
Common host responses in DENV infection and replicon containing cells 
The dysregulated proteins and biological processes commonly found in DENV 
infection and REP cells could pertain to downstream effects of viral replication or a direct 
consequence of the interaction of viral and host proteins, or a combination of the two.  
The cellular proteins that were commonly dysregulated in DENV infected 
HEK293T and REP cells were enriched in proteins participating in metabolic pathways, 
especially mitochondrial proteins involved in cellular respiration for the production of ATP 
(Figure 4.9A). Mitochondrial markers including HSP60 and voltage-dependent anion 
channel 1 (VDAC1) were non-significantly increased in DENV-2 infected HEK293T cells 
but significantly increased in REP cells. As mentioned earlier, the COX family of proteins 
comprise enzymes that act in the last step of the mitochondrial electron transport chain. 
Multiple COX proteins were significantly increased in either DENV infected or REP cells; 
however, only COXC6 and COX20 were significantly increased in the proteome of both 
DENV-2 infected HEK293T and REP cells. Both functional and structural alterations in 
mitochondria were previously identified in DENV infected liver cells (El-Bacha et al., 
2007; Barbier et al, 2017). The functional mitochondrial bioenergetic changes observed in 
response to DENV-2 infection of HepG2 cells included increases in cellular respiration 
and oxygen consumption and a decrease in ATP production (El-Bacha et al., 2007). These 
changes led to a decrease in mitochondrial membrane electrochemical potential which is a 
hallmark of pro-apoptotic viruses (El-Bacha et al., 2007). The study of Barbier et al., 
(Barbier et al, 2017) reported elongation of mitochondria together with an increase in 
mitochondrial respiration in DENV infected Huh-7 cells (Barbier et al, 2017). Co-
localization of the mitochondria with the DENV RC was identified (Sripada et al, 2009), 
which suggests that dysregulation of mitochondria structures and functions results from 
DENV replication.  
CALR, a multifunctional protein, plays important roles in protein folding, calcium 
homeostasis and regulation of gene expression. CALR regulates mitochondrial calcium 




CALR acts as an ER chaperone and works together with calnexin (CNX) to regulate 
oligosaccharide degradation in the calreticulin/calnexin cycle. Previously, an in silico 
computational drug repositioning approach was used to perform an integrated multi-omics 
analysis, resulting in the identification of five proteins/genes commonly altered in DENV 
infection: ACTG1, CALR, ERC1, HSPA5, SYNE2 (Amemiya et al., 2019). CALR was 
proposed as a potential therapeutic target (Amemiya et al., 2019). Thus, the common 
increase in CALR amounts in both DENV infected HEK293T and REP cells was selected 
for validation by Western blot analysis, which confirmed the proteomic results (Figure 
4.15). CALR has been reported to interact with both the DENV E protein (Limjindaporn 
et al., 2009) and NS5 (Khadka et al., 2011) and knockdown of CALR resulted in a 
reduction of DENV replication in both DENV infected (Limjindaporn et al., 2009) and 
replicon expressing cells (Khadka et al., 2011). Furthermore, colocalization of CALR with 
cytoplasmic NS5, NS3 and dsRNA was detected in DENV infected Huh-7 cells (Khadka 
et al., 2011). These findings suggest a vital role for CALR in early viral replication. The 
increase in CALR levels identified in this study, both in DENV infected HEK293T and 
REP cells, may occur in response to DENV modulation, in order to facilitate viral 
replication. 
Interestingly, a group of DEAD-Box helicase (DDX) proteins were significantly 
altered in the secretomes of both DENV infected HEK293T and REP cells: DDX42 and 
DDX39A increased whilst DDX3X decreased. Furthermore, eukaryotic initiation factor 
4A-III (also known as EIF4A3 and DDX2) was significantly increased in only the REP 
cell secretome. DDX proteins are multifunctional ATP-dependent RNA helicases involved 
in metabolic processes and host immunity. DDX42 induces IFN-β production and plays an 
important role in antiviral responses. A previous study proposed that an interaction between 
the JEV NS4A protein and DDX42 may antagonise the IFN response (Lin et al., 2008). 
Decreases in DDX3X in DENV-2 infected Huh-7 and A549 cells at 48 hpi have been 
previously reported (Kumar et al, 2017). Moreover, the antiviral properties of DDX3X 
were demonstrated by knock down of DDX3X which resulted in an increase in viral titre, 
whilst overexpression caused a decreased infection rate and viral titre (Kumar et al, 2017). 
Interactions between DDX3X and the DENV C (Kumar et al, 2017) and NS5 proteins 




components which act in cell-cell signal transduction, the alteration of this group of 
proteins in response to DENV replication may play and important role in the antiviral 
immune response. 
Selected biological processes that were only dysregulated by DENV infection. 
A unique advantage of this study is that it facilitates a direct comparison of the 
proteomes and secretomes of DENV infected and replicon containing HEK293T cells. A 
focused analysis on the proteins and cellular processes which were only dysregulated in 
DENV infection was done to better understand the effect of specific viral processes on the 
host cell. Furthermore, this analysis could highlight any limitations in the use of replicon 
containing cells as models for DENV infection, apart from the obvious differences in viral 
assembly and release. 
ER processing the UPR and UPS. 
Bioinformatic analysis of the data showed that proteins associated with the GO 
terms “response to unfolded protein” and “ubiquitin-dependent ERAD pathway” and the 
KEGG pathway term “protein processing in endoplasmic reticulum” were enriched in 
DENV infected HEK293T cells but not in REP cells (Figure 4.13A). The increase in UPR 
stress is well documented as a general response to DENV infection and has been reported 
to occur in various cell lines including Huh-7 and A549 cells (Lee et al., 2018) as well as 
the HEK293T cells used in this study.  
Crosstalk between the UPR, UPS and autophagic processes are known to occur, 
including in DENV infection (Blazquez et al., 2014; Lee et al., 2018), whilst crosstalk 
between ER processes and phagocytosis has also been reported. Several ER proteins 
including CALR, HSPA5 and protein transport protein Sec61 (SEC61) play a role in 
phagocytosis process via “ER-mediated  phagocytotic” processes; for example, HSPA5 
also acts as a phagocytosis  receptor (Desjardins et al., 2003).    
DAVID analysis of the data presented in this chapter demonstrated enrichments in 
UPR and UPS terms in response to DENV infection. The ER markers, HSPA5 and 
SEC61B, were significantly increased in DENV infected HEK293T cells only. By contrast, 




proteins that are key markers of autophagy such as autophagy related 5 (ATG5) and 
microtubule-associated proteins 1A/1B light chain 3B (MAP1LC3B2 or LC3) did not 
change in amount in response to infection. Although there was a significant enrichment of 
proteins associated with the GOBP term “lipid metabolic process” (Figure 4.13A) this may 
be due to the involvement of lipid metabolic processes apart from autophagy, such as 
lipogenesis (via FASN).   
DENV replication occurs on ER membranes and structural changes to these 
membranes have been observed in DENV replicon containing cells by electron microscopy 
(Hafirassou et al., 2014). It is of interest that the results of this study revealed that replicon 
replication has a ‘weaker’ effect on ER responses than DENV replication. This suggests 
that virion maturation, assembly and budding may cause ER stress and directly activate the 
UPR. Alternatively, cell lines that successfully stably express replicons may have been 
self-selected that maintain a balance with the ER stress response to avoid cytopathic 
effects.  
The UPR is triggered by the binding of misfolded proteins to HSPA5, an important 
ER chaperone. HSPA5 has many alternative names including 78 kDa glucose-regulated 
protein (GRP78) or binding-immunoglobulin protein (BiP) and heat shock protein 70 
family protein. HSPA5 contributes to DENV infection in many ways, it was identified as 
a DENV receptor in HepG2 cells (Jindadamrongwech et al., 2004) and is involved in viral 
protein production/secretion (Wati et al., 2009; Songprakhon et al., 2018); although the 
effect of HSPA5 on virion secretion is controversial. HSPA5 knockdown did not affect 
transiently expressed DENV replicon replication (viral genome production) but caused a 
decrease in both intracellular NS1 and sNS1 levels (Songprakhon et al., 2018). Decreasing 
HSPA5 by siRNA knockdown resulted in a decrease in viral titre (Limjindaporn et al., 
2009) whilst inhibiting HSPA5 expression by cleavage with a toxin did not (Wati et al., 
2009). In addition, protein-protein interactions between HSPA5 and the DENV E 
(Limjindaporn et al., 2009) and NS1 proteins (Songprakhon et al., 2018) have been 
reported by yeast two-hybrid and co-IP analyses, respectively. The observed increase in 
HSPA5 in response to DENV infection in data presented here may represent an 




this effect in replicon containing cells suggests that this viral replication alone does not 
induce the same level of ER stress. 
Phagosome 
There were significant increases in key phagosomal proteins (Huynh et al, 2007; 
Garin et al, 2001) including V-type proton ATPase A, lysosome-associated membrane 
proteins 1 and 2 (LAMP-1 and LAMP-2) as well as CD63 antigen (an endocytosis marker) 
in DENV-2 infected cells but not in REP cells, compared to mock infected. However, other 
important phagosomal proteins such as HSP60, cathepsins and Ras-related proteins (Rabs) 
did not change in amount in response to infection. We can hypothesise that the significant 
enrichment of proteins involved in phagosomal and lysosomal activity in DENV infected 
cells but not in REP cells could be explained by a potential lack of the cellular response to 
pathogen invasion in REP cells. An increase in proteins involved in FcɤR-mediated 
phagocytosis with a corresponding decrease in proteins involved in lysosomal processes 
was detected in a proteomic analysis of THP cells infected with DENV (under conditions 
of ADE) compared with mock infected cells, by iTRAQ and LC-MS/MS (Ong et al., 2017). 
The increase in Fc-ɤ receptor-mediated phagocytosis, in combination with a reduction in 
the acidification of the phagosome was proposed to facilitate DENV escape from 
lysosomal degradation (Ong et al., 2017).  
ERC1 was one of five proteins commonly identified to play a role in DENV 
infection by an integrated analysis of ‘omics data, as described above (Amemiya et al., 
2019). Similar to the proteomic study of Chiu et al. (Chiu, 2014), a decrease in ERC1 was 
identified to occur in DENV-2 infected HEK293T cells but not in REP cells. The specific 
role of ERC1 in DENV infection remains unknown.  However, an interaction between 
ERC1 and DENV NS5 was reported by yeast two-hybrid analysis (Khadka et al., 2011). 
The interaction between ERC1 and NS5 was further defined as serotype 2 specific, by co-
IP analysis (Chiu, 2014). Cellular depletion of ERC1 by siRNA knockdown resulted in a 
significant decrease in the replication of a DENV replicon (Khadka et al., 2011) and DENV 
infection efficiency (Chiu, 2014). 
In conclusion, high throughput proteomic analyses of the proteomes and 




performed. Although HEK293T is a transformed cell line with unidentified tissue 
phenotype, results obtained from these cells still provided general host cell responses to 
DENV such as ER processes and UPR. The results from DENV infected HEK293T cell 
model will be compared with in vivo results from clinical specimens of DEN patient in 
Chapter 6 to determine the usefulness of this cell model in studying the pathogenesis of 
DENV. Overall, there was a good correlation between the proteomic results obtained using 
DENV infected HEK293T and REP cells, suggesting utility of the replicon system for this 
sort of analysis. Unfortunately, the limited number of proteins that changed in secretomes 
suggests that HEK293T cells may not represent the ideal cell model for analysing the 
effects of DENV infection on the cellular secretome. Nevertheless, proteins that might 
potentially play roles in host-virus immune responses such as DDX proteins and XRCC5 
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  Introduction 
 Hepatocytes, the major liver cell type, synthesize the majority of plasma proteins 
including carrier proteins, lipoproteins, complements, coagulation factors, acute phase 
response proteins and hormones (Kuscuoglu et al., 2018). The other functions of 
hepatocytes include detoxification, drug metabolism and bile production. The liver is one 
of the major target organs in DENV infection. Most symptomatic DEN patients have 
hepatomegaly (enlarged liver) and abnormal liver function tests (Dissanayake et al., 2017). 
Liver involvement in DEN patients can vary from mild abnormal liver function tests to 
liver failure, the latter resulting in high mortality from coagulopathy and uncontrolled 
bleeding. Previous studies using autopsy specimens from fatal DEN cases have provided 
evidence of DENV antigen and DENV replication in hepatocytes, Kupffer cells and liver 
endothelial cells (Póvoa et al, 2014). Due to the difficulties in examining DENV replication 
in the liver of infected individuals, liver hepatocyte cell lines such as Huh-7 and HepG2 
provide useful in vitro models to study DEN pathogenesis and test potential therapeutics 
(Senevirantne et al., 2006). Importantly, previous studies have demonstrated that results 
obtained from the use of liver cell models can correlate well with results obtained from 
clinical studies. For example, increased levels of alpha-enolase (ENO1) in the plasma of 
DEN patients paralleled a large increase in the amounts of ENO1 in the secretome of 
DENV-2 infected HepG2 cells (Higa et al., 2014). Moreover, an increase in macrophage 
migration inhibitory factor (MIF) in the secretomes of DENV-2 infected cells was 
correlated with disease severity in patients (Salazar et al, 2014).  Nevertheless, the 




As the liver is the major producer of plasma proteins, proteomic analysis of DENV 
infected liver cells and/or the associated secretomes has the potential to increase our 
understanding of the role of the liver in DEN pathogenesis. This is especially true in 
relation to alterations in the levels of plasma proteins, produced by hepatocytes, that occur 
during DENV infection. As described above, a limited number of previous studies have 
analysed either the proteome of DENV infected liver cells or the associated secretome, but 
a simultaneous combined study of both has not been undertaken. Moreover, the results 
from previous proteomic studies on liver cell lines/secretomes in response to DENV 
infection were inconsistent and did not lead to an improved understanding of the effect of 
DENV infection on important biological hepatic processes. These include alterations in 
complement and coagulation cascades, platelet activation/degradation and lipid 
metabolism, as well as the acute phase response (Will et al., 2012; Nascimento et al., 2014; 
Fragnoud et al., 2015). Proteomic analysis of DENV-2 infected HepG2 cells revealed 
changes in 17 proteins which were primarily involved in transcription and translational 
processes (Pattanakitsakul et al., 2008). By contrast, proteomic analysis of DENV-2 
infected Huh-7 cells using high-throughput label-free LC-MS/MS, identified 155 
differentially expressed proteins compared to mock infected cells (Pando-Robles et al., 
2014). The differentially expressed proteins were involved in mitochondrial function 
including energy metabolism, RNA processing and negative regulation of apoptosis.  
All secretome studies were conducted on samples derived from DENV-2 infected 
HepG2 cells with an initial study identifying secreted proteins found in serum protein 
databases (Higa et al., 2008). A follow-up study focused on a single protein, alpha-enolase 
(ENO1), and reported an increase in secretome but no changes in the intracellular 
production of this protein of DENV infected HepG2 cells (Higa et al., 2014). More 
recently, a study was done that focused on secreted proteins that had been subject to 
proteolysis, rather than a general analysis of secreted proteins (Caruso et al., 2017). A 
simultaneous analysis of the alterations of the secretion that occur in both the proteome 
and secretome of liver cells in response to DENV infection could provide more systematic 
information on the dynamic changes that occur in the amounts of proteins that are secreted 




Therefore, in this study simultaneous proteomic analysis of cell lysates and culture 
supernatants prepared from DENV-2 infected Huh-7 liver cells was done. The results 
identified relationships between cellular and secreted proteins and important biological 
pathways that are altered in Huh-7 liver cells in response to DENV infection. To determine 
if Huh-7 cells are a relevant model to study DEN pathogenesis, the results of the Huh-7 
analysis were analysed together with the results of the serum proteomic analysis of clinical 
specimens presented in chapter 6.  
Results 
 Proteomic analysis of the proteomes and secretomes from DENV-2, 
inactivated DENV-2 and mock infected Huh-7 cells. 
To analyse the effects of DENV-2 infection on the total cell proteome and 
secretome of Huh-7 cells, these cells were infected with DENV-2, heat-inactivated DENV-
2 (iDENV-2) or mock infected. An MOI of 5 was used to ensure all cells were infected; 
infections with iDENV-2 was conducted to control for the effects of viral particle uptake 
on the cells or for media effects. Additionally, the DENV-2 (and iDENV-2 derivative) 
stock was prepared from the supernatant of C6/36 cells infected with DENV-2 and may 
have contained stimulatory components from insect cells. Prior to infection, the cells were 
grown in complete media. After infection the cells were washed extensively with PBS and 
then grown in SFM for 30 h, at which time the culture supernatants and cells were 
harvested. The cell culture supernatants were then concentrated and cell lysates prepared 
using RIPA buffer (Figure 5.1). The infection rate was estimated to be 95%-100% at 30 
hpi by IFA (Figure 5.2). The experiments were performed independently in triplicate. The 
amount of protein in the concentrated supernatants and cell lysates was estimated by BCA 
assay. Equal amounts of each sample were then used for TMT labelling and LC-MS/MS 






















Figure 5.1 Study flow of the high-throughput proteomic analysis of the cellular proteomes 
and secretomes of DENV-2 infected Huh-7 cells. 
 In brief, Huh-7 cells were grown in CM for 24 h, divided into 3 groups and infected with 
DENV-2 and iDENV-2 at a MOI of 5 or mock infected. After infection, the cells were 
extensively washed with PBS and further grown in SFM for 30 h. At 30 hpi, the cells were 
harvested and cell cultured supernatants were concentrated. Experiments were done in 
triplicate. Proteins in the cell lysates and concentrated supernatants were TMT labelled and 
analysed by LC-MS/MS. 
  
Grow cells for 24 h in CM until 
60-80% confluent.  
-Infect with DENV-2/ iDENV-2 or mock infect. 
-Extensively wash with PBS. 
-
Grow infected cells 




















Figure 5.2 IFA analysis of Huh-7 cells infected with DENV-2, iDENV-2 or mock infected. 
 Huh-7 cells were infected with DENV-2 and iDENV-2 at MOI=5 or mock infected. After 
30 h of incubation in SFM, the cells were fixed with ice cold methanol and immunostained 
with an antibody against the DENV-2 E protein (Anti-E, green), nuclear DNA was 






 Quantitative LC-MS/MS analysis 
 The spectral files from the LC-MS/MS analyses were analysed using Proteome 
Discoverer and statistical analysis and downstream processing was done using Perseus as 
described in section 2.8. A total of 7010 proteins were identified in the cell lysates, of 
which 6367 were reliably identified and quantified using ≥ 2 peptides (hereafter termed the 
proteome). Of these, 5706 host proteins that were quantified in at least 2 of 3 experiments 
were analysed further. The abundance of host proteins in the proteomes of DENV-2 and 
iDENV-2 infected cells were compared with their abundance in mock infected cells. The 
total number of proteins and proteins that significantly changed (P-value < 0.05) in amount 
(with fold cut-off values of ≥ 2, ≥ 1.5 and ≥ 1.3) between DENV and iDENV-2 and mock 
infected cells are summarised in Table 5.1.  
A total of 3421 proteins were identified in the cell culture supernatants of which 
2818 were reliably identified and quantified using ≥ 2 peptides (hereafter termed the 
secretome). Of these, 1811 host proteins that were quantified in at least 2 of 3 experiments 
were analysed further. The abundance of host proteins in the DENV-2 and iDENV-2 
infected cells were compared with their abundance in mock infected cells. The total number 
of proteins and proteins that significantly changed (p < 0.05) in amount (with fold cut-off 
values of ≥ 2, ≥ 1.5 and ≥ 1.3) between DENV and iDENV-2 and mock infected cells are 





Table 5.1 Summary of the number of host proteins that changed in abundance in the 
proteomes of DENV-2 and iDENV-2 infected Huh-7 cells compared with mock 
infected cells. 
 Number of proteins 
changed in abundance 
Number of proteins significantly changed in 











Increased ≥ 2 fold 74 9 49 1 1 
Increased ≥ 1.5 fold 225 64 121 6 3 
Increased ≥ 1.3 fold 479 179 217 16 4 
Decreased ≥ 2 fold 71 2 58 0 0 
Decreased ≥ 1.5 fold 195 10 147 2 0 
Decreased ≥ 1.3 fold 389 42 246 5 1 
 
 
Table 5.2 Summary of the number of proteins that changed in abundance in the 
secretomes of DENV-2 and iDENV-2 infected Huh-7 cells compared with mock 
infected cells. 
 Number of proteins 
changed in abundance 
Number of proteins significantly changed in 











Increased ≥ 2 fold 23 5 9 1 1 
Increased ≥ 1.5 fold 90 45 27 3 2 
Increased ≥ 1.3 fold 207 147 48 11 4 
Decreased ≥ 2 fold 43 2 21 0 0 
Decreased ≥ 1.5 fold 182 20 75 0 0 






 Almost all DENV-2 structural and NS proteins, except NS2A and NS2B were 
detected in the proteome of DENV-2 infected Huh-7 cells, whilst all structural proteins, 
NS1 and NS4B were detected in the associated secretomes by LC-MS/MS analysis.  The 
% coverage, number of peptides, unique peptides and PSMs of the DENV-2 proteins 
detected in the proteome/secretome of DENV-2 infected Huh-7 cells are summarised in 
Table 5.3. 
 

















C 13.2 29.82 5 5 18 39.47 5 5 21 
E 54.3 20.61 3 3 27 36.57 18 18 86 
pr 18.7 41.62 25 25 180 26.67 4 4 12 
NS1 39.9 53.13 25 2 140 51.99 23 2 166 
NS2A 23.7 ND ND ND ND ND ND ND ND 
NS2B 14 ND ND ND ND ND ND ND ND 
NS3 69.3 75.89 59 59 286 ND ND ND ND 
NS4A 14 29.13 3 3 10 ND ND ND ND 
NS4B 26.8 26.21 5 1 20 3.23 1 1 1 
NS5 103.
1 
62.22 63 63 314 ND ND ND ND 
ND = not detected 
 Overall, the proteins that changed in abundance in the proteome and secretome of 
DENV-2 infected Huh-7 cells compared with mock infected cells decreased rather than 
increased. Proteins that significantly changed in the proteome and secretome of DENV-2 
but not iDENV-2 infected cells were selected for further study and validation. Proteins that 
significantly changed in abundance, with a cut-off of a ≥ 1.5 fold change, in the proteome 
and secretome of DENV-2 infected cells compared to mock infected cells (listed in Tables 




Table 5.4 Proteins that were significantly changed ≥ 1.5 fold in amount, in proteome 
of DENV-2 infected Huh-7 cells compared to mock infected cells. 





Increased in the proteome of DENV-2 infected cells compared to mock infected cells. 
Q8NEH6 Meiosis-specific nuclear structural 
protein 1  
MNS1 32.71 1.77E-03 
B4DDR3 Apoptosis inhibitor 5  API5 9.55 2.84E-04 
S4R322 Centrosomal protein of 290 kDa  CEP290 8.70 3.79E-05 
A8K171 Nuclear receptor interacting protein 1  NRIP1 6.90 2.21E-03 
B4DHW9 Pantothenate kinase 4  PANK4 6.78 1.91E-04 
Q9BXT8 RING finger protein 17  RNF17 6.74 2.62E-02 
P51587 Breast cancer type 2 susceptibility 
protein  
BRCA2 4.71 6.85E-03 
Q15773 Myeloid leukemia factor 2  MLF2 4.55 2.86E-03 
P0C7P0 CDGSH iron-sulfur domain-containing 
protein 3  
CISD3 4.52 2.40E-04 
Q13049 E3 ubiquitin-protein ligase TRIM32 TRIM32 4.48 8.23E-05 
B4DZC6 Bardet-Biedl syndrome 5 protein N/A 4.22 1.00E-02 
Q8IXZ2 Zinc finger CCCH domain-containing 
protein 3  
ZC3H3 4.16 8.16E-03 
P35080 Profilin-2  PFN2 4.04 5.05E-03 
Q14687 Genetic suppressor element 1  GSE1 3.50 1.66E-02 
E7ETM0 Casein kinase I isoform alpha  CSNK1A1  3.05 2.24E-04 
Q59GV6 Zinedin variant (Fragment) STRN4 3.02 3.40E-02 
Q8N9N7 Leucine-rich repeat-containing protein 
57  
LRRC57 2.93 6.71E-04 
B9EH95 Armadillo repeat gene deletes in 
velocardiofacial syndrome  
ARVCF 2.84 1.99E-02 
Q6NSJ0 Uncharacterized family 31 glucosidase 
KIAA1161  
KIAA1161 2.83 2.87E-03 
B4DGG2 Sorting nexin-13  SNX13 2.82 7.65E-03 
Q15697 Zinc finger protein 174  ZNF174 2.81 4.07E-02 
Q63ZY3 KN motif and ankyrin repeat domain-
containing protein 2  
KANK2 2.74 4.03E-02 
B2RBJ5 Alanine-glyoxylate aminotransferase 2 
(AGXT2), nuclear gene encoding 
mitochondrial protein,  
AGXT2 2.72 1.32E-02 
Q6EMK4 Vasorin  VASN 2.64 5.60E-03 
Q8NEB9 Phosphatidylinositol 3-kinase catalytic 
subunit type 3  
PIK3C3 2.54 3.17E-03 
Q9BZE9 Tether containing UBX domain for 
GLUT4  
ASPSCR1 2.48 4.82E-03 




Q9BX84 Transient receptor potential cation 
channel subfamily M member 6  
TRPM6 2.46 4.92E-02 
Q96LX8 Zinc finger protein 597  ZNF597 2.46 1.02E-02 
J9JIC5 Protein Njmu-R1 OS=Homo sapiens  C17orf75 2.39 2.68E-02 
Q86X83 COMM domain-containing protein 2  COMMD2 2.33 7.37E-03 
Q502W7 Coiled-coil domain-containing protein 
38  
CCDC38 2.31 3.71E-02 
Q13627 Dual specificity tyrosine-
phosphorylation-regulated kinase 1A  
DYRK1A 2.30 4.40E-02 
B4DTB1 cDNA FLJ52936, weakly similar to 
Tropomyosin alpha-4 chain  
TPM4 2.29 4.59E-02 
Q96SL4 Glutathione peroxidase 7  GPX7 2.27 2.07E-03 
Q9H1A3 Methyltransferase-like protein 9  METTL9 2.26 1.88E-05 
X5D907 Fragile X mental retardation 1 isoform C 
(Fragment) 
FMR1 2.23 2.32E-02 
E9PNJ4 Stromal interaction molecule 1  STIM1 2.21 3.31E-02 
B4E0C5 Mitochondrial carrier homolog 1  MTCH1 2.11 2.96E-02 
A0A0A0
MTQ8 
Coiled-coil domain-containing protein 
175  
CCDC175 2.09 8.95E-04 
Q06787 Fragile X mental retardation protein 1  FMR1 2.09 7.70E-04 
Q00577 Transcriptional activator protein Pur-
alpha  
PURA 2.08 3.83E-03 
Q9UQL5 DEAD-box protein p72  DDX17 2.07 2.42E-02 
B2R623 RNA guanylyltransferase and 5'-
phosphatase (RNGTT), mRNA  
RNGTT 2.07 5.67E-03 
B3KQT6 Tetraspanin-13  TSPAN13 2.04 7.16E-03 
C9JIF9 Acylamino-acid-releasing enzyme  APEH 2.03 3.01E-03 
Q2Q1W2 E3 ubiquitin-protein ligase TRIM71  TRIM71 2.01 1.10E-03 
Q9H008 Phospholysine phosphohistidine 
inorganic pyrophosphate phosphatase  
LHPP 2.00 2.26E-02 
P58107 Epiplakin  EPPK1 2.00 1.20E-02 
Q15645 Pachytene checkpoint protein 2 homolog  TRIP13 1.99 6.56E-03 
P16383 GC-rich sequence DNA-binding factor 2  GCFC2 1.98 4.60E-02 
H0Y449 Nuclease-sensitive element-binding 
protein 1 (Fragment)  
YBX1 1.98 3.10E-03 
Q09428 ATP-binding cassette sub-family C 
member 8  
ABCC8 1.97 3.62E-02 
O00425 Insulin-like growth factor 2 mRNA-
binding protein 3  
IGF2BP3 1.94 4.07E-04 
H7BYT1 Casein kinase I isoform delta  CSNK1D 1.93 5.41E-03 
B7Z565 Alpha-actinin-1  ACTN1 1.93 1.31E-02 
B4DY32 Asparagine synthetase (glutamine-
hydrolyzing)  
ASNS 1.91 1.28E-02 
Q9NZI8 Insulin-like growth factor 2 mRNA-
binding protein 1  
IGF2BP1 1.91 1.49E-04 




Q9NZE8 39S ribosomal protein L35, 
mitochondrial  
MRPL35 1.89 4.87E-04 
B3KM36 BAG family molecular chaperone 
regulator 2  
BAG2 1.87 3.47E-03 
Q96L93 Kinesin-like protein KIF16B  KIF16B 1.86 4.89E-02 
Q01991 Dihydrolipoamide S-acetyltransferase 
(Fragment) 
DLAT 1.83 2.75E-02 
E5KMK5 Mitochondrial DNA topoisomerase I  TOP1MT 1.83 5.13E-03 
Q9P2P6 StAR-related lipid transfer protein 9  STARD9 1.83 3.39E-02 
Q6PJG6 BRCA1-associated ATM activator 1  BRAT1 1.82 7.93E-03 
A8K6I6 Golgi associated, gamma adaptin ear 
containing, ARF binding protein 3 
(GGA3) 
GGA3 1.81 2.38E-03 
A1L3A7 Nuclear fragile X mental retardation 
protein interacting protein 2  
NUFIP2 1.80 9.68E-04 
Q92539 Phosphatidate phosphatase LPIN2  LPIN2 1.79 3.52E-02 
Q96K19 E3 ubiquitin-protein ligase RNF170  RNF170 1.78 1.36E-03 
P16989 Y-box-binding protein 3  CSDA;YBX
3 
1.78 2.11E-03 
Q14117 Dihydropyrimidinase  DPYS 1.78 3.16E-02 
Q96A46 Mitoferrin-2  SLC25A28 1.77 4.42E-02 
Q96QR8 Transcriptional activator protein Pur-beta  PURB 1.77 5.27E-03 
Q9UN79 Transcription factor SOX-13  SOX13 1.77 9.00E-03 
A0A0F7K
YT8 
Fragile X mental retardation autosomal 
homolog variant p2K  
FXR1 1.76 3.12E-05 
P51116 Fragile X mental retardation syndrome-
related protein 2 
FXR2 1.76 5.84E-04 
Q9HAB8 Phosphopantothenate--cysteine ligase  PPCS 1.73 2.89E-02 
A0A024R
5Y1 
Spastic paraplegia 21 (Autosomal 
recessive, Mast syndrome), isoform  
SPG21 1.70 1.04E-03 
Q69YJ7 Putative uncharacterized protein 
DKFZp667H197 (Fragment)  
RBM12 1.69 1.13E-02 
O15090 Zinc finger protein 536  ZNF536 1.69 3.45E-02 
D3DTX6 Neurabin-2  PPP1R9B 1.68 6.11E-03 
Q53G85 Elongation factor 1-alpha  EEF1A1 1.68 3.65E-02 
Q9UKD1 Glucocorticoid modulatory element-
binding protein 2  
GMEB2 1.67 1.93E-02 
Q59GL1 Synaptotagmin binding, cytoplasmic 
RNA interacting protein variant 
(Fragment)  
SYNCRIP 1.67 3.37E-03 
O15466 Alpha-2,8-sialyltransferase 8E  ST8SIA5 1.66 7.77E-03 
H0YJ17 Neuroguidin (Fragment)  NGDN 1.66 1.28E-02 
A0A024R
6Q6 
ATP-binding cassette, sub-family C 
(CFTR/MRP), member 11  
ABCC11 1.65 3.21E-02 
E7ERK9 Translation initiation factor eIF-2B 
subunit delta  
EIF2B4 1.65 4.69E-02 




Q96F86 Enhancer of mRNA-decapping protein 3  EDC3 1.65 7.20E-04 
P26196 Probable ATP-dependent RNA helicase 
DDX6  
DDX6 1.65 1.90E-03 
B2R8X4 GA binding protein transcription factor, 
alpha subunit 60kDa (GABPA), mRNA  
GABPA 1.64 2.48E-03 




A8IK34 Ankyrin repeat domain 40  ANKRD40 1.63 1.27E-02 
Q9BUN8 Derlin-1 OS=Homo sapiens  DERL1 1.61 1.64E-02 
Q9H5Z1 Probable ATP-dependent RNA helicase 
DHX35  
DHX35 1.61 2.84E-02 
P54652 Heat shock-related 70 kDa protein 2  HSPA2 1.61 1.06E-02 
A8K613 HCG37164, isoform  LYSMD3 1.60 1.83E-02 
Q8TE73 Dynein heavy chain 5, axonemal  DNAH5 1.60 4.20E-02 
B4DL78 alpha-1,2-Mannosidase  EDEM2 1.59 1.92E-02 





Methyltransferase like 17 isoform 4 
(Fragment) 
METTL17 1.59 1.06E-02 
A0A024R
1C2 
DNA topoisomerase  TOP3B 1.59 2.02E-02 
A4D1L5 Ubiquitin-conjugating enzyme E2H  UBE2H 1.58 7.70E-04 
F8W930 Insulin-like growth factor 2 mRNA-
binding protein 2  
IGF2BP2 1.58 2.86E-03 
Q9HC52 Chromobox protein homolog 8  CBX8 1.58 1.77E-03 
Q8WUD1 Ras-related protein Rab-2B  RAB2B 1.57 1.82E-02 
A0A024R
DT4 
Lymphocyte cytosolic protein 1 (L-
plastin), isoform  
LCP1 1.57 1.48E-02 
Q53XS4 Tyrosine-protein phosphatase non-
receptor type  
PTPN6 1.57 1.02E-02 
Q9ULM3 YEATS domain-containing protein 2  YEATS2 1.57 3.85E-02 
H0UI97 Zinc finger, CCCH-type with G patch 
domain, isoform  
ZGPAT 1.56 4.78E-02 
Q6Y7W6 PERQ amino acid-rich with GYF 
domain-containing protein 2  
GIGYF2 1.54 7.87E-05 
A0A024R
DB2 
Ras-GTPase activating protein SH3 
domain-binding protein 2  
G3BP2 1.54 6.38E-03 
C9JEJ2 Choline-phosphate cytidylyltransferase 
A  
PCYT1A 1.54 1.83E-03 
P13533 Myosin-6  MYH6 1.53 9.44E-03 
Q96DH6 RNA-binding protein Musashi homolog 
2 
MSI2 1.52 1.58E-02 
Q9BQF6 Sentrin-specific protease 7  SENP7 1.52 4.85E-02 
Q8WWM
7 
Ataxin-2-like protein  ATXN2L 1.52 5.63E-03 




Q9NZB2 Constitutive coactivator of PPAR-
gamma-like protein 1 
FAM120A 1.51 1.34E-03 
Decreased in the proteome of DENV-2 infected cells compared to mock infected cells. 
H3BSS0 Metallothionein  MT1G 0.08 9.71E-04 
P13640 Metallothionein-1G  MT1G 0.17 2.68E-03 
B7ZL91 Metalloendopeptidase  MEP1A 0.18 6.49E-04 
Q59EP2 Angiotensinogen variant (Fragment) AGT 0.20 5.64E-04 
A0A024R
466 
Integral membrane protein 2C, isoform  ITM2C 0.22 2.07E-02 
Q68CJ9 Cyclic AMP-responsive element-binding 
protein 3-like protein 3  
CREB3L3 0.23 4.81E-04 
Q59GX7 Stearoyl-CoA desaturase variant 
(Fragment) 
SCD 0.24 3.18E-03 
A0A0K0
K1J1 
Cystatin  CST3 0.25 1.76E-04 
Q7Z528 E3-16  ITM2B 0.28 3.84E-05 
A8K6C9 Insulin-like growth factor 2 
(somatomedin A) 
INS-IGF2 0.29 1.71E-03 
P00995 Serine protease inhibitor Kazal-type 1 SPINK1 0.30 3.40E-04 
Q9UHP3 Ubiquitin carboxyl-terminal hydrolase 
25  
USP25 0.32 2.07E-04 
E1U340 ZNF511/PRAP1 fusion protein  ZNF511-
PRAP1 
0.33 7.19E-03 
P02760 Protein AMBP  AMBP 0.34 7.46E-04 
P02771 Alpha-fetoprotein  AFP 0.34 7.22E-04 
E9KL23 alpha-1-antitrypsin SERPINA1 0.34 6.85E-04 
O60487 Myelin protein zero-like protein 2  MPZL2 0.35 6.04E-03 
M1V487 Tyrosine-protein kinase receptor  LRIG3 0.35 1.33E-03 
X6R8F3 Neutrophil gelatinase-associated 
lipocalin  
LCN2 0.36 3.98E-02 
P02671 Fibrinogen alpha chain  FGA 0.36 1.28E-03 
Q2M3R2 Protocadherin beta 3  PCDHB3 0.36 2.72E-03 
P02763 Alpha-1-acid glycoprotein 1  ORM1 0.36 1.05E-03 
P02795 Metallothionein-2  MT2A 0.36 1.39E-02 
P80297 Metallothionein-1X MT1X 0.37 1.11E-02 
P04732 Metallothionein-1E  MT1E 0.38 1.52E-02 
A0A024R
6T4 
Metallothionein  MT1M 0.38 2.91E-02 
P02647 Apolipoprotein A-I  APOA1 0.39 9.29E-03 
E9PGN7 Plasma protease C1 inhibitor SERPING1 0.40 9.56E-03 
Q8NBJ4 Golgi membrane protein 1  GOLM1 0.40 1.17E-03 
V9HWA9 Complement C3  C3 0.40 2.77E-05 
Q86WW8 Cytochrome c oxidase assembly factor 5  COA5 0.41 5.17E-03 
V9HVY1 Fibrinogen beta chain FGB 0.43 1.01E-03 




A8K7A2 cell division cycle associated 8 CDCA8 0.44 4.08E-03 
K7ER74 Apolipoprotein C-II  APOC2 0.44 4.34E-04 
P02753 Retinol-binding protein 4  RBP4 0.44 5.58E-04 
P02679 Fibrinogen gamma chain  FGG 0.44 1.18E-03 
B2R7U4 Heme oxygenase (decycling) 1 
(HMOX1), mRNA  
HMOX1 0.45 7.61E-03 
B2R778 Cadherin 17, LI cadherin (liver-intestine) 
(CDH17), mRNA 
CDH17 0.46 2.48E-03 
O95445 Apolipoprotein M APOM 0.46 2.99E-02 
Q53H26 Transferrin variant (Fragment)  TF 0.46 2.03E-03 
A0A024R
462 
Fibronectin 1, isoform FN1 0.47 5.21E-03 
Q06481 Amyloid-like protein 2  APLP2 0.47 2.25E-03 
A8K7Q1 nucleobindin 1 (NUCB1), mRNA NUCB1 0.47 8.30E-04 
X5D2G8 Fibroblast growth factor receptor 3 
isoform A  
FGFR3 0.47 1.24E-03 
Q59F30 Fibroblast growth factor receptor 4 
variant  
FGFR4 0.48 9.83E-04 
P49715 CCAAT/enhancer-binding protein alpha  CEBPA 0.48 6.22E-03 
Q567V2 Mpv17-like protein 2  MPV17L2 0.48 4.00E-02 
Q9NQZ5 StAR-related lipid transfer protein 7, 
mitochondrial  
STARD7 0.48 3.08E-02 
Q01581 Hydroxymethylglutaryl-CoA synthase, 
cytoplasmic  
HMGCS1 0.48 3.51E-04 
Q6NT76 Homeobox-containing protein 1  HMBOX1 0.49 7.59E-04 
Q08830 Fibrinogen-like protein 1  FGL1 0.49 1.94E-02 
P07307 Asialoglycoprotein receptor 2  ASGR2 0.49 4.78E-03 
O43405 Cochlin  COCH 0.49 2.30E-02 
A8K5A4 Ceruloplasmin (ferroxidase) (CP), 
mRNA 
CP 0.49 3.90E-04 
P00738 Haptoglobin  HP 0.49 2.46E-02 
P04733 Metallothionein-1F MT1F 0.50 1.75E-02 
A0A024R
9D9 
Transcription and mRNA export factor 
ENY2  
ENY2 0.50 9.73E-04 
D0PNI2 Lysyl oxidase  LOX 0.50 8.83E-03 
P80294 Metallothionein-1H  MT1H 0.51 7.43E-03 
A0A087
WY68 
Proprotein convertase subtilisin/kexin 
type 6  
PCSK6 0.51 3.79E-02 
Q9BXS6 Nucleolar and spindle-associated protein 
1  
NUSAP1 0.52 1.15E-02 
P78556 C-C motif chemokine 20  CCL20 0.52 3.59E-02 
P34741 Syndecan-2  SDC2 0.52 9.55E-03 
Q5S3G3 MHC class I antigen  HLA-A 0.52 4.79E-03 
P18827 Syndecan-1  SDC1 0.52 1.50E-02 
B2RCP7 connective tissue growth factor (CTGF), 
mRNA 






HLA class I histocompatibility antigen, 
A-3 alpha chain  
HLA-A  0.53 3.23E-03 
Q16626 Male-enhanced antigen 1  MEA1 0.53 2.68E-04 
P42830 C-X-C motif chemokine 5 CXCL5 0.53 6.11E-03 
B4DRF2 Complement factor I  CFI 0.54 1.99E-03 
P05997 Collagen alpha-2(V) chain  COL5A2 0.54 9.92E-03 
O95864 Fatty acid desaturase 2  FADS2 0.54 1.67E-02 
Q8NG11 Tetraspanin-14  TSPAN14 0.54 3.73E-02 
Q9BRK5 45 kDa calcium-binding protein  SDF4 0.54 1.24E-03 
P01031 Complement C5  C5 0.54 7.61E-03 
B1AHL2 Fibulin-1  FBLN1 0.55 4.01E-03 
E5RIM7 Copper transport protein ATOX1  ATOX1 0.55 3.19E-02 
Q8IZ52 Chondroitin sulfate synthase 2  CHPF 0.55 5.02E-02 
P05067 Amyloid beta A4 protein  APP 0.55 2.18E-03 
O00762 Ubiquitin-conjugating enzyme E2 C UBE2C 0.55 4.81E-04 
Q12772 Sterol regulatory element-binding 
protein 2  
SREBF2 0.56 8.15E-03 
P10909 Clusterin  CLU 0.56 2.95E-02 
A0A024R
B84 
Receptor protein-tyrosine kinase  ERBB3 0.56 2.98E-03 
P84101 Small EDRK-rich factor 2  SERF2 0.56 2.82E-03 
Q8NC54 Keratinocyte-associated transmembrane 
protein 2  
C5orf15 0.56 2.29E-03 
Q9NXH8 Torsin-4A  TOR4A 0.57 2.24E-02 
B4E1Z4 Complement factor B N/A 0.58 1.84E-02 
A0A024R
9G2 
Ankyrin repeat domain 46, isoform  ANKRD46 0.58 8.74E-03 
B3KM21 Family with sequence similarity 36, 
member A, isoform  
COX20 0.58 1.66E-03 
A0A024R
E02 
Phosphoglycerate dehydrogenase like 1, 
isoform  
UBAC2 0.59 1.34E-02 
D3DRR6 Inter-alpha (Globulin) inhibitor H2, 
isoform 
ITIH2 0.59 2.23E-02 
A0A024Q
YT5 
Serpin peptidase inhibitor, clade E 
(Nexin, plasminogen activator inhibitor 
type 1), member 1, isoform  
SERPINE1 0.60 4.81E-02 
Q13530 Serine incorporator 3  SERINC3 0.60 9.30E-03 
Q9BTY2 Plasma alpha-L-fucosidase  FUCA2 0.60 3.53E-03 
A0A024R
944 
Antithrombin III  SERPINC1 0.61 3.82E-02 
F1D8T1 Hepatocyte nuclear factor 4 HNF4A 0.61 1.98E-02 
Q4ZIN3 Membralin C19orf6 
TMEM259 
0.61 1.34E-02 
Q8NET6 Carbohydrate sulfotransferase 13  CHST13 0.61 1.17E-02 
A0A087X
2H1 






Ubiquitin-like 5, isoform  UBL5 0.61 1.66E-02 
P20290 Transcription factor BTF3  BTF3 0.61 4.13E-02 
F1CME6 Hepatitis A virus cellular receptor 1a  HAVCR1 0.61 3.20E-02 
E9PGC5 Receptor-type tyrosine-protein 
phosphatase kappa  
 0.61 1.19E-02 
Q9NR09 Baculoviral IAP repeat-containing 
protein 6  
BIRC6 0.61 9.35E-03 
Q8NFH9 MLL/SEPTIN6 fusion protein 
(Fragment) 
N/A 0.62 2.13E-02 




mannosidase IA  
MAN1A1 0.62 1.16E-02 
Q8TCT8 Signal peptide peptidase-like 2A  SPPL2A 0.62 3.04E-02 
A0A024R
3H2 
Sortilin-related receptor, L(DLR class) A 
repeats-containing  
SORL1 0.62 1.02E-02 
P00734 Prothrombin  F2 0.62 3.72E-02 
P48740 Mannan-binding lectin serine protease 1  MASP1 0.62 3.68E-03 
P14543 Nidogen-1  NID1 0.62 7.47E-03 
B3KUE5 Phospholipid transfer protein, isoform  PLTP 0.62 2.86E-02 
B2R8Y9 Tissue factor pathway 
inhibitor(lipoprotein-associated 
coagulation inhibitor) (TFPI), mRNA  
TFPI 0.63 1.61E-02 
Q9H0X4 Protein FAM234A  ITFG3 
FAM234A 
0.63 1.16E-02 
Q6IAX1 FDFT1 protein  FDFT1 0.63 2.18E-02 
A0A024Q
YX3 
RNA binding motif (RNP1, RRM) 
protein 3, isoform  
RBM3 0.63 1.04E-02 
Q53YP0 PreS1 binding protein GLTSCR2; 
NOP53 
0.63 3.62E-02 
Q96EH3 Mitochondrial assembly of ribosomal 
large subunit protein 1  
MALSU1 0.63 2.62E-02 
A0A024R
9N5 
Solute carrier family 35, member D2, 
isoform  
SLC35D2 0.64 3.51E-02 
A0A024R
9G0 
Polymerase (RNA) II (DNA directed) 
polypeptide K, 7.0kDa, isoform  
POLR2K 0.64 3.79E-02 
Q658Y4 Protein FAM91A1 FAM91A1 0.64 1.86E-02 
B3KMC8 WW domain-binding protein 4  WBP4 0.64 2.45E-02 
A0A024R
0T8 
Apolipoprotein C-I, isoform  APOC1 0.64 3.61E-03 
Q9ULW0 Targeting protein for Xklp2  TPX2 0.64 8.24E-03 
A0A024R
D39 
Phospholipase A2, group VII (Platelet-
activating factor acetylhydrolase, 
plasma), isoform  
PLA2G7 0.65 1.70E-03 
Q59ER8 Leucine-rich repeat-containing G 
protein-coupled receptor 4 variant 
(Fragment)  




G3XAN8 Mitochondrial import inner membrane 
translocase subunit Tim8 B 
TIMM8B 0.65 2.44E-02 
H7C3C4 Anion exchange protein (Fragment)  SLC4A7 0.65 8.14E-03 
Q15904 V-type proton ATPase subunit S1  ATP6AP1 0.65 2.78E-02 
A6NMH8 Tetraspanin  CD81 0.65 1.05E-02 
Q96KR6 Protein FAM210B  FAM210B 0.65 3.39E-03 
Q59FM9 TYRO3 protein tyrosine kinase variant 
(Fragment)  
TYRO3 0.65 6.65E-03 
Q9HAT2 Sialate O-acetylesterase  SIAE 0.65 1.84E-03 
A0A024R
6U8 
Matrix metallopeptidase 15 (Membrane-
inserted), isoform  
MMP15 0.65 2.83E-02 
O75506 Heat shock factor-binding protein 1  HSBP1 0.66 4.42E-03 
A0A024R
3K2 
RNA pseudouridylate synthase domain 
containing 4, isoform  
RPUSD4 0.66 4.96E-02 
Q8NC42 E3 ubiquitin-protein ligase RNF149  RNF149 0.66 8.93E-03 
A0A0C4
DFL7 
Lanosterol 14-alpha demethylase  CYP51A1 0.66 2.87E-02 
A0A0S2Z
3Y2 
Interferon gamma receptor 1 isoform 1 
(Fragment)  
IFNGR1 0.66 1.24E-03 
Q07954 Prolow-density lipoprotein receptor-
related protein 1  
LRP1 0.66 1.46E-03 
Q5SRD1 Putative mitochondrial import inner 







A8KAF0 CCR6 chemokine receptor (CMKBR6) 
gene  
CCR6 0.67 4.35E-03 
A0A0A0
MR51 
Fatty acid desaturase 1  FADS1 0.67 6.40E-03 
Q9BU23 Lipase maturation factor 2  LMF2 0.67 5.79E-03 





Table 5.5 Proteins that were significantly changed ≥ 1.5 fold in amount, in the 
secretome of DENV-2 infected Huh-7 cells compared to mock infected cells. 





Increased in the secretome of DENV-2 infected cells compared to mock infected cells. 
Q13724 Mannosyl-oligosaccharide glucosidase  MOGS 7.01 1.03E-02 
Q5SRE5 Nucleoporin NUP188 homolog  NUP188 3.00 1.19E-02 
Q9UKL6 Phosphatidylcholine transfer protein  PCTP 2.80 3.50E-02 
Q8WWI1 LIM domain only protein 7  LMO7 2.77 2.45E-02 
Q5T5H1 Alpha-endosulfine  ENSA 2.54 1.36E-04 
P05204 Non-histone chromosomal protein HMG-
17  
HMGN2 2.23 2.79E-02 
Q9H2M9 Rab3 GTPase-activating protein non-




B2RA03 Keratin 18 (KRT18), mRNA  KRT18 2.13 1.24E-02 
P05787 Keratin, type II cytoskeletal 8  KRT8 2.07 9.34E-03 
P58166 Inhibin beta E chain  INHBE 1.93 2.43E-02 
O00469 Procollagen-lysine,2-oxoglutarate 5-
dioxygenase 2  
PLOD2 1.86 1.95E-03 
B7Z809 C-1-tetrahydrofolate synthase, 
cytoplasmic  
MTHFD1 1.75 9.84E-03 
Q01970 1-phosphatidylinositol 4,5-bisphosphate 
phosphodiesterase beta-3 
PLCB3 1.73 3.09E-02 
B2RA34  BCL2-associated athanogene 4 (BAG4), 
mRNA  
BAG4 1.69 4.69E-02 
Q13740 CD166 antigen  ALCAM 1.69 5.10E-03 
A8K8X0 Nap1 P120  NAA25 1.68 1.70E-02 
Q92484 Acid sphingomyelinase-like 
phosphodiesterase 3a  
SMPDL3A 1.67 2.36E-02 
Q59GW6 Acetyl-CoA acetyltransferase, cytosolic 
variant (Fragment) 




Q8N1G4 Leucine-rich repeat-containing protein 47  LRRC47 1.64 4.18E-02 
Q9H4F8 SPARC-related modular calcium-binding 
protein 1 
SMOC1 1.63 2.74E-03 
Q9NP79 Vacuolar protein sorting-associated 
protein VTA1 homolog  
VTA1 1.63 2.20E-02 
Q92896 Golgi apparatus protein 1 GLG1 1.60 3.26E-02 
A0A024R
AF7 
Endothelin converting enzyme 1, isoform  ECE1 1.58 4.43E-02 
P35222 Catenin beta-1  CTNNB1 1.57 4.86E-02 
E7EPT4 NADH dehydrogenase [ubiquinone] 
flavoprotein 2, mitochondrial  
NDUFV2 1.56 2.26E-02 
P30048 Thioredoxin-dependent peroxide 
reductase  
PRDX3 1.51 3.61E-02 
A0A0A1T
TQ0 
Lutheran blood group glycoprotein BCAM 1.50 1.77E-02 
Decrease in the secretome of DENV-2 infected cells compared to mock infected cells. 
P19652 Alpha-1-acid glycoprotein 2  ORM2 0.67 1.624E-02 
P16870 Carboxypeptidase E  CPE 0.67 1.527E-02 
P08697 Alpha-2-antiplasmin  SERPINF2 0.67 3.539E-02 




ST3GAL1 0.67 4.361E-03 
E9KL23 Alpha-1-antitrypsin SERPINA1 0.66 5.140E-03 
P02768 Serum albumin ALB 0.65 2.584E-03 
Q9NZL9 Methionine adenosyltransferase 2 subunit 
beta  
MAT2B 0.65 3.979E-02 
A0A0R7F
JH5 








E7ETH0 Complement factor I  CFI 0.65 4.296E-02 





(heparan glucosaminyl) 1  
NDST1 0.64 1.801E-02 
D9ZGG2 Vitronectin  VTN 0.64 2.278E-02 
A0A0K0
K1J1 
Cystatin  CST3 0.64 1.318E-02 
A0A024R
6I9 
Serpin peptidase inhibitor, clade A (Alpha-
1 antiproteinase, antitrypsin), member 4, 
isoform  
SERPINA4 0.64 8.577E-03 
Q9BTY2 Plasma alpha-L-fucosidase  FUCA2 0.63 2.949E-02 
Q9UHG3 Prenylcysteine oxidase 1  PCYOX1 0.63 6.875E-03 
A0A0S2Z
4L3 
Protein S isoform 2 (Fragment) PROS1 0.63 4.254E-02 
B2R9F2 Proteinase inhibitor, clade A (alpha-1 
antiproteinase, antitrypsin), member 6  
SERPINA6 0.63 6.231E-04 
B3KME2 Cartilage-associated protein  CRTAP 0.62 2.342E-02 
P05160 Coagulation factor XIII B chain  F13B 0.62 1.876E-02 
Q8WXD2 Secretogranin-3  SCG3 0.62 1.078E-02 
P05546 Heparin cofactor 2 SERPIND1 0.62 7.537E-03 
C0JYY2 Apolipoprotein B  APOB 0.61 3.347E-02 
Q8NE71 ATP-binding cassette sub-family F 
member 1  
ABCF1 0.61 9.291E-03 
P22352 Glutathione peroxidase 3  GPX3 0.60 4.154E-03 
Q8NBP7 Proprotein convertase subtilisin/kexin type 
9  
PCSK9 0.60 4.762E-03 
P34096 Ribonuclease 4  RNASE4 0.60 9.785E-03 
P10909 Clusterin  CLU 0.60 2.182E-02 
O94985 Calsyntenin-1  CLSTN1 0.59 2.240E-02 
B3KUE5 Phospholipid transfer protein, isoform  PLTP 0.59 1.184E-03 
D0PNI2 Lysyl oxidase  LOX 0.59 3.187E-02 
Q8IWW6 Rho GTPase-activating protein 12  ARHGAP12 0.59 4.523E-02 
A4D2D2 Procollagen C-endopeptidase enhancer  PCOLCE 0.58 1.211E-02 
Q9BRP8 Partner of Y14 and mago OS=Homo 
sapiens  




P02771 Alpha-fetoprotein  AFP 0.57 8.815E-04 
P23142 Fibulin-1 FBLN1 0.57 1.386E-02 
P00742 Coagulation factor X  F10 0.57 1.335E-02 
P15169 Carboxypeptidase N catalytic chain CPN1 0.56 9.341E-05 
E9PLM6 Midkine  MDK 0.56 1.908E-02 
P03950 Angiogenin  ANG 0.56 1.124E-02 
B4DM05 Nidogen-1  NID1 0.56 2.183E-02 
O95445 Apolipoprotein M  APOM 0.56 6.453E-03 
A0A024R
D39 
Phospholipase A2, group VII (Platelet-
activating factor acetylhydrolase, plasma), 
isoform  
PLA2G7 0.56 5.919E-04 
B7Z4R3  T-complex protein 1 subunit beta  CCT2 0.55 2.933E-02 
O00264 Membrane-associated progesterone 
receptor component 1  
PGRMC1 0.55 3.648E-02 
P35443 Thrombospondin-4  THBS4 0.55 3.386E-02 
O75787 Renin receptor  ATP6AP2 0.54 4.417E-02 
B4DUV1 Fibulin-1  FBLN1 0.54 2.460E-02 
A0A024R943 Torsin family 3, member A, isoform  TOR3A 0.54 4.635E-04 
B7ZL91 Metalloendopeptidase  MEP1A 0.54 1.163E-02 
P09668 Pro-cathepsin H  CTSH 0.52 1.670E-02 
B3KM35  Beta-1,4-galactosyltransferase 4  B4GALT4 0.52 4.009E-02 
Q15904 V-type proton ATPase subunit S1  ATP6AP1 0.52 2.149E-02 
P55001 Microfibrillar-associated protein 2  MFAP2 0.51 6.122E-03 
A8K5T0 Complement factor H (CFH), mRNA  CFH 0.51 1.813E-02 
Q08830 Fibrinogen-like protein 1  FGL1 0.50 8.244E-03 
P07307 Asialoglycoprotein receptor 2  ASGR2 0.50 7.190E-03 
P22792 Carboxypeptidase N  CPN2 0.46 6.812E-03 
P02679 Fibrinogen gamma chain  FGG 0.45 1.017E-02 
Q13443 Disintegrin and metalloproteinase domain-
containing protein 9  
ADAM9 0.45 4.531E-02 
V9HVY1 Epididymis secretory sperm binding 
protein Li 78p  
FGB 0.44 2.673E-03 




P02671 Fibrinogen alpha chain  FGA 0.44 1.894E-02 
O95025 Semaphorin-3D  SEMA3D 0.43 4.898E-02 
B4DN31 Chitinase domain-containing protein 1  CHID1 0.43 2.612E-02 
F5H8G6 Probable 28S rRNA (cytosine(4447)-
C(5))-methyltransferase  
NOP2 0.43 4.641E-02 
Q86UD1 Out at first protein homolog  OAF 0.41 3.596E-03 
P02647 Apolipoprotein A-I  APOA1 0.40 7.162E-04 
D3DP16 Fibrinogen gamma chain, isoform  FGG 0.40 2.487E-02 
V9GYM3 Apolipoprotein A-II  APOA2 0.39 3.569E-04 
E1U340 ZNF511/PRAP1 fusion protein  ZNF511-
PRAP1 
0.38 4.794E-06 
K7ER74 Apolipoprotein C-II  APOC2 0.36 8.661E-03 
Q13444 Disintegrin and metalloproteinase domain-
containing protein 15  
ADAM15 0.35 2.843E-02 
Q5U676 B3GAT3 protein (Fragment)  B3GAT3 0.33 3.872E-02 
B0YIW2 Apolipoprotein C-III  APOC3 0.11 3.394E-02 
A0A087
WW81 






In addition to the individual analysis of the proteins that changed in abundance in 
either the proteome or secretome of DENV-2 infected cells compared to mock infected 
cells, an integrated analysis of the proteins that significantly changed in both was done to 
determine the relationship of intracellular and secreted proteins. There were 1469 host 
proteins that were commonly identified in both proteome and secretome (Figure 5.3). A 
lower cut-off of 1.3 fold was used to analyse the combined data set, to ensure all proteins 
that changed in abundance in the same direction were identified. There were 30 proteins 
that were found to be significantly altered (≥1.3 fold) in both the proteome and secretome 
of DENV2 infected cells compared to mock infected cells (Figure 5.4 and Table 5.6).  As 
for the individual datasets, it was found that the majority of the commonly modulated 
proteins were decreased in abundance upon infection. There were 1 and 27 host proteins 
that significantly increased and decreased in both the proteome and secretome, 
respectively. Whereas, 2 proteins, mannosyl-oligosaccharide glucosidase (MOGS) and 
cadherin 17 (CDH17), were identified to significantly decrease in the proteome but 
increase in the secretome after infection. Among the 27 proteins that significantly 
decreased in both the proteome and secretome, 20 proteins that decreased ≥ 1.5 fold were 
subjected to further bioinformatic analysis. A higher cut-off was applied for this analysis 









Figure 5.3 Overlap between the cellular and secreted proteins detected. 
Venn diagram shows the number of proteins that were detected in the proteome and 











Figure 5.4 Overlap between cellular and secreted proteins significantly altered (≥ 1.3 fold) 
in DENV-2 infection. 
Venn diagram shows the number of proteins that significantly (P-value < 0.05) increased 
and decreased (≥1.3 fold) in the proteome and secretome of DENV-2 infected Huh-7 cells 




Table 5.6 Proteins that were commonly significantly changed ≥ 1.3 fold in amount in 
both proteome and secretome of DENV-2 infected Huh-7 cells compared to mock 
infected cells. 





































Increased in both the proteome and secretome of DENV-2 infected Huh-7 cells  
P25685 DnaJ homolog subfamily B 
member 1 
DNAJB1 1.34 1.64E-02 1.42 3.11E-02 
Increased in the proteome but decreased in the secretome of DENV-2 infected Huh-7 cells 
None 
      
Decreased in the proteome but increased in the secretome of DENV-2 infected Huh-7 cells 
Q13724 Mannosyl-oligosaccharide 
glucosidase  
MOGS 0.67 8.12E-03 7.01 1.03E-02 
B2R778 Cadherin 17, LI cadherin  CDH17 0.46 2.48E-03 1.39 1.43E-02 
Decreased in both the proteome and secretome of DENV-2 infected Huh-7 cells 
B3KQT8 Procollagen C-endopeptidase 
enhancer 2  
PCOLCE2 0.69 9.31E-03 0.44 7.50E-03 
Q15904 V-type proton ATPase 
subunit S1  
ATP6AP1 0.65 2.78E-02 0.52 2.15E-02 
A0A024R
D39 
Phospholipase A2, group VII 
(Platelet-activating factor 
acetylhydrolase, plasma)  
PLA2G7 0.65 1.70E-03 0.56 5.92E-04 
B3KUE5 Phospholipid transfer 
protein, isoform 
PLTP 0.62 2.86E-02 0.59 1.18E-03 
P00734 Prothrombin  F2 0.62 3.72E-02 0.72 3.47E-02 
P33908 Mannosyl-oligosaccharide 
1,2-alpha-mannosidase IA  
MAN1A1 0.62 1.16E-02 0.69 1.54E-02 
Q9BTY2 Plasma alpha-L-fucosidase  FUCA2 0.60 3.53E-03 0.63 2.95E-02 
P10909 Clusterin  CLU 0.56 2.95E-02 0.60 2.18E-02 




P07307 Asialoglycoprotein receptor 
2  
ASGR2 0.49 4.78E-03 0.50 7.19E-03 
Q08830 Fibrinogen-like protein 1  FGL1 0.49 1.94E-02 0.50 8.24E-03 
Q53H26 Transferrin variant  TF 0.46 2.03E-03 0.71 3.51E-02 
O95445 Apolipoprotein M  APOM 0.46 2.99E-02 0.56 6.45E-03 
P02679 Fibrinogen gamma chain  FGG 0.44 1.18E-03 0.45 1.02E-02 
P02753 Retinol-binding protein 4  RBP4 0.44 5.58E-04 0.69 1.57E-02 
K7ER74 Apolipoprotein C-II APOC2 0.44 4.34E-04 0.36 8.66E-03 
V9GYM3 Apolipoprotein A-II  APOA2 0.44 8.43E-04 0.39 3.57E-04 
V9HVY1 Fibrinogen beta chain FGB 0.43 1.01E-03 0.44 2.67E-03 
P02647 Apolipoprotein A-I  APOA1 0.39 9.29E-03 0.40 7.16E-04 
P02763 Alpha-1-acid glycoprotein 1  ORM1 0.36 1.05E-03 0.71 7.53E-03 
P02671 Fibrinogen alpha chain FGA 0.36 1.28E-03 0.44 1.89E-02 
E9KL23 Alpha -1-Antitrypsin SERPINA1 0.34 6.85E-04 0.66 5.14E-03 
P02771 Alpha-fetoprotein  AFP 0.34 7.22E-04 0.57 8.82E-04 
P02760 Protein AMBP  AMBP 0.34 7.46E-04 0.68 1.05E-02 




0.33 7.19E-03 0.38 4.79E-06 
A0A0K0
K1J1 
Cystatin  CST3 0.25 1.76E-04 0.64 1.32E-02 
B7ZL91 Metalloendopeptidase  MEP1A 0.18 6.49E-04 0.54 1.16E-02 
 Fibulin-1 FBLN1 0.55 4.01E-03 0.54 2.46E-02 
*The proteins that significantly (P-value <0.05) decreased ≥1.5 fold in both proteome and 





 Bioinformatic analysis of cellular and secreted proteins altered in 
abundance in response to DENV-2 infection  
 Bioinformatic analysis of cellular proteins altered in abundance in response to 
DENV-2 infection.  
 The 121 and 147 proteins that significantly increased and decreased ≥ 1.5 fold, 
respectively, in the proteome of DENV-2 cells compared to mock infected cells were 
subjected to gene enrichment and network analysis using the DAVID and STRING 
analysis programs (Figures 5.5 and 5.6 and Supplementary Table S 5.1).  
DAVID analysis of the proteins that significantly increased in response to DENV-
2 infection identified three functional annotation clusters associated with significantly 
enriched GO terms (Figure 5.5). The GOBP term “negative regulation of translation” 
(GO:0017148) was the most enriched, followed by the terms “CRD-mediated mRNA 
stabilization” (GO:0070934) and “negative regulation of transcription from RNA 
polymerase II promoter” (GO:0000122). The biological processes related to DEN 
pathogenesis identified by the STRING analysis included “negative regulation of gene 
expression” (GO:0010629), “negative regulation of translation” (GO:0017148) and 
“cytoplasmic stress granule” (GO:0010494) (Figure 5.6A). None of the proteins were 









Figure 5.5 DAVID analysis of cellular proteins that were altered in abundance in DENV-
2 infected Huh-7 cells. 
Proteins that were significantly (P-value < 0.05) altered in amount by ≥ 1.5 fold in DENV-
2 infected Huh-7 cells compared to mock infected cells were analysed using the DAVID 
database. The GO accession numbers/terms that were significantly enriched and the 
properties of the corresponding protein clusters are shown. The GES of protein clusters 
associated with GO terms that significantly increased and decreased in response to 
infection are shown in red and blue, respectively. The shading shows the type of GO term 
(GOBP, GOCC or GOMF), UP keywords, Interpro term or KEGG pathway. The number 
of proteins in each cluster (count), number of proteins associated with each GO term/total 
number of proteins in the dataset (%) and P-value for each of the annotation terms are listed 






Figure 5.6 STRING analysis of cellular proteins that were altered in abundance in DENV-
2 infected Huh-7 cells. 
 The STRING database was searched to analyse cellular proteins that significantly (P-
value < 0.05) increased (A) and decreased (B) ≥ 1.5 fold in response to DENV-2 
infection. (A) Nodes representing proteins associated with the significantly enriched GO 
terms “negative regulation of gene expression”, “negative regulation of translation” and 
“cytoplasmic stress granule” are shaded in red, blue and green, respectively. (B) Nodes 
representing proteins associated with the significantly enriched GO terms “lipid 
metabolic process”, “acute-phase response”, “complement and  coagulation cascades” 
and “mineral absorption”  are shaded in red, blue, green and yellow respectively. The 
number of coloured nodes/total proteins involved for each term and the FDR of each GO 





By contrast, DAVID analysis of the proteins that significantly decreased in DENV-
2 infected Huh-7 cells compared to mock infected cells identified 19 functional annotation 
clusters that were associated with significantly enriched GO terms (the top ten clusters are 
shown in Figure 5.5). The most significantly enriched GO terms were the GOCC terms 
“extracellular region” (GO: 0005576; with keywords “signal peptide”), followed by 
“integral component of plasma membrane” (GO:0005887) and the GOBP terms, “negative 
regulation of growth” (GO:0045926; with keywords “metal-binding/metallothionein”), 
“negative regulation of endopeptidase activity” (GO:0010951), “blood coagulation” 
(GO0072378) and “innate immune response” (GO0045087) (Figure 5.5; Supplement table 
S 5.2).  
STRING analysis revealed that cellular proteins that decreased in response to 
DENV-2 infection included clusters of proteins associated with the significantly enriched 
GOBP terms, “acute-phase response” (GO:0006953) and “lipid metabolic process” 
(GO:0006629) (Figure 5.6B). Protein clusters were also associated with the enriched 
KEGG pathways “complement and coagulation cascades” (hsa04610) followed by 
“mineral absorption” (hsa04978).  
 Bioinformatic analysis of the secretome from DENV-2 infected Huh-7 cells  
 The 27 and 75 host proteins that significantly increased and decreased ≥ 1.5 fold, 
respectively, in the secretome of DENV-2 infected Huh-7 cells compared to mock were 
subjected to gene enrichment and network analysis using the DAVID and STRING 
analysis programs (Figures 5.7 and 5.8). The analysis revealed the same trends as for the 
cellular proteome analysis. DAVID analysis showed that the proteins that were increased 
in amount after DENV-2 infection were not associated with a significant enrichment of any 
GO term. Whereas STRING analysis identified only one cluster of proteins, associated 
with the GOMF term “protein C-terminus binding” (GO:0008022) (Figure 5.8A). 
By contrast, DAVID analysis of the proteins significantly decreased in abundance 
in the secretome from DENV-2 infected cells identified 6 functional annotation clusters 
that were associated with significantly enriched GO terms (Figure 5.7, Supplementary 




peptide/secreted”, followed by the GOCC “blood microparticle” (GO:0072562) and GOBP 
“lipoprotein metabolic process” (GO:0042157). Furthermore, the GOBP term “innate 
immune response” (GO:0045087) was also significantly enriched. The most enriched 
KEGG pathway was “complement and coagulation cascades” (hsa04610: 11 proteins count 
(15.23%), P-value =1.94 E-07) followed by “PPAR signaling pathway” (hsa03320: 4 
proteins count (5.55%), P-value = 4.20 E-03) (Supplementary Table S 5.2).  In addition, 
STRING analysis revealed protein clusters significantly enriched in the complementary 
GOBP terms, “post-translational protein modification” and “regulation of acute 
inflammatory response” as well as the KEGG pathway terms “complement and coagulation 








Figure 5.7 DAVID analysis of proteins that were altered in abundance in the secretomes of 
DENV-2 infected cells.  
Proteins that were significantly (P-value < 0.05) altered in amount by ≥ 1.5 fold in the 
secretomes of DENV-2 infected Huh-7 compared to mock infected cells were analysed 
using the DAVID database. The GO accession numbers/terms that were significantly 
enriched and the properties of the corresponding protein clusters are shown. The GES of 
protein clusters associated with significantly enriched GO terms are plotted as bar graphs 
(blue) with the corresponding GES score shown. The shading shows the type of GO term 
(GOBP, GOCC or GOMF), UP keywords, Interpro term or KEGG pathway. The number 
of proteins in each cluster (count), number of proteins associated with each GO term/total 
number of proteins in the dataset (%) and P-value for each of the annotation terms are listed 












Figure 5.8 STRING analysis of proteins that were altered in abundance in the secretome of 
DENV-2 infected cells. 
The STRING database was searched to analyse secreted proteins that significantly (p < 
0.05) increased (A) and decreased (B) ≥ 1.5 fold in response to DENV-2 infection. (A) 
Nodes representing proteins associated with the significantly enriched GO terms “protein 
C-terminus binding” are coloured in red. (B) Nodes representing proteins associated with 
the significantly enriched GO terms  “post-translational protein modification”, “regulation 
of acute inflammatory response”, “complement and  coagulation cascades” and 
“Cholesterol metabolism”  are coloured in yellow, blue, green and red, respectively. The 
number of coloured nodes/total proteins involved for each term and the FDR of each GO 




 Focused analysis on proteins that decreased in both proteome and secretome in 
response to DENV infection  
Further GO term enrichment analysis was also done for the 20 proteins (shaded in 
red in Table 5.6) that significantly decreased ≥ 1.5 fold in both the proteome and secretome 
of DENV infected Huh-7 cells compared with mock.  DAVID analysis identified 5 
functional annotation clusters that were associated with significantly enriched GO terms 
(Figure 5.9). The most significantly enriched GO terms were the keywords “signal 
peptides/secreted”, followed by the GOCC term “extracellular space” (GO:0005615) and 
the GOBP terms “platelet degranulation” (GO:0002576), “lipid transport” (GO:0006869) 
and “cellular protein metabolic process” (GO:0044267) (Figure 5.9, Supplement table S 
5.3). 
STRING analysis identified protein clusters associated with the significantly 
enriched GO terms “cholesterol metabolism”, “PPAR signaling pathway” and “platelet 
activation” and the enriched KEGG pathway “complement and coagulation cascades” 
(Figure 5.10). Of note, some proteins are multifunctional and involved in many pathways. 
For instance, fibrinogen peptides (including fibrinogen α chain (FGA), fibrinogen β chain 
(FGB) and fibrinogen ɤ chain (FGG)) were associated with the KEGG pathway terms 
“complement and coagulation cascades” and “platelet activation”. Similarly, 
apolipoprotein A1 and A2 and phospholipid transfer protein (PLTP) were associated with 













Figure 5.9 DAVID analysis of proteins that decreased in abundance in the proteome and 
secretome of DENV-2 infected Huh-7 cells. 
 Proteins that were significantly (P-value < 0.05) altered in amount by ≥ 1.5 fold in both 
the proteome and secretome of DENV-2 infected Huh-7 cells compared to mock infected 
cells were analysed using the DAVID database. The GO accession numbers/terms that 
were significantly enriched and the properties of the corresponding protein clusters are 
shown. The GES of protein clusters associated with significantly enriched GO terms are 
plotted as bar graphs (blue) with the corresponding GES score shown. The shading shows 
the type of GO term (GOBP, GOCC or GOMF), UP keywords, Interpro term or KEGG 
pathway. The number of proteins in each cluster (count), number of proteins associated 
with each GO term/total number of proteins in the dataset (%) and P-value for each of the 










Figure 5.10 STRING analysis of proteins that decreased in abundance in both the proteome 
and secretome of DENV-2 infected cell 
The STRING database was searched to analyse proteins that significantly (p < 0.05) 
decreased ≥ 1.5 fold in both the proteome and secretome in response to DENV-2 infection. 
Nodes representing proteins associated with the significantly enriched KEGG pathway 
terms “Complement and coagulation cascades”, “Cholesterol metabolism”, “PPAR 
signaling pathway” and “Platelet activation” are shaded in red, blue, green and yellow, 
respectively. The number of coloured nodes/ total proteins involved for each term and the 




  Validation of the LC-MS/MS analysis 
In order to validate the results of the proteomic analyses, a selection of viral and 
cellular proteins that were detected to change in abundance were analysed by Western 
blotting. The rationale for the selection of the proteins and the results of the validation are 
described below. 
  Viral proteins 
Similar to the results presented in Chapter 4, DENV NS1 and NS4B were selected 
for validation in the cell lysates by Western blotting. As expected, the DENV-2 NS1 and 
NS4B proteins were detected in cell lysates from DENV-2 but not iDENV-2 nor mock 
infected Huh-7 cells (Figure 5.11). For the supernatants, DENV NS1 was also selected for 
validation. The results showed the presence of NS1 only in the supernatant from DENV-2 
infected Huh-7 cells (Figure 5.11). 
 Host proteins 
 Based on the results of the bioinformatic analysis and a review of the literature, 
selected host proteins, that were associated with the KEGG pathway terms “complement 
and coagulation cascades” and “cholesterol metabolism”, were selected for validation by 
Western blotting. All of the proteins significantly decreased ≥1.5 fold in DENV-2 infected 
Huh-7 cells and/or secretomes compared to mock infected cells. The rationale for selecting 
the specific proteins is as follows.  
Proteins involved in complement and coagulation cascades  
 Proteins associated with “complement and coagulation” pathways were found to be 
the major group of proteins that were commonly dysregulated intracellularly and in the 
secretome from DENV infected Huh-7 cells. Mapping of the identified proteins on the 
KEGG “complement and coagulation” pathways showed that they were involved in a 
number of diverse processes in both the coagulation and complement cascades (Figure 
5.12). Proteins associated with the complement and coagulation pathways have previously 




Well et al, 2012; Conde et al, 2017). Therefore, it was decided to focus on this group of 







Figure 5.11 Detection of viral proteins in cell lysates and cell culture supernatants of DENV-2 
infected Huh-7 cells.  
Huh-7 cells were infected with DENV-2 or iDENV-2 at a MOI of 5 or mock infected, harvested at 
30 hpi and collected as a total cell lysate and concentrated supernatants. Equal amounts of protein 
from cell lysates (10 µg) and equal volumes of the concentrated culture supernatants (5 µl) were 
loaded in each lane and the proteins separated by SDS-PAGE prior to Western blotting. Antibodies 
raised against the NS1, NS4B and GAPDH proteins were used to detect the respective proteins 
(expected positions arrowed). GAPDH was used as a loading control for cell lysates. Relevant 






CD46 molecule(CD46), CD55 molecule (Cromer blood group)(CD55), CD59 molecule(CD59), alpha-2-macroglobulin(A2M), 
bradykinin receptor B1(BDKRB1), bradykinin receptor B2(BDKRB2), carboxypeptidase B2(CPB2), coagulation factor II, thrombin 
receptor(F2R), coagulation factor II, thrombin(F2), coagulation factor III, tissue factor(F3) ,coagulation factor IX(F9), coagulation factor 
V(F5), coagulation factor VII(F7), coagulation factor VIII(F8), coagulation factor X(F10), coagulation factor XI(F11), coagulation 
factor XII(F12), coagulation factor XIII A chain(F13A1), coagulation factor XIII B chain(F13B), complement C1q A chain(C1QA), 
complement C1q B chain(C1QB), complement C1q C chain(C1QC), complement C1r(C1R), complement C1s(C1S), complement 
C2(C2), complement C3(C3), complement C3a receptor 1(C3AR1), complement C3b/C4b receptor 1 (Knops blood group)(CR1), 
complement C3d receptor 2(CR2), complement C4A (Rodgers blood group)(C4A), complement C4B (Chido blood group)(C4B), 
complement C5(C5), complement C5a,receptor 1(C5AR1), complement C6(C6), complement C7(C7), complement C8 alpha 
chain(C8A), complement C8 beta chain(C8B), complement C8 gamma chain(C8G), complement C9(C9), complement component 4 
binding protein alpha(C4BPA), complement component 4 binding protein beta(C4BPB), complement factor B(CFB), complement factor 
D(CFD), complement factor H(CFH), complement factor I(CFI), fibrinogen alpha chain(FGA), fibrinogen beta chain(FGB), fibrinogen 
gamma chain(FGG), kallikrein B1(KLKB1), kininogen 1(KNG1), mannan binding lectin serine peptidase 1(MASP1), mannan binding 
lectin serine peptidase 2(MASP2), mannose binding lectin 2(MBL2), plasminogen activator, tissue type(PLAT), plasminogen activator, 
urokinase receptor(PLAUR), plasminogen activator, urokinase(PLAU), plasminogen(PLG), protein C, inactivator of coagulation factors 
Va and VIIIa(PROC), protein S (alpha)(PROS1), serpin family A member 1(SERPINA1), serpin family A member 5(SERPINA5), 
serpin family C member 1(SERPINC1),serpin family D member 1(SERPIND1), serpin family E member 1(SERPINE1), serpin family 
F member 2(SERPINF2), serpin family G member 1(SERPING1), thrombomodulin(THBD), tissue factor pathway inhibitor(TFPI), von 
Willebrand factor(VWF) 
Figure 5.12 Complement and coagulation cascade pathways. 
 Proteins that significantly decreased (≥1.5 fold) in DENV-2 infected Huh-7 cells and 
secretomes compared with mock infected cells are identified on the KEGG pathway 
“complement and coagulation cascades” (KEGG pathway term hsa04610). The yellow and 
purple stars indicate proteins that significantly decreased in cells and secretomes, 
respectively, in response to DENV-2 infection. Anti-thrombin III (SERPINC1), a protein 
which decreased, but not significantly, in DENV-2 infected cells, is indicated in faint 





5.5.2.1 5.6.2.1 Fibrinogen (FBG) 
 Fibrinogen (FBG) or coagulation factor I is the most important protein in the 
coagulation process. Furthermore, it also plays an important role as a liver acute phase 
protein and in platelet activation. The fibrinogen protein is composed of three 
fibrinopeptides: FGA, FGB and FGG. All fibrinopeptides were found to be significantly 
decreased (≥2 fold) in both DENV-2 infected Huh-7 cells and the associated secretomes 
compared with mock infected cells and did not change in amount in iDENV-2 infected 
cells. These results were validated by Western blotting analysis. For all fibrinopeptides 
there was a decrease in the band intensity in lysates from DENV-2 infected cells compared 
with mock infected cells (Figure 5.13). For the secretome samples, equal volumes of 
concentrated supernatants were analysed as there was no standard loading control. The 
results clearly showed a decrease in all fibrinopeptides in the secretomes of DENV-2 














Figure 5.13 Analysis of fibrinopeptides in cell lysates and secretomes of DENV-2 infected 
Huh-7 cells. 
 Huh-7 cells were infected with DENV-2 at a MOI of 5 or mock infected, harvested at 30 
hpi and collected as total lysates and concentrated supernatants. Twenty µg of protein from 
each cell lysate and 10 µl of the concentrated supernatants were loaded in each lane and 
the proteins separated by SDS-PAGE prior to Western blotting. Antibodies against FGA, 
FGB, FGG and GAPDH were used to detect the relevant proteins. GAPDH was used as 
loading control for cell lysates and the positions of relevant molecular mass markers are 





5.5.2.2 5.6.2.2 Alpha-1-antitrypsin (SERPINA1) 
Alpha-1-antitrypsin (SERPINA1), encoded by the SERPINA1 gene, is a 
multifunctional protein in the serpin family. SERPINA1, a highly abundant glycoprotein 
in plasma is synthesized mainly by the liver but also by cells in the lung (Kalsheker et al, 
2002). It plays an important role in coagulation and like FBG, is one of the liver acute 
phase response proteins. In this study, SERPINA1 significantly decreased ≥2 fold and ≥ 
1.5 fold in DENV-2 infected Huh-7 cells and secretomes respectively, compared with 
mock infected cells. These changes were confirmed by Western blotting (Figure 5.14A).  
5.5.2.3 5.6.2.3 Antithrombin III (SERPINC1) 
 Antithrombin III (SERPINC1), encoded by the SERPINC1 gene, is a glycopeptide 
in the serpin (serine protease inhibitor) superfamily. SERPINC1 significantly decreased > 
1.5 fold in DENV-2 infected Huh-7 cells. Although the results from the LC-MS/MS 
analysis identified a non-significant decrease (1.73 fold decrease, P-value = 0.059) in 
amount in the secretomes of DENV-2 cells compared with mock infected cells, this protein 
was selected because it plays important roles in multiple steps in the coagulation pathways 
(as shown in Figure 5.12). SERPINC1 is also a liver acute phase response protein similar 
to FBG and SERPINA1. The results of the Western blotting analysis showed a clear 
decrease in the amount of the protein in cell lysates and secretomes from DENV-2 infected 











Figure 5.14 Analysis of SERPINA1 and SERPINC1 in cell lysates and secretomes of 
DENV-2 infected Huh-7 cells. 
 Huh-7 cells were infected with DENV-2 at a MOI of 5 or mock infected, harvested at 30 
hpi and collected as total lysates and concentrated supernatants for Western blotting 
analysis for SERPINA1 (A) and SERPINC1 (B). Equal amounts of protein in cell lysates 
(30 µg for SERPINA1 and 20 µg for SERPINC1) and 10 µl of concentrated supernatants 
were loaded in each lane and the proteins separated by SDS-PAGE prior to Western 
blotting. Antibodies against SERPINA1, SERPINC1 and GAPDH were used to detect the 
relevant proteins. GAPDH was used as loading control for cell lysates and the positions of 





5.5.2.4 5.6.2.4 Clusterin (CLU) 
 Clusterin (CLU) or apolipoprotein J has many isoforms with different molecular 
weights. The mature form is composed of two subunits, the α- and β-chains, around 40 kDa 
in size. In the complement pathway this protein inhibits terminal complement complex 
formation. In this study, CLU was found to be significantly decreased (≥1.5 fold) in 
DENV-2 infected Huh-7 cells and secretomes compared with mock infected cells. 
However, Western blotting analysis only demonstrated a decrease in the CLU 40 kDa 
bands in cell lysates of DENV-2 infected Huh-7 cells (Figure 5.15A). CLU could not be 
detected in the corresponding secretome samples from either mock or DENV-2 infected 
cells (data not shown).  
 
5.5.2.5 5.6.2.5 Vitronectin (VTN) 
 Vitronectin (VTN) is a multifunctional glycoprotein. Similar to CLU, VTN blocks 
membrane attack complex formation (MAC) at the end of the complement cascade to 
prevent cell lysis (Figure 5.12). In this study, VTN was not changed in abundance in cells 
in response to DENV-2 infection but significantly decreased in abundance (≥1.5 fold) in 
the secretome of DENV-2 infected Huh-7 cells compared with mock infected cells. 
Western blotting analysis demonstrated a decrease in VTN amount in the supernatants of 















Figure 5.15 Analysis of CLU and VTN by Western blotting. 
 Huh-7 cells were infected with DENV-2 at a MOI of 5 or mock infected, harvested at 30 
hpi and collected as total lysates and concentrated supernatants for Western blotting 
analysis for CLU (A) and VTN (B). Equal amounts of protein in either cell lysates (20 µg 
for CLU) and 10 µl of concentrated supernatants (for VTN) were loaded in each lane and 
the proteins separated by SDS-PAGE prior to Western blotting. Antibodies against CLU, 
VTN and GAPDH were used to detect the relevant proteins. GAPDH was used as a loading 






Analysis of proteins involved in cholesterol metabolism 
 Apolipoproteins and proteins involved in “cholesterol metabolism” were 
significantly altered in Huh-7 cells and the associated secretomes in response to DENV-2 
infection. Mapping of the identified proteins on the KEGG “cholesterol metabolism” 
pathways showed that they were particularly involved in lipoprotein production/formation 
(Figure 5.16). Additionally, DENV infection is well known to modulate host lipid 
metabolism (Fischl and Bartenschlager, 2011). Thus, a selection of proteins that were 
identified to be altered in response to DENV-2 infection and involved in “cholesterol 








Figure 5.16 Cholesterol metabolism pathways 
Proteins that significantly decreased (≥1.5 fold) in DENV-2 infected Huh-7 cells and 
secretomes compared with mock infected cells are identified on the KEGG pathways 
“cholesterol metabolism” (KEGG pathway term hsa04979). The yellow and purple stars 
indicate proteins that significantly decreased in cells and secretomes, respectively in 





5.6.2.6 Apolipoprotein AI (APOA1) 
 Apolipoprotein AI (APOA1), encoded by the APOA1 gene, is an important 
component of the high-density lipoprotein complex in plasma. Thus, it plays an important 
role in lipid metabolism and was proposed as a biomarker for many diseases including 
DEN (Manchala et al, 2017).  
 APOA1 was identified to be significantly decreased (≥2 fold) in both DENV-2 
infected Huh-7 cells and secretomes compared to mock infected cells by LC-MS/MS 
analysis. Although Western blotting analysis successfully detected a recombinant APOA1 
down to a level of 50 ng, APOAI was not detectable in cell lysates from mock or DENV-
2 infected cells (Figure 5.17A). Whereas a decrease in APOA1 abundance in the 
supernatants from Huh-7 infected cells compared to mock infected cells was detected by 
Western blotting analysis (Figure 5.17B).  
In addition to APOA1, validation of the amounts of the APOC2 protein was 
attempted. However, the protein was not detectable in either cell lysates or the 
corresponding secretomes (data not shown). As for some of the proteins analysed this may 
reflect the sensitivity of LC-MS/MS in comparison to the Western blotting /antibodies used 
to detect these proteins.  
List of Supplementary Tables 
Table S5.1 DAVID analysis of the cellular proteins that were altered in abundance in 
DENV-2 infected Huh-7 cells compared to mock infected cells. 
Table S5.2 DAVID analysis of the proteins that were altered in abundance in secretome 
of DENV-2 infected Huh-7 cells compared to mock infected cells. 
Table S5.3 DAVID analysis of proteins that significantly decreased ≥ 1.5 fold in both the 




















Figure 5.17 Analysis of APOA1 in cell lysates and secretomes of DENV-2 infected Huh-
7 cells.  
Huh-7 cells were infected with DENV-2 at a MOI of 5 or mock infected, harvested at 30 
hpi and collected as total lysates and concentrated supernatants. (A) Recombinant APOA1 
protein ranging from 1-250 ng and mock infected Huh-7 cell lysate containing 10 - 30 µg 
of protein was analysed by Western blotting. (B) Ten µl of concentrated supernatants from 
DENV-2 and mock infected cells was used for Western blotting. Antibodies against 
APOA1 and GAPDH were used to detect the relevant proteins. GAPDH was used as 
loading control for cell lysates and the positions of relevant molecular mass markers are 





  Discussion 
This study reports for the first time an integrated analysis of the Huh-7 cellular 
proteome and secretome in response to DENV-2 infection. A total of 268 (121 up- and 
/147 down-regulated) cellular proteins and 102 (27 up- and 75 down-regulated) secreted 
host proteins were significantly dysregulated (≥1.5 fold in amount) in DENV-2 infected 
Huh-7 cells compared with mock infected cells, respectively. Bioinformatic analysis of 
proteins that increased in the cellular proteome during infection, revealed an enrichment of 
proteins associated with the GO terms “negative regulation of gene expression” and 
“negative regulation of translation”, whilst for proteins that decreased during infection, 
proteins associated with the terms “lipid metabolic process”, “complement and coagulation 
cascades”, “innate immunity/acute phase response” and “mineral absorption” were 
enriched. By contrast, during infection, the secretome was enriched in proteins that 
decreased in amount and were associated with the GO terms “lipid metabolic process”, 
“complement and coagulation cascades”, “innate immunity” and “post-translational 
protein modification”. As the major change in both the proteome and secretome was the 
proteins that decreased in response to infection and many of these proteins participated in 
biological pathways that appeared relevant to DEN pathogenesis, they are the focus of this 
discussion.  
Correlation of protein alterations in the cellular proteome and secretome. 
Although liver cell models are widely used for DENV studies, an integrated 
analysis of the changes that occur in the proteome and secretome of any liver cell line in 
response to DENV infection has never been done. One fourth of cellular proteins (1469 of 
5706) were detected in secretome, presumably as they were secreted (Figure 5.3). This 
reflects the role of hepatocytes in secretory and plasma protein production (Kuscuoglu et 
al., 2018).  
Proteins that were commonly dysregulated in the proteome and secretome changed 
in abundance in the same direction implying that dysregulation of these proteins in the 
cellular proteome affected their abundance in the secretome. The proteins highlighted in 
this study that were decreased in both the proteome and secretome of Huh-7 cells in 




cascade” and “cholesterol metabolism”, both of which are important in DEN pathogenesis. 
The results suggest that DENV infection leads to a decrease in cellular complement and 
coagulation proteins as well as lipoproteins, which in turn decreases the amounts of these 
proteins secreted from hepatocytes.  
However, the changes revealed in the proteome cannot explain all changes detected 
in the secretome. Amongst the 104 proteins that were significantly altered (≥1.5 fold) in 
the secretome of DENV-2 infected cells compared with mock infected cells, 67 were also 
found in cell lysates. Of these, only 21 proteins were significantly changed in amount, both 
intracellularly and in the secretomes, whilst the alterations in the amounts of the majority 
of the proteins (46) in the secretome cannot be explained by the change in the cellular 
protein level. These proteins may be mainly found as secreted proteins and are not stored 
or function intracellularly. Further studies on the effect of DENV infection on protein 
secretory pathways are required to fully answer this question.  
Comparison with previous studies. 
The proteins that were significantly altered in the cellular proteome in this study 
were compared with previous proteomic studies (listed in section 1.6.1 and also in the 
introduction of this chapter) that analysed DENV-2 infected liver cell lines (both Huh-7 
and HepG2) using a systematic search by gene name (Figure 5.18 and Table 5.7). The 
comparison also included two unpublished studies done in the laboratory in which the 
cellular proteomes of DENV-2 (at the high MOI) and mock infected Huh-7 cells were 
analysed by SILAC and TMT labelling and LC-MS/MS by Dr. Han-Chen Chiu and Dr. 
Amjad Yousuf, respectively (Chiu, 2014; Yousuf, 2016). The only previous secretome 
analysis of DENV infected liver cells described only the presence or absence of the secreted 
proteins in the secretome and did not perform statistical analysis (Higa et al., 2008). Thus, 
this comparison was described in the text.  
Commonalities between the proteins identified to alter in response to DENV 
infection between the studies described above are summarised and compared in Figure 5.18 
and Table 5.7. Overall, the results of this study were more comparable with the studies 
done in the laboratory (Chiu, 2014; Yousuf, 2016). The difference in the results across 




infection conditions, infection rate and proteomic analysis techniques used for the studies. 
The results from Pattanakitsakul and coworkers identified only two proteins in common 
with other studies, this may be due to the analysis of DENV-2 infected HepG2 cells  (while 
other studies used Huh-7 cells) or more likely the limitations of 2D SDS-PAGE based 
proteomic approach used for the study (Pattanakitsakul et al., 2007). There were three 
cellular proteins that were identified to increase in response to infection in the study of 
Pando-Robles et. al. (Pando-Robles et al., 2014), but decreased in this study; heme 
oxygenase (decycling) 1 (HMOX1), fibronectin 1 (FN1) and RNA binding motif protein 3 
(RBM3) (Table 5.7).  HMOX1 was also identified to decrease significantly in the proteome 
of DENV infected Huh-7 cells compared to mock infected cells in the study of Dr. Chiu 
and FN1 was significantly decreased in both previous proteomic studies in the laboratory 
(Chiu, 2014; Yousuf, 2016), whereas RBM3 was only identified to significantly decreased 
in this study.  Although the study from Pando-Robles et al., also used a DENV-2 infected 
Huh-7 cell model, the low infection rate (13.96%) and shorter time of infection (24 hpi) 
might explain the difference in results (Pando-Robles et al., 2014). Interestingly, among 
the 146 proteins identified to significantly decrease (≥1.5 fold) in proteome of DENV 
infected cells in this study, 43 proteins were also reported to decrease in previous studies. 
This set of proteins included proteins involved in complement and coagulations including; 
FGA, FGB, FGG, CLU, SERPINA1, SERPINE1 and C3 as well as other proteins of 
interest including APOA2, CD81, HMOX1 and FN1.  
A number of acute phase proteins (APPs), including FBG, SERPINA1, and 
transferrin (TS), were identified to decrease in the proteome of DENV infected liver cells 
in this study and previous studies (Table 5.7). Furthermore, this study also identified 
decreases in the cellular levels of SERPINC1, haptoglobin (HP) and ceruloplasmin (CP) 
and a decrease in both the cellular and secreted levels of prothrombin (F2) in response to 
DENV infection. APPs can be divided into positive and negative APPs which increase and 
decrease, respectively, in the blood in response to infection/inflammation, APPs are 
reviewed in detail in section 7.1. The decrease in the negative APPs SERPINC1 and TF 
was predictable. However, the decrease in positive APP (FBG, SERPINA1, F2, HP, and 
CP) levels, both in the cellular proteome and secretome, was an interesting finding, as these 




infections. Further studies surrounding the mechanism by which DENV infection 
modulates this important host response is required to determine if the effect may have an 











Figure 5.18 A comparison of the liver cell proteins identified to alter in amount in response 
to DENV-2 infection in this study and previous proteome studies. 
 The proteins that significantly (P-value < 0.05) increased and decreased (≥1.5 fold) in cell 
lysates from this study were searched using the gene names against the corresponding gene 
names of proteins identified to change in previous proteomic studies of DENV-2 infected 
liver cells. The numbers of proteins that were commonly detected between these studies 
are shown and the total number of differentially expressed proteins that were reported to 





Table 5.7 A list of the liver cell proteins identified to alter in amount in response to 
DENV-2 infection in this study and previous proteomic studies. 
Increased in this study Decreased in this study 
Protein Description Protein Description 
Increased in Pando-Robles et al., 2014 
EEF1A1 Elongation factor 1-alpha  HMOX1 Heme oxygenase  
FN1 Fibronectin 1, isoform 
RBM3 RNA binding motif protein 3 
Decreased in Pando-Robles et al., 2014 




HSPB1 Heat shock protein  beta 1 
Increased in Yousuf, 2016 




Decreased in Yousuf, 2016 
None 
 
MEP1A Metalloendopeptidase  
AGT Angiotensinogen variant  
SCD Stearoyl-CoA desaturase variant  
CST3 Cystatin  
AMBP Protein AMBP  




FGA Fibrinogen alpha chain  
GOLM1 Golgi membrane protein 1  
C3 Complement C3 
FGB Fibrinogen beta chain 
TF Transferrin variant  
FN1 Fibronectin 1 
FGFR3 Fibroblast growth factor receptor 3 
isoform A  
FGFR4 Fibroblast growth factor receptor 4 
variant  
ASGR2 Asialoglycoprotein receptor 2  
NUSAP1 Nucleolar and spindle-associated 
protein 1  
SDC2 Syndecan-2  
SDC1 Syndecan-1  
COL5A2 Collagen alpha-2(V) chain  
APP Amyloid beta A4 protein  
SERF2 Small EDRK-rich factor 2  
TOR4A Torsin-4A  
FUCA2 Plasma alpha-L-fucosidase  
HECTD
1 








alpha-mannosidase IA  
NID1 Nidogen-1  
Increased in Chiu, 2014 
TRIM32 E3 ubiquitin-protein ligase TRIM32 None 
 
PFN2 Profilin-2  
ENO1 Enolase 1  
TRIP13 Pachytene checkpoint protein 2 
homolog  
ACTN1 Alpha-actinin-1  
ASNS Asparagine synthetase  
IGF2BP
1 
Insulin-like growth factor 2 mRNA-
binding protein 3  
BRAT1 BRCA1-associated ATM activator 1  
PPCS Phosphopantothenate--cysteine ligase  
EEF1A1 Elongation factor 1-alpha  
EIF2B4 Translation initiation factor eIF-2B 
subunit delta  
EDC3 Enhancer of mRNA-decapping protein 
3  




Insulin-like growth factor 2 mRNA-
binding protein 3  
GIGYF
2 
PERQ amino acid-rich with GYF 
domain-containing protein 2  
ATXN2
L 
Ataxin-2-like protein  
Decreased in Chiu, 2014 
METTL
9 
Methyltransferase-like protein 9  AGT Angiotensinogen variant (Fragment) 
TSPAN
13 
Tetraspanin-13  ITM2C Integral membrane protein 2C, 
isoform  
EPPK1 Epiplakin  SCD Stearoyl-CoA desaturase variant    
ITM2B Integral membrane protein 2B 
AFP Asialoglycoprotein receptor 2  
FGA Fibrinogen alpha chain  
GOLM1 Golgi membrane protein 1  
FGB Fibrinogen beta chain 
APOA2 Apolipoprotein A-II  
FGG Fibrinogen gamma chain  
HMOX1 Heme oxygenase (decycling) 1  
CDH17 Cadherin 17, LI cadherin 
FN1 Fibronectin 1, isoform 
APLP2 Amyloid-like protein 2  
NUCB1 Nucleobindin 1 (NUCB1) 




CLU Clusterin  
TOR4A Torsin-4A  
SERPIN
E1 
Plasminogen activator inhibitor type 
1 
HNF4A Hepatocyte nuclear factor 4 
GLTSC
R2 
PreS1 binding protein 
CD81 Tetraspanin  
RNF149 E3 ubiquitin-protein ligase RNF149  
LRP1 Prolow-density lipoprotein receptor-
related protein 1  
Increased in Pattanasakul et al., 2007 
DDX17 DEAD-box protein p72  None 
 








 The results of the secretome analysis were compared with a study analyzing the 
secretome of DENV-2 infected HepG2 cells, which identified 65 (of a total of 107) proteins 
previously reported (Higa et al., 2008). However, amongst the 65 proteins, only 5 proteins 
were significantly altered (≥1.5 fold) in this study; only nucleophosmin (NPM1) was 
increased while the four proteins; proprotein convertase subtilisin/kexin type 9 (PCSK9), 
calsyntenin-1 (CLSTN1), fibulin-1 (FBLN1) and ALB were decreased. 
ENO1 was previously identified to increase in the secretome of DENV-2 infected 
HepG2 cells without either a change in cellular protein or mRNA levels (Higa et al., 2014). 
ENO1 was also found to increase in the plasma of DEN patients compared to healthy 
patients (Higa et al., 2014).  By contrast, in this study and the study of Chiu (Chiu, 2014) 
a significant increase (≥ 1.5 fold) in the cellular level of ENO1 was identified, in response 
to DENV infection of Huh-7 cells, but the level in the secretome remained unchanged. This 
difference may be due to a cell type specific response or the difference in the study 
protocol, as discussed in detail in Chapter 3. 
FBLN1, a protein believed to play a role in thrombosis (Argraves et al., 2009) was 
also found to be significantly decreased in both the proteome and secretome of DENV 
infected cells compared with mock infected cells. FBLN1 was previously detected in the 
secretome of both DENV and mock infected HepG2 cells, although the relative levels were 
not quantitated (Higa et al., 2008). FBLN1 can bind with fibronectin and FBG and play a 
role in extracellular matrix (ECM) formation and clot formation respectively (Argraves et 
al., 2009). Furthermore, binding of FBLN1 with fibrinogen can facilitate platelet adhesion 
(Godyna et al., 1996).  
Tissue factor pathway inhibitor (TFPI), a major anti-coagulant, was identified only 
in the secretome of DENV infected HepG2 cells but not in those of mock cells in a previous 
study (Caruso et al., 2016). Although this protein significantly decreased (≥1.5 fold) in the 
cellular proteome, it was non-significantly decreased >1.3 fold in the secretome of DENV 
infected Huh-7 cells in this study. The change in the cellular concentration may not have 
been sufficient to cause a significant decrease in TFPI in the secretome. The difference in 
the methods used for secretome preparation may also explain this result, as the study of 




The results of this study were also compared with other proteomic studies using 
various DENV infected cell lines. The similarities and differences in cellular proteins 
commonly identified and a major focus of previous proteomic studies are highlighted 
below.  
HSPA5 has commonly been identified to increase in response to DENV infection 
in many studies and was also identified to increase >1.3 fold in DENV-2 infected Huh-7 
cells but not in the associated secretome in this study. The alteration in HSPA5 amounts 
was similar to the results found after proteomic analysis of DENV-2 infected HEK293T 
cells, as described in Chapter 4. The details of HSPA5 and DENV infection were reviewed 
and discussed in Chapter 4. 
A number of translation elongation factors have been reported to be dysregulated 
in DENV infection in many studies using various cell lines. Elongation factor 1-alpha 
(EEF1A1) is a protein chaperone and translation factor and has been shown to be recruited 
as a cofactor for RNA virus replication, including DENV (Li et al, 2013). EEF1A1 was 
found to significantly increased in the cellular proteome, in response to DENV infection, 
in this study and two previous studies (Pando-Robles et al., 2014; Chiu, 2014). However, 
EEF1A1 was reported to decrease in DENV infected endothelial cells (Kanlaya et al., 
2010) which might be due to a cell-specific response to infection. Apart from EEF1A1, 
significant increases in translation initiation factor eIF-2B subunit delta (EIF2B4) and 
eukaryotic translation initiation factor 4E nuclear import factor 1(EIF4ENIF1) ( ≥ 1.5 and 
≥ 1.3 fold, respectively) were also detected in the proteome of DENV infected Huh-7 cells.   
Proteomic studies have identified an increase in elongation factor tu (EF-tu) in DENV 
infected HepG2 cells (Pattanakitsakul et al., 2007) and a decrease in elongation factor 2 
(EF2) in DENV infected endothelial cells (Kanlaya et al., 2009; Kanlaya et al., 2010). Both 
EF-tu and EF2 were detected in this study but did not change in amount in response to 
infection. A recent study also reported changes (both increased and decreased) in a number 
of additional proteins involved in translation elongation (including EIF3E, EIF3J, EIF4A2, 
EIF5, EIF4EBP2, EEF1B2, EEF2K and TSFM) in DENV infected K562 cells (Miao et al., 
2019); however, none of these proteins were detected in this study. The role of translation 




Other host proteins that were only identified to be dysregulated in response to 
DENV infection in this study and worthy of mention include, alpha-fetoprotein (AFP) and 
cadherin 17 or LI cadherin (CDH17). AFP was significantly decreased in both the 
proteome and secretome of DENV infected cells, whilst CDH17 was decreased in the 
proteome but increased in the secretome in response to DENV-2 infection (Table 5.6).  
Both AFP and CDH17 were extensively studied in other disease conditions but have never 
been linked with DEN. Both proteins are used clinically as tumor markers for 
hepatocellular carcinoma and gastric cancer, respectively. AFP was also proposed as a 
marker of acute liver injury (Schiodt et al., 2006). Increased levels of AFP, related to 
hepatic regeneration have been associated with a favorable outcome in patients with acute 
liver failure (Schiodt et al., 2006).  However, as Huh-7 cells are a cancer derived cell line, 
the results obtained with these two tumor markers should be used with caution.   
Interestingly, alpha subunit of metalloendopeptidase meprin A (MEP1A) 
significantly decreased ≥1.5 fold in both the proteome and secretome in response to 
DENV-2 infection. Moreover, a number of proteins associated with the GO term “metal-
binding/metallothionein” were significantly decreased in the proteome, including many 
forms of metallothionein (MT1G, MT1F, MT1X, MT1M, MT1E, MT2A) and HMOX1 
(Table 5.4, Figure 5.5 and 5.6B). However, only MEP1A was found to be decreased in the 
secretome. Compared with previous proteomic studies using DENV infected liver cells, 
changes in level of metallothionein proteins has never been reported and there is 
inconsistency in reports describing the cellular level of HMOX1; an increase was identified 
in the study of Pando-Robles et al. (Pando-Robles et al., 2014), whilst HMOX1 was 
reported to decreased in the study of Chiu (Chiu, 2014) and this study (Table 5.7). A 
decrease in cellular MEP1A was also identified in the study of Yousuf (Yousuf, 2016). In 
contrast, the mRNA transcript levels of HMOX1 and multiple proteins in metallothionein 
group (MT1A, MT2A, MT1E, MT1F, MT1G, MT1H and MT1X) but not MEP1A were 
reported to be increased as a component of the anti-oxidant response to DENV-2 infection 
in dendritic cells (Olagnier et al, 2014). Moreover, overexpression of HMOX1 was found 
to inhibit DENV replication in Huh-7 cells (Tseng et al, 2016). Secreted merpins are 
important extracellular proteolytic enzymes that regulate the levels of inflammatory 




(IL6R) and thymosin-β4 as well as collagen proteins type 1 (Arnold et al, 2017). 
Dysregulation of MEP1A secretion may therefore affect host immune responses. So far, 
MEP1A has never be linked with DENV or any other viral infection. Thus, validation and 
further studies regarding the role of MEP1A in DENV pathogenesis are required.  
Pathway of complement and coagulation cascades 
Dysregulation of the coagulation system, both in the levels of coagulation factors 
(pro-clot formation effect) and proteins inhibiting coagulation (anti-clot formation 
effect/fibrinolysis), has been described as playing a key role in DEN pathogenesis 
(Mairuhu et al., 2003). Activation of the complement system has been widely studied as a 
major contributing factor to the pathogenesis of plasma leakage and shock (reviewed in 
Conde et al., 2017). Furthermore, both complements and coagulation proteins (eg. 
thrombin, plasmin, C1q, C3, C4 and C5) can regulate platelet function (Peerschke et al, 
2009). The liver is the key organ for protein synthesis, including complement and 
coagulation proteins and the alteration of these proteins in the sera of DEN patients has 
been previously reported (discussed in detail in Chapter 6). Thus, the dysregulation of these 
proteins in the cellular proteomes and secretomes of DENV-2 infected hepatocytes was 
expected. However, so far, previous DENV proteomic studies using liver cell models 
(summarised in Table 1.2) have not focused on investigating any alterations in the levels 
of proteins involved in complement and coagulation cascades. The complement and 
coagulation proteins that decreased in both proteome and secretome and/or were previously 
reported to be dysregulated in clinical specimens from DENV patient were therefore 
selected for validation and further study. The selected complement and coagulation 
proteins included FBG, SERPINA1, SERPINC1, CLU and VTN. 
Decreased levels of FBG in the plasma of DENV infected patients has been 
previously documented in clinical studies and found to be associated with disease severity 
(Will et al., 2002). The significant decrease in the cellular level of FBGs identified in this 
study, are consistent with previous proteomic studies of DENV infected Huh-7 cells, which 
identified either decreases in all FBGs (Chiu, 2014) or decreases in FGA and FGG (Yousuf, 




reported. Apart from its major role in clot formation, FBG is also involved in wound 
healing and platelet degranulation.  
Similar to FGB, SERPINA1 and SERPINC1 were selected for validation as they 
play important roles in the coagulation system and are liver APPs that are regulated by 
acute inflammation/infection. SERPINA1, a protease inhibitor, inhibits plasmin, thrombin 
and plasminogen activator. In the coagulation system, there are three main anticoagulant 
pathways; the protein C system, antithrombin (SERPINC1) and TFPI (de Azeredo et al., 
2015). SERPINC1 is important in regulating the balance of coagulation. There is limited 
in vitro information about changes that may occur in the levels of these two proteins in 
DENV infection. However a yeast two-hybrid study has identified an interaction between 
SERPINC1 and DENV NS3 (Silva et al., 2019). Similarly, an interaction between 
SERPINA1 and the DENV-2 E protein was identified using affinity purification followed 
by MS analysis (Huerta et al., 2016).  
Both CLU and VTN inhibit membrane attack complex (MAC), resulting in the 
prevention of cell lysis in the final stage of the complement pathway. Decreases in both 
CLU and VTN in the secretome of DENV infected cells in this study might result in cell 
lysis due to stimulation of the complement system. CLU was found to interact with both 
the DENV-2 C and prM proteins in an in vitro yeast two-hybrid experiment (Folly et al., 
2011). Furthermore, an interaction between DENV NS1 and CLU in the plasma of DEN 
patients was also detected by co-IP followed by MS (Kurosu et al., 2007). Kurosu et al. 
proposed that the clearance of NS1-CLU complexes from plasma by the host immune 
response may cause a decrease in CLU levels in DENV patients (Kurosu et al., 2007); 
however, decreased amounts of CLU in clinical specimens have never been reported 
before. The decrease in CLU in both the proteome and secretome of DENV-2 infected 
Huh-7 cells identified in this study implies that a decrease in cellular levels results in a 
decrease in CLU secretion from hepatocytes which may affect levels in plasma. 
Furthermore, a significant decrease in CLU in the proteome of DENV-2 infected Huh-7 
cells was also detected in another study (Chiu, 2014). VTN was proposed as biomarker for 
diagnosis and to predict DEN disease severity of DEN in a previous serum proteomic study 




all forms of DEN compared with healthy controls and VTN levels decreased in more severe 
DEN cases compared with DF (Poole-Smith et al., 2014). An interaction between VTN 
and NS1 was previously detected using a yeast two-hybrid system and a NS1–VTN 
complex was also identified in plasma from DEN patients (Conde et al., 2016). To date a 
change in the cellular/secretome level of VTN has never been reported and the cellular 
mechanisms involved in the dysregulation of VTN in DEN patienst is still unknown. 
Pathway of cholesterol metabolism 
 Flaviviruses, including DENV, modulate host cell lipid metabolism to facilitate 
viral entry, replication complex formation, viral assembly, virion secretion and control of 
the IFN response (Osuna-Ramos et al., 2018). The liver is the key organ for apolipoprotein 
and lipoprotein production (Feingold KR and Grunfeld, 2000); thus, the alterations in 
proteins involved in cholesterol/lipid metabolism in DENV infected Huh-7 cells identified 
in this study were expected.  
APOA1, synthesised by the liver and intestine, functions in lipid metabolism as a 
lipid transporter and the major protein component of HDL. Moreover, it has anti-
inflammatory effects (Vuilleumier et al., 2013). So far, no study has identified a change in 
apolipoprotein amounts in DENV infected cells. The decrease in both cellular and secreted 
APOA1 in response to DENV infection identified in this study implies that the decrease in 
secreted APOA1 is due to a decrease at the cellular level. The decrease in APOA1 could 
not be validated, although a recombinant APOA1 protein could be detected down to a level 
of 50 ng. Therefore it appeared that the detection of APOAI by LC-MS/MS analysis was 
more sensitive than the Western blot detection system used in this study. As APOA1 is a 
secretory protein mainly synthesised and secreted from hepatocytes, it may be present at a 
very low level in liver cells whilst being enriched in the secretome. A previous study using 
HepG2 cells found that replication of hepatitis virus B (HBV) resulted in a decrease in both 
the protein and mRNA levels of APOA1 (Wang et al., 2016). High-throughput yeast two-
hybrid assay analysis revealed an interaction between APOA1 and the DENV NS2A 
protein (Khadka et al., 2011). Moreover, pre-incubating U937 cells with supernatants 
derived from HEK293 cells transfected with an APOA1 expression plasmid resulted in an 




promote DENV infection in cell experiments (Li et al., 2013). The decrease in the cellular 
levels and secretion of APOA1 found in this study may be a host cell response to suppress 
DENV replication.  
In conclusion, this study identified novel alterations in the proteome and secretome 
of Huh-7 cells in response to DENV infection, as well as changes in the levels of proteins 
that have previously been reported. An integrated analysis of the proteome and secretome 
datasets was done, which revealed dysregulation of specific proteins involved in 
“complement and coagulation cascade” and “cholesterol metabolism” at the cellular level 
leading to alterations in the amounts of these proteins in the secretome. The proteomic data 
was validated for representative proteins associated with these biological pathways, which 





  HI GH - T HR O U GHPU T 
PR OT E OM I C A N A LY SI S  O F S E R U M  FROM  
D E N V I N FE CT E D  I N DI V I D U A L S  
 Introduction 
 A major challenge in the diagnosis of DEN is the lack of diagnostic markers in the 
late phase of the disease (when there is no antigenemia or viremia) which coincides with 
the onset of severe disease and the lack of biomarkers to predict whether a patient will 
progress to severe disease. Serum/plasma proteomic analysis has been widely used to 
identify potential biomarkers for many infectious diseases, including DEN (Ray et al., 
2014). The workflow of serum/plasma proteomic analysis starts with clinical specimen 
selection, followed by sample processing and storage, then downstream proteomic analysis 
(Ray et al., 2014). A discovery proteomic approach is typically used to first identify a panel 
of potential biomarkers of interest. These potential biomarkers are then validated on a 
larger population size using immunoassays and/or targeted proteomics to measure the 
amounts of specific proteins in clinical specimens, to produce a refined set of biomarkers 
(Ray et al., 2014). A challenge with plasma/serum proteomic analysis is that human blood 
contains a wide dynamic range of proteins, varying by up to 1010 fold, whilst the detection 
range of LC-MS/MS is only 103-106 fold (Jacobs et al., 2005). Unfortunately, many 
potential biomarkers are only present at a low concentration in blood; for example, the 
basal level of IL-6 is only 5 pg/ml whilst the level of ALB is 50 mg/ml (Geyer et al., 2017). 
To enhance the detection of these low concentration “secreted proteins” which have 
typically been transiently secreted from cells in response to different disease conditions, 
protein depletion strategies are often applied to decrease the level of highly abundant 
proteins “classic proteins” in blood, such as ALB, IgG, and serum amyloid A (Jacobs et 
al., 2005).  
Among previous proteomic studies that analysed the differential expression of 
serum/plasma proteins in response to DENV infection, there were seven studies that used 




al., 2017; Huy et al. 2013; Ray et al. 2013; Kumar et al., 2012; Albuquerque et al., 2009; 
Thayan et al., 2009a; Thayan et al., 2009b) whilst other studies compared only patients 
with different DEN disease severities (Brasier et al., 2012; Fragnoud et al., 2105, Nhi et 
al.,2016). A comparison of the seven studies is summarized in Table 6.1. Of note, in two of 
these studies either, peripheral blood mononuclear cells (PBMC) or circulating immune 
complexes (CIC) were isolated from plasma and used for proteomic analysis rather than 
analysing whole serum/plasma (Thayan et al., 2009a; Huy et al., 2013). Overall, there were 
more proteins that were significantly up-regulated than down-regulated in DEN patients 
compared to healthy controls. The total numbers of proteins identified, and the number 
which were shown to be significantly differentially expressed in DEN patients, varied 
between studies. Variations in the populations analysed (in terms of race, age, infecting 
DENV serotype and study time after infection), serum/plasma preparation techniques, as 
well as proteomic analysis techniques are all factors that potentially contribute to the 
variation in the results in these studies. Almost all of the previous studies included only DF 
and DHF patients (only the study of Huy et al. included a SD group) which were compared 
with heathy controls. All studies except that of Albuquerque et al. (Albuquerque et al., 
2009), enrolled DEN patients infected with all DENV serotypes. Four of the studies used 
2D-DIGE followed by LC-MS/MS for proteomic analysis, which is relatively low-
throughput and led to the identification of a limited number of differentially expressed 
proteins. The other three studies used isobaric labelling in combination with LC-MS/MS 
which led to the quantitation and identification of a much larger number of proteins but 
using a small number of patient samples for analysis. Kumar et al., used pooled patient 
serum for analysis, which increased the number of samples analysed, but may have masked 





Table 6.1 Summary of proteomic studies using clinical specimens from DENV infected 
patients compared with healthy persons. 
 





Comparisons between cellular and/or secreted proteins that are dysregulated in 
response to DENV infection in cell-based experiments and in clinical specimens are very 
limited and have often focussed on specific proteins. For example, an increase in serum 
ENO1 during DEN has been correlated with increased amounts of ENO1 in the secretome 
of DENV-2 infected HepG2 cells (Higa et al., 2014). A review article by Salazar and 
coworkers (Salazar et al., 2014) linked the detection of macrophage migration inhibitory 
factor (MIF) in the secretome of DENV infected HepG2 cells (Higa et al., 2008) with 
increased MIF in patient serum, as a predictor of DEN disease severity (Chen et al., 2006). 
A systematic study to compare the results of cell-based experiments and clinical studies is 
required to determine which cell-based systems are relevant models for the study of DEN 
pathogenesis and can serve as a relevant tool for translational medicine studies.  
 Therefore, in this chapter, a high-throughput proteomic analysis of sera from 
patients with different DEN disease severities was undertaken, to identify proteins 
dysregulated in response to DENV infection and which may correlate with disease severity. 
An integrated comparative analysis of the results of the proteomic analyses of both DENV 
infected HEK293T and Huh-7 cells and the associated secretomes, with the results of the 
serum proteomic analysis was then done. By undertaking an integrated analysis it was 
aimed to determine whether DENV replication in cultured cells results in changes in the 
levels of cellular and secreted proteins that are also modulated in clinical samples.  
Results  
 Study setting and clinical characteristics of the study population 
The Philippines is a DEN endemic country in which the incidence of laboratory 
confirmed cases varies from 16-66 per 1,000 person years depending on the study (Agrupis 
et al., 2019). Moreover, both the DEN incidence and mortality rate were estimated to 
increase by 24% and 29%, respectively, over the last three decades (Agrupis et al., 2019). 
The sera used in this study (and associated clinical and DENV diagnostic data) were 
collected from a multicentre cohort in Metropolitan Manila, from August 2014 to 
November 2015. Among the 119 cases in cohort, there were 66 cases of DEN. Specimens 




PCR and NS1 postivity) and an early sampling time (day after fever onset). The ages and 
genders were balanced in each group as much as possible.  
A total of 41 serum samples from DENV infected patients with varying disease 
severities were selected for proteomic analysis: 19 cases of DEN w/o WS, 13 cases of DEN 
w WS and nine cases of SD (Table 6.2 and Supplementary Table 6.1). The cohort included 
both adult and paediatric patients. The age and sex distribution in each group of DENV 
infected patients were not obviously different. However, the sera of nine healthy persons 
were collected from only adult volunteers. It should be noted that, the time of specimen 
collection (days after onset of fever) was longer in the SD group compared with the other 
groups. The diagnosis and confirmatory tests for DENV infection were performed in the 
Philippines at the time of enrolment.  A DENV specific RT-PCR test was performed for 
all cases whilst DENV NS1 and specific IgM (using rapid tests) were performed in some 
cases. The DENV serotype was identified in ~ 57% of RT-PCR positive cases.  
 
Table 6.2 Basic characteristics of DENV infected patients and healthy controls  
 
DEN (N=41) Healthy 







Age (years), Median (range)  14 (3-39)*1 14 (8-40) 13 (2-40) 25 (19-27)*1 
Male:Female 9:10 7:6 4:5 4:4*1 
Specimen collection  
(days after onset of fever), Median 
(range) 
4 (2-7) 5 (3-6) 6.5 (5-7)*2 NA 
NS1 Ag (no. of positive/available 
data) 
7/8 3/5 1/7 NA 
Dengue IgM (no. of positive/available 
data) 
7/19 7/10 7/7 NA 
Positive Dengue RT-PCR (no. of 
positive/available data) 
18/19 13/13 4/9 NA 
Serotype, 1:2:3:4 3:3:6:1 3:1:1:0 2:0:0:0 NA 




 Quantitative LC-MS/MS analysis of serum proteomic 
The sera were depleted of ALB and IgG (performed by Dr. Davidson) as described 
in Chapter 2 (section 2.6.2). The amount of protein in each specimen was determined by 
BCA assay (performed by Dr. Davidson). TMT labelling was performed by Dr. Davidson 
and Dr. Kate Heesom and co-workers at the Proteomic Facility. A total of six sets of 10-
plex TMT labelled samples were analysed by LC-MS/MS were performed. A “mastermix” 
reference (described in section 2.6.2) was included in all runs to compare the results across 
different runs.   
The spectral files from the LC-MS/MS analysis of all clinical specimens were 
combined, and protein identification and quantitation performed using Proteome 
Discoverer 2.1. The spectra were searched against the human proteome retrieved from 
Uniprot as well as the individual protein, and complete polyprotein, amino acid sequences 
encoded by 20 DENV reference strains covering all serotypes. Further refined 
quantification of the proteins was then done using the software BayesProt, a mixed-effects 
model (Freeman et al., 2016), recently extended to support TMT 
(https://github.com/biospi/bayesprot); (done by Professor Andrew Dowsey (University of 
Bristol) and PhD student Alex Philips (University of Liverpool)). There were a total of 
1818 proteins that were reliably quantified using at least 1 unique peptide in the clinical 
samples.  
Students t-tests, assuming unequal variance, were performed for each pair of 
conditions to calculate P-values, and these were FDR-adjusted using the Benjamini-
Hochberg method by Dr Philip Lewis. Statistical significance was determined by an FDR-
adjusted P-value (FDR) of less than 0.05 (Benjamini and Hochberg, 1995).     
 Proteomic analysis of serum protein altered in response to DENV infection  
To identify proteins changed during disease processes, the healthy group was used 
as a control group. Proteins that changed by a statistically significant amount were defined 
by global FDR of < 0.05 and a cut-off of a ≥1.2 fold increase or decrease. A significant 
increase/decrease in at least one comparison (DEN w/o WS/healthy, DEN w WS/healthy 




were 216 proteins that significantly altered in amount (both increased and decreased) in 
DENV infected patients compared with healthy persons, listed in Table 6.3. This set of 





Table 6.3 A list of proteins significantly (FDR < 0.05) altered (≥ 1.2 fold) in abundance in the serum of DENV infected patients 

















A8K3K1 Actin, cytoplasmic 1  ACTC 2.97 5.28E-05 3.14 1.15E-04 4.52 3.20E-03 
Q76LX8 A disintegrin and metalloproteinase with thrombospondin 
motifs 13  
ADAMTS13 0.84 8.69E-02 0.80 3.27E-02 0.73 7.59E-03 
P43652 Afamin  AFM 0.63 4.26E-03 0.53 5.08E-03 0.72 2.46E-01 
P00352 Retinal dehydrogenase 1  ALDH1A1 2.21 2.31E-02 1.90 9.66E-02 1.35 6.46E-01 
J3KPS3 Fructose-bisphosphate aldolase A  ALDOA 1.65 5.82E-04 1.57 5.89E-03 1.80 3.43E-02 
B7Z8Q2 Alpha-2-HS-glycoprotein AHSG 0.73 9.22E-04 0.75 7.22E-03 0.77 4.02E-02 
P02760 Protein AMBP  AMBP 0.69 4.92E-03 0.72 1.12E-02 0.74 4.82E-02 
P02647 Apolipoprotein A-I  APOA1 0.73 4.69E-03 0.60 1.18E-03 0.55 1.17E-02 
P06727 APOA4 protein APOA4 0.47 3.61E-05 0.46 4.04E-03 0.65 4.47E-02 
C0JYY2 Mutant Apo B 100  APOB 0.64 4.92E-03 0.65 4.90E-03 0.66 1.52E-01 
A0A024R0T
8 
Apolipoprotein C-I  APOC1 0.43 1.69E-06 0.38 1.15E-04 0.48 6.60E-02 
B0YIW2 Apolipoprotein C-III  APOC3 0.43 6.13E-05 0.52 2.85E-03 0.77 4.16E-01 
P55056 Apolipoprotein C-IV APOC4 0.35 5.97E-04 0.37 1.34E-03 0.38 1.51E-02 
K7ER74 Apolipoprotein C-II  APOC2 0.36 2.06E-04 0.44 2.17E-03 0.90 8.30E-01 
C9JF17 Apolipoprotein D  APOD 0.79 6.61E-02 0.71 2.07E-02 0.70 1.17E-02 
Q13790 Apolipoprotein F  APOF 0.86 4.80E-01 0.71 4.07E-02 0.66 2.38E-02 
P02749 Beta-2-glycoprotein 1  APOH 0.38 1.27E-05 0.33 3.09E-05 0.42 5.54E-03 




O75882 Attractin  ATRN 0.81 4.58E-03 0.78 2.61E-03 0.75 2.95E-02 
P25311 Zinc-alpha-2-glycoprotein  AZGP1 0.55 1.87E-04 0.52 1.64E-04 0.61 1.94E-02 
P80723 Brain acid soluble protein 1  BASP1 2.72 5.17E-04 1.77 8.58E-03 2.20 8.16E-02 
D3DNN4 Carboxylic ester hydrolase  BCHE 0.78 3.27E-02 0.81 5.55E-02 0.81 1.18E-01 
B4E0X1 Beta-2-microglobulin  B2M 1.90 5.97E-04 1.77 1.97E-03 1.90 3.96E-03 
P02745 Complement C1q subcomponent subunit A  C1QA 0.59 1.05E-05 0.59 2.22E-03 0.54 8.14E-02 
P02746 Complement C1q subcomponent subunit B  C1QB 0.73 3.05E-03 0.70 1.06E-02 0.75 3.10E-01 
P02747 Complement C1q subcomponent subunit C  C1QC 0.69 1.67E-03 0.65 9.55E-03 0.67 1.91E-01 
Q9NZP8 Complement C1r subcomponent-like protein  C1RL 1.17 1.94E-01 1.32 1.05E-02 1.16 5.73E-01 
P09871 Complement C1s subcomponent  C1S 0.81 2.20E-02 0.91 5.04E-01 0.93 8.65E-01 
Q53HP3 Complement component 2 variant  C2 1.16 1.67E-01 1.27 2.35E-02 1.22 2.69E-01 
P01031 Complement C5  C5 0.74 3.22E-02 0.72 2.61E-02 0.68 3.92E-02 
P13671 Complement component C6  C6 0.84 1.33E-01 0.80 1.14E-01 0.72 1.67E-02 
P07357 C8A protein  C8A 0.84 4.57E-02 0.79 1.60E-02 0.74 4.11E-03 
P07358 Complement component C8 beta chain C8B 0.87 2.42E-01 0.76 9.16E-02 0.60 5.94E-03 
A0A024R035 Complement component 9, isoform  C9 1.32 2.49E-02 1.27 5.58E-02 1.26 3.38E-01 
E7EMB3 Calmodulin 2  CALM2 2.16 4.49E-03 2.22 1.06E-02 3.84 2.18E-02 
B2R888 Monocyte differentiation antigen CD14  CD14 1.66 2.27E-07 1.78 4.23E-06 1.46 1.72E-01 
Q86VB7 Scavenger receptor cysteine-rich type 1 protein M130  CD163 1.39 1.92E-02 1.30 1.52E-01 1.67 3.20E-03 
A8K6C1 Cholesteryl ester transfer protein  CETP 0.55 3.04E-03 0.55 4.77E-03 0.61 2.12E-01 
A6XNE2 Complement factor D  CFD 0.84 4.87E-01 0.74 2.36E-01 0.61 3.42E-02 
P08603 Complement factor H  CFH 0.62 4.39E-02 0.68 1.06E-01 0.57 8.99E-03 
B2RA39 Complement factor H-related 5 (CFHL5) CFHL5 0.46 9.41E-04 0.44 1.34E-03 0.36 3.77E-03 
Q03591 Complement factor H-related protein 1  CFHR1 0.65 9.04E-02 0.65 6.76E-02 0.60 2.24E-02 
P36980 Complement factor H-related protein 2  CFHR2 0.54 4.59E-02 0.58 8.77E-02 0.72 4.49E-01 
B4DRF2 Complement factor I  CFI 0.80 3.23E-02 0.76 9.15E-03 0.77 2.60E-02 
E9PK25 Cofilin-1  CFL1 1.94 1.79E-02 1.77 9.74E-03 2.60 4.11E-02 




Q05315 Galectin-10  CLC 2.98 2.77E-02 1.94 3.55E-01 4.23 1.94E-01 
Q2KHT3 Protein CLEC16A  CLEC16A 0.60 7.87E-01 0.11 2.80E-01 0.09 3.34E-02 
P12109 Collagen alpha-1(VI) chain  COL6A1 1.74 2.93E-04 1.87 1.64E-04 2.21 2.27E-02 
A0A024R9J3 Collectin sub-family member 10  COLEC10 0.73 5.76E-03 0.79 1.85E-01 0.94 8.37E-01 
A0A024R611 Coronin CORO1A 1.72 8.59E-02 1.70 1.30E-01 2.79 1.03E-02 
Q96IY4 Carboxypeptidase B2 CPB2 0.41 3.04E-08 0.41 2.33E-06 0.45 3.64E-04 
P02741 C-reactive protein  CRP 7.63 7.81E-05 4.42 5.54E-03 1.53 5.27E-01 
Q9NQ79 Cartilage acidic protein 1  CRTAC1 0.75 4.63E-02 0.64 4.85E-03 0.67 1.81E-02 
B2RBF5 Di-N-acetylchitobiase CTBS 0.76 4.49E-03 0.87 2.48E-01 0.97 9.44E-01 
J3KQ18 D-dopachrome decarboxylase  DDT 2.23 3.83E-03 2.67 1.62E-03 1.82 3.41E-01 
Q6MZL2 Putative uncharacterized protein  DKFZp686M
0562 
0.69 1.43E-03 0.66 2.59E-04 0.81 2.72E-01 
B4DID6 Dickkopf-related protein 3G DKK3 4.27 3.27E-02 2.92 1.45E-01 2.97 4.49E-01 
Q16610 Truncated extracellular matrix protein 1  ECM1 0.65 7.13E-04 0.65 4.77E-03 0.58 1.57E-03 
P13639 Elongation factor 2 EEF2 3.07 7.67E-02 5.06 1.32E-02 3.79 6.08E-02 
P08246  Neutrophil elastase  ELANE 2.95 4.53E-02 1.93 3.11E-01 0.97 9.84E-01 
A0A024R6D3 Ectonucleoside triphosphate diphosphohydrolase 5  ENTPD5 2.25 4.29E-02 2.01 6.44E-02 1.48 4.16E-01 
Q9NZ08  Endoplasmic reticulum aminopeptidase 1  ERAP1 1.71 3.81E-02 1.78 3.03E-02 1.29 5.42E-01 
P00742 Coagulation factor X  F10 0.71 5.96E-03 0.75 1.61E-02 0.80 2.63E-01 
P03951 Coagulation factor XI  F11 0.61 3.84E-04 0.56 4.04E-03 0.44 4.74E-04 
B2R6V9 Coagulation factor XIII, A1 polypeptide  F13A1 0.40 1.30E-05 0.58 3.15E-02 0.48 5.92E-02 
P05160 Coagulation factor XIII B  F13B 0.58 7.37E-05 0.60 1.75E-04 0.72 7.71E-02 
P00734 Prothrombin  F2 0.71 1.84E-03 0.73 4.50E-03 0.67 6.20E-03 
F2RM37 Coagulation factor IX  F9 0.57 3.61E-05 0.60 2.04E-04 0.60 3.20E-03 
Q15485 Ficolin-2  FCN2 0.67 6.97E-02 0.63 2.07E-02 0.52 9.94E-02 
P02671 Fibrinogen alpha chain FGA 0.32 4.19E-04 0.46 1.33E-01 0.22 7.10E-02 
C9JEU5 Fibrinogen gamma chain  FGG 0.30 9.73E-04 0.48 1.53E-01 0.22 7.63E-02 
D3DP16 Fibrinogen gamma chain FGG 0.23 5.69E-04 0.49 2.06E-01 0.21 9.19E-02 




Q14314 Fibroleukin  FGL2 2.01 2.28E-02 1.90 3.37E-02 1.91 1.03E-01 
A0A024R462  Fibronectin  FN1 0.55 6.57E-03 0.63 9.66E-02 0.66 1.94E-01 
B4DTH2  Fibronectin splice variant E   FN1 0.63 3.97E-02 0.74 2.98E-01 0.86 6.51E-01 
Q12841  Follistatin-related protein 1 FSTL1 1.43 4.88E-04 1.25 3.03E-02 1.41 1.04E-01 
P04066 Tissue alpha-L-fucosidase  FUCA1 1.56 1.21E-02 1.62 2.27E-02 1.08 9.39E-01 
Q9BTY2  Plasma alpha-L-fucosidase  FUCA2 1.34 8.81E-02 1.48 2.65E-02 1.72 6.89E-02 
P04406 Glyceraldehyde-3-phosphate dehydrogenase   GAPDH 2.19 3.22E-04 2.25 2.45E-04 2.19 4.27E-02 
A8K335 Gamma-glutamyl hydrolase GGH 1.22 3.83E-02 1.37 5.56E-03 1.72 6.31E-03 
P09681 Gastric inhibitory polypeptide  GIP 0.07 4.42E-02 0.19 NA 0.38 NA 
A0A024R056 Guanine nucleotide-binding protein subunit beta-4  GNB1 2.78 2.32E-03 2.42 1.33E-02 3.13 1.33E-02 
Q8NBJ4 Golgi membrane protein 1  GOLM1 3.77 1.30E-05 3.12 1.15E-04 2.38 1.67E-02 
P40197 Platelet glycoprotein V  GP5 2.14 3.22E-02 0.84 7.25E-01 2.41 8.27E-02 
A0A0A0MT
S2 
Glucose-6-phosphate isomerase  GPI 1.84 1.10E-04 1.97 1.95E-04 1.83 3.43E-02 
P80108 Phosphatidylinositol-glycan-specific phospholipase D  GPLD1 0.65 4.38E-03 0.56 4.50E-03 0.52 5.81E-03 
P06396 Gelsolin  GSN 0.50 6.57E-03 0.44 1.46E-03 0.39 3.20E-03 
V9H1C1 Gelsolin exon 4  GSN 0.56 1.47E-03 0.58 4.85E-03 0.51 3.20E-03 
B2R983 Glutathione S-transferase omega-1  GSTO1 1.80 5.99E-04 2.00 2.54E-04 2.08 1.54E-02 
R4GMU1 GDH/6PGL endoplasmic bifunctional protein H6PD 1.40 3.17E-02 1.30 1.29E-01 1.33 2.63E-01 
Q6LAM1 Complement factor I  CFI 0.79 5.20E-02 0.75 1.68E-02 0.75 3.13E-02 
V9HWK2 Vinculin VCL 1.55 1.39E-04 1.54 1.64E-04 2.32 2.88E-02 
V9HWC7 Peroxiredoxin-6 PRDX6 1.54 4.56E-02 1.90 1.87E-02 1.42 5.47E-01 
A0A0K0K1L
8 
Proteasome activator complex subunit 1  PSME1 3.26 1.03E-02 3.12 8.74E-03 4.54 2.71E-02 
V9HWI3 Cathepsin D  CTSD 2.61 1.66E-07 2.08 3.74E-04 1.87 4.82E-02 
A0A0K0K1K
4 
Proteasome subunit alpha type  PSMA7 1.91 1.10E-01 1.96 1.20E-01 3.37 3.30E-02 
V9HWC9 Superoxide dismutase  SOD1 1.52 3.27E-02 1.72 1.33E-02 1.44 5.04E-01 
V9HWA9 Complement C3  C3 0.84 1.58E-01 0.76 6.50E-02 0.77 2.98E-02 




V9HVY1 Fibrinogen beta chain FGB 0.29 5.97E-04 0.48 1.65E-01 0.24 6.79E-02 
V9HWB4 Endoplasmic reticulum chaperone BiP HSPA5 0.73 4.49E-03 0.87 3.97E-01 1.11 5.80E-01 
V9HW88 Calreticulin  CALR 1.35 4.63E-05 1.50 2.04E-04 1.80 3.30E-02 
B2R4R0 Histone H4  HIST1H4H 2.96 1.52E-02 3.55 5.89E-03 3.52 1.37E-02 
P07900 Heat shock protein HSP 90-alpha  HSP90AA1 3.76 1.18E-04 4.32 1.72E-04 4.16 8.22E-03 
P14625 Endoplasmin  HSP90B1 1.56 9.41E-04 1.75 1.18E-03 1.77 1.52E-02 
A0A0G2JIW
1 
Heat shock 70 kDa protein 1  HSPA1B 2.40 7.59E-03 2.51 5.89E-03 2.52 2.20E-02 
P05362 Intercellular adhesion molecule 1 ICAM1 1.34 8.47E-04 1.34 9.90E-03 1.39 6.80E-03 
B2R5M8 Isocitrate dehydrogenase, cytoplasmic  IDH 2.07 3.27E-02 2.04 3.62E-02 1.86 1.88E-01 
P05019  Insulin-like growth factor 1   IGF1 0.56 2.21E-01 0.67 4.19E-01 0.42 4.82E-02 
P17936  Insulin-like growth factor binding protein 3  IGFBP3 0.58 5.17E-04 0.54 5.89E-03 0.47 1.51E-02 
P24592  Insulin-like growth factor-binding protein 6  IGFBP6 0.77 2.58E-02 0.74 9.15E-03 0.70 6.56E-02 
S6BGF5  IgG H chain IgGHchain 7.81 1.99E-02 3.48 2.84E-01 3.78 3.72E-01 
A0A087WW
F0 
 Protein IGHV3-64 IGHV3-64 0.64 2.54E-01 0.62 2.66E-02 0.36 3.31E-02 
P01703 Ig lambda chain V-I  IGLV1-40 1.93 3.67E-01 2.27 2.02E-01 5.15 1.67E-02 
G3V1C5 Interleukin-18-binding protein IL18BP 3.01 2.32E-03 2.59 6.51E-03 2.15 1.62E-01 
B7Z8B6 Inter-alpha-trypsin inhibitor heavy chain H1 ITIH1 0.68 2.76E-03 0.62 9.93E-04 0.62 3.20E-03 
D3DRR6 Inter-alpha-trypsin inhibitor heavy chain H2 ITIH2 0.64 1.67E-03 0.63 1.83E-03 0.69 2.91E-02 
H0YAC1 Kallikrein B KLKB1 0.61 5.93E-04 0.59 1.34E-03 0.54 3.20E-03 
G3XAI2 Laminin subunit beta-1  LAMB1 1.12 3.15E-01 1.27 8.28E-03 1.18 3.63E-01 
P18428 Lipopolysaccharide-binding protein  LBP 1.98 2.28E-06 1.68 2.17E-03 0.95 9.35E-01 
P04180 Phosphatidylcholine-sterol acyltransferase  LCAT 0.72 1.84E-03 0.71 1.92E-03 0.75 2.89E-02 
A0A024RDT
4 
Lymphocyte cytosolic protein 1  LCP1 1.94 1.09E-04 2.10 1.25E-03 2.79 1.51E-02 
P00338 L-lactate dehydrogenase A chain  LDHA 1.61 1.52E-03 1.62 4.72E-03 1.84 1.11E-02 
Q5U077 L-lactate dehydrogenase B chain  LDHB 1.41 8.10E-03 1.41 2.63E-02 1.85 2.24E-02 
A0A0S2Z3Y
1 




H2B4M4 Leukocyte immunoglobulin-like receptor A LILRA3 2.58 1.29E-01 4.07 1.61E-02 3.31 9.63E-02 
Q6NXN2 Hypothetical LOC441242  LOC441242 0.31 1.01E-01 0.21 4.56E-02 0.19 1.22E-01 
Q07954 Prolow-density lipoprotein receptor-related protein 1  LRP1 1.15 3.38E-01 1.28 5.58E-02 1.58 3.36E-02 
P33908 Mannosyl-oligosaccharide 1,2-alpha-mannosidase IA  MAN1A1 1.18 7.69E-02 1.31 1.29E-02 1.50 3.58E-02 
Q16706 Alpha-mannosidase 2  MAN2A1 1.44 1.67E-03 1.42 2.77E-03 1.42 8.12E-02 
P29966 Myristoylated alanine-rich C-kinase substrate  MARCKS 2.26 4.81E-03 2.38 5.47E-03 3.61 8.79E-03 
P48740 Mannan-binding lectin serine protease 1 MASP1 0.77 2.77E-02 0.82 1.26E-01 0.92 8.09E-01 
B2R7D2 Multiple inositol polyphosphate histidine phosphatase 1 MINPP1 0.76 9.96E-02 0.82 2.89E-01 0.66 3.42E-02 
A0A024R6R
4 
Matrix metallopeptidase 2 MMP2 0.76 2.58E-02 0.84 3.76E-01 0.95 8.81E-01 
P05164 Myeloperoxidase  MPO 1.72 2.20E-02 1.41 1.47E-01 1.38 2.51E-01 
B9EJA8 Macrophage mannose receptor 1  MRC1L1 1.23 7.95E-02 1.34 3.80E-02 1.29 2.22E-01 
P26038 Moesin  MSN 2.74 5.56E-06 2.64 3.26E-05 3.11 3.10E-03 
G3XAK1 Macrophage stimulating 1 (Hepatocyte growth factor-
like)  
MST1 0.80 1.14E-02 0.78 2.09E-02 0.87 2.49E-01 
B7Z809 Methylenetetrahydrofolate dehydrogenase (NADP+ 
dependent) 1 
MTHFD1 1.33 5.74E-01 2.33 3.88E-02 1.86 5.81E-01 
A8K8T3 Bifunctional heparan sulfate N-deacetylase/N-
sulfotransferase 1  
NDST1 0.53 5.60E-02 0.46 1.41E-02 0.37 4.53E-02 
P14543 Nidogen-1  NID1 1.95 2.90E-06 2.04 2.26E-05 2.52 3.20E-03 
J3KNK3 NTPase KAP family P-loop domain-containing protein 1  NKPD1 0.60 2.35E-01 0.57 3.84E-02 0.45 4.02E-02 
A8K7Q1 Nucleobindin 1  NUCB1 3.40 1.69E-06 4.05 1.15E-04 3.08 9.49E-02 
Q86UD1 Out at first protein homolog  OAF 1.58 2.95E-04 1.72 1.92E-03 1.52 2.15E-01 
B4DI63 Osteoglycin OG  OGN 1.62 4.53E-01 2.94 3.03E-02 1.85 3.24E-01 
B2R7N9 Osteomodulin  OMD 2.22 8.10E-03 3.19 6.30E-03 4.09 3.13E-02 
P02763 Alpha-1-acid glycoprotein 1  ORM1 1.69 5.47E-04 1.78 3.23E-04 1.52 7.65E-02 
P19652 Alpha-1-acid glycoprotein 2  ORM2 1.32 6.74E-02 1.49 9.86E-03 1.27 3.85E-01 
Q99497 Protein deglycase DJ-1  PARK7 2.06 2.07E-03 2.12 1.83E-03 2.00 3.27E-02 
Q8NBP7 Proprotein convertase subtilisin/kexin type 9  PCSK9 1.59 1.37E-05 1.62 2.97E-03 1.54 6.07E-02 




P02776 Platelet factor 4  PF4 3.05 2.12E-04 2.90 1.97E-03 5.72 3.20E-03 
P17858 ATP-dependent 6-phosphofructokinase PFKL 3.91 1.31E-01 5.44 6.24E-02 7.92 3.27E-02 
P07737 Profilin-1  PFN1 3.63 1.74E-05 3.20 6.68E-05 5.40 1.11E-02 
Q6FHK8 Phosphoglycerate mutase 1  PGAM1 2.88 4.86E-02 4.09 1.28E-02 3.91 7.81E-02 
Q96PD5 N-acetylmuramoyl-L-alanine amidase  PGLYRP2 0.62 2.57E-05 0.60 2.01E-04 0.71 1.33E-02 
P00747 Plasminogen PLG 0.70 1.15E-03 0.73 4.77E-03 0.76 2.88E-02 
B3KUE5 Phospholipid transfer protein  PLTP 0.81 1.92E-01 0.77 3.94E-02 0.78 4.93E-01 
P27169 Serum paraoxonase/arylesterase 1  PON1 0.78 4.59E-02 0.70 9.90E-03 0.61 3.10E-03 
A8K486 Peptidyl-prolyl cis-trans isomerase  PPIA 1.87 2.78E-03 1.86 1.17E-03 2.47 2.74E-02 
B2R4P2 Peroxiredoxin-1  PRDX1 1.89 1.07E-02 2.02 5.54E-03 1.62 3.72E-01 
A0A024QZL
1 
Proteoglycan 1 PRG1 1.81 8.20E-02 1.32 5.55E-01 2.53 3.30E-02 
B4DPQ3 Protein C PROC 0.63 6.57E-03 0.64 9.90E-03 0.68 8.27E-02 
A0A0S2Z4L
3 
Protein S  PROS1 0.78 1.41E-02 0.77 1.71E-02 0.71 1.14E-02 
Q59EN5 Prosaposin PSAP 1.94 1.69E-06 1.65 8.48E-04 1.44 8.22E-03 
P25786 Proteasome subunit alpha type-1  PSMA1 2.18 9.99E-03 2.76 1.18E-02 3.98 1.51E-02 
P25788 Proteasome subunit alpha type-3  PSMA3 1.67 2.27E-02 1.96 2.61E-03 2.46 2.18E-02 
P25789 Proteasome subunit alpha type-4 PSMA4 1.74 2.64E-02 2.13 8.14E-03 3.21 3.49E-02 
G3V5Z7 Proteasome subunit alpha type-6  PSMA6 1.81 8.95E-02 2.18 2.72E-02 3.46 3.30E-02 
P20618 Proteasome subunit beta type-1  PSMB1 2.39 2.77E-02 3.12 5.00E-03 4.06 3.67E-02 
O00391 Sulfhydryl oxidase 1 QSOX1 0.78 4.81E-03 0.66 4.31E-03 0.74 2.20E-02 
A0A024RB8
7 
Ras-related protein Rap-1b  RAP1B 3.49 1.97E-02 1.95 2.92E-01 2.93 5.25E-02 
P02753 Retinol binding protein 4 RBP4 0.50 1.20E-03 0.57 6.51E-03 0.66 8.85E-02 
A8K9C4 Elongation factor 1-alpha 2  EEF1A2 3.43 2.24E-02 3.39 5.58E-02 6.65 1.01E-01 
B4DUP2 UTP--glucose-1-phosphate uridylyltransferase  UGP2 2.53 4.07E-02 3.31 1.18E-02 3.57 5.77E-02 
Q59ER5 WD repeat domain 1 WDR1 2.17 8.46E-02 2.19 6.45E-02 3.47 3.42E-02 
B4E3S9 Leiomodin-1  LMOD1 1.63 3.77E-01 1.80 2.90E-01 4.26 3.30E-02 




B7Z539 Inter-alpha-trypsin inhibitor heavy chain H1  ITIH1 0.64 6.27E-04 0.62 5.67E-04 0.60 2.96E-03 
Q6ZVX0 Protein Tro alpha1 H,myeloma  N/A 0.54 1.01E-01 0.66 1.82E-01 0.42 2.07E-02 
B2R582 C-type lectin domain family 3, member B  CLEC3B 0.46 4.02E-02 0.72 3.76E-01 0.59 4.77E-02 
A0A125QYY
7 
IBM-B1 heavy chain variable region  N/A 0.45 6.57E-01 0.34 5.04E-01 0.20 4.77E-02 
A0A068LKQ
8 
Ig heavy chain variable region N/A 0.26 2.58E-02 0.35 8.22E-02 0.27 1.42E-01 
Q8TE92 cDNA FLJ23782 fis, clone HEP20947  N/A 0.20 3.25E-04 0.51 2.35E-01 0.26 8.12E-02 
P06702 Protein S100-A9  S100A9 2.52 1.59E-01 3.59 3.03E-02 2.26 4.16E-01 
Q6UWP8 Suprabasin  SBSN 1.63 3.25E-02 1.55 2.21E-02 1.28 5.47E-01 
P18827 Syndecan 1  SDC1 19.65 3.79E-02 24.53 2.50E-01 38.99 5.27E-01 
Q13228 Selenium-binding protein 1  SELENBP1 1.44 4.44E-02 1.67 5.89E-03 1.34 4.97E-01 
P49908 Selenoprotein P  SELENOP 0.54 1.25E-05 0.51 3.94E-05 0.52 3.20E-03 
A0A024R8Z
0 
L-selectin  SELL 1.30 2.41E-03 1.27 1.06E-02 1.24 1.70E-01 
Q86U17 Serpin A11  SERPINA11 1.25 7.69E-02 1.42 4.77E-03 1.27 2.03E-01 
B3KS79 Alpha-1-antichymotrypsin SERPINA3 1.57 1.18E-04 1.53 2.50E-04 1.42 1.09E-01 
A0A024R6I9 Alpha-1 antiproteinase SERPINA4 0.56 3.96E-05 0.55 1.64E-04 0.61 3.76E-03 
A0A024R6N
9 
Plasma serine protease inhibitor SERPINA5 0.30 1.66E-07 0.34 1.58E-04 0.34 4.21E-05 
A0A024R944 Antithrombin III SERPINC1 0.72 2.87E-03 0.87 4.59E-01 0.88 6.38E-01 
P36955 Pigment epithelium-derived factor  SERPINF1 0.74 2.08E-02 0.68 7.98E-03 0.63 3.20E-03 
P05155 Plasma protease C1 inhibitor  SERPING1 1.21 1.68E-01 1.36 2.61E-02 1.38 2.63E-01 
D3DPK5 SH3 domain binding glutamic acid-rich protein like 3 SH3BGRL3 3.18 6.74E-02 2.47 1.47E-01 4.31 2.27E-02 
A0A024RDE
2 
Secreted phosphoprotein 1  SPP1 3.67 6.56E-02 5.45 3.08E-02 3.02 3.85E-01 
Q13103 Secreted phosphoprotein 24  SPP2 0.59 1.92E-03 0.96 8.96E-01 1.21 5.64E-01 
P37802 Transgelin-2  TAGLN2 2.39 1.84E-03 1.79 1.17E-03 4.10 3.30E-02 
P37837 Transaldolase  TALDO1 2.17 1.09E-04 2.37 3.15E-04 3.20 3.20E-03 
P29401 Transketolase  TKT 2.77 2.29E-05 3.02 3.09E-05 3.45 6.20E-03 




P60174 Triosephosphate isomerase  TPI1 1.97 8.25E-03 2.05 6.69E-03 1.96 1.42E-01 
P67936 Tropomyosin alpha-4 chain  TPM4 1.98 2.28E-02 1.57 2.35E-02 3.00 1.14E-01 
H9ZYJ2 Thioredoxin  TXN 1.67 1.62E-01 1.93 3.84E-02 1.91 1.60E-01 
P19320 Vascular cell adhesion protein 1 VCAM1 2.03 2.27E-07 2.24 1.72E-04 2.53 1.51E-02 
P23381 Tryptophan--tRNA ligase  WARS 3.89 2.79E-05 5.08 1.64E-04 5.50 3.76E-03 
P62258 14-3-3 protein epsilon  YWHAE 2.56 7.41E-02 3.70 1.22E-02 3.63 9.62E-02 
P61981 14-3-3 protein gamma  YWHAG 3.64 1.92E-02 4.55 7.57E-03 9.58 3.10E-03 




  Analysis of the serum proteome of DEN patients with different grades of disease 
severity  
 To identify potential protein markers to predict DEN disease severity, the DEN w/o 
WS group was used as control to compare with DEN w WS and SD. In addition, the SD 
and DEN w WS groups were compared. From this analysis, there were no proteins that 
were significantly differentially regulated between SD and either DEN w WS or DEN w 
WS compared with DEN w/o WS. While, there were two proteins that were significantly 
(FDR < 0.05) altered (≥ 1.2 fold) in SD compared with DEN w/o WS: C-reactive protein 
(CRP) and APOC2 (Table 6.4). Interestingly, these two proteins were also significantly 
altered in DENV infected patients compared with healthy controls (Table 6.3). 
   
Table 6.4 Proteins significantly (FDR < 0.05) altered (≥ 1.2 fold) in abundance in the 







 Bioinformatic analysis of proteins that were significantly altered in 
the serum of DEN patients compared to controls. 
  Because of the low number of significantly altered proteins in patients with SD 
compared to DEN w/o WS, further bioinformatics analysis and discussion were focused 
on the serum proteins that significantly changed in DENV infected patients compared with 
healthy persons. 
The 216 proteins that significantly increased/decreased ≥ 1.2 fold in DENV 
infected patients compared to healthy controls were subjected to gene enrichment and 
network analysis using the DAVID and STRING analysis programs (Figures 6.1-6.2 and 
Supplementary Table S6.3).  
DAVID analysis showed that the proteins that were significantly altered in the 
serum of DEN patients compared to controls were enriched in eight clusters of proteins 
(Figure 6.1). The top three clusters were associated with the GOCC term “extracellular 
region/secreted” (GO:0005576), the GOMF term “serine-type endopeptidase activity” 
(GO:0004252) and the GOBP term “fibrinolysis” (GO:0042730), respectively. Other 
protein clusters associated with GO terms related to DENV infection included; “lipoprotein 
metabolic process” (GO:0042157) and “ubiquitin protein ligase binding” (GO:0031625) 
as well as the KEGG pathway “Complement and coagulation cascades” (hsa04610). 
STRING analysis revealed that serum proteins that were significantly altered in the 
serum of DEN patients compared to controls were associated with multiple significantly 
enriched GO terms. Those related to DEN pathogenesis included “immune response” 
(GO:0006955), “platelet degranulation” (GO:0002576), lipid transport (GO:0006869) and 
“acute-phase response” (GO:0006953) (Figure 6.2).  Protein clusters were also associated 
with the enriched KEGG pathways “complement and coagulation cascades” (hsa04610) 














Figure 6.1 DAVID analysis of proteins that were significantly altered in the serum of DEN 
patients compared to controls. 
 Proteins that were significantly (FDR < 0.05) altered in amount by ≥ 1.2 fold in the serum 
of DEN patients compared to controls were analysed using the DAVID database. The GO 
accession numbers/terms that were significantly enriched and the properties of the 
corresponding protein clusters are shown. The GES of significantly enriched GO terms are 
plotted as bar graphs with the corresponding GES score shown. The shading shows the 
type of GO term (GOBP, GOCC or GOMF), UP keywords, Interpro term or KEGG 
pathway. The number of proteins in each cluster (count), number of proteins associated 
with each GO term/total number of proteins in the dataset (%) and P-value for each of the 







Figure 6.2 STRING analysis of proteins that were significantly altered in the serum of DEN 
patients compared to controls. 
The STRING database was searched to analyse serum proteins that significantly (FDR < 
0.05) increased or decreased ≥ 1.2 fold in response to DENV-2 infection. Nodes 
representing proteins associated with the significantly enriched GO terms “immune 
response”, “platelet degranulation”, “secretion by cell”, “lipid transport” and “acute-phase 
response” as well as the KEGG pathway “complement and coagulation cascades” and 
“cholesterol metabolism”  are shaded in green, purple, yellow, brown, light blue, red and 
blue, respectively. The number of coloured nodes/ total proteins involved for each term 




  Comparative analysis proteins that were commonly found in 
proteomes and secretomes of DENV-2 infected HEK293T cells and 
clinical specimen from DEN patients. 
  Proteins that were commonly detected in the proteomes and secretomes of DENV-
2 infected HEK293T cells and clinical specimens from DEN patients. 
To determine whether HEK293T cells may be a useful model for examining DENV 
infection in vitro, the results of the proteome and secretome analysis of DENV-2 infected 
HEK293T cells (described in Chapter 4) were compared with the proteomic analysis of 
serum samples from DENV infected patients compared to healthy persons. Overall, 407 
and 441 proteins that were detected in the proteome and secretome of HEK293T cells, 
respectively, were also detected in the serum proteomic analysis (Figure 6.3). Among 















Figure 6.3 Overlap between proteins identified in the proteome and secretome of DENV-
2 infected HEK293T cells and the serum proteome of DENV infected patients. 
Venn diagram shows the number of proteins that were detected in DENV-2 infected 





 Proteins which altered significantly (P-value < 0.05 and ≥ 1.3 fold) in abundance 
across both the proteomes and secretomes of DENV-2 infected HEK293T cells compared 
with mock cells,were compared with the proteins that significantly altered (FDR < 0.05 
and ≥ 1.2 fold) in the serum of DENV infected patients patients compared to healthy 
persons (Figure 6.4, Table 6.5). Four proteins which fit both of these criteria were HSPA5, 
CALR, Peptidyl-prolyl cis-trans isomerase (PPIC) and Folate gamma-glutamyl hydrolase 
(carboxypeptidase G). Of these proteins, CALR and HSPA5 were significantly increased 
> 1.5 fold and > 1.3 fold, respectively, in DENV-2 HEK293T cells validated by Western 
blotting (described in Chapter 4).   
 Histone H4 (HIST1H4L) was the only secreted protein that significantly increased 
> 2 fold in both the secretomes from DENV-2 infected cell HEK293T cells and the serum 
of DENV infected patients (Figure 6.4 and Table 6.5). Unfortunately, there were no 
proteins that were significantly altered in all data sets (proteome, secretome and serum 
proteome) in response to DENV infection. 
 Bioinformatic analysis of proteins that were significantly altered in both HEK293T 
cells and serum in response to infection 
As there were only four proteins that were significantly altered in both HEK293T 
cells and patient serum in response to infection, DAVID analysis was not possible. 
Interestingly, STRING analysis revealed that this set of proteins was associated with the 
significantly enriched GOBP term “ATF6-mediated unfolded protein response” 
(GO:0036500) and the KEGG pathway term “Protein processing in endoplasmic 





Table 6.5 A list of proteins commonly significantly altered in the proteomes and secretomes 
of DENV-2 infected HEK293T cells and clinical specimen from DEN patients. 
 










Figure 6.4 Proteins that were commonly significantly altered in the proteomes and 
secretomes of DENV-2 infected HEK293T cells and clinical specimen from DEN patients.  
(A)  Venn diagram shows the number of proteins that were significantly (P-value <0.05) 
altered ≥1.3 fold in DENV-2 infected HEK293T cells or the associated secretomes 
compared with mock cells or significantly (FDR <0.05) altered ≥1.2 in the serum of DENV 
infected patients compared with healthy controls. (B) STRING analysis of proteins that 
were significantly altered in abundance in both DENV-2 infected HEK293T cells and 
serum of DENV infected patients. The STRING database was searched to analyse proteins 
that significantly altered in abundance in both DENV-2 infected HEK293T cells and the 
serum of DENV infected patients. Nodes representing proteins associated with the 
significantly enriched GOBP “ATF6-mediated unfolded protein response” and the KEGG 
pathway “Protein processing in endoplasmic reticulum” are shaded in red and blue, 
respectively. The number of coloured nodes/ total proteins involved for each term and the 





  Comparative analysis of proteins that were commonly found in 
both the proteomes and secretomes of DENV-2 infected Huh-7 cells 
and clinical specimens from DEN patients. 
  Proteins that were commonly detected in the proteomes and secretomes of DENV-
2 infected Huh-7 cells and clinical specimen from DEN patients. 
 To determine whether Huh-7 cells may be a useful model for examining DENV 
infection in vitro, the results of the proteome and secretome analysis of DENV-2 infected 
Huh-7 cells (described in Chapter 5) were compared with the proteomic analysis of serum 
samples from DENV infected patients compared to healthy persons.  Overall, 533 and 489 
proteins that were detected in the proteomes and secretomes of Huh-7 cells, respectively, 
were also detected in the serum proteome (Figure 6.5). Among these, 379 proteins were 












Figure 6.5 Proteins identified in the proteome and secretome of DENV-2 infected Huh-7 
cells and the serum proteome of DENV infected patients.  
Venn diagram shows the number of proteins that were detected in the proteome and 





Of the proteins found in both proteomics datasets, there were 50 proteins that were 
significantly (P-value < 0.05 and ≥ 1.3 fold) changed in the proteomes and/or secretomes 
from DENV-2 infected Huh-7 cellscompared with mock infected cells and significantly 
(FDR < 0.05 and ≥ 1.2 fold) altered in abundance in the serum of DENV infected patients 
compared to healthy persons (Figure 6.6 and Table 6.6). There were 18 proteins that were 
significantly altered only in Huh-7 cells and patient serum in response to DENV infection 
and 16 proteins that were significantly altered only in the secretome from Huh-7 cells and 
patient serum in response to DENV infection. Interestingly, there were 16 proteins that 
were significantly altered in response to DENV infection in all data sets (Huh-7 cells and 
associated secretomes and the serum of DEN patients).  
Twelve of 16 proteins that were significantly altered in all three data sets in 
response to DENV infection were significantly decreased in response to DENV infection 
in cells, secretomes and serum (Table 6.6). These 12 proteins were FGA, FGB, FGG, F2, 
CFH, CFI, APOA1, APOC2, phospholipid transfer protein (PLTP), protein AMBP 
(AMBP), retinol binding protein 4 (RBP4) and nidogen-1(NID1). Interestingly, most of 
them were proteins involved in coagulation and lipid metabolism. In contrast, Fibrinogen-
like protein 1 (FGL1), plasma alpha-L-fucosidase (FUCA2), mannosyl-oligosaccharide 
1,2-alpha-mannosidase IA (MAN1A1) and alpha-1-acid glycoprotein 1 (ORM1) were 
significantly decreased in both DENV-2 infected Huh-7 cells and the associated secretome 





Table 6.6 A list of proteins commonly significantly altered in the proteomes and secretomes of DENV-2 infected Huh-7 cells 
and clinical specimen from DEN patients. 





















Cellular proteome, secretome and serum proteome 
Apolipoprotein C-II  APOC2 0.44 4.34E-04 0.36 8.66E-03 0.36 2.06E-04 0.44 2.17E-03 0.90 8.30E-01 
Apolipoprotein A-I  APOA1 0.39 9.29E-03 0.40 7.16E-04 0.73 4.69E-03 0.60 1.18E-03 0.55 1.17E-02 
Fibrinogen alpha chain FGA 0.36 1.28E-03 0.44 1.89E-02 0.32 4.19E-04 0.46 1.33E-01 0.22 7.10E-02 
Fibrinogen beta chain FGB 0.43 1.01E-03 0.44 2.67E-03 0.29 5.97E-04 0.48 1.65E-01 0.24 6.79E-02 
Fibrinogen-like protein 1  FGL1 0.49 1.94E-02 0.50 8.24E-03 2.83 3.12E-05 2.76 1.66E-03 1.40 6.46E-01 
Phospholipid transfer protein PLTP 0.62 2.86E-02 0.59 1.18E-03 0.81 1.92E-01 0.77 3.94E-02 0.78 4.93E-01 
Plasma alpha-L-fucosidase  FUCA2 0.60 3.53E-03 0.63 2.95E-02 1.34 8.81E-02 1.48 2.65E-02 1.72 6.89E-02 
Protein AMBP  AMBP 0.34 7.46E-04 0.68 1.05E-02 0.69 4.92E-03 0.72 1.12E-02 0.74 4.82E-02 
Retinol-binding protein 4  RBP4 0.44 5.58E-04 0.69 1.57E-02 0.50 1.20E-03 0.57 6.51E-03 0.66 8.85E-02 
Mannosyl-oligosaccharide 1,2-
alpha-mannosidase IA  
MAN1A1 0.62 1.16E-02 0.69 1.54E-02 1.18 7.69E-02 1.31 1.29E-02 1.50 3.58E-02 
Alpha-1-acid glycoprotein 1  ORM1 0.36 1.05E-03 0.71 7.53E-03 1.69 5.47E-04 1.78 3.23E-04 1.52 7.65E-02 
Prothrombin O F2 0.62 3.72E-02 0.72 3.47E-02 0.71 1.84E-03 0.73 4.50E-03 0.67 6.20E-03 
Fibrinogen gamma chain FGG 0.44 1.18E-03 0.40 2.49E-02 0.23 5.69E-04 0.49 2.06E-01 0.21 9.19E-02 
Complement factor I  CFI 0.54 1.99E-03 0.65 4.30E-02 0.80 3.23E-02 0.76 9.15E-03 0.77 2.60E-02 
Nidogen-1  NID1 0.62 7.47E-03 0.56 2.18E-02 1.95 2.90E-06 2.04 2.26E-05 2.52 3.20E-03 
Complement factor H CFH 0.68 3.51E-03 0.51 1.81E-02 0.62 4.39E-02 0.68 1.06E-01 0.57 8.99E-03 
Cellular proteome and serum proteome 
Golgi membrane protein 1  GOLM1 0.40 1.17E-03 NSC NSC 3.77 1.30E-05 3.12 1.15E-04 2.38 1.67E-02 
Complement C3 C3 0.40 2.77E-05 NSC NSC 0.84 1.58E-01 0.76 6.50E-02 0.77 2.98E-02 
Fibronectin 1 FN1 0.47 5.21E-03 NSC NSC 0.55 6.57E-03 0.63 9.66E-02 0.66 1.94E-01 
Nucleobindin 1  NUCB1 0.47 8.30E-04 NSC NSC 3.40 1.69E-06 4.05 1.15E-04 3.08 9.49E-02 
Syndecan-1  SDC1 0.52 1.50E-02 NSC NSC 19.65 3.79E-02 24.53 2.50E-01 38.99 5.27E-01 
Complement C5  C5 0.54 7.61E-03 NSC NSC 0.74 3.22E-02 0.72 2.61E-02 0.68 3.92E-02 
Inter-alpha (Globulin) inhibitor H2 ITIH2 0.59 2.23E-02 NSC NSC 0.64 1.67E-03 0.63 1.83E-03 0.69 2.91E-02 




Mannan-binding lectin serine 
protease 1  
MASP1 0.62 3.68E-03 NSC NSC 0.77 2.77E-02 0.82 1.26E-01 0.92 8.09E-01 
Apolipoprotein C-I APOC1 0.64 3.61E-03 NSC NSC 0.43 1.69E-06 0.38 1.15E-04 0.48 6.60E-02 
Prolow-density lipoprotein receptor-
related protein 1  
LRP1 0.66 1.46E-03 NSC NSC 1.15 3.38E-01 1.28 5.58E-02 1.58 3.36E-02 
Beta-2-glycoprotein 1  APOH 0.69 1.58E-02 NSC NSC 0.38 1.27E-05 0.33 3.09E-05 0.42 5.54E-03 
Selenoprotein P  SEPP1 0.74 6.43E-03 NSC NSC 0.54 1.25E-05 0.51 3.94E-05 0.52 3.20E-03 
Lymphocyte cytosolic protein 1  LCP1 1.57 1.48E-02 NSC NSC 1.94 1.09E-04 2.10 1.25E-03 2.79 1.51E-02 
Heat shock cognate 71 kDa protein HSPA8 1.44 2.96E-03 NSC NSC 2.33 1.33E-04 2.52 3.23E-04 2.88 4.65E-03 
Endoplasmic reticulum chaperone 
BiP 
HSPA5 1.38 1.03E-02 NSC NSC 0.73 4.49E-03 0.87 3.97E-01 1.11 5.80E-01 
Plasma protease C1 inhibitor  SERPING1 0.40 9.56E-03 NSC NSC 1.21 1.68E-01 1.36 2.61E-02 1.38 2.63E-01 
Tropomyosin alpha-4 chain  TPM4 2.29 4.59E-02 NSC NSC 1.98 2.28E-02 1.57 2.35E-02 3.00 1.14E-01 
Secretome and serum proteome 
Apolipoprotein B  APOB NSC NSC 0.61 3.35E-02 0.64 4.92E-03 0.65 4.90E-03 0.66 1.52E-01 
Apolipoprotein C-III  APOC3 NSC NSC 0.11 3.39E-02 0.43 6.13E-05 0.52 2.85E-03 0.77 4.16E-01 
Monocyte differentiation antigen 
CD14  
CD14 NSC NSC 0.65 9.75E-03 1.66 2.27E-07 1.78 4.23E-06 1.46 1.72E-01 
Carboxypeptidase B2  CPB2 NSC NSC 0.68 2.50E-03 0.41 3.04E-08 0.41 2.33E-06 0.45 3.64E-04 
Coagulation factor X  F10 NSC NSC 0.57 1.34E-02 0.71 5.96E-03 0.75 1.61E-02 0.80 2.63E-01 
Coagulation factor XIII B chain  F13B NSC NSC 0.62 1.88E-02 0.58 7.37E-05 0.60 1.75E-04 0.72 7.71E-02 
C-1-tetrahydrofolate synthase, 
cytoplasmic  
MTHFD1 NSC NSC 1.75 9.84E-03 1.33 5.74E-01 2.33 3.88E-02 1.86 5.81E-01 
N-deacetylase/N-sulfotransferase 1  NDST1 NSC NSC 0.64 1.80E-02 0.53 5.60E-02 0.46 1.41E-02 0.37 4.53E-02 
Out at first protein homolog  OAF NSC NSC 0.41 3.60E-03 1.58 2.95E-04 1.72 1.92E-03 1.52 2.15E-01 
Alpha-1-acid glycoprotein 2  ORM2 NSC NSC 0.67 1.62E-02 1.32 6.74E-02 1.49 9.86E-03 1.27 3.85E-01 
Proprotein convertase 
subtilisin/kexin type 9  
PCSK9 NSC NSC 0.60 4.76E-03 1.59 1.37E-05 1.62 2.97E-03 1.54 6.07E-02 
Prenylcysteine oxidase 1  PCYOX1 NSC NSC 0.63 6.87E-03 0.58 7.14E-05 0.62 4.31E-03 0.60 2.97E-02 
Serum paraoxonase/ 
arylesterase 1  
PON1 NSC NSC 0.72 1.21E-02 0.78 4.59E-02 0.70 9.90E-03 0.61 3.10E-03 
Protein S isoform 2  PROS1 NSC NSC 0.63 4.25E-02 0.78 1.41E-02 0.77 1.71E-02 0.71 1.14E-02 
Alpha-1 antiproteinase SERPINA4 NSC NSC 0.64 8.58E-03 0.56 3.96E-05 0.55 1.64E-04 0.61 3.76E-03 






Figure 6.6 Proteins that were significantly altered in the proteome and secretome from 
DENV-2 infected Huh-7 cells and the serum proteome of DENV infected patients.  
(A)  Venn diagram shows the number of proteins that were significantly (P-value <0.05) 
altered ≥1.3 fold in DENV-2 infected Huh-7 cells or associated secretomes compared with 
mock cells or significantly (FDR <0.05) altered ≥1.2 in serum of DENV infected patients 
compared with healthy controls (B) The table lists 16 intersect proteins that were 
significantly altered in abundance in response to infection in DENV-2 infected Huh-7 
cells/secretomes and serum of DENV infected patients (C) STRING analysis of 16 
intersect proteins that were significantly altered in abundance in response to infection in 
DENV-2 infected Huh-7 cells/secretomes and serum of DENV infected patients. The 
STRING database was searched to analyse proteins that were commonly significantly 
altered in abundance in the proteome and secretome of DENV-2 infected Huh-7 cells and 
the serum proteome of DEN patients compared to controls. Nodes representing proteins 
associated with the significantly enriched GOBP “regulation of immune system process”, 
“platelet degranulation”, acute-phase response and “lipid transport” as well as the KEGG 
pathway of “Complement and coagulation cascades” and “Cholesterol metabolism” are 
shaded in purple, green, light blue, yellow, red and blue, respectively. The number of 
coloured nodes/ total proteins involved for each term and the FDR of each GO term are 





 Bioinformatic analysis of proteins that were commonly significantly altered in the 
proteomes and secretomes of DENV-2 infected Huh-7 cells and serum samples 
from DEN patients. 
 To identify proteins and cellular processes that were commonly dysregulated in 
Huh-7 cells and patient serum in response to DENV infection, 50 proteins that were 
significantly altered in the serum of DEN patients and the proteome and/or secretomes of 
Huh-7 cells were subjected to downstream bioinformatics analysis.  
DAVID analysis revealed that common proteins that were significantly altered in 
amount in Huh-7 cells and/or secretomes and in patient serum in response to infection were 
enriched in 12 clusters of proteins (Figure 6.7, Supplementary Table S6.4). The top three 
clusters were associated with the UP keywords “secreted/signal peptide”, the GOCC term 
“extracellular region” (GO:0005576) and the GOBP term “negative regulation of 
endopeptidase activity” (GO:0010951), respectively. Moreover, the common dysregulated 
proteins were also significantly enriched in proteins associated with the GOCC term “blood 
microparticle” (GO:0072562) and the GOBP terms “innate immune response” 
(GO:0045087) and “lipoprotein metabolic process” (GO:0042157).  
STRING analysis revealed that serum proteins that were altered in response to 
DENV-2 infection were associated with multiple significantly enriched GO terms. GOBP 
terms that were associated with DEN pathogenesis included “immune response” 
(GO:0006955), “platelet degranulation” (GO:0002576), “acute-phase response” 
(GO:0006953) and “post-translational protein modification” (GO:0043687) (Figure 6.8).  
Protein clusters were also associated with the enriched KEGG pathways “complement and 
coagulation cascades” (hsa04610) and “Cholesterol metabolism” (hsa04979).  
In addition, 16 proteins that were significantly altered in all data sets (Huh-7 
proteome and secretome and serum proteome) were also analyzed by STRING analysis. 
The results revealed that these 16 proteins were associated with significantly enriched 
GOBP terms that were also related to DENV infection including “regulation of immune 
system process” (GO:0002682), “platelet degranulation” (GO:0002576), “acute-phase 




pathway terms “Complement and coagulation cascades” (hsa04610) and “Cholesterol 








Figure 6.7 DAVID analysis of proteins that were commonly altered in abundance in the 
cellular proteome and/or secretome of DENV-2 infected Huh-7 cells and the serum 
proteome. 
 Proteins that were significantly (FDR < 0.05) altered in amount by ≥ 1.2 fold in DENV-
infected patient serum compared to healthy controls and significantly (P-value < 0.05) 
altered (≥ 1.3 fold) in the proteome and/or secretomes of DENV-2 infected Huh-7 cells 
were analysed using the DAVID database. The GO accession numbers/terms that were 
significantly enriched and the properties of the corresponding protein clusters are shown. 
The GES of significantly enriched GO terms are plotted as bar graphs with the 
corresponding GES score shown. The shading shows the type of GO term (GOBP, GOCC 
or GOMF), UP keywords, Interpro term or KEGG pathway. The number of proteins in 
each cluster (count), number of proteins associated with each GO term/total number of 








Figure 6.8 STRING analysis of cellular proteins that were altered in abundance in the 
cellular proteome and/or secretome of DENV-2 infected Huh-7 cells and the serum 
proteome. 
 The STRING database was searched to analyse proteins that were significantly (FDR < 
0.05) altered in amount by ≥ 1.2 fold in DENV-infected patient serum compared to healthy 
controls and significantly (P-value < 0.05) altered (≥ 1.3 fold) in the proteome and/or 
secretome of DENV-2 infected Huh-7 cells. Nodes representing proteins associated with 
the significantly enriched GOBP “platelet degranulation”, “immune response”, “acute-
phase response”, and “post-translational protein modification” as well as the KEGG 
pathway “Complement and coagulation cascades” and “Cholesterol metabolism”  are 
shaded in yellow,  green, purple, light blue, red and blue, respectively. The number of 
coloured nodes/ total proteins involved for each term and the FDR of each GO term are 




  Effect of DENV infection on in vitro and in vivo changes of the 
complement and coagulation cascades  
The integrated analysis of the proteome and secretome data from DENV infected 
Huh-7 cells and the serum proteomic data from DENV infected patients, and the 
subsequent downstream bioinformatic analysis, identified proteins involved in 
“complement and coagulation cascades” to be commonly dysregulated in response to 
DENV infection. Thus, these proteins, highlighted in the KEGG pathway “complement 
and coagulation proteins” (Figure 6.9.) were a focus of further investigation.  
In terms of the “coagulation cascade”, there were common alterations in proteins 
involved in both the coagulation and fibrinolysis systems. The decrease in the cellular level 
of all FBG subunit proteins and F2 in response to DENV infection could explain their 
decrease in the cell secretome which also correlated with the decreased amounts detected 
in the serum from DEN patients compared with healthy individuals. Proteins involved in 
the anticoagulation system including SERPINC1, heparin cofactor II (HCII or SERPIND1) 
and protein C inhibitor (PCI or SERPINA5) were also altered in the Huh-7 cell model 
and/or in the serum proteome. In terms of proteins involved in the complement system, 
DENV infection effected proteins involved in all three pathways (classical, alternative and 
lectin) both in vitro and in vivo.  
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CD46 molecule(CD46), CD55 molecule (Cromer blood group)(CD55), CD59 molecule(CD59), alpha-2-macroglobulin(A2M), 
bradykinin receptor B1(BDKRB1), bradykinin receptor B2(BDKRB2), carboxypeptidase B2(CPB2), coagulation factor II, thrombin 
receptor(F2R), coagulation factor II, thrombin(F2), coagulation factor III, tissue factor(F3) ,coagulation factor IX(F9), coagulation factor 
V(F5), coagulation factor VII(F7), coagulation factor VIII(F8), coagulation factor X(F10), coagulation factor XI(F11), coagulation 
factor XII(F12), coagulation factor XIII A chain(F13A1), coagulation factor XIII B chain(F13B), complement C1q A chain(C1QA), 
complement C1q B chain(C1QB), complement C1q C chain(C1QC), complement C1r(C1R), complement C1s(C1S), complement 
C2(C2), complement C3(C3), complement C3a receptor 1(C3AR1), complement C3b/C4b receptor 1 (Knops blood group)(CR1), 
complement C3d receptor 2(CR2), complement C4A (Rodgers blood group)(C4A), complement C4B (Chido blood group)(C4B), 
complement C5(C5), complement C5a,receptor 1(C5AR1), complement C6(C6), complement C7(C7), complement C8 alpha 
chain(C8A), complement C8 beta chain(C8B), complement C8 gamma chain(C8G), complement C9(C9), complement component 4 
binding protein alpha(C4BPA), complement component 4 binding protein beta(C4BPB), complement factor B(CFB), complement factor 
D(CFD), complement factor H(CFH), complement factor I(CFI), fibrinogen alpha chain(FGA), fibrinogen beta chain(FGB), fibrinogen 
gamma chain(FGG), kallikrein B1(KLKB1), kininogen 1(KNG1), mannan binding lectin serine peptidase 1(MASP1), mannan binding 
lectin serine peptidase 2(MASP2), mannose binding lectin 2(MBL2), plasminogen activator, tissue type(PLAT), plasminogen activator, 
urokinase receptor(PLAUR), plasminogen activator, urokinase(PLAU), plasminogen(PLG), protein C, inactivator of coagulation factors 
Va and VIIIa(PROC), protein S (alpha)(PROS1), serpin family A member 1(SERPINA1), serpin family A member 5(SERPINA5), 
serpin family C member 1(SERPINC1),serpin family D member 1(SERPIND1), serpin family E member 1(SERPINE1), serpin family 
F member 2(SERPINF2), serpin family G member 1(SERPING1), thrombomodulin(THBD), tissue factor pathway inhibitor(TFPI), von 
Willebrand factor(VWF) 
Figure 6.9 Complement and coagulation cascade pathways. 
Proteins that significantly (P-value < 0.05) altered (≥ 1.3 fold) in DENV-2 infected Huh-7 
cells and associated secretomes compared to mock infected cells as well as serum proteins 
that were significantly (FDR < 0.05) altered (≥1.2 fold) in DENV infected patients 
compared to healthy controls are identified on the KEGG pathways “complement and 
coagulation cascades (KEGG pathway term hsa04610). The yellow, purple and black stars 
indicate proteins that significantly altered in proteomes, secretomes and serum proteome, 
respectively in response to DENV-2 infection. SERPINC1, a protein which decreased, but 





 In this chapter, the proteomic analysis of serum from a cohort of DENV infected 
patients and healthy individuals was performed. In total, 216 serum proteins were 
significantly altered in abundance in response to DENV infection and two proteins (CRP 
and APOC2) were significantly altered which correlated with disease severity. The serum 
proteome was then compared with cellular proteomes and secretomes from HEK293T and 
Huh-7 cell models to identify common protein responses to DENV infection.  
Analysis of serum and other samples from such a cohort can provide invaluable 
insight into the global protein changes in the blood in response to DENV infection. A 
significant strength of the human cohort analysed in this study is the large age range and 
disease severity coverage it achieved. However, owing to the logistics of sample collection 
and processing, analysis of this cohort does carry certain caveats which are presented 
below. The nature of retrospective studies using archived clinical specimens meant that 
some data, both clinical and relating to basic characteristics, were not available or not 
collected. Moreover, age matching was not complete between healthy and DENV infected 
individuals. Additionally, over half of the patients with SD (five of nine cases) were 
diagnosed using a positive IgM test result but had a negative DENV RT-PCR result. This 
was not unexpected as SD typically manifests after viremia or NS1 antigenemia subside.  
Some aspects of the serum proteomic analysis are worth mentioning to clarify the 
interpretation of the results. First is the effect of ALB and IgG depletion, which is an 
essential part of serum/plasma proteomics sample preparation. ALB and IgG were depleted 
but due to varying starting concentrations and depletion efficiencies in different samples it 
is challenging  to normalise the total amounts of protein in each sample. This step might 
also result in the loss of proteins that bind to ALB (Jacobs et al., 2005). Both endogenous 
and exogenous (drug and toxin) molecules/substances bind with ALB in serum, the 
endogenous molecules included hormones, ions (such as calcium and copper), fat-soluble 
vitamins, fatty acids and lipoproteins (Throop et al., 2004). Furthermore, the effect of DEN 
on ALB as a key volume regulator and negative APP cannot be interpreted because it was 




Importantly, when measuring the levels of proteins involved in coagulation, blood 
samples are collected into tubes containing anticoagulants to prevent clot formation, then 
cells are removed by centrifugation to produce plasma. By contrast, in serum preparation, 
blood is left around 30–60 mins at RTemp for clot formation, before centrifugation, to 
remove the clot and cells. Therefore, coagulation factors are consumed during clot 
formation in the preparation of serum. Because coagulation factors such as FBG, 
SERPINA1 and alpha-2-macroglobulin (A2M) are present in high abundance in whole 
blood (Kuscuoglu et al., 2018), the coagulation proteins may still be present in serum after 
clot formation. Thus, when analysing serum using proteomics, results pertaining to 
coagulation proteins should be interpreted with caution. To help solve this problem, the 
results from the serum proteomic analysis in this study were compared with the results of 
available clinical studies primarily designed to study complement and coagulations 
proteins in DENV infected patients (discussed in the next section). On the other hand, the 
levels of complement proteins can be analysed in either serum or plasma samples however 
the ‘normal range’ of these proteins differs between the two sample types (Yang et al., 
2015).  
Finally, other factors including gender, genetics, nutritional status and co-
morbidities as well as previous or current medications are likely to affect the serum 
proteomic profiles of all sampled individuals. However, due to lack of data about other 
mentioned factors, only age and gender could be used for interpretation. All these aspects 
(serum effects and available demographic data) were taken in account in the interpretation 
of the serum proteomic results presented here.  
Proteomic analysis of serum samples from DENV infected patients 
The major serum proteins dysregulated in response to DENV infection identified 
in this study are associated with processes relating to “complement and coagulation” 
proteins and “lipoproteins/lipid transport” proteins. The results presented in this thesis were 
compared with previous studies that analysed blood samples from DENV infected patients 
compared with healthy controls (summarised in Table 6.1). In terms of methodology, four 
of these studies conducted 2D-DIGE followed by MS/MS (Ray et al. 2013; Albuquerque 




iTRAQ based proteomic analysis (Jadhav et al., 2017; Kumar et al., 2012). In comparison 
to these previous serum/proteomic studies, the data presented in this thesis represents the 
biggest non-pooled serum study conducted to date. The disadvantage of pooling specimens 
is that outlier values can skew the results and information pertaining to with-in group 
variation is lost (Geyer et al., 2017). Moreover, our use of advanced TMT labelling LC-
MS/MS enabled a substantially higher resolution proteomic analysis, enabling the 
detection of a greater number of DENV induced protein alterations than in previously 
published studies.  
The overlap of proteins which were identified to be altered in abundance in 
response to DENV infection in different studies is shown in Figure 6.10 and listed in Table 
6.7.  The study of Huy et al., (Huy et al., 2013) was excluded from this comparison as they 
reported only proteins detected in CIC for each group of patients but quantification data 
was not provided. Overall, proteins with an altered abundance in response to DENV 
infection that were commonly detected between our study and other studies are involved 
in complement coagulation cascades and lipid metabolism including; FGG, F2, C3, 
SERPINC1, alpha 1-antichymotrypsin (SERPINA3), C1 inhibitor (SERPING1), APOA1, 
APOA4 and APOB.  
Overall the majority of the proteins commonly altered in the “complement and 
coagulation” pathways in this study and previous studies change in the same direction. A 
similar decrease in F2 was reported in this study and the study of Albuquerque et al. 
(Albuquerque et al., 2009). Similarly, SERPINA3 and SERPING1 were increased in DEN 
patients in this study and previous studies. C3 was decreased in this study and the study of 
Albuquerque et al. but increased in the study of Ray et al. (Ray et al., 2012). Similar 
increases in C9 were observed in this study and the study of Kumar et al., (Kumar et al., 
2012). Opposite results were reported for both FGG and SERPINC1, these two proteins 
were decreased in this study but increased in other previous studies. However, the results 
of this study, which were more similar to clinical studies primarily done to study these two 
proteins in DEN patients, may be more accurate (discussed later). However, SERPINA1, 
which was not significantly decreased in our data, was found to be significantly altered in 
DENV infected patients in four other studies (Ray et al. 2013; Thayan et al., 2009a; Jadhav 




SERPINA1 while the other three studies reported significant increases in SERPINA1 












Figure 6.10 Comparison of proteins altered in DENV infected patients compared to healthy 
controls from published studies and the data presented in this thesis.  
The proteins that were significantly (FDR < 0.05) increased and decreased (≥1.2 fold) in 
the serum of DENV infected patients compared to healthy persons in this study were 
compared with reported changes in previous serum/plasma proteomic studies of DENV 
infected patients using the gene name. The numbers of proteins that were commonly 
detected between these studies are showed and the total number of differentiated proteins 





Table 6.7 A list of serum proteins commonly altered in response to DENV infection 
in this study and other studies 
Study Kumar et 
al., 2012 
Albuquerque 









no. of common altered 
proteins/total proteins altered in 
the study 
















































The observed significant decreases in complement and coagulation proteins in 
serum from infected individuals compared to controls in our study is in line with data from 
other clinical studies previously done on DENV patients with standard protocols for blood 
collection to study complement and coagulation proteins (Wills et al., 2002, Bokischet et 
al., 1973). The significant decreases in FBG, protein C (PROC), protein S (PROS1) and 
SERPINC1 in patients with DEN compared to healthy patients presented in this study is 
similar to previous findings. Specifically, Wills et al., prospectively studied the levels of 
coagulation proteins in plasma samples from children with DSS at the time of illness 
compared with one month after illness (used as a control) (Wills et al., 2002). Similarly, 
decreases in C1q, C3, C5 and C8 but increases in C9 were also observed in complement 
samples from children with DHF or DSS compared to healthy control children (Bokisch et 
al., 1973). By contrast, Viktor et al., (Viktor et al., 1973) observed a reduced abundance 
of C2 and C4 in DHF patients was not observed in this study. Moreover, decreases in 
plasma FBG levels but an increase in fibrinogen degradation product (FDP) were also 
demonstrated in DHF patients compared to healthy children in the study of Bokisch et al., 
(Bokisch et al., 1973).   
Similar decreases in lipoproteins including APOA1, APOA4, APOB and APOC 
were observed in DENV infected patients compared with healthy individuals in this study 
and all previous studies. However, the interpretation of lipoproteins as potential biomarkers 
for DEN has some limitations. Firstly, certain types of lipid sub-classes such as cholesterol 
and triglycerides (TG) should be measured using samples collected from individuals in a 
fasting state  (≥ 9 h); however, collection of such samples from DENV infected patients 
during their first presentation is not possible. Importantly, comorbidities such as 
hyperlipidaemia and cardiovascular diseases directly affect baseline lipid profiles. The high 
APOB levels and a low APOA1 level were proposed to be a strong predictor of ischemic 
heart diseases and mortality (Walldius et al., 2001). Moreover, lipid lowering agents which 
are commonly used nowadays may modulate the results of lipid profiles. Finally, as this 
study was retrospective in nature, data describing comorbidities and medications as well 
as baseline lipid profiles were not available. As such the dysregulation of lipoproteins 




The functional groups of proteins, biological processes and pathways changed in 
response to DENV infection identified in this study were also reported in previous studies. 
In the iTRAQ-based serum proteomic study of DEN patients compared with healthy, the 
most common functional group of proteins was the acute phase response, followed by 
serpin group proteins, lipid transporters and complement factors (Kumar et al., 2012). A 
study that analysed virus-enriched fractions from pooled plasma of DF and SD patients by 
LC-MS/MS identified the top enriched pathways as “acute phase response signalling” 
followed by, “LXR/RXR activation pathway”, “complement system” and “coagulation 
system” (Fragnoud et al., 2105). Moreover, proteins associated with the KEGG pathway 
“complement and coagulation cascades” were significantly enriched in patients infected 
with DENV compared with healthy controls in non-pooled serum proteomic studies (Ray 
et al., 2012, Jadhav et al., 2017). 
Apart from clinical parameters such as Hct, Plt and WBC count and liver enzyme 
levels, CRP has been proposed as a potential protein biomarker to distinguish DEN from 
other OFI.  CRP, a liver APP, is an inflammatory marker widely used in clinical practice; 
moreover, the RDTs for CRP is available.  As a positive APP, CRP is elevated above the 
normal range in all infection including DEN. Many studies have compared clinical and 
laboratory findings to distinguish between disease caused by DEN and OFI and reported 
that the CRP level in DEN was significantly lower than infections of other origins including 
leptospirosis (Le Turnier et al., 2019) and malaria (Kutsuna et al., 2014). One prospective 
study in Thailand proposed CRP levels as an indicator of viral vs bacterial infection, with 
a greater reduction in CRP observed for the former compared with the latter 
(Wangrangsimakul et al., 2018). Whilst the normal level of serum CRP in healthy patients 
is < 3 mg/L, values of mean IQRs for CRP in DENV infected patients of 5.1 (IQR 2.7–9.3) 
and 12.5 (6.0–26.0) respectively have been reported (Kutsuna et al., 2014; 
Wangrangsimakul et al., 2018). This study also detected significant increases in CRP 
abundance in DENV infected patients when compared with healthy controls. 
Serum proteins correlate with disease severity  
 As an inflammatory marker, CRP was also previously proposed as a predictive 




in serum from patients with SD compared to other DEN patients was identified in this 
study. In contrast, analysis of CRP levels in adult DEN patients demonstrated a 
significantly higher level of CRP in severe compared with non-severe DEN in both the 
febrile and critical phases (Chen et al., 2015). Another study, which compared clinical and 
laboratory findings to predict severity of DEN in children, reported no difference in CRP 
in different severities of the disease (Prabhavathi et al., 2017). The contradictory results 
may result from differences in the age range of sampled patients between these studies. 
This is supported by results of a study of clinical and laboratory findings which included 
both children and adult DEN patients and revealed significantly lower CRP in children 
compared to adults (Ho et al., 2013). 
Decreases in APOC2 in response to DENV infection were found both in vivo and 
in vitro (Huh-7 cells and the associated secretome). There is only one in vivo study which 
previously reported changes in APOC2 in DENV. An analysis of sera from DF, DHF and 
healthy individuals by iTRAQ/LC-MS/MS also reported a significant decrease in APOC2 
abundance in samples from DF patients compared to healthy controls in the acute phase of 
the disease (Kumar et al, 2012). However, APOC2 is a component of very low density 
lipoproteins (LDL) and chylomicrons; thus, fasting blood is required for reliable 
measurement.  Further investigation of the role of APOC2 as a biomarker for DENV 
diagnosis and predicting disease severity are required.  
Comparative analysis of proteins dysregulated in both the proteome and secretome from 
HEK293T cells and serum in response to DENV infection. 
Whilst there were hundreds of proteins that were commonly detected in the 
proteome and secretome of  HEK293T cells and serum samples, only four cellular and one 
secreted protein were significantly altered in response to DENV infection, both in vitro and 
in vivo. The cellular proteins that were significantly altered in both HEK293T cells and 
patient sera in response to infection were associated with the UPR.  
 As mentioned in Chapter 4, HSPA5 and CALR are ER chaperones that were 
commonly found to be increased in response to DENV infection in many cell-based 
proteomic studies (Pando-Robles et al., 2014; Chiu et al., 2014; Chiu, 2014) and an 




and CALR has not been reported in a clinical study. The data presented here therefore 
constitutes the first reported alteration of these two proteins in clinical specimens in 
response to DENV infection. The significant increase in the abundance of CALR in 
response to infection in DENV-2 infected HEK293T cells correlates with an increase in 
the abundance of CALR in the sera of DEN patients of all severities compared to the 
healthy controls. However, whilst HSPA5 was increased in various DENV-2 infected cell 
lines (Pando-Robles et al., 2014; Chiu et al., 2014) including those used in this study, it’s 
abundance was significantly decreased in serum from patients with DEN w/o WS 
compared to healthy controls (and not significantly decreased in DEN w WS and SD 
compared to controls). The use of HSPA5 and CALR as biomarkers for diagnosis warrants 
further investigation as well as analysis of the mechanism driving the opposing changes in 
protein abundance between cellular and serum HSPA5 levels in response to DENV 
infection. 
However, other proteins that were significantly enriched in serum in response to 
DENV infection and associated with GO terms such as “complement and coagulation 
cascades”, “lipid metabolism” and “immune response” were either not detected or not 
significantly enriched in HEK293T cells infected with DENV compared to mock controls. 
This may be because HEK293T cells are not major contributors to haemostatic and lipid 
protein synthesis. 
As a part of the histone complex, HIST1H4L, is a major protein component of 
chromatin and plays a role in gene regulation.  HIST1H4L was significantly increased in 
response to DENV infection in both the secretome from HEK293T cells and sera. To date 
there is only a single study analyzing the interplay between histones and DENV infection. 
An interaction between the DENV C protein and all types of histones (analysed by tandem-
affinity purification and Co-IP) and co-localization between DENV C protein and histones 
was demonstrated using DENV-2 infected Huh-7 cells (Colpitts et al., 2011). Moreover, 
the DENV C protein was proposed to act as a histone mimic, forming heterodimers with 
core histones and binding with DNA (Colpitts et al., 2011). This may explain the increase 




Taken together, these results show that HEK293T cells may be used as a model for 
studying changes in general host cellular pathways such as the UPR or ER in response to 
DENV infection in vivo. In contrast, they have limited utility for studying processes such 
complement and coagulation pathways, lipid metabolism and immune response proteins in 
vivo. Unfortunately, the low number of significantly altered proteins in the secretomes of 
DENV-2 infected HEK293T cells detected in this study correlates poorly with the serum 
proteomic results. Thus, the relevance of the HEK293T cell secretomes study to DENV 
infection in vivo is inconclusive.  
Comparative analysis of proteins that are dysregulated in the proteome and secretome from 
Huh-7 cells and serum in response to DENV infection. 
Bioinformatic analysis revealed that the proteins that were significantly altered in 
response to DENV infection in both the serum from infected patients and the proteome 
and/or secretomes of Huh-7 cells were associated with the GO terms ‘complement and 
coagulation”, “lipid metabolism” as well as “immune response”. This demonstrated the 
usefulness of DENV infected liver cell models for the study of pathogenesis and 
therapeutic intervention in these processes/pathways.  
Among the 50 serum proteins (listed in Table 6.6) that were significantly altered in 
response to DENV infection in both the serum of patients and the proteome and/or 
secretome of liver cells, the majority (36 of 50 proteins) were changed in the same direction 
(decreased in cells and/or secretome and serum). Most of these proteins were involved in 
“complement and coagulation cascades” and “lipid metabolism”. The effect of DENV on 
the liver cells, as the source of serum proteins (Kuscuoglu et al., 2018), may explain in part 
the pathogenesis of DENV in vivo in relation to “complement and coagulation” and “lipid 
metabolism” processes.  
There were 13 proteins that were significantly decreased in liver cells and/or the 
associated secretome but increased in serum in response to DENV infection. This may be 
due to these proteins being synthesized by other cell types; for example, ORM1 and ORM2. 
These proteins act as APPs and transport proteins; ORM is mainly synthesized in the liver 




to inflammation (Taguchi et al., 2013). Similar to the results obtained from HEK293T cells, 
HSPA5 was increased in the proteome but decreased in the serum proteome. 
The main group of lipids that are dysregulated in response to DENV infection in 
both Huh-7 cells and clinical specimens are the apolipoproteins, APOA1, APOC and 
APOB. The liver and intestine are the main source of apolipoproteins. The apolipoproteins 
are the major component of lipoproteins and function as carrier molecules for lipids in 
blood and the lymphatic system (Dominiczak and Caslake, 2011). The concentration of 
apolipoproteins are regulated by production (eg in APOA2) or degradation (eg in APOB 
and APOA1) (Dominiczak and Caslake, 2011). Most clinical studies focused on using 
serum lipoproteins to predict disease severity. Only one study reported significant 
decreases in LDL and HDL but increased TG and VLDL in DEN patients compared with 
healthy controls (Marin-Palma et al., 2019). The decreases in serum HDL and LDL 
reported in Marin-Palma’s study correlates with decreases of APOA1, APOC and APOB 
in both clinical specimens and Huh-7 cells because APOA1 and APOC are the components 
of HDL while APOB is a component of LDL. However, the increase of VLDL in Marin-
Palma’s study (Marin-Palma et al., 2019) does not correlate with the decreases in APOA4, 
APOC and APOB (which are components of VLDL) in the sera and/or Huh-7 cells in this 
study. Furthermore, the limitations mentioned earlier especially age and the race of subjects 
in the study should be considered in the interpretation and comparison of the results of this 
group of proteins.  
The focus of this thesis on the role of coagulation cascades was informed by the 
following. Firstly, it was one of the more enriched biological processes among proteins 
that were dysregulated in response to infection in both in vivo and in vitro studies. FBG is 
the most important element in formation of the fibrin clot and plays an important role in 
PLT activation. Moreover, SERPINA1 is strongly bound within the fibrin clot (Talens et 
al., 2013). F2 plays an important role in the activation of FBG to fibrin and coagulation 
factor XIII (F13) also stabilizes clot formation. On the other hand, the important 
anticoagulants that regulate the balance of clot formation are SERPINC1, PROC and 
PROS1. The results of this study demonstrate for the first time that decreases in the cellular 




secretion of these proteins which correlates with the findings obtained analyzing serum 
from DEN patients. Secondly, dysregulation of coagulation cascades due to an imbalance 
between coagulation and fibrinolysis processes may play a key role in the pathogenesis of 
infectious diseases including DEN (Gorp et al., 2002). A deficiency in coagulation factors 
and thrombocytopenia result in coagulopathy and bleeding, a characteristic feature of SD. 
Additionally, excessive clots in DIC (which are also found in DEN) consume the 
coagulation factors which can lead to aggravation of the coagulopathy. Finally, some of 
the coagulation proteins including FBG, F2, SERPINA1 and SERPINC1 are also liver 
APPs. The dysregulation of APPs in DENV infected cells was demonstrated in this study 
and previous proteomic studies, as discussed before.  
Although a decrease in complement and coagulation proteins has been previously 
demonstrated as a key feature of DEN pathogenesis in vivo, it was believed to result from 
increases in its consumption and/or loss from leakage processes. The increase in 
consumption of coagulation factors was confirmed by an increase in DIC (Srichaikul et al., 
1977; Bokisch et al., 1973). Apart from increased in consumption, Wills et al., studied 
plasma levels and urinary clearance of proteins including ALB, IgG and SERPINC1 in 
DSS and reported reductions in the plasma concentrations of all proteins with increased 
fractional clearance (Wills et al., 2004). Thus, a decrease in the cellular levels of 
complement and coagulation proteins, with a concomitant decrease in their secretion from 
hepatocytes, may play a role in the pathogenesis of DEN and merits further analysis.  
In summary, the use of an advanced serum proteomic approach employing 10plex-
TMT labelling of non-pooled samples and LC-MS/MS for the analysis of a large DEN 
patient cohort, encompassing all disease severities, enabled detection of 216 serum proteins 
that were significantly altered in response to DENV infection. This group of proteins were 
associated with the biological processes “complement and coagulation cascades”, 
“cholesterol metabolism”, “immune response”, “acute-phase response” and UPS. 
Furthermore, CRP and APOC2 were identified as proteins that correlated with more severe 
disease forms. DENV infected Huh-7 cells represent a good model for studying 
complement and coagulation proteins, APPs as well as lipoproteins in vivo. The 




represent a key step in pathogenesis and was further investigated in the studies described 







  FB G A N D  A PPS  I N  D E N V  
I N FE C TE D  LI V E R  C EL L S  
  Introduction 
 The studies described in the previous chapters showed that the dysregulation of 
FBG and other APPs that occurred in Huh-7 cells in response to DENV infection correlated 
well with the changes that occurred in the levels of these proteins in the serum of DEN 
patients. Furthermore, the in vitro results agreed with other studies that reported an 
enrichment of APPs among dysregulated proteins in the blood of DEN patients (Kumar et 
al., 2012; Brasier et al., 2015). Thus, the dysregulation of FBG and APPs that occurred in 
Huh-7 cells during DENV infection was further investigated to understand the mechanisms 
involved and provide a greater understanding of DEN pathogenesis.  
  Fibrinogen (FBG): structure, function and regulation. 
 FBG consists of two copies of three peptide chains Aα, Bβ, and ɤ encoded by the 
FGA, FGB and FGG genes respectively (Fish and Neerman-Arbez, 2012). The FBG 
subunits are synthesised in hepatocytes and secreted into the blood as a hexamer. FBG is 
an abundant plasma protein with a normal concentration of 1.5-3.5 g/L (almost equal to 
that of albumin) and a half-life of approximately four days (Kuscuoglu et al., 2018). In clot 
formation, thrombin (active form of F2) and F13 cleave FBG in to fibrin. Crosslinking of 
fibrin with PLT forms a clot to stop bleeding. In fibrinolysis, the clot is dissolved by 
plasmin into fibrin degradation products (FDPs). Apart from its role in haemostasis, FBG 
plays a major role in wound healing and inflammation, acting as an APP. As a pro-
inflammatory mediator, FBG interacts with vascular endothelial cells to modulate 
permeability, PLT to promote PLT aggregation as well as monocytes and macrophages to 
induce the release of cytokines (Davalos and Akassoglou, 2012).  
 The regulation of FBG gene expression in the basal and acute phase response are 
summarized in Figure 7.1. In the basal state, hepatocyte nuclear factor 1 (HNF1) and 
CAAT/enhancer-binding protein (CEBP) bind to the FGA, FGB and FGG gene promotors 




factor 4α (HNF4A) regulates the transcription of hepatocyte genes including HNF1, 
apolipoproteins and coagulation factors. Apart from the FBG genes, HNF4A also regulates 
SERPINA1, SERPINC1 and angiotensinogen (AGT) (Kalsheker et al., 2002; Gonzalez et 
al.2008). Studies using mouse models have shown that HNF4A controls F5, F9, F11, F12 
and F13B transcription (Inoue et al., 2006). MicroRNAs (miRNA) are involved in the post-
transcriptional regulation of the FBG genes; for instance, many miRNA including miR-
29a, miR-218, miR-409-3p miR-let7e and miR-let7c down-regulate FBG  while a smaller 
number including miR769-5 and miR-106a up-regulate FBG protein production (Fort et 
al., 2010). Furthermore, miR-18a, miR-629 and miR-24 are involved in the regulation of 
HNF4A expression (Babeu and Boudreau, 2014).  
 In the acute phase response, cytokines modulate transcription of the FBG genes. 
The main regulator is interleukin (IL) 6. IL-6 activated signal transducer and activator of 
transcription 3 (STAT3) phosphorylation leads to increased transcription of the FBG genes 
(Fish and Neerman-Arbez, 2012). Whereas IL-1β down-regulates FBG gene transcription 
by prolonged STAT3 phosphorylation (via NFkB). Glucocorticoids (GC) up-regulate FBG 
transcription via both the glucocorticoid receptor (GR) and by indirectly reducing negative 
control of IL-6.  
The synthesis of fibrinogen β chain takes longer than the other chains and is the 
rate limiting step of FBG production (Redman and Xia, 2001). After translation, all chains 
of FBG translocate to the ER lumen for assembly. ER chaperones including HSPA5 
contribute to the folding and assembly of FGB (Redman and Xia, 2001). Any unassembled 
FBG chains are degraded. A study investigating FGB stability by radiolabeling HepG2 
cells expressing single FBG chains found that the Aα-ɤ chains were degraded via 
















Figure 7.1 Regulation of FBG transcription in the basal state and acute phase response.  





  Hepatic APPs and IL-6 
APPs are defined as plasma proteins that are altered in concentration by at least 
25% in response to inflammatory disorders (Morley and Kushner, 1982). Hepatocytes are 
the main cells that produce APPs in response to stimuli (Gabay and Kushner, 1999). 
Hepatic APPs contain many categories of proteins including secreted pathogen recognition 
receptors (e.g. CRP, soluble CD14 and serum amyloid P), proteinase inhibitors (e.g. 
SERPINA1, A2M), complements, proteins involved in iron homeostasis (hepcidin and 
transferrin), transport proteins (ALB, HP and CP) and coagulation proteins (e.g. FBG, F2, 
plasminogen (PLG) and PROC) as well as other unclassified proteins (e.g. AGT and 
fibronectin) (Gabay and Kushner, 1999; Bodes et al., 2012). Under the stress from 
infection, inflammation, injury or during tumor growth, cytokines released from 
macrophages, monocytes and Kupffer cells (liver macrophages) modify the production of 
liver APPs. The main cytokines that regulate liver APPs are IL-6and IL-1β. Liver APPs 
can be classified into two subclasses (Bode et al., 2012). Class I APPs are synergistically 
regulated by IL-1β and IL-6, and include CRP, HP and SAA. Whereas Class II APPs 
include FBG and A2M and are mainly regulated by IL-6. Furthermore, the regulation of 
APPs also depends on the nature of the inflammatory stimuli and other hormones, 
particularly glucocorticoids and insulin (Bode et al., 2012). 
APPs are also classified by their change in concentration in response to stress into 
positive (increased in level) and negative (decreased in level) APPs. Examples of positive 
APPs are CRP, FBG, F2, SERPINA1, HP, CP, serum amyloid A (SAA) and complements 
while negative APPs include ALB, SERPINC1, transferrin (Jain et al., 2011). 
In in vitro experiments, IL-6 has been added to hepatocytes in various doses 
(ranging from 5-100 ng/ml final concentration) and treatment times (6-24 h) to study the 
APP response (Ray et al, 2000; Ait-Goughoulte et al., 2009; Brock et al., 2011). However, 
limited studies have been done on the effect of IL-6 treatment on flavivirus infection. In a 
study on YFV, pre-incubating PH5CH8 hepatocytes with 5 ng/ml of IL-6 for five days 
before infection resulted in a decrease in viral titre (Woodson and Holbrook, 2011) and an 




Unfortunately, the effect of IL-6 on DENV infection, either pre- or post-infection, and its 
effect on liver APP production during DENV infection are unknown.  
  FBG and APPs in DEN 
A decrease in FBG amount in peripheral blood has been associated with DEN 
severity (Mairuhu et al., 2003) and suggested to arise as a result of increased consumption 
by DIC processes (Sricahiakul et al., 1977). Nevertheless, the overt process of DIC was 
not detected by clinical or laboratory studies in all patients with severe DEN (Wills et al., 
2002). Increases in IL-6 and IL-1β concentrations in the blood of DENV infected patients 
has been reported (Bozza et al., 2008; Priyadarshini et al., 2010). Thus, increases in the 
production of FBG and other positive APPs from hepatocytes are expected. Surprisingly, 
all FBG chain were found to be decreased in liver cells in response to DENV infection in 
this study and previous proteomic studies investigating DENV infection of Huh-7 liver 
cells (Chiu, 2014; Yousuf, 2016). Dysregulation of liver production and secretion of FBG, 
an important multifunctional protein that potentially plays a key role in DEN pathogenesis, 
warrants further investigation. A better understanding of the mechanisms underlying these 
processes could potentially lead to an increased understanding of DEN pathogenesis and 
identify targets against which therapeutics could be designed.  
Apart from FBG, changes in the amounts of other APPs including SERPINA1, 
SERPINC1, CRP and HP in the serum/plasma of DEN patients have been reported. 
However, there are some inconsistencies between studies. For example, both increases and 
decreases in the serum/plasma levels of CRP and SERPINA1 have been reported (as 
discussed in Chapter 6). SERPINC1 has been proposed as a biomarker for both diagnosis 
of DEN and predicting severe disease based on previous proteomic analyses of 
serum/plasma from patients with DEN, but with inconsistent results between studies. A 
decrease in SERPINC1 was found in the serum proteome of DEN patients compared with 
healthy controls in the investigation presented in Chapter 6, whereas increased levels were 
found in the previous serum proteomic studies comparing DEN patients to healthy controls 
(Kumar et al., 2012).  In an iTRAQ-based plasma proteomic study comparing children 
with SD to those with DEN with WS (Nhi et al., 2016), SERPINC1 was increased in 




children with SD compared with DF (Fragnoud et al., 2012). Although HP was not 
significantly changed in the sera of DENV infected patients compared with healthy patients 
in this study (as described in Chapter 6), HP was significantly increased in DENV infected 
patients compared with healthy controls in a previous serum proteomic analysis (Kumar’s 
et al., 2012). Furthermore, changes in the levels of APPs have predominantly been reported 
in vivo studies and there is limited data about changes that occur in liver cells.  
Therefore, this chapter focused on examining the dysregulation of liver APPs at the cellular 
level using cultured cell lines. The mechanisms underlying the changes were explored.  
 
Results  
According to the results presented in Chapter 5, the decreased amounts of FGA, 
FGB and FGG and other APPs in the secretome of DENV infected Huh-7 cells correlated 
with a decrease in intracellular levels. Therefore it was decided to study the mechanism/s 
underlying the dysregulation of these proteins by examining their intracellular levels rather 
than the level in the secretome, as the previous results showed that the proteins could be 
more robustly detected in cell lysates and the levels of RNA transcripts corresponding to 
the FGB /APP genes could be simultaneously analysed. Moreover, some APPs of interest, 
such as HP, were only altered in amount in the proteome of DENV-2 infected cells.   
As IL-6 is a major regulator of FBG and APP gene transcription and increased 
levels of IL-6 have been reported during DENV infection, studying the effect of IL-6 on 
the cellular levels of FBG and APPs was vital. Therefore initially experiments were done 
to optimise the induction of the IL-6 regulated genes. The next step was then to explore the 
mechanism underlying the decreased in FGB/APP amounts by analysing mRNA levels and 





  Protocol optimization 
 Optimal dose and duration of IL-6 treatment 
 To study the effect of IL-6 on the FBG protein levels, firstly conditions for IL-6 
treatment were optimised. The dosage and duration of IL-6 treatment of liver cell lines 
were varied, based on previous studies, ranging from 5-100 ng/ml (final concentration) in 
dose and 6-24 h of duration of treatment (Ray et al, 2000; Ait-Goughoulte et al., 2009; 
Brock et al., 2011). The appropriate dose and duration of IL-6 treatment on FBG protein 
levels was identified by adding 20, 50 and 100 ng/ml of recombinant human IL-6 to Huh-
7 cells for 6, 12 and 24 h before harvesting and preparing cell lysates. Then, the cell lysates 
were analysed by Western blotting (Figure 7.2). As expected, IL-6 treatment resulted in an 
increase in the level of all FBG protein subunits and this effect depended on the dose and 
duration of treatment. The optimal dose of IL-6 and duration of treatment were 50 ng/ml 










Figure 7.2 Effect of dose and duration of IL-6 treatment on the level of FGA, FGB and 
FGG proteins in Huh-7 cells.  
To determine the appropriate dose and duration of IL-6 treatment, various doses of IL-6 
(0 as a negative control, 20, 50, 100 ng/ml, (final concentration)) were added to Huh-7 
cells for varying times (6, 12, 24 h before harvesting as cell lysates). Twenty µg of cell 
lysate was loaded in each lane and the proteins separated by SDS-PAGE prior to Western 
blotting. Antibodies against FGA, FGB, FGG and GAPDH were used to detect the 
amount of relevant proteins. GAPDH was used as loading control for cell lysates and the 





  Effect of IL-6 on DENV infection 
 It is well known that some cytokines such as type I IFNs have anti-viral effects 
against DENV; however, the effect of IL-6 on DENV replication has not been studied. 
Thus, the effect of IL-6 treatment on DENV infection was tested to ensure that the effect 
of IL-6 on the proteins of interest was not due to an alteration in DENV infection. 
Previously, treatment with IFN-α and β  either pre- or post-DENV infection resulted in a 
decreased infection rate in many cell types, including HepG2 cells, as determined by flow 
cytometry and plaque assay (Diamond et al., 2000). Thus, the effect of IL-6 on DENV 
infection, either pre- or post- infection, was tested by adding 50 ng/ml of IL-6 to Huh-7 
cells 12 h before infection and 6 hpi (followed by a 24 h duration of IL-6 treatment which 
had the maximum effect on FBG protein levels from the previous experiment). Mock and 
DENV-2 infections were done as previously described. The cells were fixed at 30 hpi 
followed by IFA (Figure 7.3A). The supernatants were collected to measure virus titre and 
viral genome copies (Figure 7.3B and C). The experiments were done independently in 
duplicate. The infection rate determined by IFA was approximately 100% using a MOI of 
5 when IL-6 was added either pre- or post-infection. The viral titres were not significantly 
different (P-value > 0.05) when comparing infection either with or without IL-6 treatment 





    
  
Figure 7.3 Analysis of the effect of IL-6 on the number of cells that DENV-2 infected, titre 
and genome levels.  
 Huh-7 cells were infected with DENV-2 at MOI=5 or mock infected. IL-6 (50 ng/ml) was 
added either 12 h before infection or 6 hpi. At 30 hpi, the cell culture supernatants were 
collected and the cells fixed and permeabilised with ice cold methanol. (A) IFA analysis 
was performed by immunostaining with an antibody against the DENV-2 E protein (Anti-
E, red), nuclear DNA was visualised with DAPI (blue). Images were taken using a Leica 
widefield microscope with 40X magnification. The viral titre in culture supernatants were 
measured by IF (B) and viral RNA copies by qPCR (C). The experiments were done 
independently in duplicate. Plaque assays were done in duplicate in each experiment and 
qRT-PCR was done in triplicate.  Data are presented in terms of mean ± SEM. An 
independent Students t-test was performed to compare IL-6 treatment to the non-treatment 




 Selecting proteins/genes for study 
 According to the previous results, the proteins involved in “complement and 
coagulation cascades” and “acute phase response” processes were significantly enriched in 
the cellular proteome and secretomes of DENV-2 infected Huh-7 cells. This data correlates 
with the results of the clinical proteomic study of DENV infected patients presented in 
Chapter 6, and with previous studies (Fragnoud et al., 2105; Ray et al., 2012, Jadhav et al., 
2017). Thus, this part of the investigation focussed on an examination of liver proteins that 
i) were significantly dysregulated in response to infection ii) involved in coagulation and 
iii) were APPs (FGA, FGB, FGG, SERPINA1, F2 and SERPINC1). HP, as a positive liver 
APP was also targeted. The levels of HNF4A and CEBPA, which are the modulators of 
FBG production were also significantly decreased in DENV-2 infected Huh-7 cells and 
included in the examination. Although IL-6 was not detectable in the proteomic analysis 
of Huh-7 infected cells, it was also examined as a protein/gene of interest. The alterations 
that occurred in the selected proteins in the proteome/secretome of DENV-2 infected Huh-
7 cells compared with mock infected cells (Chapter 5) and the sera of DENV patients 
compared with healthy controls (Chapter 6) are summarised in Table 7.1.  The successful 
validation of these selected proteins in DENV and mock infected Huh-7 cells by Western 
blotting was achieved for FGA, FGB, FGG, SERPINA1 and SERPINC1 in Chapter 5 as 





Table 7.1 Summary of coagulation proteins and APPs changed in the 
proteome/secretome of DENV-2 infected Huh-7 cells compared with mock cells and 






 Primer optimisation for qRT-PCR  
Before analysis of the mRNA levels of the genes of interest (Table 7.1) by qRT-
PCR, primer sets were selected for each gene transcript, purchased commercially (Table 
2.6) and analysed for specificity and sensitivity. To determine if the mRNAs of interest 
were expressed at detectable levels in Huh-7 cells and determine the quality of primers, 
total RNA extracted from Huh-7 cells, both with and without IL-6 treatment, was amplified 
by RT-PCR and the products analysed by agarose gel electrophoresis (Figure 7.4). A cDNA 
reaction without RT was used as negative control. The results revealed no detectable RT-
PCR product using the IL-6 primer set and only faint bands for the F13B RT-PCR products, 
using RNA extracted from Huh-7 cells treated with and without IL-6. RT-PCR products 
were obtained for all the other gene transcripts isolated from Huh-7 cells with and without 
IL-6 stimulation. The primer sets that were suitable for RT-PCR detection were then tested 











Figure 7.4 Detection of selected RT-PCR products using RNA from Huh-7 cells with and 
without IL-6 treatment.  
Total RNA was extracted from Huh-7 cells without (A and C) and with IL-6 (B and D) 
treatment (50 ng/ml for 12 h). After cDNA synthesis using random primers, primer sets for 
FGA, FGB, FGG, SERPINA1, SERPINC1, F2, F13B, HNF4A, CEBP, HP and IL-6 were 
used for PCR amplification. Equal amounts of DNA RT-PCR product were loaded into 
each lane and analysed using a 2% agarose gel. The no RT reactions (C and D) were used 
as negative controls. The positions of relevant nucleic acid markers are shown in bp. A= 
Huh-7 without IL-6 + RT, B= Huh-7 with IL-6 +RT, C= Huh-7 without IL-6, no RT, D= 





After the primer sets were confirmed to be capable of amplifying detectable RT-
PCR products they were further tested for their use in qRT-PCR. Standard curves were 
produced for the primer sets corresponding to the FGA, FGB, FGG, SERPINA1, 
SERPINC1, F2, HNF4A, CEBP, HP and GAPDH (used as control) transcripts as described 
in section 2.4. GAPDH was selected as a control for both Western blotting analysis and 
qRT-PCR as its’ level did not change in the proteomic analysis of DENV-2 infected cells 
described in Chapter 5.  Theoretically, the acceptable efficiency ranges from 90 to 110% 
(with a slope of the curve approximately of -3.3 (for an efficiency of 100%)). The 
appropriated R2 of the curve should be > 0.99 for a good correlation. Moreover, standard 
curves for all of the selected genes should have a similar slope as the housekeeping gene  ̶  
GAPDH in this study. The acceptable standard curves for the selected primer sets are 







Figure 7.5 Standard qRT-PCR amplification curves for the selected primers.  
Total RNA was extracted from Huh-7 cells and used for cDNA synthesis. Ten ng of cDNA 
was used neat or subjected to 10-fold serial dilution and used for qRT-PCR amplification. 
Primer sets for FGA, FGB, FGG, SERPINA1, SERPINC1, F2, HNF4A, CEBP, HP and 
GAPDH (as a house keeping gene) were used for PCR amplification. The SoftMax Pro 
program was used to quantify CT values and calculate efficiency curves. The efficiency 





Gene transcripts were selected for further study based on the change in protein 
amount in DENV-2 infected Huh-7 cells, the results of the validation with Western 
blotting, the results of the serum proteomic analysis of DENV infected patients described 
in Chapter 6, review of the literature and primer suitability. Finally, the six APPs selected 
for examination were FGA, FGB, FGG, SERPINA1, SERPINC1 and HP as well as 
HNF4A (as an important regulator of FBG and other APPs). 
 Effect of IL-6 on FBG and APPs in DENV infected liver cells 
 FBG proteins 
To determine whether IL-6 could stimulate an increase in the levels of the FBG 
proteins and APPs during DENV infection, Huh-7 cells were either infected with DENV-
2 at MOI=5 or mock infected. Immediately after infection, IL-6 (50 ng/ml) was added to 
media and at 6, 12 and 24 hpi, which corresponded to treatment durations of 30, 24, 12, 
and 6 h respectively, at the time of harvest. The cells were harvested at 30 hpi and used to 
prepare cell lysates that were analysed by Western blotting (Figure 7.6). The results 
revealed that an IL-6 treatment period of 24 h had an optimal stimulation on the amount of 
cellular FBG proteins in mock cells and DENV-2 infection blunted the IL-6 stimulated 











Figure 7.6 Analysis of FGB proteins in cell lysates from DENV-2 infected Huh-7 cells 
after IL-6 treatment.  
Huh-7 cells were infected with DENV-2 at a MOI of 5 or mock infected. IL-6 treatment 
was performed by adding IL-6 (50 ng/ml) to the media immediately after infection or at 6, 
12 and 24 hpi. The cells were harvested at 30 hpi and collected as total lysates. Twenty µg 
of cell lysate was loaded in each lane and the proteins separated by SDS-PAGE prior to 
Western blotting. Antibodies against FGA, FGB, FGG, NS4B and GAPDH were used to 
detect the amount of the relevant proteins. GAPDH and NS4B were used as a loading 
control and marker of infection, respectively. The positions of relevant molecular mass 






  HNF4A  
The previous proteomic results (Table 5.4) demonstrated that HNF4A decreased in amount 
in DENV infected Huh-7 cells which might modulate the production of FBG. Although 
HNF4A is not an APP and theoretically regulates FBG production in the basal state, the 
effect of IL-6 stimulation on HNF4A was also studied by Western blotting. A single IL-6 
treatment duration of 24 h was selected for the experiment based on the previous results 
examining FBG amounts. Either no IL-6 or 50 ng/ml of IL-6 was added to DENV and 
mock infected Huh-7 cells at 6 hpi (24 h treatment) and harvested at 30 hpi to prepare cell 
lysates for Western blotting (Figure 7.7A). The amount of HNF4A changed in a similar 
fashion as FBG in DENV-2 infected Huh-7 cells with or without IL-6 stimulation.  
 Other APPs: SERPINA1, SERPINC1 and HP 
The effect of IL-6 treatment on the amounts of SERPINA1, SERPINC1 and HP in 
DENV-2 infected Huh-7 cells was studied in the same manner as described above for 
HNF4A (Figure 7.7B). For SERPINA1 and HP which are positive APPs, similar results as 
for FBG were observed. The proteins increased in amount in mock infected cells after IL-
6 treatment but this effect was not found in DENV infected Huh-7 cells. In contrast, there 
was no increase in the amount of SERPINC1, which is a negative APP, with IL-6 treatment 
in either mock or DENV-2 infected Huh-7 cells. Similar to FBG, the effects of IL-6 









Figure 7.7 Analysis of HNF4A and APPs in cell lysates from DENV-2 infected Huh-7 cells 
after IL-6 treatment.  
Huh-7 cells were infected with DENV-2 at a MOI of 5 or mock infected. IL-6 (50 ng/ml) 
was added or not to the media at 6 hpi. Cells were harvested at 30 hpi and collected as total 
lysates. The amount of HNF4A (A) and the APPs, SERPINA1, SERPINC1 and HP, (B) 
were analysed by Western blotting.  Twenty µg of cell lysate (30 µg for SERPINA1) were 
loaded in each lane and the proteins separated by SDS-PAGE prior to Western blotting. 
Antibodies against HNF4A, SERPINA1, SERPINC1, HP, NS4B and GAPDH were used 
to detect the amounts of the relevant proteins. GAPDH and NS4B were used as a loading 
control and a marker of infection, respectively. The positions of relevant molecular mass 





  Effect of IL-6 treatment on HepG2 cells  
To confirm that the effects of DENV infection on FBG and APP levels were not 
specific to Huh-7 cells, the same set of experiments were then performed with another liver 
cell line, HepG2 cells, in the same manner (Figures 7.8). At 24 h after seeding, HepG2 
cells were infected with DENV-2 (at MOI of 5) or mock infected and IL-6 treatment was 
performed by either adding IL-6 (50 ng/ml final concentration) or media alone at 6 and 18 
hpi (24 and 12 h treatment duration). At 30 hpi, the cells were fixed for IFA and/or 
harvested as cell lysates. The results showed approximately 95% infection rate either with 
or without IL-6 treatment (Figure 7.8A). An increase in the amounts of the FBG proteins 
was detected after IL-6 treatment of mock cells (the peak effect was after 24 h of treatment) 
but the increase was much less in DENV-2 infected HepG2 cells, which was similar to 
results obtained using Huh-7 cells (Figure 7.8B).  
The effect of DENV infection and IL-6 treatment on HNF4A amounts was also 
studied. There was a decrease in the amount of HNF4A in DENV-2 infected HepG2 cells 
compared with mock infected cells which was similar to the result obtained using Huh-7 
cells. In contrast, IL-6 stimulation did not affect the amount of HNF4A in HepG2 cells as 
was observed for Huh-7 cells (Figure 7.8C).  
Unfortunately, SERPINA1 and HP could not be detected in lysates from HepG2 
cells by Western blotting under any conditions. SERPINC1 was successfully detected and 
similar to the results obtained using Huh-7 cells, the amount of SERPINC1 decreased 
during DENV-2 infection compared with mock infected cells (Figure 7.8D). In contrast to 
Huh-7 cells, there was an increase in the amount of SERPINC1 after IL-6 treatment of 
mock infected cells. Interestingly, DENV infection also blunted the IL-6 stimulatory effect 











Figure 7.8 Analysis of the FBG proteins and APPs in cell lysates from DENV-2 infected 
HepG2 cells after IL-6 treatment.  
HepG2 cells were infected with DENV-2 at a MOI of 5 or mock infected. IL-6 (50 ng/ml) 
was added or not to the media at 6 hpi (and 18 hpi for FBG). At 30 hpi, the cells were fixed 
for IFA and/or collected as total lysates. IFA analysis was performed (A) by 
immunostaining with an antibody against the DENV-2 E protein (Anti-E, red), nuclear 
DNA was visualised with DAPI (blue). Images were taken using a Leica widefield 
microscope with 40X magnification. The amounts of the FBG proteins (A), HNF4A (B) 
and SERPINC1 (C) were analysed by Western blotting.  Twenty µg of cell lysate was 
loaded in each lane and the proteins separated by SDS-PAGE prior to Western blotting. 
Antibodies against FGA, FGB, FGG, HNF4A, SERPINC1, NS4B and GAPDH were used 
to detect the amounts of the relevant proteins. GAPDH and NS4B were used as a loading 
control and a marker of infection, respectively. The positions of relevant molecular mass 





 FBG and APP transcript levels in DENV infected liver cells 
To study whether or not the alterations in FBG and the APPs in DENV infected 
cells were a result of altered mRNA transcript levels corresponding to those proteins, the 
mRNA transcript levels were quantified by qRT-PCR. Huh-7 and HepG2 cells were 
prepared in the same manner as described above for the Western blotting analysis. The 
cells were infected with DENV-2 and IL-6 added to a final concentration of 50 ng/ml at 6 
hpi. The cells were harvested at 30 hpi and used for total RNA extraction. In these 
experiments the cells were only analysed at a single time point, after infection and IL-6 
treatment. The time point selected was based on the Western blot analysis and previous 
gene expression analysis.  Total RNA was used for qRT-PCR analysis of the levels of each 
gene transcript. The experiments were done in triplicate (Figure 7.9).  
In DENV-2 infected Huh-7 cells not treated with IL-6, there was a significant 
decrease in the FGA, FGB, HP and HNF4A transcript levels compared with mock infected 
cells (Figure 7.9A). These results correlated with the decrease in protein levels.  In contrast, 
there was no change in the FGG and SERPINA1 transcript levels and the SERPINC1 
transcript showed a non-significant increase in response to DENV-2 infection.  
Analysis of the mRNA transcript levels in mock infected cells in response to IL-6 
treatment showed that the transcript levels of the positive APPs including FGA, FGB and 
FGG and HP increased in response to IL-6 treatment but the trend was only statistically 
significant for the FGA and HP transcripts. The SERPINA1 and SERPINC1 transcript 
levels significantly decreased after IL-6 stimulation. The HNF4A transcript level did not 
change after IL-6 treatment.  
Analysis of the effects of both DENV infection and IL-6 treatment showed that the 
mRNA transcript levels for FGA, FGB, FGG, HP and HNF4A increased in DENV-2 
infected Huh-7 cells in comparison to infected cells not treated with IL-6 but that the 
transcript levels were still lower than in mock infected cells treated with IL-6. In contrast 
to the Western blotting results there was a significant increase in SERPINA1 and non-
significant increase in SERPINC1, transcript levels in DENV-2 infected Huh-7 cells treated 




The same experiment was done using HepG2 cells. Overall, the changes observed 
in the mRNA transcript levels corresponding to FGA, FGB, FGG and the APPs in response 
to DENV-2 infection and IL-6 treatment corresponded to those that occurred in Huh-7 
cells. This included a decrease in the FGA, FGB, FGG and HP transcript levels in response 
to DENV-2 infection with a positive response to IL-6 treatment, no significant differences 
in the SERPINA1 transcript levels in response to DENV-2 infection or IL-6 treatment and 
an increase SERPINC1 transcript levels in response to DENV-2 infection with negative 
response to IL-6 treatment (Figure 7.9B). However, the effects on the HNF4A transcripts 
in HepG2 cells showed some dissimilarity. There was no decrease HNF4A transcript levels 
in DENV-2 infected HepG2 cells as for Huh-7 cells but a significant decrease in the 
HNF4A transcript level in response to IL-6 treatment. 
The dysregulation in mRNA transcript levels in response to DENV-2 infection both 
with and without IL-6 stimulation could not explain all of the changes in protein amounts 
observed in response to DENV infection. Multiple mechanisms might be involved in the 
dysregulation of the APPs. Therefore the role of post-translational protein stability 






Figure 7.9 Analysis of the effect of IL-6 on FBG and APPs mRNA transcript levels by 
qRT-PCR.  
Huh-7 (A) and HepG2 (B) cells were infected with DENV-2 at a MOI of 5 or mock 
infected. IL-6 (50 ng/ml) was added or not to the media at 6 hpi. Cells were harvested for 
analysis at 30 hpi. Relative quantitation of mRNA level was performed by qRT-PCR. The 
experiments were done in triplicate. Data was presented in term of mean ± SD. * = P-value 




  Posttranslational protein degradation 
 Because the majority of proteins are degraded by the ubiquitin-proteasome system, 
MG132, which is a potent proteasome inhibitor was used to investigate whether the 
alteration in proteins level observed in response to DENV-2 infection were a result of 
proteasomal degradation. Firstly, the dose and duration of MG132 treatment were 
determined. The survival and general condition of Huh-7 cells incubated with MG132 at 
doses of 1-5 µM for up to 24 h was determined by microscopic examination (data not 
shown). Then the effect of MG132 on protein stability during DENV-2 infection was 
analysed by adding either a low (1 µM) or high dose (5 µM) of MG132 to both DENV-2 
(at MOI of 5) and mock infected cells at 6 and 12 hpi (18 and 24 h of treatment, 
respectively). An equivalent volume of DMSO was used as control. There was no 
difference in the DENV-2 infection rate due to MG132 treatment as determined by IFA 
(Figure 7.10). The effect of MG132 treatment on the level of the proteins of interest during 
DENV-2 infection was then determined by Western blotting. STAT2 was selected as a 
positive control because it is known to be degraded by the proteasome during DENV 
infection (Ashour et al., 2008). The addition of MG132 was found to rescue the decrease 
in the FBG proteins, HNF4A and SERPINC1 observed in DENV infection (Figure 7.11). 
Moreover, the effect was dose dependent more than time dependent.  
These findings reveal that the decrease the amounts of FBG and APPs in response 







Figure 7.10 Analysis of the effects of MG132 on DENV-2 infection of Huh-7 cells by IFA.  
Huh-7 cells were infected with DENV-2 at a MOI of 5 or mock infected. MG132 (1 and 5 
µM in DMSO) or DMSO alone as indicated was added at 6 and 12 hpi. After 18 h or 24 h 
of MG132 or DMSO treatment, the cells were fixed and immunostained with an antibody 
against the DENV-2 E protein (Anti-E, green), nuclear DNA was visualised with DAPI 









Figure 7.11 Analysis of the effects of MG132 on FBG, HNF4A and SERPINC1 amounts 
in DENV-2 infected Huh-7 cells by Western blotting.  
Huh-7 cells were infected with DENV-2 at a MOI of 5 or mock infected. MG132 (1 or 5 
µM in DMSO) or DMSO alone as indicated was added. After 18 and 24 h of MG132 or 24 
h of DMSO treatment, the cells were harvested as total cell lysates.  Twenty µg of cell 
lysate were loaded in each lane and the proteins separated by SDS-PAGE prior to Western 
blotting. Antibodies against STAT2, FGA, FGB, FGG, HNF4A, SERPINC1, NS4B and 
GAPDH were used to detect the amount of relevant proteins. GAPDH and NS4B were used 
as a loading control and marker of infection, respectively. The positions of relevant 





 Imaging analysis of FGB and FGG 
 The intracellular level and/or distribution of the FBGs proteins in DENV-2 infected 
Huh-7 cells was examined by IFA. FGB and FGG were successfully immunostained while 
attempts to immunostain FGA were unsuccessful (data not shown for FGA) (Figure 7.12). 
There was no obvious change in the staining of FGB, but a decrease in the staining of FGG 
in response to DENV-2 infection. The distribution of FGG was also altered in DENV-2 
infected Huh-7 cells. Further analysis by confocal microscopy was then performed to 
examine the change in the distribution of FGB and FGG in DENV-2 infected cells at both 
low and high MOI (MOI of 1 and 5) (Figures 7.13 and 7.14). In mock infected cells, FGB 
and FGG had a diffuse cytoplasmic distribution. Whereas in DENV-2 infected cells, FGG 
showed a more speckled cytoplasmic distribution and was found to condense in some area 
as bright spots. The patterns of FGB and FGG in DENV-2 infected Huh-7 cells were not 
obviously different when cells were infected at a low and high MOI (Figure 7.13 for FGB 
and 7.14 for FGG).  Interestingly, the distribution of FGG in infected cells was similar to 
that of the DENV E protein used as marker of infection.  
 A further experiment was done examining potential co-localisation between FGB / 
FGG and the E protein. Huh-7 cells were infected with DENV-2 at varying MOIs (MOI of 
1-5). The degree of co-localisation was measured by the Pearson’s correlation coefficient 
(R) using the ImageJ program. The Pearson’s R value ranges from -1 (perfect negative 
correlation) to 1 (perfect positive correlation); however, only a score <0.5 or >0.5 can be 
considered as showing a degree of correlation (Adler and Parmryd, 2010). Preliminary 
analysis revealed a Pearson's R score for co-localisation of the FGB and E protein of 0.35, 
so a conclusive correlation could not be made (Figure 7.13). By contrast the Pearson's R 
score for co-localisation of the FGG and E protein showed a positive correlation at the two 
different MOIs used for infection (Figure 7.14). Thus, the co-localisation of the FGG and 
E proteins was more extensively examined in both DENV-2 infected Huh-7 and mock 
infected cells (10 fields each) which revealed a Pearson's R score of 0.62 ±0.10 (mean 
±SD) for DENV-2 infected cells compared with 0.089 ±0.05 in mock cells (P-value = 




 In summary, FGB and FGG showed a different distribution pattern in DENV-2 
infected cells compared to mock infected Huh-7 cells. Co-localisation between the FGG 











Figure 7.12 Analysis of FGB and FGG in DENV-2 infected Huh-7 cells by IFA.  
The amount and pattern of distribution of FGB (A) and FGG (B) in DENV-2 infected cells 
compared with mock infected cells were analysed by IFA. Huh-7 cells were infected with 
DENV-2 at a MOI of 5 or mock infected. At 30 hpi, the cells were fixed and immunostained 
with an antibody against the DENV-2 E protein (Anti-E, red) and either FGB or FGG 
(Green), nuclear DNA was visualised with DAPI (blue). Images were taken using a Leica 












Figure 7.13 Confocal microscopic analysis of FGB in DENV-2 infected Huh-7 cells.  
The pattern of distribution of FGB in DENV-2 infected cells compared with mock infected 
cells was analysed by confocal microscopy. Huh-7 cells were infected with DENV-2 (at a 
MOI of 1 and 5) or mock infected. At 30 hpi, the cells were fixed and immunostained with 
an antibody against the DENV-2 E protein (Anti-E, red), and FGB (Green), nuclear DNA 
was visualised with DAPI (blue). Images were taken using Leica SP5-AOBS confocal laser 













Figure 7.14 Confocal analysis of FGG in DENV-2 infected Huh-7 cells.  
(A) The pattern of distribution and co-localization of FGG with the E protein in DENV-2 
infected cells compared with mock infected cells was analysed by confocal microscopy. 
Huh-7 cells were infected with DENV-2 (at a MOI 1-5) or mock infected. At 30 hpi, the 
cells were fixed and immunostained with an antibody against the DENV-2 E protein (Anti-
E, red), and FGG (Green), nuclear DNA was visualised with DAPI (blue). Images were 
taken using Leica SP5-AOBS confocal laser scanning microscope. (B) Co-localisation was 
determined using the Pearson’s correlation coefficient using the ImageJ program. 
Statistical analysis was performed to compare co-localisation of FGG and E protein in 
DENV-2 infected and mock cells, using 10 images per group. Data is shown in terms of 





 FGG-virus protein-protein interaction (PPI) analysis  
Previous interactomic studies have identified an interaction between FGA and the 
DENV NS2A and NS5 proteins as well as an interaction between FGB and NS3 (Khadka 
et al., 2011). FGG has not been detected to interact with DENV proteins.  In this study, an 
examination of potential PPIs between FGG and DENV E proteins was undertaken as there 
was no change in the FGG mRNA transcript level in DENV-2 infected Huh-7 cells and 
FGG and the DENV E protein were identified to co-localise. Co-IP analysis using an anti-
FGG antibody was performed to identify potential interactions between FGG and DENV 
proteins as well interactions between FGG and other FBG chains. Lysates prepared from 
DENV-2 (at MOI of 5) and mock infected Huh-7 cells were incubated with either anti-
FGG (a mouse monoclonal) or control mouse serum (described in section 2. and Table 
2.5). After Co-IP, the protein eluates were analysed by SDS-PAGE and Western blotting 
using antibodies against FGA, FGB and DENV E protein.  
The detection of FGG bands in FGG-IPs from both mock and DENV-2 infected 
cells (but not using control serum) indicated the IP was successful (Figure 7.15). Although 
interactions between FGG and both FGA and FGB were expected, the results revealed a 
detectable interaction only between FGG and FGB.  Stronger FGB bands were observed 
in the FGG-IP using the mock cell lysate compared with the lysate from DENV-2 infected 
cells. Interestingly, there were a consistent detection of the E protein in the FGG-IP 
compared to the serum control, indicating an interaction between FGG and the DENV E 
protein. The results for other viral proteins (prM, NS4B and NS5) were inconclusive due 











Figure 7.15 Protein-protein interactions with FGG identified by Co-IP.  
Co-IP analysis was performed using cell lysates from DENV-2 (at MOI of 5) and mock 
infected Huh-7 cells. Equal amounts of cell lysates and anti-FGG antibody was used for 
Co-IP. A matched mouse serum was used as a negative control (Con). Western blotting 
analysis of the immunoprecipitates was performed using antibodies against FGG, FGA, 
FGB, DENV E and GAPDH. The experiment was done in triplicate (Co-IP 1-3). The 





  Discussion 
In this chapter, the results of experiments investigating the dysregulation of FBG 
and APPs during DENV infection of infected liver cell lines are described. Multiple 
techniques were applied to identify the mechanism/s underlying the decrease in liver APPs 
in DENV infected cells. 
Optimisation of IL-6 stimulation condition 
To study the cytokine response of APPs in an experimental setting, IL-6 which is 
the key regulator of APPs was selected. The secretion and effects of IL-6 in Huh-7 and 
HepG2 cells are different from those of type I IFNs. The hepatoma derived cell lines, both 
Huh-7 and HepG2 have a low basal level of IFN signaling proteins and needs higher doses 
of IFNα to stimulate the antiviral response compared with non-hepatoma derived cancer 
cell lines (Melen et al., 2000). In contrast, previous studies revealed that both the Huh-7 
and HepG2 cell lines exhibited robust IL-6 responses and as such, have been widely used 
to study the effect of IL-6 on APPs in vitro (Ray et al., 2000; Ait-Goughoulte et al., 2009; 
Brock et al., 2011; Lukowski et al., 2015).  In in vivo conditions, IL-6 is secreted from 
endothelial cells, monocytes and macrophages and transported to the liver via blood 
circulation. Furthermore, Kupffer cells in the liver also secrete local IL-6 to neighbouring 
hepatocytes (Schmidt-Arras and Rose-John, 2016). A previous study reported that Huh-7 
and HepG2 cells neither express IL-6 mRNA nor secret IL-6 (Matsuguchi et al., 1990). In 
support of this finding, neither intracellular IL-6 nor a IL-6 RT-PCR product were detected 
using Huh-7 cell lysate in this study (proteomic results from Chapter 5 and RT-PCR results 
in this chapter). Thus, IL-6 was added to liver cells to mimic in vivo conditions.  
The effect of IL-6 on the level of APPs in (uninfected) hepatocytes in this study 
was similar to the effects reported in previous studies. There was an increase in the effect/s 
of IL-6 with increased dose and duration of IL-6 treatment. The effect reached a peak at 50 
ng/ml (final concentration) and 24 h of treatment after which there was a decreased effect 
with a high dose of Il-6 (100 ng/ml) and a longer duration of treatment (30 h). A previous 
study in which HepG2 cells were treated with different doses of IL-6 (ranging from 5-100 




h of treatment) reported a peak effect at a dose of 20-50 ng/ml and a decrease in mRNA 
levels at the dose of 100 ng/ml (Brock et al., 2011). The effect of treatment time on IL-6 
stimulation of APPs was studied in primary human hepatocytes (PHH) and revealed 
parallel increases of positive APPs (FBG, CRP and SERPINA1) with the duration of 
treatment until a steady state was reaching after 25-30 h (Heinrich et al., 1990). 
 Dissimilar to type I IFN (Diamond et al., 2000), the addition of IL-6 both pre- and 
post-infection did not lead to a significant decrease in the efficiency of DENV infection 
(determined by IFA) or viral production from liver cells. In this study, IL-6 was added to 
DENV infected liver cells after infection to mimic the in vivo pathophysiology of DENV 
infection on APPs. 
Alteration in proteins and mRNA levels of FBG and APPs in Huh-7 and HepG2 cells in 
response to DENV infection with and without IL-6. 
At the protein level, the results revealed similar changes in the amounts of the 
proteins of interest (all FBG, HNF4A and SERPINC1) in Huh-7 and HepG2 cells in 
response to DENV infection. Thus, the decreases in liver APPs during DENV infection 
was not specific to a particular liver cell line. However, it is should be kept in mind that 
both cell lines may share similar characteristics as they are hepatoma-derived in nature. 
HNF4A is the key hepatic gene regulator, the decrease in HNF4A during infection may 
contribute to the decrease in proteins regulated by HNF4A, including the FBG proteins and 
SERPINA1. 
Overall the analysis of FBG and APP mRNA transcript levels in Huh-7 and HepG2 
cells in response to DENV infection showed the same trends. The significant decreases in 
the mRNA transcript levels of FGA, FGB, HP and HNF4A in DENV-2 infected Huh-7 
cells as well as those of FGA and FGG in HepG2 cells correlated with decreases in the 
amounts of the corresponding proteins. However, the mRNA transcript levels of FGG, 
SERPINA1, and SERPINC1 in DENV infected Huh-7 cells and SERPINC1 and HNF4A in 
DENV infected HepG2 cells did not correlate with the decreases in protein amounts. In a 
previous study that analysed changes in the transcriptome in response to DENV-2 infection 
of Huh-7 cells (using a whole genome microarray), no changes were detected in the mRNA 




differences in the results may be from the different experimental conditions and techniques 
used in the studies. Goh’s study were performed by using MOI of 10 and studying mRNA 
level at 24 hpi using microarray technique, while this study used MOI of 5 and studied 
mRNA level at 30 hpi with qRT-PCR. However, collectively, the changes in mRNA 
transcript levels detected in this and previous studies do not fully explain all of the 
decreases in the FBG proteins and APPs found in liver cells in response to DENV infection 
in this study. Several studies have previously documented the disagreement between gene 
expression and protein levels in human cell lines; for example, a study analysing the 
transcriptome and proteome of a medulloblastoma cell line (by microarray and LC-
MS/MS, respectively) demonstrated that mRNA abundance could explain only 67% of 
protein abundance variation, with a positive correlation score (R2) of 0.32 (Vogel et al., 
2010). Moreover, changes in mRNA transcripts in response to DENV infection is a 
dynamic process. For example, a study of gene expression signatures associated with lipid 
metabolism in DENV-2 infected HepG2 cells by qRT-PCR revealed increases in specific 
mRNA transcripts until 24 hpi before decreases at 48 and 72 hpi (Tongluan et al., 2017). 
The mRNA transcript levels in this study were measured at the same time as protein levels 
(30 hpi). Thus, the results from single time point measurement might not explain the 
relationship between mRNA and protein levels of all the selected APPs. 
As expected, IL-6 treatment resulted in an increase in the FBG and HP protein and 
mRNA transcript levels in both liver cell lines. Increases in the mRNA transcript levels of 
FGA, FGB, FGG (Lukowski et al., 2015) and HP (Brock et al., 2011) in HepG2 cells after 
24 h treatment with IL-6 have been reported. The decrease in the mRNA transcript and 
protein level of SERPINC1, which is a negative APP was expected. An increase in the 
protein level of SERPINA1 after IL-6 treatment for 24 h in Huh-7 cells in this study was 
similar to the results found using HepG2 cells and human liver tissue (Heinrich et al., 
1990). However, there was a significant decrease in SERPINA1 mRNA levels in Huh-7 
cells in response to IL-6. As mentioned earlier, changes in mRNA transcripts level might 
not correlate with a similar change in protein amount. Another possibility is the mRNA 




Infection with DENV was found to blunt the effect of IL-6 stimulation on the 
protein levels of all positive APPs in both Huh-7 and HepG2 cells. Small increases in the 
levels of some APPs (eg. HP in Huh-7 and FBG in HepG2 cells) in cells treated with IL-6 
and DENV infected were observed; however, overall the protein levels still decreased when 
compared with untreated mock infected cells for both cell lines. The analysis of the 
corresponding mRNA transcripts revealed a more marked response to IL-6 treatment. In 
contrast to the protein levels, the mRNA transcript levels of almost all of the positive APPs 
(except FGA and FGB in Huh-7 cells) in DENV infected cells treated with IL-6 increased 
to level higher than in mock infected cells not treated with IL-6. These results suggested 
that the decreases observed in the amounts of APPs in liver cells in response to DENV 
infection is mainly due to a mechanism distinct from any changes observed in APP gene 
transcription.  
It was concluded that even under conditions of high IL-6 stimulation (mimicking 
the pathophysiology of a severe DENV infection), there were still decreases in APP protein 
amounts that in turn, led to decreased secretion of liver APPs. The increases in mRNA 
transcript levels but decreases in protein amounts for FBG and APPs during DENV 
infection and IL-6 stimulation suggested post-transcriptional changes. However, apart 
from an increase of IL-6, increases in the amounts of other cytokines including IL-8 and 
IL-1β (another key regulator of APPs) have been reported in DEN patients (Bozza et al., 
2008; Priyadarshini et al., 2010). This may explain the different results observed between 
this study and studies investigating in vivo pathophysiology. 
Post transcriptional regulation of FBG and APPs  
 The APPs are known to be post-transcriptionally regulated by transcript stability, 
miRNA dependent transcriptional control and protein degradation (Bode et al., 2012). 
Several studies have reported post-transcriptional modulation of APPs; for example, 
degradation of the SAA mRNA transcript mediated by the 3´-untranslated regions was 
reported in IL-1β and IL-6 stimulated HepG2 cells (Longley et al., 1999).  
The role of miRNAs in the regulation FBG and APPs has been widely documented. 
For example, a study in which Huh-7 cells were transfected with a library of human 




increased FBG production, respectively (Fort et al., 2010). Furthermore, over expression 
of miR-18a could induce both mRNA and protein levels of HP and FBG in IL-8 stimulated 
HepG2 cells (Brock et al., 2011). Dysregulation of miRNA in DENV infection has been 
widely studied in both cell-based experiments (Escalera-Cueto et al., 2014; Kanokudom et 
al., 2017) and using patient blood samples (Diosa-Toro et al., 2017). An upregulation of 
miR-let7c (measured by microarray and qRT-PCR) in DENV-2 infected Huh-7 and U937 
DC-SIGN cells has been reported since 12 hpi (Escalera-Cueto et al., 2014). An 
overexpression of miR-let7c after miR-let7c transfection resulted in a significant decrease 
in FBG secretion from Huh-7 cells (Fort et al., 2010). Collectively, these studies suggest 
an increase in miR-let7c may contribute to a decrease in FBG levels in DENV infected 
Huh-7 cells. Thus, further experiments investigating the role of miRNAs in the modulation 
of FBG and APPs in the context of DENV infection should be performed.  
The instability and degradation of APPs was previously mentioned. After assembly 
of FBG in the ER, the unassembled/misfolded FBG chains are degraded by the ERAD 
using a proteasomal dependent system (Redman and Xia, 2001). A previous study using 
an ERAD assay proposed that the mutant FGG chain, named fibrinogen Aguadilla, was 
targeted by ERAD and subsequently degraded by the proteasome (Kruse et al., 2006). 
Furthermore, the excess fibrinogen Aguadilla that accumulated in ER was also sent to the 
vacuole via autophagy (Kruse et al., 2006).   
According to the published literature, this is the first time that proteasomal 
degradation has been demonstrated to be a mechanism used to decrease key coagulation 
proteins and APPs in DENV infection. Furthermore, both positive (FBG) and negative 
(SERPINC1) APPs were degraded in DENV infection. It is well established that an 
interaction between DENV NS5 and STAT2 results in a decrease in STAT2 via 
proteasome-mediated degradation during DENV infection (Ashour et al., 2008; Mazzon et 
al., 2009). Thus, based on the results produced in this investigation it is hypothesised that 
interaction/s between APPs and DENV proteins results in misfolded APPs that are then 
degraded in a proteasome dependent manner. Alternatively, DENV replication on ER 
membranes leads to ER stress and dysfunction which may cause a defect in assembly of 




stimulation via cytokines released during DENV infection, the overexpressed unassembled 
APPs are then processed via proteasomal degradation (which is the part of ERAD). 
Furthermore, DENV infection itself also stimulates ER stress, which triggers UPR 
responses and ERAD functions which may lead to increased degradation of multiple 
proteins including APPs in hepatocytes.  
The results from Chapter 5 revealed decreases in multiple coagulation proteins and 
APPs as well as proteins involved in complement systems and lipid metabolism. However, 
only FBG and key APPs were selected for investigation in this chapter. Thus, further 
experiments to investigate the effect of proteasomal degradation in the proteomes of 
DENV-2 infected Huh-7 cells with high throughput LC-MS/MS should be done.  
FGG and DENV E protein PPI 
 Co-localisation of FGG and the DENV-2 E protein was observed. Theoretically, 
co-localisation means two proteins are present in the same area or associated with the same 
structure in cells (Dunn et al., 2010). The change in the distribution of FGG and co-
localisation of FGG and the E protein in DENV infected Huh-7 cells may be a result of an 
interaction between FGG and the DENV E protein (or other proteins that bound with E 
protein e.g. prM) leading to a change in the distribution of FGG in DENV infected cells. 
Another possible explanation is that both the FGG and E proteins are present in the same 
organelle/structures such as in ER. The ER is where FBG assembly, degradation of 
unassembled/misfolded FBG and DENV replication occur. Further co-localisation studies 
examining the localization of FGG and ER or UPS markers may provide a better 
understanding of this process.   
 To provide more evidence for the interaction between FGG and the E protein, co-
IP analysis was done which confirmed an interaction between FGG and the E protein. As 
the DENV prM protein interacts with the E protein in the immature virion, an antibody 
against the DENV prM was also used to analyse the immunoprecipitates by Western 
blotting. However, an interaction between prM and FGG was not detected (data now 
shown). The FBG-DENV protein interaction was previously identified in one study 
(Khadka et al., 2011). Using yeast two-hybrid analysis, Khadka et al., reported an 




NS3 and FGA and FGB were also detected (Khadka et al., 2011). Thus, this is the first 
time that an interaction between FGG and a DENV protein has been identified. The results 
of the FBG co-IP analysis were limited as the co-IP was performed only for FGG and 
analysed with limited antibodies against DENV proteins. Future studies using a combined 
co-IP / LC-MS/MS approach may provide more information about proteins that interact 
with FBG.  
It is established that DENV NS5 targets proteins for degradation via the proteasome 
in DENV infected cells (Ashour et al., 2008) and the DENV E protein interacts with key 
ER chaperones, including HSPA5 (Limjindaporn et al., 2009). Collectively, the interaction 
between FGG and DENV E protein identified here and the interaction between FGA and 
NS5 previously suggests multiple DENV proteins may contribute to proteasomal 
degradation of FBG.  
  One of the limitations of this study is that the experiments performed only with 
DENV-2 may not be generalised to other serotypes. Although the results from previous 
proteomic analyses of DENV-2 and DENV-4 infected Huh-7 cells (done in the laboratory) 
revealed similar trends (Chiu, 2014; Yousuf, 2016), the serotype-specific differences in the 
properties of DENV proteins have been previously reported. For example, the nuclear 
localisation of DENV-2 and DENV-4 NS5 differs in infected cells (Hannemann et al., 
2013) as well as the interaction between ERC1 and NS5, which was determined to be 
serotype 2 specific (Chiu, 2014). 
In conclusion, the investigations reported in this chapter suggest the mechanisms 
underlying the alterations in APPs are multifactorial. Evidence was provided of 
dysregulation at both the mRNA transcript and proteins stability levels but the major 
determinant appears to be proteasomal degradation of the FBG proteins and APPs. An 
interaction between FGG and the DENV-2 E protein was identified by co-localisation and 
co-IP. Furthermore, using experimental conditions mimicking in vivo infection, IL-6 
stimulation could not overcome the degradation of FBG and APPs proteins. Future high 
throughput studies and protein interaction studies are required to further understand the 




whether this effect is entirely mediated by viral host protein interactions or due to a 






  GE N E R A L DI S C U S S I ON  A N D  
FU T U R E  PE RS PE C T I VE S   
 
As an emerging disease, DEN has become a major global public health issue within 
decades of the first isolation of DENV in 1943. The disease not only effects people in 
endemic areas but also international travellers. The high number of cases and the 
complicated course of disease have stimulated intensive research into identifying the 
underlying causes of DEN pathogenesis, which would facilitate the development of 
treatments for clinical intervention, that are limited. Unfortunately, despite much effort and 
many studies, good biomarkers to either diagnose DEN in the late stage of disease or to 
predict disease severity are lacking and there are no specific antiviral treatments or a fully 
safe and protective vaccine. The lack of an animal model to study pathogenesis is a major 
impediment in DEN research. As such, pathogenesis studies have used clinical samples or 
relevant cell-based models. Most clinical studies have focussed on the analysis of blood 
from DEN patients to quantify mRNA, proteins or cytokines. Studies using cell-based 
systems should be used with caution when trying to understand pathogenesis, which should 
ideally be done in clinical studies. Multiple cell lines have been used in DENV studies, to 
date, there is no consensus concerning the most relevant cell models for studying DEN 
pathogenesis. In addition, studies systematically comparing the results of cell-based studies 
with those using clinical specimens are limited. In this study, high throughput proteomic 
analyses of the proteomes and secretomes of DENV infected HEK293T and Huh-7 cells 
were simultaneously done and the results reported in Chapters 4 and 5 respectively. 
Importantly, an integrated analysis of the proteome and secretome of DENV infected cells 
was performed for the first time. Furthermore, a comparative proteomic analysis of cells 
stably maintaining a DENV replicon (which is a useful model for studying DENV 
intracellular replication) and DENV infected cells was described in Chapter 4. The results 
from cell-based models were then compared with the results of a proteomic analysis of 
serum from patients with differing grades of DEN and described in Chapter 6. This 
comparison identified decreases in FBG and liver APPs as common to DEN patient serum 




FBG and liver APPs were further investigated as described in Chapter 7. Importantly, the 
work described in this thesis demonstrates the use of cell based models for the study of 
clinically relevant proteins and highlights cellular processes perturbed during DENV 
replication which have direct relevance to DEN pathogenesis. 
  
  Secretome analysis: challenges and potential applications 
Overall, analysis of the proteomes and secretomes of REP cells (in Chapter 4) and 
DENV infected Huh-7 cells (in Chapter 5) showed that the changes that occurred in protein 
levels in the cellular proteome were reflected in the secretome, suggesting that 
dysregulation of protein levels  intracellularly, led to the alterations observed in the 
secretome. The relationship between the cellular proteome and secretome of DENV 
infected HEK293T cells could not be explored due to the low number of proteins that 
significantly changed in amount. Furthermore, comparison of the proteomic analyses 
obtained using the Huh-7 cell model (in Chapter 5) with that using serum from DEN 
patients (in Chapter 6) demonstrated the relationships between the cellular proteome, 
secretome and serum proteome. This highlighted the potential of secretome studies for 
increasing our understanding of DEN pathogenesis.  
Interestingly, a large number of proteins were detected in the secretomes but not 
detected in the proteomes, 883 and 342 proteins in the HEK293T (Figure 4.3) and Huh-7 
cell (Figure 5.3) secretomes respectively. These proteins might not accumulate or function 
intracellularly but be secreted to act as signal proteins or components of the extracellular 
matrix. This hypothesis is supported by the results of the STRING analysis of the 883 
proteins detected only in secretome of HEK293T cells, which revealed an enrichment of 
proteins associated with the GOBP term “cell adhesion”, GOCC term “collagen-containing 
extracellular matrix” and GOMF term “signaling receptor binding”. The group of DDX 
proteins that significantly changed only in the secretomes of DENV infected cells and/or 
REP cells (but not in the proteomes) were highlighted in Chapter 4 as proteins potentially 




However, there are many challenges in secretome analysis that need to be solved. 
Firstly, methods to minimise the amount of BSA in cell culture supernatants need to be 
improved. Growing cells in SFM affects their energy metabolism and may affect proteomic 
analysis of proteins involved in energy metabolism. Secondly, ideally the concentration 
method needs to be effective and fast (as described in Chapter 3) so that proteins are not 
unequally concentrated from the secretome or subject to proteolytic activity. Thirdly, the 
method used to validate the proteomic results requires consideration. Many previous 
secretome studies were not able to validate the results of LC-MS/MS analyses; for 
example, a previous study examining the secretome of DENV infected HepG2 cells (Higa 
et al., 2008). Western blotting was not always sensitive enough to detect proteins which 
were present in low amounts in the secretome samples, even though there was a large fold 
increase in the amount of a protein between conditions. Only proteins that are known to be 
secreted in high amounts such as FBG and APPs were successfully validated in this study.  
  Applications of in vitro cell models for the study of DENV infection  
Unfortunately, despite a number of advantages of HEK293T cells for general 
molecular virology studies on DENV, as mentioned in Chapter 4, they appear not to be an 
optimal cell line for studies related to DEN pathogenesis. However, this study 
demonstrated that there was a good overall correlation between the proteomic results 
obtained using DENV infected HEK293T cells and the same cells expressing a DENV 
replicon. Few studies have compared changes in the transcriptome or proteome in cells 
containing a DENV replicon to those infected with DENV, although replicon systems are 
widely employed for antiviral screening. This finding supports the use of a DENV replicon 
system for studying general host cell responses to DENV replication, and the interaction 
of viral and cellular proteins. Recently, Huh-7 cells stably maintaining a DENV replicon 
were developed in the laboratory by Dr. Maia Kavanagh Williamson. As the results from 
this study revealed that Huh-7 cells were a useful model for some aspects of DEN 
pathogenesis, the replicon containing Huh-7 cells will be useful to dissect these processes 
further.  
Although PHHs are the ideal model for studying human liver pathophysiology, 




low passage lifespan and limited availability (Zeilinger et al., 2016; Shi et al., 2018). Thus, 
transformed hepatic cell lines have been extensively used in biological studies to overcome 
the limitations of PPH. Huh-7 and HepG2 cell lines are derived from well differentiated 
hepatocellular carcinoma liver tissue. Both cell lines are highly permissive to DENV 
infection and widely used as in vitro models for DENV studies. At the protein level, a 
proteomic study using high throughput LC-MS/MS and targeted proteomics to compare 
liver microsomes isolated from pooled liver samples (membrane fragments prepared from 
homogenized liver) using three hepatoma-derived cell lines (HepG2, Hep2B and Huh-7) 
revealed a correlation among the three cellular proteomes of 0.65, by principal component 
analysis (PCA)) (Shi et al., 2018). However, a marked difference between the protein 
profiles of pooled liver microsomes and the hepatoma cell lines was observed (Shi et al., 
2018). Pathway analysis revealed significant differences between human liver cells and 
Huh-7 / HepG2 cells in biological processes related to metabolism including; drug 
metabolism-cytochrome P450, steroid hormone biosynthesis, spliceosome and ribosomes 
(Shi et al., 2018), however, these processes were not dysregulated in response to DENV 
infection in Huh-7 cells in the experiments presented in this thesis. Unfortunately, there 
was no available data which could be used to compare the coagulation proteins and APPs 
in liver cell lines and human liver tissue.  
Therefore, for the first time, the hepatoma derived cell line, Huh-7, has been 
demonstrated to be a relevant cell-based model to study changes in the serum proteome in 
response to DENV infection, particularly in regards to APPs and proteins involved in 
“complement and coagulation” and “lipid metabolism” pathways. To better model in vivo 
pathophysiology, future investigations using PHH or a 3-dimensional culture system which 
includes non-parenchymal cells (eg. Kupffer cells as the source of cytokines) will be of 
much use in studying the dysregulation of APPs in DEN (Zeilinger et al., 2016). 
  Potential clinical applications of the study  
 Biomarkers to diagnose DEN and predict severity  
The major problems in clinical practice are the lack of reliable test to diagnose DEN 




be specific to DEN infection in all stages of disease (febrile, critical, recovery), not 
influenced by other host conditions (age, sex, race and comorbidity) and able to predict the 
severity of DEN. Unfortunately, this and previous studies have not identified a protein or 
set of proteins that satisfies all of these criteria. Moreover, although some candidate 
biomarkers have been proposed (ie. CRP, SERPINA1, SERPINC1 and HP) there are 
inconsistencies between different studies, as mentioned in the discussion of Chapter 6 and 
introduction of Chapter 7. NS1 has been widely used as marker for the diagnosis of DEN. 
Although NS1 based tests have great sensitivity and specificity in the acute phase of 
infection, they have a number of limitations (reviewed in Chapter 1) such that these tests 
are not ideal for diagnosis, especially in severe cases or cases that present in the late phase 
of disease.    
Not all of the proteins that significantly differentiated between DEN patients and 
healthy controls (described in Chapter 6) potentially can be used as biomarkers for DEN 
diagnosis. Candidate protein biomarkers should alter (increase or decrease) in the same 
direction in all disease conditions. They should also be detectable in clinical specimens 
without ALB/IgG depletion, using routine clinical methods such as an ELISA assay. The 
relative alteration in protein amounts detected by shot-gun proteomics requires absolute 
quantification before use in clinical practice. Importantly, any candidate biomarkers need 
to be validated in much larger patient cohorts using quantitative methods that can determine 
the specificity and sensitivity values suitable for application in clinical practice. To 
decrease the time from discovery proteomics to biomarker validation, the selection of 
candidate protein biomarkers for which tests are already available with known information 
(ie approved clinical tests, normal healthy values, conditions that effect the level) is 
optimal, rather than validation of novel proteins for which no tests and little clinical 
information exists. Thus, coagulation proteins and APPs that are present in high amounts 
in blood, can be assayed using available tests, and have been studied in clinical conditions 
other than DEN (for which little information exists) were selected for further analysis in 
this study, although they are still not ideal biomarkers for predicting whether an individual 
will progress to severe DEN. Coagulation proteins and APPs (FBG, F2, SERPINC1, 




infectious diseases, including bacterial sepsis.  Furthermore, underlying liver diseases will 
affect the interpretation of liver APP amounts.  
Although low levels of CRP were reported to distinguish viral disease (mainly 
DEN) from bacterial infection (Wangrangsimakul et al., 2018), the study included only 24 
cases of viral infection and did not mention DEN severity. In another study the CRP level 
in severe DEN was still high enough to overlap with the range observed in bacterial 
infections (Chen et al., 2015). Thus, CRP needs to be used in combination with other 
biomarkers for the diagnosis of DEN and the cut-off to predict severe diseases (in each age 
group) needs to be determined.    
 Potential therapeutic application of the results from this study 
 This study revealed a decrease in the serum level of liver APPs which the in vitro 
analyses suggested is a result of decreased production and secretion of these proteins from 
the liver. Moreover, proteasomal degradation was proposed as a key mechanism for the 
decrease in APPs. Since alterations in liver APPs occur to combat infection/inflammation, 
reversing the decrease in APPs, either by blocking proteasomal degradation or replacement 
therapy may restore the host immune response to DENV infection.   
Apart from preventing the dysregulation of FBG and APPs in response to DENV 
infection shown in this study, the antiviral effect of proteasome inhibitors has been 
previously documented. Treatment of DENV infected BHK-21 cells with MG132 and 
curcumin (a traditional Asian herb with a proteasome inhibitory effect) resulted in reduced 
viral titres (Padilla et al., 2014). Pre-incubating HepG2 cells with a low dose (as low as 0.4 
µM) of MG132 and N-acetyl-leucinyl-leucinyl-norleucinal (ALLN) (another proteasome 
inhibitor) resulted in a decrease in viral titre from DENV infected HepG2 cells without 
cytotoxic effect (Fink et al., 2007). Pre-treatment of THP-1 cells with β-lactone, a 
proteasome inhibitor, before infection with DENV-2, also resulted in a decrease in viral 
titre and accumulation of the DENV E protein, suggesting that DENV egress was blocked 
(Coy et al., 2015).  
Bortezomib is an FDA approved proteasome inhibitor used for cancer treatment. A 
study which investigated the effects of pre-treating THP-1 cells with Bortezomib before 




EC50 (a dose that can inhibit 50% of viral replication) of less than 20 nM while the 
cytotoxic dose was 1µM (Coy et al., 2015). Bortezomib was also found to inhibit DENV-
2 infection using a mouse model with decreased DENV replication in the spleen and a 
decrease in the severity of disease as determined by the levels of Hct, Plt, leakage and pro-
inflammatory cytokines (Coy et al., 2015). Curcumin, a traditional herb with many 
medicinal properties including antiviral and anti-cancer effects, has been used safely in 
humans as a dietary complement (Hewlings and Kalman, 2017). 
 Another potential therapeutic approach is replacement therapy. The intravenous 
administration of concentrated proteins such as SERPINA1 and SERPINC1 is used as a 
replacement therapy for other conditions in clinical practice. Purified SERPINA1 prepared 
from pooled plasma has been used for decades as a therapeutic option for α1-antitrypsin 
deficiency, a genetic disease (Teschler, 2015). In this study it was proposed that decreased 
SERPINC1 was a result of decreased secretion from the liver, however increased filtration 
by the kidney has also been proposed to result in decreased SERPINC1 levels (Wills et al., 
2004). A randomized control trial showed the potential benefit of high dose intravenous 
SERPINC1 (in a subgroup that did not receive concomitant heparin) in patients with severe 
sepsis (Warren et al., 2001). Replacement therapy with purified coagulation proteins might 
have role in SD similar to the administration of fresh frozen plasma and concentrated Plt, 
that that is given to those with SD and uncontrolled bleeding. However, this strategy would 
need further investigation in a clinical trial.  
Overall the in vitro results presented in this study may not be robust enough to 
demonstrate a clear therapeutic role for proteasome inhibitors in the treatment of DEN. 
However, given their potential for restoring liver/serum APP levels, in combination with 





A PPE N D I X  A  
Culture media 
 2X MEM 
Prepared from 10X MEM (Invitrogen) containing 25 mM HEPES, 0.1 mM NEAA, 
2 mM L-glutamine and 2% FCS, 100 μg/ml streptomycin and 100 U/ml penicillin 
Protein analysis 
 1.5 M Tris-HCl pH 8.8 
36.30 g Tris base in 100ml of dH2O 
Adjust pH with HCl and make up to 200 ml with autoclaved dH2O 
 0.5 M Tris-HCl pH 6.8 
6 g Tris base in 60 ml of dH2O 
Adjust pH with HCl and make up to 100 ml with autoclaved dH2O 
 10% (w/v) SDS solution 
20 g of SDS in 200 ml of autoclaved dH2O 
 10% (w/v) ammonium persulphate for electrophoresis, ≥ 98% (APS) 
0.05 g ammonium persulphate in 0.5 ml of autoclaved dH2O 
 10X Electrode Buffer pH8.3 (not adjust pH) 
30.3 g Tris base, 144 g Glycine, 10 g SDS in 1000 ml of dH2O 
 6X sample buffer 
7 ml 0.5 M Tris-HCl pH6.8, 3 ml Glycerol, 1.2 g SDS,  
1.2 mg Bromophenol blue 
Make up to 10 ml with autoclaved dH2O 
 2X sample buffer 
 2 ml of 6X sample buffer added to 4 ml of autoclaved dH2O 
 Coomassie Brilliant Blue R-250 staining solution  
0.575 g Coomassie Brilliant Blue R-250, 200 ml methanol, 50 ml acetic acid, 250 ml 
dH2O 
 SDS-PAGE Destain solution 
Add 50 ml of glacial acetic acid to 350 ml of dH2O 
Add 100 ml of methanol and mix 




 1X Western Blot transfer buffer 
100 ml methanol, 12.5 g Tris base, 5.63 g glycine 
Make up to 500 ml with dH2O 
 1X PBS 
8 g NaCl, 0.2 g KCl, 1.44 g Na2HPO4, 0.24 g KH2PO4 in 1000 ml of dH2O 
Autoclave for 20 min at 121°C 
 PBST 
1000 1X PBS, 1 ml Tween 20 
 10X TBS 
12.115 g Trizma HCl (C4H11NO3), 40.03 g NaCl in 400 ml of dH2O 
Adjust pH to 7.5 with HCl and make up to 500 ml with dH2O 
Autoclave for 20 min at 121°C  
 TBST 
50 ml 10X TBS, 450 ml dH2O, 0.5 ml Tween 20 
 Western blot blocking solution 
5 g skim milk powder added to 100 ml of PBST 
 Abcam mild stripping buffer 
15 g glycine 
1 g SDS 
10 mL Tween 20 
Dissolve in 800 mL dH2O 
Adjust pH to 2.2 
Bring volume up to 1 L with dH2O 
 Immunofocus assay blocking solution  
10% (v/v) FBS in PBS 
 RIPA buffer 
25 mM Tris-HCl pH 7.6 
150 mM NaCl 
1% (v/v) Tween-20 
1% (w/v) sodium deoxycholate 




 Protease inhibitor (cOmplete, Mini, EDTA-free Protease Inhibitor Cocktail – 
Roche)  
1 tablet added directly to 10 ml of RIPA buffer 
 Co-IP lysis buffer (same as RIPA buffer) 
 Co-IP wash buffer  
25 mM Tris/Cl pH7.5 
150 mM NaCl 
0.05% - Tween-20 
Resolving gel: 
 10% 
H2O 1.9 ml  
30% acrylamide mix 1.7 ml 
1.5M Tris pH 8.8 1.3 ml   
10% SDS 0.05 ml  
10% APS 0.05 ml  
TEMED  0.003 ml  




H2O 2.2 ml 
30% acrylamide mix 0.67 ml  
0.5M Tris pH 6.8 1 ml 
10% SDS 0.04 ml  
10% APS 0.04 ml  
TEMED  0.004 ml  
TOTAL 4 ml 
 
Electrophoresis of RNA and DNA 
 6X DNA loading dye 
10 mM Tris-HCl pH 7.6, 0.03% bromophenol blue, 0.03% xylene cyanol FF, 60% 




 10X TBE Buffer   
108 g Tris base, 55 g Boric acid, 40 ml 0.5M EDTA (pH 8.0) 
Adjust volume to 1 L with dH2O 
Autoclave for 20 min at 121°C 
 1X TBE running buffer 
50 ml 10X TBE buffer 
Adjust volume to 500 ml with dH2O 
 4% (w/v) agarose 
4 g agarose in 100 ml of 1X TBE 
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